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ABSTRACT 
Existing comprehensive drug screening procedures employ either batteries of 
analytical techniques which target specific drugs and structurally related drug groups, 
or relatively non-specific broad screens for either acidic or basic drugs which require 
additional confirmation of the identity of drugs detected. A single, automated, semi-
quantitative gas chromatography/mass spectrometry (GC/MS) screening procedure 
for approximately 100 structurally and chemically diverse drugs in 2.5 mL of whole 
blood was developed and validated. A drug extraction strategy was developed which 
employed both liquid-liquid and solid-phase extraction techniques to produce four 
blood extracts for separate GC/MS analysis in selected ion monitoring (SIM) mode. 
The chromatograms produced were processed automatically by a novel macro which 
generated reports detailing the drugs identified and their approximate concentrations 
in blood. 
Target drugs were selected for potential inclusion in the screening procedure on the 
basis of their ability to impair driving performance, their toxicological significance 
(forensic application) and their relative prevalence in the community (clinical 
application). As licit and illicit drug use in the community changes, these target 
drugs would change, however, those selected were representative of a range of 
chemical structures and functionalities broad enough to permit the development of a 
general analytical screening procedure which could be applicable to additional drugs. 
The qualitative and quantitative characteristics of underivatised and derivatised 
(butyl- and pentafluoropropionyl-) target drugs were investigated to:- 
1. determine retention indices and select suitable target m/z ions by which drugs 
would be identified; 
2. establish quantitative parameters which were then used to estimate blood drug 
concentrations; 
3. determine instrument detection limits and establish whether or not they were 
comparable with expected therapeutic drug blood concentrations; and 
4. identify drugs not suitable for GC/MS analysis. 
The recovery of 90% of target drugs was greater than 75% using the automated drug 
screening procedure. 
The automated drug screening procedure was validated in blood specimens from a 
forensic laboratory and a hospital. The procedure identified 97% of drugs spiked at 
known concentrations in blood specimens prepared as part of a Proficiency Testing 
Program for Australian and New Zealand forensic laboratories. The developed 
screening procedure compared favourably with current toxicological methods 
routinely employed at the Government Analytical and Forensic Laboratory 
(Tasmania), identifying a greater number of drugs in the same blood specimens. 
During the analysis of blood specimens from hospital patients, it was found that the 
screening procedure was likely to identify the majority of drugs at therapeutic levels 
particularly if the blood taken was from an individual who had been previously 
administered the drug within two half-lives. 
A pilot study which identified the drugs present in the blood of a limited sample of 
Tasmanian drivers involved in road traffic accidents indicated the applicability of the 
drug screen to studies which investigate the possible causal role of drugs in road 
accidents. The suitability of the screening procedure to other clinical and forensic 
applications was indicated. 
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Preface 
This thesis is contained in two volumes. Volume I contains the text and figures 
and Volume II contains the tables and reports. The separation of the text from the 
tables and reports was done to make it easier to read the thesis, for the following 
reasons:- 
1. the thesis contains a large number of tables and reports; 
2. often a single table or report consists of multiple pages; 
3. tables are presented in both 'portrait' and 'landscape' orientations; and 
4. some tables are referred to on more than one occasion throughout the text. 
Having all tables and reports in Volume II allows the reader to have a table/report 
open for quick reference while reading the text, to orientate the second volume 
appropriately (landscape or portrait) and have a more manageable volume of text 
to read. 
Volume II also contains Appendices A, B and C. 
The pages of Volume II are not numbered sequentially as in Volume I but are 
numbered with the table/report identifier. For example, Table 7.2 consists of 7 
pages and the third page of the table is numbered 7.2/3. In this way, each table 
can be quickly located and the reader can determine whether or not the table or 
report has multiple pages. 
Chapter 1. 
COMPREHENSIVE BROAD DRUG SCREEN 
IN WHOLE BLOOD 
1.1 Introduction 
The major aims of the research project were to:- 
1. develop and validate an automated, semi-quantitative screening procedure for 
structurally and chemically diverse drugs in whole blood by benchtop GC/MS, 
2. design a screening procedure particularly suited to forensic applications but which 
may also be useful in clinical settings, and 
3. apply the screening procedure in a pilot study investigating drugs in Tasmanian 
drivers involved in road traffic accidents. 
A comprehensive screen for a diverse range of drugs which both identifies drugs and 
indicates their concentration would be useful for:- 
1. the treatment of patients in hospital Accident and Emergency wards, 
2. the screening of employees and prison inmates with the view to detecting and 
preventing drug problems, and 
3. the administration of law enforcement with regard to drug involvement in 
industrial and traffic accidents, breaches of State laws (eg. driving under influence 
of drugs, use of prohibited substances), and unexpected death (eg. overdose - 
accidental or otherwise). 
In the design of any drug screening procedure, however, the particular needs and 
limitation of the laboratory in which it was to be employed, would need to be 
accommodated. Consequently, the needs and limitations of a Tasmanian forensic 
laboratory at the Government Analytical and Forensic Laboratory (GAFL) were 
considered for this study. 
1.2 Needs and Limitations of a Forensic Laboratory 
The forensic laboratory routinely analyses drugs in blood samples most often 
submitted by either the Police or the Coroner. The Police obtain fresh blood samples 
from individuals during their investigation of offences in connection with:- 
1. driving under the influence of drugs, 
2. use of prohibited substances, 
3. motor vehicle accidents arising from possible driver impairment through drugs, 
4. assaults, rapes and murders where drug use by either the victim and/or suspect 
impaired judgement and/or was otherwise related to the crime. 
The Coroner obtains blood from individuals who have died unexpectedly, for 
example as a result of mechanical injury (eg. car accident, fall, suicide by hanging or 
gunshot), chemical injury (eg. drug poisoning, suicide by overdose, carbon monoxide 
poisoning) or homicide. 
In such an environment the screening procedure is primarily a toxicological tool to 
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identify the drug/s present and their level in an individual's blood at a critical time. 
Although clients suspect that drugs are affecting individuals, very rarely do they have 
reliable evidence to identify the drug/s they suspect. Consequently, the ideal 
toxicological tool would detect any drug currently available, at a range of blood 
levels (sub-therapeutic to toxic). 
In the majority of cases, the sample the client supplies is whole, haemolysed blood. 
Other than tissue samples, whole, haemolysed blood is the most difficult sample 
matrix from which to extract drugs as they must be separated from the protein, 
ruptured cell membranes and other interfering endogenous compounds which form 
the blood matrix. Although whole blood is a difficult specimen from which to 
extract drugs when compared with urine, serum or plasma, the client has difficulty 
obtaining these other specimens. For example, there is no current legislation which 
allows a urine specimen to be taken by the Tasmania Police without the consent of 
the individual being investigated. In coronial cases, often the bladder was voided on 
death and no urine could be obtained. The blood samples obtained from coronial 
cases range from being completely haemolysed to severely decomposed depending 
on how long the individual has been dead, and consequently, there is no chance that 
serum or plasma may be obtained from it. Blood taken under the Tasmania Road 
Safety (Alcohol and Drugs) Act is usually little better than post-mortem blood 
despite anticoagulants and preservatives being added. It is almost always 
haemolysed by the time the laboratory receives it, most often as a result of either poor 
mixing or poor storage prior to its arrival. 
Drug levels determined in blood are of much greater interpretative value than drugs 
detected in a urine specimen. All that can be concluded with regard to drugs detected 
in a single 'snatched' urine specimen is that the individual was exposed to the drug in 
the recent past but no opinion could be given as to how much drug was taken, when 
it was last taken, or what effect that drug may have had on the individual. In 
contrast, pharmacokinetic drug data and information regarding the relationship 
between clinical effects of drugs and their concentration in blood plasma, allow a 
pharmacologist to give an educated opinion as to the likely effect detected drugs may 
have had on an individual at around the time their blood was taken. Consequently, 
for the forensic laboratory, a drug screen in whole blood is of the most practical and 
interpretative value. 
The volume of blood submitted to the laboratory for analysis is sometimes restricted. 
The current legislation under which the Tasmania Police operate allows no more than 
10 mL of blood to be drawn from the individual. This blood sample is drawn and 
separated by eye into three bottles, only one of which is available to the laboratory 
for analysis. Depending on the co-operativity and health of the individual and the 
availability of the hospital staff, significantly less than 3 mL of blood may be 
obtained for analysis. In most cases, the post-mortem blood volumes submitted by 
the Coroner are not limited unless there was either significant blood loss during or 
after death, or destruction of the body (eg. incineration, decomposition). 
According to the scientific literature, broad drug screening and quantitation are 
generally not performed by the same assay on the same aliquot of blood unless the 
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assay specifically targets a group of structurally-related drugs. Consequently, 
multiple assays must be performed, using several aliquots of the blood, to identify 
and quantitate a diverse range of drugs. Such an approach to comprehensive drug 
screening requires that the laboratory:- 
1. possess several major analytical instruments - eg. GC, HPLC and their appropriate 
detectors, GC-MS, and possibly RIA, 
2. possess enough qualified staff to maintain and operate the instrumentation, 
3. obtain sufficient specimen for analysis to both identify and quantitate drugs 
detected by the different techniques, 
4. conduct analyses concurrently to ensure a timely result to the client. 
Therefore, a screening procedure which both identifies and quantitates a large 
number of chemically diverse drugs in the same aliquot of blood would be most 
advantageous. 
Quality control in any laboratory requires that the same analytical findings be 
obtained for a given specimen although a variety of different staff members perform 
the analyses and interpret the data. In the case of chromatograms generated by mass 
spectrometry, searching complex, multi-peak chromatograms for drugs is performed 
either:- 
1. automatically by commercial or 'in-house' full-scan library search programs, or 
2. manually by the experienced operator. 
Commercially available library search programs (eg. those supplied with Hewlett 
Packard and Varian mass spectrometers) integrate and search all peaks in the 
chromatogram. The spectrum for each peak is compared with all spectra in the 
library and if a match is found, the 'goodness' of the match is reported as a 
percentage of an ideal match. Automating the search of a chromatogram for drugs 
ensures reproducibility and consistency of interpretation. However, although the 
search of each chromatogram is rapid and automated, there is generally no use made 
of the correlation between matched spectra and known drug retention time. In 
addition, unresolved peaks which give mixed mass spectra may lead to either false 
positives or negatives. Peaks which elute on the leading or tailing edge of a larger 
peak may not be integrated and may again result in false negatives. 
In contrast, although manual searching of chromatograms against a library of drug 
mass spectra is much more laborious and time consuming, the expertise of the 
operator in interpreting the chromatogram provides special advantages. The 
experienced operator will detect peaks which appear on the shoulder of another peak. 
Similarly, the operator may have some knowledge of drug retention time and 
structure and may quickly dismiss a 'hit' if:- 
1. the peak spectrum matched has the wrong retention time for that drug, 
2. the suggested drug match could not possibly be chromatographed on the current 
system, or 
3. the shape of the peak matched is different when compared with a known drug 
standard chromatographed on the same system. 
Consequently, a screening procedure which automates the interpretation of complex 
multi-peak chromatograms and mimics the skills routinely employed by an 
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experienced operator would be highly advantageous. 
The nature of forensic work often makes it the subject of legal scrutiny and 
confirmation of drug results by full-scan mass spectrometry is now almost a legal 
requirement. However, full-scan mass spectrometry is likely to lack the sensitivity of 
the initial screening technique. In the absence of full-scan mass spectra, 
confirmatory techniques which positively identify a drug by at least two different 
procedures satisfies the court. Again, this may be difficult if the sample volume is 
limited. Consequently, a drug screening technique which is rigorous enough to 
satisfy court requirements by confirming the presence of any drug it identifies would 
be highly desirable. 
1.3 The Ideal Drug Screening Technique 
The needs and limitations of the forensic laboratory outlined above would, in most 
cases, apply to any working laboratory (hospital, forensic, research). Therefore, the 
ideal comprehensive drug screening procedure has to satisfy several important 
criteria. The screen must:- 
1. be broad enough to detect all drugs currently available and cover a sub-therapeutic 
to toxic range, 
2. be suited to whole, haemolysed blood (< 3 mL), 
3. both identify and quantitate the drugs detected, 
4. be able to sustain court scrutiny, 
5. not be reliant on the availability of multiple instruments and staff, and 
6. provide automated interpretation of screening results to ensure timeliness and 
independence from the operator. 
The ideal drug screening technique as described above has not yet appeared in the 
literature despite comprehensive research in the area for over 30 years. Although 
each criterion may be possible when approached independently of the others, in 
combination, they are impossible to satisfy. For example, no single analytical 
instrument is suited to the analysis of such a structurally diverse group of compounds 
as drugs. Drugs may have a polarity and structure which either prevent 
chromatography or ensure that chromatography will be poor. No single extraction 
technique provides great enough scope to extract all drugs due to limitations in the 
achievable pH range, solvent polarity etc. Some drugs-will not be extracted while 
others will be extracted with poor or non-reproducible recoveries. The possible use 
of multiple extraction techniques and/or multiple instrumentations is restricted by the 
limited sample volume. 
Consequently, in the development of an automated, quantitative, broad drug 
screening procedure, a compromise on the ideal must be made to satisfy achievable 
criteria. Realistic, achievable criteria can be described as follows. 
1. A drug screen in whole, haemolysed blood. 
2. The extraction of the majority of available drugs with at least one representative 
drug from each of the major drug classes (eg. diuretics, benzodiazepines, anti-
depressants etc). 
3. The detection of the majority of drugs at therapeutic blood concentrations. 
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4. Relatively high (>50%) and reproducible drug recovery. 
5. Drug quantitation which provides an indication of whether the drug is present at 
sub-therapeutic, therapeutic or toxic levels. 
6. The identification and confirmation of the majority of drugs by at least two 
different methods. 
7. The chromatography of the majority of drugs with relatively good peak shape and 
with an instrument detection limit below the therapeutic range of the drug. 
8. The automation of data analysis which provides greater specificity than 
commercially available library-based search programs and reproduces the skills of 
an experienced analyst. 
1.4 Analytical Technique 
1.4.1 Review of Current Literature 
Most analytical techniques employed in drug detection can be broadly classified into 
two groups - chromatographic techniques and radio-immuno assay (RIA) techniques. 
The RIA techniques are most often seen in the hospital environment and the 
instrument and assays are generally commercially supplied. These methods are 
potentially expensive as their reagents have limited shelf-lives, and the screening 
assays can usually only be applied to urine samples, although there are some limited 
applications in serum. Radio-immuno assays require that separate analyses be 
performed for each individual drug or drug group rather than having one procedure 
which will encompass identification of drugs from different groups. These screening 
assays are not drug specific and consequently detection of a `benzodiazepine' is 
reported rather than identifying a particular drug such as diazepam or nitrazepam. 
Similarly, quantitation of different drugs within the group is generally based on the 
calibration curve for a single representative drug. 
There has been a vast amount of literature published in the area of drug analysis in 
biological materials over the past 30 years. Changing drug usage, the explosion in 
the number of new drugs (licit and illicit), increasing drug potency and greatly 
improved analytical instrumentation (more specific and sensitive detectors) over that 
period of time has made much of the early literature (pre-1985) obsolete. Even if the 
literature published in the last 15 years were extensively reviewed, the resulting 
document would be unmanageable. Consequently, the literature of this review will 
be considered in the light of the varied approaches used by researchers in drug 
analyses (extraction procedure, instrumentation) rather than documenting the specific 
details of the multitude of published analytical techniques. In addition, the review 
will be limited to chromatographic analyses in blood and blood products. The 
volume of literature devoted to the subject of drug analysis via chromatographic 
techniques indicates that it is constantly being explored, for example, an entire issue 
of the Journal of Chromatography was devoted to the chromatography of drugs and 
other toxic compounds. (I) 
In large laboratories, batteries of analytical methods (RIA, TLC, GC, HPLC) which 
target groups of drugs are employed to conduct a comprehensive drug screen. With 
unlimited resources (time, staff, instrumentation, sample volume) an analyst could 
find in the current literature any number of procedures which identify and/or 
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quantitate either specific drugs, or groups of structurally-related drugs in biological 
fluids. In combination, these procedures could adequately provide a comprehensive 
and quantitative drug screen. Other than RIA techniques, there are a great variety of 
specific GC and HPLC based analyses for drug groups such as 13-blockers, (24) 
tricyclic anti-depressants, ( ' -9) benzodiazepines, (10-19) anti-inflammatories ,(9,20,21) drugs 
of abuse, (22-26) diUretiCS,(27) oral anti-diabetics, (28) anticonvulsants, (29) and opiates. (30- 
32) 
As an alternative to enlisting a number of drug assays in combination, there are many 
references to preliminary drug screening procedures employing GC. Earlier 
literature employed the flame ionisation detector (FID) particularly where drug 
identification was based on Kovats retention indices (RI). (' -3)) There are many more 
studies which utilised a more specific detector - the nitrogen/phosphorus specific 
detector (NPD) with both dual and single column analyses. (''36-)°) GC-NPD provides 
a single analytical procedure which is sufficiently sensitive to detect large numbers 
of drugs. Nitrogen-containing drugs, endogenous blood products, blood and 
extraction contaminants, which elute from the capillary column as peaks, are 
described by specific retention times or RI. The retention time or RI is matched 
against those of drug reference standards run under the same chromatographic 
conditions. If the retention time of the eluted peak matches that of a drug standard, it 
is tentatively identified as that drug. However, the match is based on only a single 
criterion (retention time or RI) and, consequently, the drug screen is relatively non-
specific compared with other techniques outlined below. The identity of the eluting 
peak requires additional confirmation. An endogenous blood product or other 
contaminant possessing characteristics which cause it to elute with the same retention 
time as a drug would be falsely identified as that drug. Similarly, should conditions 
arise which cause the retention time of an eluting drug to shift slightly (Section 8.4.1 
and Appendix A.4) then it would not match that of the corresponding drug standard 
and a false negative would result. 
Another important deficiency associated with GC-NPD based drug screening is that 
important non-nitrogenous drugs such as THC and its metabolites, and anti-
inflammatory agents are not detected. (51) As with any chromatographic method, 
drugs which cannot be chromatographed under particular conditions go undetected 
unless their chromatography can be improved by derivatisation or altered capillary 
column polarity. One study also reported a large number of extraneous peaks which 
eluted close to the retention times of drugs, (52) making the interpretation of 
chromatograms difficult and further confirmatory techniques necessary. Many of the 
cited GC-NPD screening procedures did not give an indication of blood 
concentration as did the specific assays for individual drugs or drug groups. 
The nature of forensic work often makes it the subject of legal scrutiny and 
confirmation of any drug identified is necessary. Recently, broad drug screening by 
( 	 , diode array detectors (DAD) has become more prevalent in the literature. 953-63)I 
Diode array detectors are useful confirmatory detectors as they provide a full 
ultraviolet (UV) spectrum of the compound eluting from the column. One study used 
automated detection based on both the UV spectrum and relative retention time of the 
eluting HPLC peak which were matched against a library of reference drug UV 
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spectra. (64) The drawback of DAD, however, is that many UV drug spectra are 
remarkably similar. This reduces the specificity of the screen and, consequently, for 
these drugs identification is again based on only one criterion (retention time). 
Another major disadvantage of DAD or UV detection is that it is too insensitive to 
detect many basic drugs as they possess such low specific extinction coefficients. 
Drug specific extinction coefficients cover an extremely wide range. For example, 
that of chlorpromazine in aqueous acid (k max=255 nm) is 1025, while that of 
methylamphetamine under the same conditions (k.=257 nm) is 12. (65) 
Consequently, the detectors have great sensitivity for some drugs while other drugs 
can be detected only at concentrations well above the therapeutic range. In the 
literature, HPLC-DAD is successfully employed in screening for acidic drugs which 
are generally administered in much larger doses than basic drugs. 
The mass selective detector (MSD) is another useful confirmatory detector and well 
recognised and accepted in legal areas. The advantages and deficiencies of mass 
spectrometry are discussed below (Section 1.4.2). GC/MS has been used in 
screening procedures for specific drug groups such as opiates, (31) tricyclic anti- 
depressants,(6) drugs of abuse, (66 '67) diUretiCS,(68) 13-blOCkerS, (69 ' 70) beriZOdiaZepirieS, (71- 
74) anti-inflammatory analgesics, (75) neuroleptics,(76) and the subject is covered by 
reviews. (77-82) Some studies have automated data processing to identify drugs in 
multi-peak chromatograms on the basis of either unique mass spectra or groups of 
distinguishing m/z ions. In general however, automated drug searches involved 
matching the full-scan mass spectra of eluting drugs against commercial and 
purpose-built full scan mass spectral libraries (Section 8.1). 
Just as there is a great variety of chromatographic instrumentation used for both 
broad drug screening and specific drug group analyses, so are there an even greater 
number of sample preparation and drug extraction techniques cited in the literature. 
The great majority of studies employ either liquid-liquid extraction (LLE) or solid-
phase extraction (SPE) techniques where drugs are extracted from their matrix by 
partitioning them between two phases (Section 7.1). Despite the number of 
publications, many of the described procedures differ only subtly from others as 
researchers manipulate a limited number of parameters to optimise their procedure 
for the particular drug analyte. For example, LLE assays are described with a variety 
of buffers, pH conditions, extraction solvents, protein precipitation steps and extract 
clean-up steps. (36,38,39,50,53,60,83-90) Many pre-1980 papers described techniques for the 
extraction of drugs from tissues where drug concentrations are greater and, 
consequently, enzyme digestion techniques are also cited. (91) However, as instrument 
sensitivity improved with advancing technology, drug extraction from whole blood, 
serum and plasma eliminated the need for preliminary enzyme digestion. Solid-
phase extraction techniques are described with a variety of packing materials, eluants, 
cartridge washing and pH adjusting solutions, and conditioning buffers. (4,5,13,18- 
20,41,45,88,92-102) The nature of SPE lends itself to automation. (9' 1°3) Both types of 
extraction techniques may also have additional derivatisation steps prior to 
Gc(31,34,66,68,104,105) 
It was not uncommon to find that important information with regard to the 
limitations and capabilities of the cited extraction techniques was not covered in all 
8 
publications. For example, data regarding which drugs could or could not be 
extracted by the technique, the detection limit and reproducibility of the assay, 
specific drug recovery, and the stability and reproducibility of derivatives formed, 
was often missing, incomplete, or provided for only a selection of drugs. Data was 
available for either a discrete number of drugs from a particular drug group or for 
representative drugs from specific drug groups while excluding some drugs from the 
same group which are more difficult to either extract or chromatograph. In short, not 
a single publication describing a comprehensive drug screen in whole blood was 
found that provided recovery and reproducibility data for a diverse group of drugs 
such as oxazepam, temazepam, morphine, paracetamol, salicylic acid and quinine or 
that indicated whether or not the technique did, in fact, extract all these drugs. 
This general deficiency in the literature suggests a ninth criterion suitable for 
inclusion in the design of the achievable (and ideal) comprehenisive drug screen as 
follows. 
The extraction technique details which drugs it can and cannot extract and 
indicates the extraction efficiency of the procedure for each drug. 
1.4.2 The Mass-Selective Detector 
The proposed drug screening technique is based on GC/MS analysis using a 
benchtop MSD. Mass spectrometry is concerned with the ionisation and subsequent 
fragmentation of compounds. The fragmentation is directed by the functional groups 
of the compound and occurs reproducibly. A result of reproducible fragmentation is 
a unique mass spectrum for each compound which displays the relative abundance of 
the ions produced by fragmentation and the determined mass to charge ratio (m/z). A 
widely used method of fragmentation is by electron impact (El) in which the 
vaporised sample compounds are bombarded by a stream of high energy electrons. (65) 
The detector can be operated in one of two ways as follows:- 
1. it detects and records the sum of all the ions from the vaporised sample at any 
instant in time, displaying the total ion current (TIC), or 
2. it detects only a selected number of specified target m/z ions in the vaporised 
sample while operating in selected ion monitoring (SIM) mode. 
Total ion current mass spectra are invaluable for confirmation of drug identity as they 
display a fragmentation pattern that is unique for the drug and the molecular ion (M +) 
may, sometimes, be stable enough to be apparent in the spectrum. The disadvantage 
of the TIC mode of operation is that sensitivity is reduced as a result of searching for 
up to 500 m/z ions, three times per second. 
Many of the broad drug screening chromatographic procedures utilised NPD. This 
detector is more sensitive than an MSD operating in full-scan mode (TIC). However, 
when the MSD acquires data in the SIM mode, it has equivalent sensitivity and the 
more modern MSD instruments provide even greater sensitivity. 
Although the MSD operating in SIM mode does not offer the same indisputable 
confirmation of drug identity provided by full-scan data, the detector will more 
reliably identify a drug than any other GC detector or the HPLC-DAD. Not only 
must the unknown compound elute from the column at the known retention time of 
9 
the drug standard but both the ratio and peak profiles of the target m/z ions monitored 
must mirror those of the drug reference standard. The target m/z ions selected for 
each drug generally incorporate both unique (eg. M +) and abundant m/z ions giving 
specificity and sensitivity respectively. This additional evidence of the identity of a 
drug makes it very unlikely that false negatives will be reported. 
In SIM mode, endogenous blood products and other sample contaminants go 
undetected as they elute from the column if they do not contain the target m/z ions 
currently monitored. As a consequence, chromatograms appear very 'clean' (smooth 
baseline) and the background is so low that even small peaks can be detected and 
integrated baseline to baseline. 
The use of the MSD in the SIM mode, however, implies that only target drugs can be 
identified. The major disadvantage of SIM is that if a new, non-target drug was 
present in the blood sample, it would not be detected. The same could be said of 
other specific GC detectors (NPD or electron-capture detectors) which may not be 
sensitive to the new drug. The FID, however, would chromatograph the drug as a 
peak. In that instance, although the new drug may not match any reference drug 
standards currently run on that system, the operator would at least be aware of the 
presence of an extra peak which he/she would then have to determine by some means 
to be a drug and not simply an endogenous blood product or contaminant. 
From a practical perspective, the MSD operated in SIM mode provides much greater 
specificity and information about an eluting compound than a non-specific FID while 
still matching the FID for the absolute number of compounds detected. The MSD 
will detect many more compounds than selective detectors such as NPD or ECD 
while still providing specific information with regard to m/z ions present. Benchtop 
MSDs are now common with up to 50 Hewlett Packard GC/MSDs now placed in 
laboratories around Australia and 11 GC/MS instruments in Tasmanian laboratories. 
Consequently, a comprehensive drug screen based on benchtop GC/MSD should 
provide an invaluable resource to Australian laboratories undertaking drug analyses. 
1.5 Drug Selection 
A comprehensive drug screening procedure employing benchtop GC/MSD operated 
in SIM mode requires that the screen target specific drugs. Consequently, a choice 
was made as to which drugs would be selected for investigation given that not all 
drugs currently available could be included in the time frame of the research project. 
It was important to the pilot study that all drugs of abuse (DOA) or potential abuse be 
identified by the screening procedure because of their capacity to alter mood and 
impair psychomotor functions and judgement. If the screening procedure was to be 
applicable in broader forensic and clinical settings, however, it must identify a wider 
range of drugs than psychotropic agents. Ideally, it should identify all drugs 
available to the community. Drug use in the community was indicated by the "1992 
Australian Statistics on Medicines" (106) published in 1994. Figure 1.1 shows the 
introductory page of the publication which describes the source of the data, how the 
data is presented, and the units of measurement. Table 1.1 lists medications ranked 
in descending order by the defined daily dose/1000 head of population/day (DDD), 
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Introduction 
The data contained in the 1992 ASM are drawn from two sources. The first is the 
Health Insurance Commission records of prescriptions submitted for payment of a 
subsidy under the Pharmaceutical Benefits and Repatriation Pharmaceutical 
Benefits Schemes. The second is an ongoing survey of a representative sample of 
computerised pharmacies, which provides an estimate of the non-subsidised use 
of prescription medicines in the Australian community. The usage of prescription 
medicines dispensed in public hospitals is not available in this report. 
The units of measurement are the prescription and the defined daily dose per 
1000 inhabitants per day (DDD/1000/day). The defined daily dose is established 
by the WHO Collaborating Centre for Drug Statistics Methodology on the basis of 
the assumed average dose per day of the drug, used for its main indication by 
adults. The drugs presented in this publication are arranged using the Anatomical 
Therapeutic Chemical classification system. For more detail on this classification 
and the unit of measurement, please read the chapter 'Information on the 
Australian Statistics on Medicines'. 
The data are presented in two major tables. Table 1 includes estimates of 1992 
community (ie, subsidised and non-subsidised) prescription numbers and cost 
(government and patient cost). Table 2 includes community prescription drug use, 
in DDDs/1000/day, for the years 1990 to 1992. 
1 
Figure 1.1: The introductory page of the "1992 Australian Statistics on Medicines" 
(ASM) compiled by the Commonwealth Department of Human Services and Health. 
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and indicates the major use of the medication by a brief description. An arbitrary 
cut-off point (DDD > 0.3) was selected to produce a more manageable number of 
drugs for consideration. Clearly, drug selection based on DDD alone would be 
inappropriate as many mineral supplements (calcium, iron), hormonal medications, 
anti-bacterial and anti-fungal agents, and topical or localised (non-systemic) 
medications appear with high DDD values but would have little significance to the 
Police or Coroner. In addition, it is immediately apparent that some of these 
medications (excluding some of the non-systemic medications) would not be suited 
to GC analysis. Absent from a list based on DDD alone would be:- 
1. Some DOA (eg amphetamine and analogues, THC and metabolite). 
2. Other drugs of significance in forensic applications such as drugs which are 
relatively toxic or lethal in overdose amounts (eg methadone, barbiturates, 
oxycodone, desipramine) and drugs with the potential for abuse (eg. pethidine, 
pseudoephedrine). 
3. Common social drugs apart from DOA (eg caffeine, nicotine and its metabolite). 
4. Some drug metabolites which may be present in an individual's blood for longer 
periods of time or at greater concentrations than the drug, or are 
pharmacologically active (eg. 7-amino flunitrazepam, THC-COOH, nordiazepam, 
nortriptyline). 
Consequently, selection criteria in addition to DDD were required. Table 1.2 lists 
drugs which meet at least one of the following criteria. 
1. Relatively prevalent in the population as indicated by DDD > 0.3. (106) 
2. DOA potential. 
3. Toxicologically significant - eg. drugs which commonly cause fatality, or with the 
(107 potential to cause toxicity or fata1ity. ,108)' 
4. Possessing pharmacological properties with the potential to affect driving 
performance or judgement - eg. centrally acting drugs (CNS), drugs affecting 
blood pressure or the cardiovascular system (CV), drugs affecting eyesight (0), 
drugs with undesirable side-effects which may impair vision, cause sedation or 
vertigo etc. (1°9-111)  
5. Markers of an underlying disorder (eg. diabetes, epilepsy, Parkinsonism, gout). 
The drugs listed in Table 1.2 provided the basis for drugs selected for further 
investigation. Initially, their chromatographic properties were explored (Chapters 3- 
5; Appendices A-B). Those drugs found to be successfully chromatographed at 
therapeutic blood levels (Chapter 6), were then investigated for their extraction 
potential via the extraction strategy which was developed (Chapter 7). Drugs which 
were found to both chromatograph and extract satisfactorily were included in the 
automated drug screening procedure which was then validated (Chapter 9) and 
applied to the 'drugs in drivers' pilot study (Chapter 10). 
Although the drugs listed in Table 1.2 provided the basis for drug selection, clearly 
the list would alter over time with changing licit and illicit drug use in the 
community. The drugs listed, however, are representative of a range of chemical 
structures and functionalities and enable the development of a general analytical 
screening procedure which could be applicable to additional drugs. 
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The screening procedure targets selected drugs. It consists of two separate extraction 
procedures (LLE and SPE). Drugs isolated from whole blood by the extraction 
procedure are analysed by GC/MS in SIM mode. For each blood specimen, four 
separate GC extracts (underivatized and derivatised extracts from LLE and SPE) are 
analysed. These analyses, in combination, identify target drugs and, in many cases, 
confirm their presence by an alternate method. 
Chromatograms are processed by a macro which automatically searches for target 
drugs and indicates 'hits' detected. The estimated blood concentration of the 
suspected 'hit' is automatically calculated on the basis of predetermined quantitative 
parameters. The results from each of four reports generated by the macro are collated 
onto a summary sheet (Section 8.3.3) and the drugs present in the blood sample are 
decided by the analyst. The analyst requires only a little experience to interpret the 
macro reports correctly. 
The procedure is suitable for the analysis of most common acidic, neutral and basic 
drugs including drugs of abuse in whole blood. Additional drugs can be added to the 
screening procedure as new target drugs arise. The procedure is sensitive enough to 
detect most drugs at sub-therapeutic and therapeutic levels although some drugs will 
be detected only at greater than therapeutic levels. 
2.2 Reagents 
2.2.1 Liquid-liquid Extraction (LLE) 
Saturated ammonium chloride 
Ethyl acetate (HPLC grade) 
Acetonitrile (HPLC grade) 
Hexane saturated with acetonitrile (HPLC grade) 
Chloroform GC injection solvent; (Section 2.2.5.7) 
HC marker solution; (Section 2.2.5.5) 
2.2.2 Solid-phase Extraction (SPE) 
Phosphate buffer (0.1 M); (Section 2.2.5.1) 
Bond Elut 'Certify' extraction column (130 mg of mixed mode sorbent) 
Acetic acid (0.01M); (Section 2.2.5.2) 
Deionised water 
Methanol (HPLC grade) 
Acetone:chloroform (1:1; HPLC grade) 
Freshly prepared 5% ammonia in dichloromethane:isopropanol (80:20; 
HPLC grade) 
Chloroform GC injection solvent; (Section 2.2.5.7) 




Trimethylammonium hydroxide (TMAH - 0.1 M) in methanol; (Section 
2.2.5.4) 
n-butyl iodide 
Chloroform GC injection solvent; (Section 2.2.5.7) 
2.2.4 Pentafluoropropionylation 
Dried acetonitrile; (Section 2.2.5.12) 
Pentafluoropropionic anhydride (PFPA) 
Dried ethyl acetate GC injection solvent; (Section 2.2.5.8) 
2.2.5 Reagent Preparation 
2.2.5.1 0.1 M Phosphate buffer 
KH2PO4 (6.805 g) was dissolved in 500 mL deionised water and adjusted to 
pH 6.0 ± 0.05 with a KOH solution (3-4 chips of KOH in 10 mL deionised water). 
The solution was stored at 4°C and discarded after 1 month. 
2.2.5.2 0.01M Acetic acid 
A 1.0 mL aliquot of glacial acetic acid (1.0 M) was diluted to 100 mL with deionised 
water. The solution was stored at room temperature and discarded after 12 months. 
2.2.5.3 1.0 M Acetic acid 
Glacial acetic acid (5.75 mL) was diluted to 100 mL with deionised water. The 
solution was stored at room temperature and discarded after 12 months. 
2.2.5.4 0.1M TMAH in methanol 
TMAH (18.12 g) was dissolved in 100 mL MEOH and stored indefinitely at room 
temperature. 
2.2.5.5 HC Marker solution 
A 10 mL aliquot of stock HC marker solution was diluted with 10 mL hexane and 
stored indefinitely at 4°C in a silanised glass culture tube. 
2.2.5.5 Stock HC Marker solution 
Consecutive, even-numbered n-alkanes (C10 to C36 - 5 mg) was dissolved in 100 mL 
of hexane and stored indefinitely at 4°C. 
2.2.5.7 Chloroform GC injection solvent 
A 50 mL aliquot of Injection Solvent HC solution (Section 2.2.5.9) was diluted with 
50 mL of chloroform. The solution was stored at room temperature and discarded 
after 12 months. 
2.2.5.8 Dried Ethyl acetate GC injection solvent: 
A 50 mL aliquot of Injection Solvent HC solution (Section 2.2.5.9) was diluted with 
50 mL of ethyl acetate and dried over molecular sieve (Section 2.2.5.11). The 
solution was stored at room temperature and discarded after 12 months. 
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2.2.5.9 Injection Solvent HC solution 
C10, C12 and C14 (5 mg) were dissolved in 100 mL of hexane. The solution was not 
stored but immediately and completely used in the preparation of chloroform and 
ethyl acetate injection solvents (Sections 2.2.5.7 and 2.2.5.8). 
2.2.5.10 Performance Test Mix 
Drug solutions (approximately 1 mg/mL) were added as indicated to 4 mL of Stock 
HC Maker solution (Section 2.2.5.5) and diluted to 10 mL with hexane. 
Fenfluramine (0.1 mL), cotinine (0.2 mL), phenobarbitone (0.15 mL), methadone 
(0.1 mL), moclobemide (0.1 mL), promethazine (0.1 mL), codeine (0.15 mL), 
nordiazepam (0.15 mL), disopyramide (0.15 mL), temazepam (0.5 mL), 
metoclopramide (0.2 mL), felodipine (0.1 mL), quinine (0.4 mL), prednisolone 
(0.4 mL), diltiazem (0.1 mL), prochlorperazine (0.2 mL), thioridazine (0.15 mL), 
verapamil (0.1 mL). The solution was stored indefinitely in a silanised glass tube at 
-18°C. 
2.2.5.11 Silanising Reagent 
Dimethyldichlorosilane (Aldrich) was prepared as a 5% solution in toluene. The 
reagent was stored in glass, and used repeatedly. The reagent was discarded if any 
yellow discolouration occurred. 
2.2.5.12 Dried Solvents 
Solvents were dried over molecular sieve (BDH No. 4A, 1/16"; approximately 
15g/200 mL solvent) which had been first washed with the appropriate solvent and 
oven dried (60 mm at 100°C). 
2.2.5.13 Reference Drug Solutions 
Drugs were of pharmaceutical grade or better and supplied in either free drug or salt 
forms. Stock solutions (approximately 1 mg/mL) of free drug were prepared in 
either chloroform, methanol, dimethylformamide (DMF) or chloroform:DMF (2:1) 
depending on the solubility of individual drugs. 
Stock solutions of drug salts were prepared as follows. 
Approximately 10 mg equivalent of free drug was dissolved (5 mL) in either 
aqueous acid (adjusted with 0.5 N HC1; pH <3) or aqueous alkali (adjusted with a 
diluted ammonia solution; pH > 9); free drug was extracted into 2 x 4 mL aliquots 
of chloroform; the solution was made up to a 10 mL volume which became the 
stock solution; the aqueous phase was analysed by UV (scanning from 360 to 
200 nm) for remaining drug and re-extracted if drug was detected; the 
concentration of free drug in stock solutions was approximately 1 mg/mL. 
2.2.5.14 Working Drug Solutions 
Groups of up to ten drugs obtained from their reference drug solutions were 
combined in a single solution to produce working drug solutions in chloroform at 
concentrations of approximately 20, 60, 100, 200, 300, 400, and 800 pg/uL, and 2, 
4, 20 and 50 ng/pt. 
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2.3 Apparatus 
2.3.1 Drug Extraction 
silanised 15 mL glass culture tubes + teflon lined screw-caps (Kimble); 
(Section 2.3.3) 
disposable plastic pipettes (Samco) 
rotary mixer; radius of 20 cm; 40 rpm is equivalent to 0.35 g 
12 port vacuum manifold (Alltech) 
sonic bath 
centrifuge; radius of 20 cm; 2000 rpm is equivalent to 895 g 
heating block and nitrogen manifold 
501AL transfer pipette and disposable tips 
2.3.2 Drug Derivatisation and GC/MS Injection 
2 mL screw-capped reaction vials with teflon liners (Alltech) 
2 mL autosampler vials (Alltech) 
2001AL autosampler vial inserts (Alltech) 
2.3.3 Preparation of Silanised Glassware 
Glassware (culture tubes and caps) were washed with general detergent, rinsed with 
deionised water and oven dried. Approximately 3 mL silanising reagent (Section 
2.2.5.11) was added to each tube, which was then capped and placed on a rotary 
mixer for 3-4 h. The silanising reagent was retained for future use. The silanised 
tubes and caps were rinsed with two washes of methanol and oven dried. 
2.4 GC/MS Analyses 
2.4.1 Instrumentation 
Low resolution electron impact mass spectrometric analyses used a Hewlett Packard 
(HP) 5890 gas chromatograph (GC), with split/splitless injector, coupled with a 
HP5970 mass selective detector (MSD) with open split interface from column to 
MSD, and operated in either full scan or selected ion mode by PC based operating 
software. Sample injection was automated with a HP 7673A autosampler. 
2.4.2 Gas Chromatography 
All analyses unless otherwise specified used a 25 m cross linked methyl silicone 
(HP-1) high performance capillary column with 0.32 mm i.d. and 0.17 p.m film 
thickness. A 50 cm length of precolumn identical to the separating column, was 
attached to the separating column by a column connector (capillary mini-union; 0.5 
mm i.d; GLTTm, SGE Analytical Products). The injector port contained a borosilicate 
glass liner (0.4 mm i.d., 990 pL) packed with a silanised glass wool plug unless 
otherwise specified. Prior to use, the liner was washed with detergent and rinsed, 
baked in a muffle furnace at 520°C for several hours and then silanised with 
silanising reagent (Section 2.2.5.11). The liner was then rinsed with toluene, dried in 
a GC oven and the silanised glass wool plug inserted and positioned at approximately 
the centre of the liner's length. The carrier gas was helium (BOC Gases, ultrahigh 
purity; 10.9 psi) and 1 pL splitless injections were made with the split closed for 
26 
1 min. Unless otherwise specified, all GC/MS methods (drugspe.m, druglle.m, 
butyl.m, pfpa.m and perform.m) used temperature parameters as follows:- 
	
injector port 	250°C (except pfpa.m =260°C) 
transfer line 290°C 
oven -initial 	40°C 	hold time = 2 min 
-final 300°C 	hold time = 6 min 
temp. rate 	10°C/min 
2.4.3 SIM Acquisition 
2.4.3.1 Drug/Drug Derivative Identification and Quantitation 
Two m/z ions were selected for their abundance and uniqueness from the full-scan 
mass spectra obtained for an underivatized or derivatised drug. The more 
characteristic of the two m/z ions selected became the target m/z ion and the other, 
the qualifier m/z ion. The ratio of the abundance of qualifier to target m/z ion was 
calculated (Qualifierpeak areafrargetpeak area). 
During quantitative drug and drug derivative experiments, acquisition parameters 
were set to monitor the target m/z ions of drugs included in the current working drug 
solution (Section 2.2.5.14). The time windows set to monitor the m/z ions were 
determined by the retention times of the drug or drug derivative and no more than 
two drugs were monitored in a time window. Ion dwell times were either 60 or 
80 ms. 
2.4.3.2 GC Methods for Comprehensive Drug Screening 
Four methods were created which both acquired and processed data from each of the 
four blood extracts prepared. Druglle.m and drugspe.m acquire and process data for 
underivatized extracts from the LLE and SPE techniques respectively. Butyl.m and 
pfpa.m acquire and process data from the butylated and pentafluoropropionylated 
extracts respectively. Groups of target m/z ion pairs were monitored over specified 
time periods for groups of closely eluting drugs. Each time period was bracketed by 
the actual or predicted elution time of consecutive HC markers. In this way new 
drugs could be easily incorporated in any method once its RI in relation to a HC 
marker was determined (Appendix A). Similarly, the methods could be easily 
transported between instruments and laboratories once the retention times of the HC 
markers were determined on each instrument. Tables 2.1 - 2.4 list the pairs of 
consecutive n-alkanes which bracket a time window, the drug target m/z ions and 
dwell times for each GC acquisition method. The HC marker target m/z ion 71.05 
was monitored continuously throughout the run time. Dwell time was set to ensure 
at least 3.0 cycles/s unless the number of m/z ions monitored at any one time 
exceeded 15. In that instance, the number of cycles/s did not fall below 2.44 for any 
group. 
Chromatographic performance was monitored prior to and during every sequence to 
ensure optimum performance. Perform.m (Table 2.5) was a GC acquisition method 
only and monitored m/z ions for drugs included in the 'performance test mix' of 
drugs (Section 2.2.5.10). There was no data processing element to this method. 
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2.5 Comprehensive Drug Screening General Procedure 
Despite the chemical diversity of the target drugs a comprehensive drug screen is 
possible due a combination of extraction procedures and chromatographic 
manipulation through drug derivatisation. A schematic of the screening procedure is 
shown in Figure 2.1, and the individual procedures detailed in Figures 2.2 to 2.5. 
The resultant extracts prepared in Figure 2.2 step 7 ('L'), Figure 2.3 step 14 ('S'), 
Figure 2.4 step 3 (13') and Figure 2.5 step 4 ('P') were ready for GC injection. 
Although the LLE and SPE procedures could be performed separately for other 
applications, the developed screening procedure required that they be performed in 
conjunction. To complete all extraction steps took up to 5 h. Derivatisation steps 
required a further 21/4 h. The first underivatized blood extracts were ready for GC 
analysis approximately 5 t/2 h after the procedure was begun. The rate-limiting step 
was the SPE. Consequently, this screening procedure was performed progressively 
through to completion without interruption to ensure the first samples were injected 
by the end of the day. No more than six blood sample (24 GC extracts) were run in a 
batch as some pentafluoropropionyl drug derivatives were known to deteriorate with 
time and their stability had only been validated over a 24 h period (Section 5.3.2.4i). 
2.6 Analysis of Drugs 
2.6.1 Chromatographic Data 
Chromatographic data was obtained with regard to peak shape, injector carry-over, 
non-linearity and column overload. Any evidence of decomposition products, of 
column-priming, or of poor sensitivity and lack of reproducibility were noted for 
each drug and drug derivative. 
Each working drug solution or derivatised working drug solution was diluted 1:1 
with the HC marker solution (Section 2.2.5.5) for all GC analyses. These solutions 
were chromatographed in duplicate and the average of the 'peak area ratios' obtained. 
The peak area ratio was obtained from the peak areas of the drug or drug derivative 
and nearest HC marker (peak area ratio = Drug peak area/HCpeak area). This ratio 
eliminated factors which effect absolute peak area from run to run such as variation 
in injected volume and injector temperature discrimination. 
Linear regression equations were determined with four to eleven different working 
drug solution concentrations. Linear regression equations determined on the narrow 
bore column were calculated with three to six different concentrations. Linear 
regression equations determined on the wider bore column were calculated with four 
to eleven different concentrations. Each different drug concentration and a blank 
were prepared at the same time and seated in the sample rack of the autosampler 
awaiting analysis. The different drug amounts were prepared as described in Section 
2.2.5.14 except where detection of the drug at the higher amounts was poor. In those 
cases, the drug amounts prepared were 2 to 3 fold greater than described in Section 
2.2.5.14. The approximate 20 ng amount was always the first sample injected. The 
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Figure 2.2: Liquid-liquid extraction procedure. 
1. 1.0 mL whole blood into silanised glass tube. 
2. sample pH + 0.5 mL saturated ammonium chloride. 
adjustment Vortexed briefly. 
3. + 5.0 mL ethyl acetate. sample 
extraction Extracted on rotary mixer; 40 rpm for 15 min. 
Centrifuged; 2000 rpm; 5 min. 
Retained supernatant in a second silanised glass tube. 
Sonicated 'plug' for 5 min and re-extracted with a 2nd 
aliquot of ethyl acetate. 
Centrifuged; 2000 rpm; 5 min. 
Combined 2nd supernatant with 1st and reduced volume 
of combined supernatant to approximately 0.5 mL under 
nitrogen. 
4. hexane Transfered remaining supernatant to 2 mL glass reaction 
clean-up vial labelled `L' and evaporated to dryness. 
+ 501.iL dried acetonitrile to dried residue. 
+ 0.5 mL hexane saturated with acetonitrile. 
Capped and agitated vigorously for 20 s. 
Centrifuged briefly; 2000 rpm. 
Discarded hexane layer above acetonitrile droplet being 
careful to discard none of the acetonitrile. 
Repeated hexane clean-up. 
5. + 1001AL of hydrocarbon marker solution; 25 vg/mL. 
+ approximately 0.5 mL of chloroform (to increase 
total volume). 
6. division into To a second reaction vial labelled 'B', transfered 
2 identical approximately half the contents of the original vial 
extracts such that each contained an approximately equal 
volume by eye. 
7. Removed organic phase under nitrogen from `L' 
extract. 
+ 50 [iL chloroform GC injection solvent ---> GC/MS 
analysis (refer Section 2.6.2). 

















Figure 2.3: Solid-phase extraction procedure. 
1. 1.5 mL whole blood in silanised glass tube. 
Sonicated; 15 min. 
2. pretreatment 
of blood 
+ 6 mL of 0.1 M phosphate buffer. 
Mixed briefly by inversion. 
Centrifuged; 2000 rpm for 15 min. 
  
NB. Vacuum was not applied in the following procedure unless specified. 
Passed 2.5 mL methanol through cartridge. 
Passed 2.5 mL 0.1 M phosphate buffer through 
cartridge being careful that the reservoir did not run 
completely dry. 
Passed pretreated blood through conditioned cartridge. 
Pulled last remnants of blood from cartridge under 
a light vacuum. 
Passed 1.0 mL deionised water through cartridge. 
Removed last remnants of water under weak vacuum. 
Passed 0.5 mL 0.01 M acetic acid through cartridge. 
(alters pH conditions for elution of acidic/neutral 
drugs). 
Removed residual water from the sorbent under strong 
vacuum; 4 min. 
+ 50 [11_, dried methanol. 
Removed residual methanol/water from the sorbent under 
strong vacuum; 1 min. 
8. 	 Dried needle from each port on the Alltech manifold 
with tissue and inserted silanised tubes to retain all 
subsequent eluants. 
9. elution of 
A/N drugs 
+ 4 mL acetone:chloroform (1:1) applied in two 
2 mL aliquots. 
10. pH adjusted 
& elution of 
B/N drugs 
+ 4 mL freshly prepared 5% ammonia in dichloro-
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Figure 2.3: continued. 
11. To the combined eluants, 150 uL of HC Marker solution 
was added. 
Reduced the volume of the combined eluant to 	2 mL. 
12. division into Transfered to three reaction vials labelled 'S', 'P' and 
3 identical `13', approximately one third of the remaining eluant 
extracts such that each contains an approximately equal 
volume by eye. 
13. Combined contents of 'Er vial with that of 'EV retained 
in Figure 2.2; step 8 (refer Figure 2.1). 
14. Removed organic phase completely from 'S' extract 
under nitrogen. 
+ 50 p.1_, chloroform GC injection solvent —> GC/MS 
analysis (refer Section 2.6.2). 
15. Under nitrogen removed contents of vials 'B' and 'P' 
Proceed to Figures 2.4 and 2.5 for derivatization of '13' and 'P' extracts, respectively. 
Figure 2.4: Butylation procedure. 
Dried residue contained in reaction vial '13' (refer 
Figure 2.3 steps 13 and 15). 
1. reaction + 20 !IL dimethylformamide. 
medium + 70 !IL TMAH. 
Vortexed briefly. 
+ 100111_, iodobutane. 
Vortexed briefly. 
2. reaction Reacted for 2 h at room temperature vortexing 
conditions periodically 
Reacted at 50°C; 15 min. 
3. Removed reaction mixture under nitrogen. 
+ 50111., chloroform GC injection solvent ----> GC/MS 
analysis (refer Section 2.6.2). 
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Figure 2.5: Pentafluoropropionylation procedure. 
Dried residue contained in reaction vial 'P' (refer 
Figure 2.3 steps 12 and 15). 
1. azeotrope + 50 pL dried acetonitrile. 
formation Vortexed briefly. 
Evaporated to near dryness under nitrogen. 
+ 50 pL dried acetonitrile. 
Vortexed and evaporated to near dryness under 
nitrogen. 
2. reaction + 50 pL dried acetonitrile. 
medium + 50 !AL pentafluoropropionic anhydride (PFPA). 
3. Reacted at 80 °C; 60 min. reaction 
conditions 
4. Removed reaction mixture completely under 
nitrogen. 
+ 50 pL ethyl acetate GC injection solvent -4 
GC/MS analysis (refer Section 2.6.2). 
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by the smallest amount (blank) to the largest remaining amounts (approximately 
4 ng). In this way, potential carry-over from higher drug amounts to lower amounts 
was avoided except in one instance which was deliberately used to identify carry-
over potential associated with each drug. 
The retention indices of drug and drug derivatives were calculated from 
approximately 20 ng/tit working drug solutions and hydrocarbon interpolation was 
based on HC markers chromatographed concurrently (Appendix A.3.2). 
Derivatisation reproducibility experiments used drug concentrations of 
approximately 4 ug/mL. Replicates were prepared on the same day to determine the 
'within-day' variations and the 'day-to-day' variations were determined on the 
following day using the same drug solution which had been stored in the dark at 
less than -18 °C. Derivatisation stability test used drug concentrations of 
approximately 20 ng/uL. The GC peak areas of test derivatives were compared with 
those obtained from a control which was derivatised and immediately analysed 
(time = 0 h). Following analysis, the control sample remained seated in the rack of 
the autosampler at room temperature for subsequent analyses after 11 h, and after 
16-21 h. 
2.6.2 Comprehensive Drug Screening 
Four GC methods were created for the acquisition and data processing of each of the 
extracts as follows:- 	extracts were run under druglle.m; `S' extract were run 
under drugspe.m; 13' extracts were run under butyl.m; 'P' extracts were run under 
pfpa.m. 
A permanent screening sequence (macro.$) was created requiring the operator to 
enter only the identifying number for each blood specimen. All 'S' extracts were 
chromatographed followed by all all 'B' and all 13 ' extracts. 
Prior to each sequence run, the injector liner was replaced by a new silanised injector 
liner and glass wool (Section 2.4) and a performance check of the chromatographic 
system carried out using the 'performance test mix' (Section 2.2.5.10). 
Figure 2.6 shows a typical acceptable chromatogram of the 'performance test mix'. 
Drug chromatographic performance was monitored over the entire temperature range 
of the GC program incorporating early and late eluting drugs. Unacceptable 
chromatographic performance was indicated by the following. 
I. Peaks such as cotinine and phenobarbitone began to tail badly and had a reduced 
peak height. 
2. Temazepam peak height may have been absent or reduced relative to HC peaks. 
3. Nordiazepam did not resolve well from disopyramide. 
4. Following an initial priming injection, fenfluramine peak height did not remain 
constant and greater than its nearest HC marker. 
5. High boilers (verapamil, thioridazine, diltiazem, prochlorperazine) became 
broader and had reduced peak heights. 
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Figure 2.6: SIM generated chromatograms of the performance test mix of drugs and n-alkanes (Section 2.2.5.10); fenfluramine (a), cotinine (b), 
phenobarbitone (c), methadone (d), moclobemide (e), promethazine (0, codeine (g), desmethyldiazepam (h), disopyramide (i), temazepam (j), 
metoclopramide (k), felodipine (1), quinine (m), prednisolone (n), prochlorperazine (o), diltiazem (p), thioridazine (q) and verapamil (r). The n-alkanes 
are not labelled. 
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Chromatographic performance was always unacceptable following analysis of the 
PFP drug derivatives. In general, chromatography could be improved to an 
acceptable level with the replacement of the injector liner and glass wool. At some 
stage, however, chromatography could be improved only with the replacement of the 
pre-column. Underivatised drugs were not analysed following analysis of PFP drug 
derivatives unless the injector liner and glass wool had been replaced. 
2.7. Automated Drug Search and Report 
A macro was incorporated in each GC method to automate data analysis of multi-
peak chromatograms. Each macro referred to information for each target drug listed 
in the drugs.txt file for that macro (Section 8.3.1). For each drug, the drugs.txt file 
listed the drug name, retention index, target m/z ion pair, the alternate extract in 
which the drug should be identified for confirmation of a macro 'hit', the HC marker 
used for quantitation (1 of 14), the C and M constants for each linear regression 
equation, and expected drug recovery. Tables 2.6 to 2.9 reproduce the drugs.txt files 
from druglle.m, drugspe.m, butyl.m and pfpa.m respectively, and list the specific 
parameters for each drug. Chapter 8 provides greater detail of macro operation. 
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Chapter 3. 
CHROMATOGRAPHY OF DRUGS 
3.1 Introduction 
The development of an automated broad drug screening procedure in whole blood by 
benchtop GC/MS required investigation of two areas. One was the isolation and 
recovery of drugs from the blood matrix (Chapter 7) and the other was drug 
identification through GC/MS analysis. Drug recovery (extraction techniques, 
individual drug recovery and reproducibility of extraction) could not be explored 
without the certainty that each drug investigated could be reproducibly 
chromatographed and detected at concentrations equivalent to expected therapeutic 
blood levels. 
The following chapters (Chapter 3-5) examine the chromatographic properties of 
drugs and drug derivatives on a single chromatographic system. The primary aim of 
these experiments was to generate data which would define the limitations of the 
instrument as an analytical tool for a large group of structurally-unrelated drugs 
which possess a variety of different functional groups. By establishing the 
chromatographic properties of different drugs and drug derivatives, it would then be 
possible to select target drugs (Table 1.2) for experiments which investigate a 
comprehensive drug extraction strategy, and eliminate those drugs for which the 
instrument and/or conditions of analysis were inappropriate (Chapter 6). 
In addition to the primary aim, by obtaining chromatographic information for a wide 
range of drugs and drug derivatives across different drug groups, a database can be 
established which records the observed behaviour of these analytes on a non-polar 
chromatographic system (eg. RI, peak shape, linearity over a defined concentration 
range, limit of instrument detection). These data would allow both individual drugs 
and drug groups to be compared and comparisons could be made between:- 
1. the observed chromatographic behaviour of both underivatised and derivatised 
drugs; 
2. the suitability of different drugs and drug groups to participate in two different 
derivatisation reactions (Chapter 4; alkylation and Chapter 5; acylation); 
3. the effectiveness of the selected derivatisation techniques to produce derivatives 
from a variety of drugs which have improved chromatographic properties from 
those of the underivatised drugs; and 
4. the reproducibility of formation of different derivatives and their stability with 
both time and chromatographic temperatures. 
The greater the peak area of an analyte reaching the detector at a given concentration, 
the greater the instrument sensitivity to that analyte. The peak area or 
chromatographic response for any drug would be greatest when all the injected drug 
passes unchanged through the separating column to the detector in a narrow focussed 
band. During the study of drug chromatography, differences in drug retention index 
(RI) and chromatographic response were investigated (Appendices A and B) 
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following the manipulation of some chromatographic parameters (eg. column-related 
variables such as internal diameter, phase ratio, gas flow and connectors joining 
precolumn and separating column; injector-related variables such as injector 
temperature, and on-column and splitless injection). It is shown in Appendix B that 
changes in some chromatographic variables significantly altered the chromatographic 
response of drug analytes while the response of n-alkanes was largely unaffected. 
Consequently, the chromatographic conditions which produced the maximum 
response for the majority of drugs were investigated (Chapters 3-5). 
Underivatised drug chromatography was studied following splitless injection using 
both a narrow bore (0.22 mm i.d) and wider bore (0.32 mm i.d) column. Both 
qualitative and quantitative aspects of individual drug chromatography were 
explored. It was hoped that in maximising the chromatographic response of these 
drugs, detection at concentrations equivalent to therapeutic blood levels and below 
would be achieved. 
3.2 Methods 
Refer to "General Procedure" (Chapter 2). In particular, for HC marker solution refer 
to Sections 2.2.5.5 and 2.2.5.6; for reference drug solutions refer to Section 2.2.5.14; 
for instrumentation refer to Section 2.4.1; and for SIM acquisition parameters refer to 
Section 2.4.3.1. Refer to Sections 2.4.2 and 3.2.1 for gas chromatographic _ 
parameters with the wider bore and narrow bore columns respectively. Qualitative 
and quantitative chromatographic data for drugs were obtained using the method 
described in Section 2.6.1 unless otherwise specified. 
3.3 Results 
3.3.1 Drug Chromatography on the Narrow Bore Column 
The chromatographic separation of a mixture of drugs on the capillary column occurs 
as a result of the distribution of the drug molecules between the gas and stationary 
phases.' ) Movement of the drugs through the column occurs as a result of repeated 
sorption/desorption along the stationary phase.' ) Separation of the drug mixture 
occurs because different drugs spend different amounts of time in the stationary 
phase and, consequently, exit the column at different times. (I) The chromatographic 
characteristics of drugs are independent of their pharmacological action and are 
governed by a number of factors including their relative 'polarities'. In the 
chromatographic literature, it is apparent that 'polarity' is a term which could loosely 
describe the potential of an analyte to participate in additional column-related 
interactions during its elution and which affect its partitioning between the gas and 
liquid phases. Consequently, it might be expected that the 'chromatographic 
polarity' of a drug is influenced by the entire chemical structure of the drug (atomic 
composition and the arrangement of the individual atoms in relation to others) but 
more specifically by the presence of potentially reactive functional groups within that 
structure. 
Table 3.1 shows chromatographic data for drug standards chromatographed on the 
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narrow bore column following splitless injection at an injector temperature of 245°C. 
Where possible, drugs in Table 3.1 are categorised under headings which reflect a 
common chemical structure ('structurally-related drugs' - eg. `xanthine', 
`phenothiazine'). These drugs are structural analogues and differ only marginally 
from others within a group, for example by the presence, absence or rearrangements 
of side-chains. Some drug groupings do describe a pharmacological action (eg. 
tricyclic anti-depressants; anti-diabetic and 13-blocking agents). In these cases, the 
pharmacological action remains unimportant to drug chromatography and 'polarity', 
but it reflects a common chemical structure which unite these drugs as structural 
analogues (eg. Figure 5.3; I3-blocking agents ). The chemical names of these groups 
are not as easily related to drug structure as others used in Table 3.1, and for 
convenience, the pharmacological action identifies these drugs. It was not valid to 
suspect, however, that all drugs with a common pharmacological action also 
possessed a common chemical structure. For example, the phenylethylamine 
derivatives are all CNS stimulants, as is cocaine. Cocaine, however, is chemically 
dissimilar to the phenylethylamine derivatives and, therefore, its chromatographic 
properties are likely to be very different. Figure 3.1 illustrates the chemical 
structures of representative drugs described by each of group headings used in Table 
3.1 for structurally-related drugs. Figure 5.3 shows 13-blocking agents. 
As the chemical structures of drugs are diverse, it was not possible to categorise 
many of the drugs selected for investigation under a 'structurally-related drug' group. 
Consequently, drugs which were otherwise structurally-unrelated were grouped with 
others which possessed a common reactive functional group ('structurally-unrelated 
drugs' - eg. a carboxylic acid or 1° amine group). Where a drug possessed two or 
more different functional groups, it was grouped with other polyfunctional drugs. 
Some structurally-unrelated drugs had no reactive functional groups and, 
consequently, both their reactivity and expected 'chromatographic polarity' were 
reduced compared with 1° amines or phenols for example. These apparently `non-
polar' drugs were grouped together. Some drugs within this large group of non-polar 
drugs were further united by common nitrogen-containing heterocyclic structures. 
Although their full chemical structures were not similar enough to be classed as 
structural analogues, the nitrogen-containing cyclic compounds shown in Figure 3.2, 
and their derivatives, formed part of the chemical structures of these drugs and, 
consequently, they were categorised as 'nitrogen heterocyclic drugs'. It should be 
noted that some of the structurally-related drug groups also describe apparently `non-
polar' drugs (eg. phenothiazine derivatives and anti-histamines have no reactive 
functional groups). The drug categories used in Table 3.1 are the same as those used 
in all tables from Chapters 3-5. 
Mixed drug solutions were analysed by low resolution El full-scan mass 
spectrometry. Where a peak was chromatographed, it was identified from its full-
scan mass spectra and target m/z ions were selected for each drug. Drug RI and ion 
abundance ratios were determined (Section 3.2). 
Data in Table 3.1 clearly show that not all drugs investigated could be 
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Figure 3.1: The chemical structures of representative drugs described by the group 










Figure 3.2: Nitrogen-containing heterocyclic compounds (Section 
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of drugs with carboxylic acid functions and polyfunctional drugs did not 
chromatograph under the selected conditions. The anti-diabetic agents and H2- 
receptor antagonists were either not chromatographed or chromatographed only as 
GC artefacts of the drug (Section 5.3.2.2). Hyoscine and hyoscyamine were 
chromatographed as GC artefacts at both the set injector temperature and a lower 
injector temperature of 235°C. In contrast, carbamazepine was detected at the lower 
injector temperature while the artefact was chromatographed at an injector 
temperature of 245°C. 
A GC peak which corresponded to the drug or a GC artefact of the drug was detected 
for the majority of drugs from all other groupings. 
Table 3.2 shows quantitative and qualitative chromatographic data for those drug 
standards able to be chromatographed on the narrow bore column following splitless 
injection. As described in Section 2.6.1, each data point employed in determining 
linear regression equations was a peak area ratio (the peak area obtained for the 
target m/z ion for that drug divided by the peak area of m/z 71.05 for the closest 
eluting n-alkane in a GC run). Table 3.2 lists both the target m/z ion monitored and 
the reference HC marker for individual drugs from which the peak area ratios were 
calculated. 
Some drugs were found to decompose at an injector temperature of 245°C (Table 5.6 
and Appendix B;Table B.3). As maximum chromatographic response was to be 
investigated, these temperature-sensitive drugs were chromatographed at a lower 
injector temperature of 235°C as indicated in Table 3.2. 
Table 3.2 shows linearity data over a defined concentration range for those drug 
standards which were able to be chromatographed. The concentration range is 
defined by the 'highest' and 'lowest' drug amounts. The 'lowest' amount injected 
refers to the smallest amount of drug injected which produced a peak that could be 
integrated. One hundred- to 1000-fold differences in amounts injected were 
chromatographed for the majority of drugs. 
Table 3.2 shows information for most drugs with regard to shape of the peak 
chromatographed (A), carry over from the injector to a following blank sample 
(B), thermal decomposition of that peak (C) and, where known, the amount 
injected which caused column overload [xi. The linear regression equation shown 
for each drug described the line of best fit for the log io of the raw data points as 
follows:- 	 logy = C + M.log x 
where 	y = peak area ratio 
x = amount of drug injected 
C and M are constants in the equation 
describing transformed data. 
Consequently, the linear regression equation for the log transformed data becomes 
Y = C + MX 
where 	Y = logy 
X = log x. 
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The equation for each drug was fitted to log transformed data points (from 3 to 6) 
over a concentration range between, and including, the 'lowest' and 'highest' 
amounts injected as listed in Table 3.2. The log transformed rather than raw data 
was employed for two reasons. 
1. It removed the bias towards large y values (nanogram versus picogram drug 
amounts) and fitted the line of best fit to equally weighted data points over the 
entire injected range. 
2. It allowed data for all drugs to be described by a simple linear equation in 
contrast to untransformed data which would be best described by linear 
equations for some drugs and more complicated non-linear equations for 
others. 
When r2 = 1.00, both the log-transformed and untransformed data would be best 
described by the given equation (Table 3.2) and anti-log of that equation 
respectively, over the entire concentration range. 
The relationship between log-transformed and raw data can be determined as 
follows:- 	 Y = C + MX 
taking the antilog of the equation 10" = 10c + mx 
then 	 10Y = 10c.10mx 
replacing Y and X with 
log y and log x 	 y= 10c.xm 
Consequently, a power equation best describes the untransformed data, and this 
equation is linear when M = 1.0. When M is greater than or less than 1.0, the 
equation describes a curve rather than a straight line. Clearly, the greater the value 
of either C or M, the greater the chromatographic response (y) to an increase in 
amount of drug injected (x). 
If the amount injected (x) was doubled from 1 to 2 then, when M = 2, the increase 
in response (y) would be four times greater than if M = 1. 
where M = 2 then 	y = 10c .x2 
where x = 1 then y= 
where x = 2 then 	y = 10C .(4) 
When M is the same, or very similar, for two drugs, the C value describes the 
magnitude of the change in detector response with a change in the drug amount 
injected and, the more positive the C value for a particular drug, the greater the 
detector response/sensitivity to the change. Consequently, C is useful for 
comparison of drugs only when M is the same, but M allows comparison of all 
drugs. 
Table 3.2 gives the factor (10m) by which chromatographic response would 
increase following an increase in the amount injected from 1 to 10 (pg or ng) for 
each drug standard. Consequently, for drug standards with regression equations 
which were approximately linear, this factor would be approximately 10. 
where M = 1 then 	 y = 10c .x 
for 1 pg or ng drug injected 	y = 10c .(1) 
for 10 pg or ng drug injected 	y= 10c.(10) 
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For drug standards with power regression equations (M # 1), the 10 m factor would 
be greater than or less than 10. The 10m factor is listed in Table 3.2 as it is 
simpler to appreciate the departure from linearity demonstrated by a ten-fold 
increase in the amount injected than by a difference between absolute M values. 
For example where M = 1.3, the 10 m value = 19.9 
where M = 1.5, the 10m value = 31.2 
Therefore, the 10m factor is a good indicator or drug linearity over the 
concentration range tested. 
Data in Table 3.2 indicate that the chromatographic properties of drug standards 
within a group were not consistent even among drugs with very similar chemical 
structures. For example, the individual drugs within the benzodiazepine, 
phenylethylamine or phenothiazine groups differed in their chromatographic 
properties despite their structural similarity. Individual drugs from these groups 
exhibited the following range of properties when compared with other drugs from the 
same group. 
1. Peak shapes ranged from Gaussian to excessively tailing. 
2. Either linear or power regression equations described the untransformed data. 
3. Drugs were detected at injected amounts which ranged from picogram to 
nanogram quantities. 
4. For some drugs, there was no evidence of carry-over of the sample to the 
following blank injection while others showed carry-over in both consecutively 
run blank injections. 
Thermal decomposition products were detected for some phenylethylamine 
derivatives and not others despite a low injector temperature of 235°C. Similarly, the 
reproducibility of duplicate peak areas was so poor for methdilazine (phenothiazine 
group) that no quantitative data was obtained while those of trimeprazine were very 
reproducible and this drug was detected at low picogram amounts. 
Structurally-related xanthine derivatives, theophylline and caffeine (methyl-
theophylline) possessed very different chromatographic properties. Theophylline 
decomposed on injection and chromatographed with a tailing peak shape. Caffeine, 
however, was detected at picogram levels, showed no evidence of thermal 
decomposition and was linear over the concentration range tested. Similar 
differences in the chromatographic properties of other drugs and their desmethyl 
metabolites were also observed (eg. amitriptyline and nortriptyline; imipramine and 
desipramine; methylphenobarbitone and phenobarbitone; diazepam and 
desmethyldiazepam). 
Data in Table 3.2 indicate that the structurally-related tricyclic anti-depressant agents 
chromatographed with Gaussian to slightly tailing peak shapes. These drugs were 
detected at picogram levels except nortriptyline, protriptyline and desipramine and its 
artefact which were detected at nanogram levels. The the data points of the anti-
depressant drugs were fit by linear regression equations which were all relatively 
linear (10m <26) except for amitriptyline and those detected at nanogram levels. 
The barbiturates were chromatographed with Gaussian peak shapes and were 
approximately linear over the concentration range tested except phenobarbitone and 
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primidone. Decomposition of the primidone peak was evident and the raw data 
points of phenobarbitone were fitted by a power equation (10 m approximately 2). 
The peak shapes of the morphine derivatives were generally poor except for that of 
dextromethorphan which was also detected at the lowest injected amount (< 70 pg). 
From data in Table 3.1 it was observed that one of the 13-blocking agents (metoprolol) 
was not able to be chromatographed. Data in Table 3.2 indicate that although the 
remaining two 13-blocking agents were chromatographed, decomposition products 
were detected. 
Structurally similar anti-histamines all chromatographed with Gaussian peak shapes 
but varied in other chromatographic properties. For example, doxylamine and 
pheniramine were detected at injected amounts ten times greater than the other drugs. 
Similarly, linearity over the concentration range tested was poor for pheniramine 
(10m = 107) while that of the other drugs was relatively better (10 m = 12 - 25). 
There was little consistency in the chromatographic properties of individual drugs 
within groups which described drugs with common functional groups but which were 
otherwise structurally unrelated. The only trend apparent was in the 10 amine and 
carboxylic acid groups in which all drugs investigated were poorly chromatographed. 
All other drugs showed the same range of different chromatographic properties (peak 
shape, lowest amount detected, linearity over the concentration range tested, carry-
over and thermal stability) as reported for the structurally-related drugs. 
3.3.2 Drug Chromatography on the Wider Bore Column 
Drug standards were chromatographed on the wider bore column following splitless 
injection at an injector temperature of 250°C. All drugs were investigated at this 
injector temperature despite their thermal instability. Consequently, no GC peak was 
detected for carbimazole (Appendix B; Table B.3) or phenylpropanolamine. The 
ranges (indicated by the upper values) within which the detection limits of 
amphetamine and methylamphetamine fell increased, from 0.2 ng and 0.24 ng 
respectively, on the narrow bore column to 18 ng and 2.0 ng respectively, on the 
wider bore column. Similarly, carbamazepine was largely chromatographed as a GC 
artefact following injection at 250°C and the range within which its detection limit 
fell increased from 0.30 - 0.76 ng on the narrow bore column to 5.7 - 28.6 ng on the 
wider bore column. 
During the investigation of the effect of altered chromatographic variables on drug 
chromatography (Appendices A and B), the following was indicated. 
1. The detection limit for 93% of the drugs chromatographed on the wider bore 
column was less than or similar to that determined on the narrow bore column 
with half the drugs in each categrory. For some drugs the detection limit on the 
wider bore column was one tenth of that determined on the narrow bore column 
(Appendix B.3.2.1ii and Table B.12). 
2. The calculated RI of a given drug was lower on the wider bore than the narrow 
bore column and the difference became greater as carbon number increased 
(Appendix A.3 and Table A.2). 
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3. The differences in film thickness and diameter between the narrow and wider bore 
columns resulted in the narrow bore column having a greater column capacity 
than the wider bore column. Consequently, for drugs chromatographed on the 
wider bore column, there was a decrease in the amount of drug injected onto the 
column which produced an overloaded peak (Section B.3.2.3). 
4. The chromatographic response of both thermally sensitive drugs and high boiling 
drugs was improved when chromatographed on the wider bore compared to the 
narrow bore column. 
The peak shapes chromatographed for some drugs on the wider bore column 
improved when compared with their chromatography on the narrow bore column. 
For example, the peak shapes of some drugs improved as follows:- amitriptyline 
(A3 to Al), desipramine (A3 to Al), dihydrocodeine (A4 to A3), dothiepin (A3 to 
Al), desmethyldiazepam (A4 to A3), dextromethorphan (A2 to Al), diltiazem (A4 to 
Al), benztropine (A5 to A3), trimethoprim (A4 to A3) and hyoscine (A3 to A2). In 
some cases, substantial improvement in chromatography on the wider bore column 
was observed from that on the narrow bore column (eg oxycodone:- peak absent to 
Al; benztropine, methdilazine and dextropropoxyphene:- AS to Al). Pilocarpine 
and methoxyphenamine, which had each chromatographed as two unresolved peak 
on the narrow bore column, chromatographed as a single tailing peak on the wider 
bore column. 
The peak shape for other drugs which did not chromatograph well on the narrow bore' 
column were so improved following their chromatography on the wider bore column 
that qualitative and quantitative chromatographic data was obtained as shown in 
Tables 3.3 and 3.4 (eg captopril, dextropropoxyphene, diclofenac, mebhydrolin, 
methdilazine, methoxyphenamine, oxycodone, pilocarpine, primidone). The drug 
groupings and types of chromatographic data shown in Tables 3.3 and 3.4 are the 
same as those in Tables 3.1 and 3.2, respectively. Although these drugs were now 
able to be chromatographed, however, the following was observed. 
1. In the majority of cases, linearity over the concentration range tested was poor 
(10m > 20). 
2. The chromatography of some drugs was too poor to obtain linearity data (eg. 
captopril artefact, theophylline, trimethoprim, quinine and quinidine). 
3. Some drugs for which linearity data was obtained showed poor sensitivity; their 
detection limit was relatively high compared with other drugs chromatographed 
under the same conditions (eg. hyoscyamine, benzodiazepine metabolites, 
oxycodone). 
The peak shapes chromatographed for some drugs on the wider bore column 
deteriorated when compared with their chromatography on the narrow bore column 
as follows:- cotinine (Al to A3), phenindione (Al to A4), metoclopramide (Al to 
A3). In addition to poor peak shape, decomposition products were detected for 
MDMA and paracetamol. 
The carry over characteristics of some drugs altered on the wider bore column from 
those observed on the narrow bore column as follows:- ibuprofen (B1 to B2), 
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methylphenobarbitone (B1 to B2), diclofenac (B4 to B2), sulphinpyrazone (B1 to 
B4), THC (B1 to B2). 
Where there was improvement in either the peak shape or the detection limit of drugs 
chromatographed on the wider bore column from that observed on the narrow bore 
column, linearity (10mw1DE) over the concentration range tested also improved 
although power equations still described the curve of best fit for untransformed data 
points (Table 3.2; 10 < 10 - - MWIDE < 10M). It should be noted that, where both 10 m and 
1 0MwiDE values are recorded, a narrower concentration range was investigated on the 
wider bore column (approximately 200 pg to 30 ng) than on the narrow bore column 
(approximately 50 pg to 50 ng). Data in Table 3.2 indicate that, in general, the 
majority of anti-depressant agents, barbiturates and anti-histamines (including 
pheniramine) were relatively linear over the concentration range tested. The non-
polar drugs and nitrogen heterocyclic drugs were relatively linear although there 
were some obvious exceptions (eg. verapamil, clonidine). In contrast, the majority of 
benzodiazepines, and 10 and 2° amines were described by power equations over the 
concentration range tested. 
Tables 3.3 and 3.4 also show chromatographic data for additional drug standards 
chromatographed on the wider bore column which had not previously been 
investigated on the narrow bore column (eg. some benzodiazepines and their 
metabolites). Data indicate that, for these drugs, power equations best described the 
curve fitted to untransformed data points except for GC artefacts of 
dextropropoxyphene and carbamazepine. 
3.4 Discussion 
The chromatographic characteristics of a wide range of drugs across different drug 
groups was investigated following splitless injection using both narrow and wider 
bore columns. The chromatographic information recorded establishes a database of 
observed behaviour for these analytes on a non-polar chromatographic system (ie. RI, 
peak shape, linearity over a defined concentration range, limit of instrument 
detection). Both qualitative and quantitative aspects of individual drug 
chromatography were reported allowing an evaluation of the chromatographic 
performance of a large number of structurally dissimilar drugs under set conditions. 
The chromatographic performance of different drugs can be compared using criteria 
such as peak shape, linearity over a defined concentration range (10m), 'carry-over' 
potential, thermal stability and instrument sensitivity (indicated by drug detection 
limit). 
The chromatographic response for any drug would be maximised when all the 
injected drug passes unchanged through the separating column to the detector in a 
narrow focussed band (Section 3.1). Consequently, chromatographic response is 
influenced by the following considerations. 
1. If the drug decomposed either partially or wholly in either the injector or during 
transit through the column, the amount of drug reaching the detector would be 
reduced. Several drugs showed evidence of decomposition products which were 
either completely or partially resolved from the drug peak (Tables 3.2 and 3.4). 
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Drug instability at elevated temperatures is discussed in Section 5.4.2.1 using the 
example of PFP-drug derivatives. 
2. If the same amount of two different drugs was injected onto the column and one 
drug was optimally re-focussed on the front of the column and underwent minimal 
longitudinal diffusion during elution (Appendix B.4.1.2), and the other was poorly 
refocussed and/or experienced relatively more longitudinal diffusion then, 
although each drug would reach the detector, one would elute as a narrow band 
and the other as a band spread over a relatively wider area. Although the detector 
would indicate the same total amount for each drug, the signal representing the 
drug eluting in a narrow band would be high and of short duration while that of 
the drug eluting in a relatively broader band would be lower and of longer 
duration. Consequently, if the same two drugs were chromatographed at a 
concentration close to the critical threshold of instrument detection, the detector 
would have greater sensitivity to the drug eluting as a narrow band; this drug 
would have the greater chromatographic response. The detection limit of a drug, 
therefore, is likely to be a very good indicator of whether or not a drug 
chromatographing under the set conditions possessed good chromatographic 
properties (Table B.12). 
3. Peak shapes in Table 3.2 and 3.4 ranged from Gaussian (Al) to excessively 
tailing (AS). Peak shape provides an indicator of band width on the column. If 
all molecules of drug were relatively uniformly distributed throughout the band 
and well focussed, only Gaussian peak shapes would result as the majority of 
molecules would be distributed towards the centre of the band and fewer and 
fewer molecules distributed towards its extremes in a 'normal/Gaussian 
distribution'. Tailing peak shapes imply that individual drug molecules are not 
normally distributed within the band but that the majority of drug molecules are 
concentrated in the leading front of the band with the remainder extending from 
there in diminishing number towards the back of the band. Longitudinal 
diffusion of the band as it moves along the column does not explain the non-
uniform distribution of drug molecules in tailing peaks. However, increasing or 
decreasing longitudinal diffusion (governed by longer or shorter elution time) 
either exaggerates or masks the 'tail' in these heterogenous bands. 
4. It was stated in Section 3.3 that the chromatographic separation of a mixture of 
drugs occurred as a result of the partitioning of drugs between the gas and 
stationary phases and that drug retention was dependent on the amount of time 
spent in the stationary phase (partition coefficient)." Drug retention, however, is 
further influenced by additional interactions of the drug with the stationary phase - 
or 'interfacial' adsorption - at both the column support and the gas-liquid 
interfaces.' ) The column support is not entirely inert and despite careful 
deactivation, cannot completely eliminate its contribution to drug retention. (I) 
Similarly, adsorption at the gas-liquid interface is likely to become increasingly 
significant as the chemical dissimilarity between the non-polar stationary phase 
(cross-linked methyl silicone) and relatively more 'polar' drugs increase. (I) There 
are few studies which explore the retention mechanism for open tubular columns 
with cross-linked stationary phase such as that used in the present experiments, 
but 'interfacial' adsorption has been shown to affect the reproducibility of 
retention for columns with non-polar phases of different thicknesses, (I) and was 
shown to contribute to the retention of polar solutes on poly(dimethylsiloxane) 
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phases which increased when the phase was cross-lin.ked. a) 
5. If individual drug molecules were partially or completely adsorbed to active sites 
either in the injector or on the column (column support) following their injection, 
then either a smaller (reduced absolute peak area) or no, peak would be detected. 
Similarly, if individual drug molecules interacted excessively with the stationary 
phase during their elution (partial or complete adsorption at the gas-liquid 
interface), broadened and/or tailing, or smaller peaks would elute from the column 
rather than the 'Gaussian' peaks anticipated from a narrow, focussed band of drug 
molecules. Both conditions would result in a decreased chromatographic response 
for that drug. Drugs of different 'polarities' interact to differing degrees with both 
active sites in the chromatographic system and the stationary phase of the column 
during their elution. These additional interactions are minimal during the elution 
of non-polar drugs as their movement along the stationary phase is governed 
largely by their partition coefficient. For more polar drugs, however, the 
interactions can be significant as their elution is affected not only by their partition 
coefficients but by 'interfacial' adsorption. Improving the chromatographic 
characteristics of polar drugs would, therefore, lead to improved chromatographic 
response and detector sensitivity. 
In general, there was an improvement in the chromatography of a drug on the wider 
bore column from that observed on the narrow bore column. This was reflected by 
improved peak shapes, a decreased range in which the limit of detection fell and 
improved linearity over the tested concentration range (10m > 10 - - mwiDE)• The major 
factors which improved the chromatographic responses of drugs are discussed in 
Appendices A.4 (higher phase ratio and faster elution times), B.4.1 (injector-related 
factors) and B.4.2 (increased gas flow through the column, and exposure to reduced 
temperature ranges prior to elution). These factors influenced both the amount of 
drug reaching the detector and the width of the band eluting from the column to the 
detector, effectively diminishing chromatographic problems associated with polarity 
for some drugs. The effect of these factors on drug chromatography is demonstrated 
by the differences observed in the chromatographic behaviour of some individual 
drugs on the two columns as follows. 
I. Thermal instability at an injector temperature of 250°C resulted in poorer 
chromatographic responses on the wider bore than narrow bore column for 
amphetamine, methylamphetamine and carbamazepine as reflected by increased 
detection limits. Similarly, thermal decomposition was complete for carbimazole 
and phenylpropanolamine which were not able to be chromatographed on the 
wider bore column. Only carbamazepine produced a GC artefact/decomposition 
product that was stable enough to be chromatographed and for which 
chromatographic data was obtained, although decomposition products were 
apparent for MDMA and paracetamol. 
2. The GC artefact of hyoscyamine was chromatographed on both narrow and wider 
bore columns. However, although hyoscyamine was not chromatographed 'intact' 
on the narrow bore column, it was apparent on the wider bore column. Higher gas 
flow through the injector at the time of injection resulted in a briefer exposure of 
the drug to the high temperatures and, consequently, some intact drug passed on to 
the wider bore column (Appendix B 3.2.2 and Section 5.4.2.1). The proportion of 
'intact' drug passing from the injector was small, however, as indicated by the 
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relatively high limit of detection for the drug. In addition, hyoscyarnine was a 
relatively polar drug compared with its GC artefact as indicated by the 10 m values 
(72.4 and 25.1, respectively). 
3. Pilocarpine and methoxyphenamine, which had each chromatographed as two 
unresolved peaks on the narrow bore column, chromatographed as a single tailing 
peak on the wider bore column. Faster elution times on the wider bore column 
resulted in poorer resolution between these drugs and their decomposition 
products giving the appearance of a single tailing peak instead of two partially 
resolved peaks. 
As the chromatographic behaviour of drugs is affected by their apparent 'polarity', 
chromatography on the wider bore could not significantly alter the chromatographic 
properties of these polar drugs. It simply tended to mask tailing/poor peak shapes 
as drugs eluted from the column more rapidly (Appendix A.4). For example, 
although selected polar drugs were now able to be chromatographed, their linearity 
over the concentration range tested was still poor. Similarly, the chromatography of 
other polar drugs was still relatively poor, as reflected by 10 m > 20, and relatively 
high detection limits. 
In general, the non-polar drugs possessed chromatographic properties which 
ensured good peak shape, linearity and low detection limits. In contrast, the 
apparently 'polar' nature of some acidic (eg carboxylic acids and phenols) and basic 
(eg amines, B-blocking agents) drugs resulted in the loss of the injected sample 
through irreversible column adsorption (higher limits of instrument detection) 
which also affected the injected range over which chromatography was linear 
(power equations were observed). The poorer chromatographic properties of 
weakly to strongly polar drugs compared with non-polar drugs resulted from 
undesirable drug-stationary phase interactions discussed in Sections 5.4.2.2 to 
5.4.2.4. Even some of the apparently 'non-polar' drugs listed in Table 3.2 (eg 
mebhydrolin) possessed residual polarity imparted to them by their total chemical 
composition which adversely affected their chromatographic performance. 
Consequently, the observed chromatographic behaviour of a wide range of 
chemically dissimilar drugs has permitted an estimation and comparison of apparent 
'chromatographic polarity' across drug groups. 
The effect of drug 'polarity' on drug chromatography was clearly illustrated when a 
comparison was made of the chromatographic properties of drugs and their 
desmethyl metabolites. The chemical structures of the metabolites differed from the 
drugs only by the absence of a methyl group. Reactive functional groups which 
increased both the reactivity and polarity of the metabolite were revealed when the 
relatively non-polar drug lost a methyl group. In the absence of the methyl group, 
poorer peak shapes, chromatographic linearity and detection limits were observed 
for each metabolite when compared with the drug. 
Although a greater chromatographic response was attained for the majority of drugs 
chromatographed on the wider bore column, cledrly the chromatographic 
• characteristics of other acidic and basic drugs require improvement if they are to be 
incorporated into a broad drug screening procedure. 
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Tables 3.1-3.4 showed qualitative and quantitative chromatographic data for 
underivatised drugs. These data indicated that drugs with carboxylic acid 
functional groups were too polar to chromatograph on the non-polar cross-linked 
methyl silicone stationary phase of either high performance capillary column 
employed, and confirmed similar findings in the literature. (1 '2' ) It was also shown 
that many weakly acidic drugs (eg phenols) were chromatographed as broad, 
tailing peaks (rather than with Gaussian peak shapes) and possessed poor linearity 
characteristics over the concentration range tested, and relatively high detection 
limits. In Tables 3.2 and 3.4 it was shown that many desmethyl drug metabolites 
were relatively poorly chromatographed in comparison with the 'methylated' 
drugs. The chromatography of acidic and basic drugs could be improved if their 
polar functional groups were shielded during elution to minimise undesirable 
column interactions which could lead to irreversible column adsorption and 
asymmetric peak shapes. Chemical derivatisation of potentially reactive 
functional groups with non-polar molecules is a technique often employed in GC 
analyses to improve analyte chromatography. (2'3) 
The term `alkylation' covers a variety of techniques in which an acidic proton can 
be replaced by a non-polar alkyl group. (I '3) Consequently, alkylation is a 
derivatisation technique particularly suited to analytes possessing acidic functional 
groups, and its application to acidic drugs was investigated. Following the 
alkylation of an acidic drug, it might be expected that the resulting alkylated 
derivative will be less polar than the underivatised drug and, consequently, 
improved chromatographic performance will result. 
The strength of an acid is given by its dissociation constant, usually as the 
negative log io or pKa, and describes the ease of dissociation of the acidic proton. 
The lower the pKa, the stronger the acid and the greater the potential for that drug 
to be derivatised by an alkylation reaction. 
Many alkylation reactions are possible employing different reagents, (I '2 '3) 
however, investigation was limited to drug alkylation using either diazomethane 
or n-butyl iodide. Diazomethane was selected as methyl derivatives are very 
commonly reported in the literature (eg. mass spectral and RI databases) (2 '4) and 
methylation is rapid. n-Butyl iodide was selected as the literature reported that 
this reagent was able to derivatise a wide range of weakly to strongly acidic drugs, 
including benzodiazepines. (1 '2 '' -9) Data in Tables 3.1-3.4 indicated that many 
benzodiazepines were poorly chromatographed. It was important that these drugs 
be included in the broad drug screening procedure, however, as they are prevalent 
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in the community, have a high potential for abuse and are of toxicological 
significance (Table 1.2). 
Developmental work for the alkylation technique was performed on the narrow bore 
capillary column. The qualitative and quantitative chromatographic characteristics of 
butyl drug derivatives were then investigated following splitless injection using both 
the narrow bore (0.22 mm i.d) and wider bore (0.32 mm i.d) columns. The 
qualitative chromatographic characteristics of methyl drug derivatives, however, 
were investigated only on the narrow bore column. It was hoped that in maximising 
the chromatographic response of these polar drugs through derivatisation, detection 
at concentrations equivalent to therapeutic blood levels and below would be 
achieved. 
4.1.2 Diazomethane 
The most commonly used reagent in diazoalkane alkylation reactions is 
diazomethane, and methyl derivatives are produced. Diazomethane is gaseous, 
toxic and explosive. (1 '2) It can be either bubbled through a solution of the acidic 
drug, or a solution of the gas in a suitable solvent can be added to the drug. 
Generally, ethereal solutions of diazomethane are prepared, but these solutions are 
not very stable and can be stored for only a few weeks at low temperature 
(-18°C). (2) The reaction does not expose the drug to high temperatures or reaction 
conditions that can cause decomposition and, provided the choice of solvent is 
correct, the rate of reaction is usually high.(1) On completion, excess reagent can 
be removed by evaporation under a stream of nitrogen. 
Methylation with diazomethane is represented by the following: 
IU-H± + diazomethane —> R-CH3 + end products 	Equation 4.1 
During reaction with diazomethane, unexpected side-reactions and cis - trans 
isomerisation have been reported. (2) The removal of excess diazomethane prior to 
analysis can minimise some side-reactions, although volatile methyl esters can be 
simultaneously lost by evaporation. (2) 
Following reaction of drugs with diazomethane, the methyl derivatives formed are 
predictable. (2) The molecular weight increases by 14 or 28 amu (mono- or bis-
derivatives respectively). The fragmentation patterns of the El mass spectra 
generated for methyl derivatives differ little from those of the underivatised drugs 
and many commercially available libraries of drug mass spectra include 
methylated derivatives. 
4.1.3 n-Butyl Iodide 
The reaction mechanisms for the alkylation of acidic compounds by alkyl halides 
and have been reviewed. (I '2 '5) Alkylation reactions employing alkyl halides are 
bimolecular nucleophilic substitutions (S N2) at a saturated carbon. (1 ' 5) A 
nucleophile (the deprotonated acid) displaces a leaving group (the halide) from the 
substrate (the alkyl halide). The displacement occurs provided that: 
1. both the nucleophile and leaving group are anionic or neutral bases with 
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unshared electron pairs, and 
2. the nucleophilicity of the deprotonated acid is greater than that of the halide. (1 ' 5) 
The deprotonation of the acidic drugs can be catalysed by the addition of a basic 
agent, for example tetramethylammonium hydroxide (TMAH). In this alkaline 
environment the acidic drug is deprotonated by the following instantaneous 
reaction and an intermediate salt formed: 
R—COOH + (CH3 )4N+OH- —> R—COO-N±(CH3 )4 + H20 Equation 4.2 
In the presence of water, therefore, the reaction will proceed more slowly.' ) For 
alkylation to proceed further, the intermediate salt must remain in solution. 
Methanol (Me0H) has been added to reaction mixtures to improve the solubility 
of the intermediate salt (I°) although alkylation has also been reported to occur in 
Me0H-free reaction mixtures.' ) In the experiments of this study, TMAH was 
prepared as a methanolic solution. 
Following the addition of an alkyl iodide to the reaction mixture, the 
corresponding alkyl derivative is formed with tetramethylammonium iodide salt 
(TMAI) precipitating. 
R—COO-N+(CH3 )4 + R 1 I —> R—COOR I + N(CH3)4I 4, 	Equation 4.3 
where R 1 = n-C,1 1-12„ 1 representing any alkyl group 
The alkyl iodide must be added to the reaction mixture only after the addition of 
TMAH. If not, the hydroxyl ions which catalyse the deprotonation of the acidic 
drug will react immediately with the carbon atom of the alkyl halide (nucleophillic 
substitution) and incomplete deprotonation of the acid may occur. (1") 
The excess TMAH is neutralised as a result of the following reaction. 
(CH3)4N+01-1- + R 1 I --> R I OH + N(CH3)4I L 	 Equation 4.4 
If the alkyl halide is sterically hindered by bulky groups, the reaction rate will be 
very low as the nucleophile must be able to approach the carbon atom for the 
reaction to proceed. (1) Similarly, a methyl halide is more reactive than higher 
n-alkyl halides as the electron density is less at the carbon atom under attack. (1) 
Alkylation reactions with alkyl halides are performed most commonly with 
iodides or bromides as the leaving group activity of F> Br- > C1 >>F - . (1) Iodine is 
displaced more easily than any of the other halides as it is the weakest base and is 
most stable as a free entity.' 1) 
Aprotic solvents provide the best medium for reaction as, in the presence of protic 
solvents, the nucleophile is stabilised by hydrogen bonding with the solvent 
molecules. In the literature, both dimethylsulphoxide and dimethylformamide 
(DMF) are used but DMF is preferred as it is more volatile. (5) 
A diverse variety of drugs with acidic functional groups have been derivatised by 
quaternary ammonium hydroxide-catalysed alkylation reactions with alkyl 
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halides. (1 '2) For example, butyl derivatives have been formed from a wide range of 
strongly to weakly acidic drugs (eg. barbiturates, phenytoin, ethosuximide, 
primidone, mefenamic and valproic acids, desmethyldiazepam, theophylline, 
paracetamol, ketoprofen, oxyphenbutazone, benzoylecgonine, probenecid and 
warfarin' ))• 
Butyl derivatives are heavier compounds than methyl derivatives, with higher 
boiling points, as the molecular weight of the underivatised drug is increased by 
56 or 112 amu (mono- and bis- derivatives respectively). Unlike diazomethane 
methylation, the occurrence of side-reactions in alkylation reactions with alkyl 
halides is rare, (2) and the reagents used have low toxicity. 
4.2 Methods 
Refer to "General Procedure" (Chapter 2). In particular, for HC marker solution refer 
to Section 2.2.5.5 and 2.2.5.6; for reference drug solutions refer to Section 2.2.5.14; 
for instrumentation refer to Section 2.4.1; and for SIM acquisition parameters refer to 
Section 2.4.3.1. Refer to Sections 2.4.2 and 3.2.1 for gas chromatographic 
parameters with the wider bore and narrow bore columns respectively. Qualitative 
and quantitative chromatographic data for drug derivatives was obtained using the 
method described in Section 2.6.1 unless otherwise specified. 
4.2.1 Methylation 
4.2.1.1 Reagents 
methanol (HPLC grade); Mallinckrodt 
redistilled diethyl ether; BDH Laboratory Supplies 
Diazald (Aldrich Chemie, West Germany). 
MethElute® (Pierce Chemical Co.); 0.2 M trimethylanilinium hydroxide in 
methanol 
reference drug solutions; (Section 2.2.5.14) 
HC marker solution; (Section 2.2.5.5) 
ethereal diazomethane (freshly prepared)(1 2) 
4.2.1.2 Apparatus (Section 2.3.2) 
'quick-fit', non-ground connector glass-ware (Corning Incorporated) for 
diazomethane preparation. 
4.2.1.3 Derivatisation with Diazomethane 
All operations with diazomethane were carried out in a fume cupboard. Each 
working drug solution (100 lit) was transferred to a 2 mL glass reaction vial (Section 
2.3.2) and evaporated to dryness under a stream of nitrogen at room temperature. 
Ethereal diazomethane (100 p.L) was added to the residue, the vial was sealed and 
allowed to react at room temperature for 30 min. On completion, it was noted that 
the solution was still yellow with unreacted diazomethane and the excess reagent 
was removed under a stream of nitrogen at room temperature. 
Chloroform (100 [tL) and the HC marker solution (100 p.L) were added to the 
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residue, briefly vortexed (10 s) and the resulting solution transferred to inserts and 
autosampler vials for GC injection (Section 2.3.2). 
Variations on the above procedure included the following: 
1. the time of reaction - 0.5 and 2 h, and 
2. the addition of Me0H as a catalyst - 50, 100 and 2001AL. 
4.2.1.4 Derivatisation with MethElute ° 
®, 
In derivatisation experiments with MethElute k0.2 M trimethylanilinium 
hydroxide in Me0H), 50 4 of the commercially prepared reagent was substituted 
for diazomethane (100 jiL) in the reaction medium (Section 4.2.1.3). The reaction 
mixture was injected directly into the GC at an injector temperature of 270°C for 
on-column methylation of drug standards. 
4.2.2 Butylation 
Refer to Sections 2.2.3 and 2.2.5.4 for details of reagents and to Section 2.3.2 for 
apparatus employed; refer to Figure 2.4 for the derivatisation procedure. During 
development of the derivatisation procedure some parameters were varied as 
follows:- 
1. the time of reaction - 15 min to 29 h, 
2. the volume of TMAH added - from 20 to 150 4, 
3. the substitution of 0.1M tetrabutylammonium hydroxide (TBAH; 70 4) for 
0.1M TMAH (70 4), 
4. continuous agitation of the reaction mixture throughout the reaction time, and 
5. heating (50°C) the reaction mixture throughout the reaction time. 
The pH of the reaction mixture was monitored during experiments which 
investigated the application of heat throughout the reaction time. A drug free 
reaction mixture was prepared and, at the given time intervals (Section 4.3.2.1v), 
50 4 removed and added to 3 mL of water. The pH of the aqueous solution was 




A selection of drugs, with a variety of functional groups and pKa values, were 
tested in preliminary alkylation experiments with diazomethane, and the results 
summarised in Table 4.1. Structurally-related drugs are grouped under headings 
which reflect a common chemical structure (Figure 3.1), and structurally-unrelated 
drugs are grouped where they possessed a common reactive functional group. The 
drug groupings used in this and other tables in the chapter are discussed in Section 
3.3.1. Unlike the 'non-polar' nitrogen heterocyclic drugs shown in Tables 3.1-3.4, 
the drugs investigated during methylation have reactive secondary amine groups 
(Figure 3.2). 
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Carboxylic acids produced a single GC peak. The El full-scan mass spectrum 
obtained from each GC peak enabled it to be identified as a methyl derivative 
(mono- or bis-). Where two sites were available for methylation (eg. enalaprilat), 
the bis- derivative was produced with a negligible yield of the mono-methyl 
derivative. The pKa values for these drugs ranged between 3.0 and 4.8. 
Data from Table 4.1 show that drugs with weakly acidic functional groups (pKa 
6), either formed no derivative or were incompletely derivatised. This was 
indicated by either the absence of any GC peak, or the presence of a GC peak 
identified as the underivatised drug. For example, diuretic agents (each 
possessing a sulphonamide grouping) and amides produced no methyl derivatives. 
Benzodiazepines were chromatographed predominantly as the underivatised drug 
although each produced GC peaks of negligible peak area identified as a methyl 
derivative. Allopurinol, captopril, methylphenobarbitone and phenytoin each 
formed methyl derivatives with significant peak areas. Their derivatisation was 
incomplete, however, as indicated by the presence of a small GC peak identified 
as the underivatised drug (except allopurinol). In the case of allopurinol which 
possesses two functional groups potentially susceptible to methylation, and for 
which the underivatised drug does not chromatograph (Table 3.1), incomplete 
derivatisation was indicated by the absence of the bis- derivative and 
chromatography of a single GC peak identified as the mono-methyl derivative. 
Anti-diabetic agents which possess a sulphonylurea grouping (pKa 5 and 5.3) 
either produced no derivative (glibenclamide), or multiple peaks which were non-
reproducibly formed (chlorpropamide, tolbutamide). Methyl derivatives of both 
chlorpropamide and tolbutamide were chromatographed together with 
underivatised and derivatised GC artefacts. The artefacts were identified as (4- 
chloro)- and (4-methyl)-benzenesulphonamide respectively (Section 5.3.2.3 and 
Table 5.6). Complicated peak profiles were also obtained for captopril and 
oxyphenbutazone which each produced three GC peaks of significant peak area 
identified as isomers of a bis- derivative. 
Data shown in Table 4.1 indicated that derivatisation with diazomethane was most 
appropriate for drugs methylated at their carboxylic acid group. Despite relatively 
low pKa values for drugs with other functional groups, methylation either did not 
proceed, or did not proceed to completion as indicated by the presence of the 
underivatised drug, or mixtures of both mono- and bis- derivatives. 
The effect of varied reaction conditions on incompletely derivatised drugs 
(nordiazepam, methylphenobarbitone, tolbutamide, oxazepam, bromazepam, 
sulindac) and a completely derivatised drug (ibuprofen) was investigated. 
Methanol (50, 100, 2004) was added to the reaction medium to catalyse 
methylation. However, increasing the volume of Me0H to 200 1.11, did not 
significantly increase the derivative yield for any drug. Similarly, increasing the 
time of reaction from 30 min to 2 h did not increase derivative yield for any drug. 
4.3.1.2 MethElute® 
The same selection of drugs investigated in experiments with diazomethane 
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(Table 4.1), were tested with a potent on-column methylating reagent - 
MethElute®. The commercially prepared reagent is a 0.2 M trimethylanilinium 
hydroxide in Me0H solution. When heated (hot GC injection at 270°C) with 
drugs possessing reactive amino, hydroxyl and carboxy functions, methylation 
occurs at these sites as illustrated by Figure 4.1. 
MethElute® formed the same methyl drug derivatives as diazomethane, and with 
similar peak areas. For many drugs, however, derivatisation with MethElute® 
produced a host of additional peaks with El full-scan mass spectra which were 
difficult to relate to either the underivatised drug, or its possible methyl 
derivatives. For example, ibuprofen (a carboxylic acid readily derivatised with 
diazomethane), produced two GC peaks. The El full-scan mass spectrum and RI 
of one peak identified the mono-methyl derivative as formed with diazomethane. 
However, the second peak was found to have an identical El full-scan mass 
spectrum but different RI despite the chemical structure of ibuprofen which 
indicates only a single derivatisation site. This could not be explained. 
4.3.2 Butylation 
The use of alkyl halides as alternative alkylating agents which successfully 
derivatise benzodiazepines is cited in the literature (Section 4.1). Preliminary 
experiments with n-butyl iodide indicated that benzodiazepines (nordiazepam, 
bromazepam, nitrazepam and clonazepam) which had been difficult to derivatise 
with either diazomethane or MethElute®, predominantly formed one mono-butyl 
derivative, with a negligible contribution from the corresponding isomer. Note 
that the benzodiazepine structure allows the possibility that tautomeric structures 
form (Figure 3.1). It was postulated that the reaction of drugs with n-butyl iodide 
may produce butyl derivatives of other weakly acidic drugs (pKa > 6), and acidic 
drugs (pKa 4.5-6) with functional groups other than carboxylic acids, which had 
been unsuccessfully derivatised with diazomethane. 
Further investigation revealed, however, that some drugs which had readily 
formed methyl derivatives with diazomethane formed either no butyl derivatives 
(phenytoin, oxyphenbutazone), or multiple derivatives (eg. salicylic acid, 
allopurinol, diflunisal). Consequently, reaction and chromatographic conditions 
were explored to optimise the derivatisation process and chromatographic 
response for the majority of drugs (Sections 4.3.2.1-4.3.2.6). 
4.3.2.1 Optimising Reaction Conditions 
i. Time of Reaction 
The effect of different reaction times (15 min to 29 h at room temperature; 100 
TMAH; 100 [It n-butyl chloride) on the formation of butyl derivatives from 
selected drugs was followed by GC (Table 4.2). The GC peak reflected the 
formation (GC peak present or absent) and yield (increased or decreased GC peak 
height) of a butyl derivative. Drugs with strong acid functions (eg. ibuprofen, 
sulindac) reacted rapidly to produce a derivative after 15 min, although sulindac 
required an additional 30 min to form the maximum yield of its derivative 
(maximum peak height). Methylphenobarbitone, with weakly acidic properties, 
showed a similar pattern of derivative formation to that of sulindac with its 
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Figure 4.1: The mechanism of reaction of trimethylanilinium hydroxide (TMAH) 
with phenobarbitone to form a methylated derivative. 
Figure was taken from educative material accompanying the on-column methylating reagent as supplied by 
PIERCE Illinios USA. 
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maximum peak height achieved at 45 min. 
Data in Table 4.2 indicate that derivatives of the benzodiazepines (bromazepam, 
clonazepam, desmethyldiazepam oxazepam) with pKa 10.5 were first apparent 
following a reaction time of 45 min. Desmethyldiazepam and oxazepam each 
produced two peaks of approximately equal height identified as mono-butyl 
isomers. Further reaction time (2 h) resulted in an increase in the peak height of 
one of these isomers and a reduction in the other such that a single mono-butyl 
derivative predominated. In contrast, bromazepam and clonazepam each formed 
two mono-butyl derivatives after a reaction time of 45 min, one of which 
predominated. The peak heights of these derivatives did not change with 
additional time. Therefore, despite similarities in both structure and pKa, the 
formation of a single major butyl derivative appeared to have proceeded at 
different rates for individual benzodiazepines. 
Following a reaction time greater than 2 h, there was no significant increase or 
decrease in the peak heights of butyl derivative/s for any drug tested. 
ii. Volume of Catalyst 
A selection of 26 drugs which possessed a variety of functional groups and pKa 
values, was tested in experiments which investigated the effect on derivative 
formation of different amounts of TMAH (20, 50, 70, 100 and 150 !IL) in the 
reaction medium (100 pl n-butyl chloride; 2 h reaction time at room 
temperature;Table 4.3 - `TMAH'). Any change in derivative formation for a 
given drug was reflected by a change in the corresponding GC peak/s. It was 
concluded that the maximum yield of a derivative had been achieved when the 
peak height did not change as the volume of TMAH increased. 
Data in Table 4.3 indicate that, of the drugs tested, the carboxylic acids were the 
most susceptible to butylation as a GC peak was detected for each of them at the 
lowest volume of TMAH added to the reaction medium. More than one derivative 
was apparent for five of these drugs (benzoylecgonine, captopril, diflunisal, 
frusemide, sulindac). 
When a greater volume of catalyst was added to the reaction mixture, the 
carboxylic acid derivative that was produced with only 201AL TMAH either:- 
1. decreased in peak height, or disappeared (captopril, frusemide, salicylic acid, 
sulindac), or 
2. increased in peak height (benzoylecgonine, captopril, enalaprilat, ketoprofen, 
naproxen, sulindac, valproic acid), or 
3. was unchanged (diclofenac, diflunisal, mefenamic acid, probenecid). 
The GC peak heights of butylated carboxylic acids which had increased with an 
increase in TMAH volume, reached their maximum with 501AL of TMAH and 
their yield did not alter when reacted with larger volumes. 
For the majority of drugs with carboxylic acid groups, the addition of larger 
volumes of TMAH (50 to 150 lit) simplified their GC peak profiles from that 
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observed with the minimum volume of TMAH (20 pL). Under reaction 
conditions of 50 pt TMAH, a single major butyl derivative was produced and 
additional derivatives, if present, were of negligible peak height. The peak 
profiles of diflunisal, frusemide and salicylic acid, however, were further 
complicated by the addition of 70 pl TMAH, because new derivatives of 
negligible yield were formed. 
Data in Table 4.3 show the effect on the GC peak height of derivatives formed 
from drugs with weaker acidic functions which had been reacted with different 
volumes of TMAH. Unlike the carboxylic acids, few of these drugs produced a 
derivative with the minimum volume of TMAH tested. For example, allopurinol 
produced mono-butyl derivatives with 20 ?AL TMAH which were replaced by bis-
derivatives at larger volumes (50 to 150 pL). Similarly, although the mono-butyl 
derivative of tolbutamide (less its terminal propyl group as determined by the El 
full scan mass spectrum) was detected following reaction with 20 pL TMAH, a 
significant GC peak was also identified as the underivatised GC artefact of 
tolbutamide which indicated incomplete derivatisation. Clearly, reaction with 20 
1AL TMAH was not sufficient to effect the butylation of weakly acidic drugs. 
Consequently, the formation of butyl derivatives from other weakly acidic drugs 
(eg desmethyldiazepam, methylphenobarbitone, phenytoin and primidone) was 
not tested at volumes of TMAH less than 70 pl (Table 4.3 - Note '3'). 
Warfarin and methylphenobarbitone were the only weakly acidic drugs tested 
which formed single butyl derivatives as might be predicted from their structures. 
All other drugs investigated formed two or more butyl related products. For the 
majority of drugs tested, 70 p.L TMAH was sufficient to produce GC peak profiles 
with a single significant butyl derivative of maximum peak height with negligible 
peak heights for additional derivatives. Often, the major derivative was apparent 
with 50 p1 TMAH but maximum peak height was achieved with a 70 pt volume. 
Allopurinol, however, produced two significant bis- derivatives with all volumes 
of TMAH tested (50 to 150 pL). 
As with the carboxylic acids, volumes of catalyst greater than 701AL (100 and 
150 ILL) were not detrimental to butyl derivatives formed from weakly acidic 
drugs regardless of the functional group derivatised, and no change in peak height 
was observed except for bromazepam, clonazepam, tolbutamide. For both 
bromazepam and clonazepam the decrease in peak height did not occur until 
150 tL TMAH was used and, for tolbutamide, it was the mono-butyl derivative 
which decreased, simplifying the peak profile for that drug. 
The butylation of the benzodiazepines was generally consistent in the formation of 
mono-butyl isomers, one of which was of negligible peak height, and the other 
with a peak height which reached its maximum with 70 pL TMAH. Oxazepam 
and lorazepam departed from this pattern with the appearance of a GC artefact of 
the underivatised drug thought to be formed in the injector (13) and, in the case of 
oxazepam, the occurrence of both mono- and bis- derivatives. 
Data shown in Table 4.3 indicate that for the majority of strongly and weakly 
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acidic drugs tested, 70 lit TMAH was adequate to ensure the formation of a 
single significant butyl derivative, with a negligible contribution to the peak 
profile of additionally formed derivatives. 
iii. Substitution of TBAH for TMAH 
Butylation with an alkyl halide requires a tetra-alkyl ammonium hydroxide as a 
catalyst (Section 4.1.3). The effect on the GC peak heights of butyl derivatives 
produced by the exchange of 70 ptL TMAH for 70 lit tetra-butyl ammonium 
hydroxide (TBAH) was investigated (Table 4.3 - `TBAH'). For all 26 drugs 
investigated, the effect of catalyst substitution on the GC peak heights of the 
major butyl derivatives was minimal regardless of pKa or the functional group 
derivatised. 
Where there were two or more derivatives formed from a drug, the peak heights of 
minor derivatives (negligible peak height) showed some variation (increase or 
decrease). For example, tolbutamide, primidone and oxyphenbutazone showed 
increases in the peak heights of minor derivatives, further complicating the peak 
profiles for those drugs. In contrast, the GC peak profiles of lorazepam, salicylic 
acid, captopril, diflunisal, phenytoin and nitrazepam were simplified following 
decreases in the peak heights of minor derivatives. 
It was observed that tetrabutylammonium iodide (TBAI; salt by-product of 
derivatisation; Equation 4.3) was soluble in the GC injection solvent. 
Consequently, TBAI would be deposited in the injector of the GC with each 
sample injected. In contrast, TMAI was insoluble and remained behind when the 
GC extract was transferred from the reaction vial to the autosampler vial prior to 
GC analyses. 
In all subsequent analyses, 70 pl TMAH was used to catalyse the butylation of 
drugs with n-butyl iodide. 
iv. Agitation 
It was observed during the investigation of reaction times that the precipitation of 
TMAI salt was slow (up to 1h), and yet, if the reaction vial was briefly vortexed, 
precipitation of the salt followed. The literature states that progression of 
derivatisation was aided by agitation (i) and so continuous agitation was also 
investigated. It was found that continuous agitation throughout the reaction time 
had no effect on the peak heights of derivatives formed for any of the 26 tested 
drugs regardless of their pKa or the functional group. 
v. Heat 
Figure 4.2 shows the changing pH of a drug free reaction mixture (Section 4.2.2) 
following reaction at room temperature and the application of heat (50°C; 15 
min). The pH of the reaction mixture decreases as excess TMAH is removed by 
the formation of TMAI salt (Equation 4.3 and 4.4). 
• 
At the beginning of the reaction at room temperature, the mixture was strongly 
alkaline (pH 10.45 ± 0.05; n = 3) and the pH remained high (> 9.4) for up to 
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Figure 4.3: The change in pH (± 0.05; n= 3) of the drug-free reaction mixture 
with time and following the application of heat* (50°C for 15 mm). 
64 
105 min. Following reaction for a further 60 min at room temperature, the pH 
decreased only marginally from that at 105 min, to pH 8.2. Consequently, at the 
completion of the normal 2 h reaction time (120 min), the mixture injected into 
the GC would be approximately pH 9. With the application of heat at 165 min 
(50°C; 15 min), the pH of the reaction mixture fell to 7.0. 
To a second drug-free reaction mixture (pH 10.5), heat (50°C; 15 min) was 
applied immediately and the pH of the reaction mixture dropped to 7.5 (Figure 
4.2). With a further 15 min at room temperature, the pH decreased to 7.1. 
Clearly, the removal of excess TMAH from the reaction mixture was aided by the 
application of heat. 
Table 4.3 shows the effect of a final heating step (50°C for 15 min following 
reaction at room temperature for 2 h) on the peak heights of butyl derivatives for 
the 26 test drugs. For the majority of strongly acidic drugs the effect was minimal 
with no change recorded in the peak heights of their derivatives. The following 
exceptions were observed. 
1. Diflunisal (peak height of the bis- derivative was reduced) and salicylic acid 
(no methyl- or methyl-butyl derivatives were formed). These changes were 
beneficial and resulted in simplified peak profiles. 
2. Sulindac (peak height of an unidentified related product increased). 
Of the drugs tested with weakly acidic functional groups, the phenols, warfarin, 
tolbutamide, methylphenobarbitone, and some benzodiazepines (bromazepam, 
desmethyldiazepam, nitrazepam) showed no significant change in the peak heights 
of corresponding butyl derivatives following the application of heat. The 
following exceptions were observed. 
1. Lorazepam and phenytoin (peak height of the most significant derivative was 
so reduced by heat, that another derivative predominated). 
2. Clonazepam (an increase in the peak height of the most significant butyl 
derivative). 
3. Oxazepam (the peak profile was simplified by the reduction in peak height of 
negligible derivatives). 
4. Primidone (maximum peak height of the bis- derivative occurred at 70 rather 
that 100 lit TMAH). 
Consequently, the effect on derivative peak height with the application of heat to 
the reaction mixture for these drugs was either beneficial (clonazepam, oxazepam, 
primidone) or of little significance (lorazepam, phenytoin). 
The effect on derivative peak height with prolonged heating was investigated (the 
reaction mixture was heated at 50°C for 2 h). The effect on derivative peak 
heights following prolonged heating was minimal compared with brief heating 
(15 min) for the majority of drugs tested regardless of their functional group or 
pKa. Primidone and diflunisal, however, did show a reduction in the peak heights 
of derivatives of negligible size which appeared only when volumes of TMAH > 
70 p.1_, were used. 
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Consequently, to avoid injecting a strongly alkaline solution into the GC and, as 
prolonged heating throughout the reaction time was not advantageous, reaction at 
room temperature followed by brief heating (50°C; 15 min) was used in all 
subsequent butylation experiments. 
Having established the optimal reaction conditions which would produce butyl 
derivatives for the majority of test drugs, other drugs selected for their potential to 
form butyl derivatives were investigated on the narrow bore column (Table 4.4). 
As might be expected from data shown in Table 4.3, carboxylic acids, the 
barbiturates and ethosuximide (very similar to phenytoin) formed single butyl 
derivatives, and the peak heights of additional peaks (where present) were 
negligible. The butyl derivative of an indomethacin artefact was formed. As no 
butyl derivative of the drug was apparent, it is postulated that the drug was 
completely converted to the artefact during reaction, and was subsequently 
butylated. Methyprylone (pKa 12.0) formed no butyl derivative. 
Those drugs listed in Table 4.4 for which no butyl derivative was formed were 
also those for which derivatisation with diazomethane was unsuccessful (Table 
4.1). Metoclopramide and procainamide where both chromatographed as 
underivatised drugs and no butyl derivatives were formed. Glibenclamide and 
drugs with sulphonamide groupings (diuretic agents) formed either no derivative, 
or multiple unidentified related products of negligible peak heights. It was 
concluded, therefore, that these drugs were not susceptible to alkylation by either 
n-butyl iodide or diazomethane under the present reaction conditions. 
As might be expected from data shown in Table 4.3, the benzodiazepines shown 
in Table 4.4 also formed a single major butyl derivative with a negligible peak 
chromatographed for the alternate isomer. 
The butylation and chromatography of chlorpropamide was the same as that of 
tolbutamide - GC peaks corresponding to a derivatised and underivatised artefact 
(Table 5.6) were present together with the mono-butyl derivative of the drug (less 
the terminal ethyl group as determined by the El full-scan mass spectrum). 
4.3.2.2. Reproducibility of Derivative Formation 
Data in Table 4.5 indicate the reproducibility of derivatisation of major butyl 
derivatives formed from some of the drugs investigated in Tables 4.3 and 4.4. 
Working drug solutions were prepared and three samples dispensed into reaction 
vials. Two of the samples were derivatised and analysed within the same day and 
the third sample was derivatised and analysed the following day (Section 2.6.1). 
The 'within day' data show the percentage difference in the relative peak areas 
between replicates (R1 and R2), and 'between day' data indicates the percentage 
by which the second day sample (S) differed from Rl. Although the 
reproducibility tests compare only single samples within and between days, the 
data does give an indication of which derivatives were formed very reproducibly 
and which were not. 
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In general, 'within day' data indicated that derivatisation at the carboxylic acid 
group was reproducible, with variations in peak area of 25%. Those derivatives 
for which the 'within day' variation was greatest (captopril, diflunisal, salicylic 
acid, sulindac) were also those derivatives for which additional derivatisation 
products were formed (related products and/or mono- and bis- derivative 
mixtures; Tables 4.3 and 4.4). Of these, the 'within day' data indicate the poor 
reproducibility of derivative formation for mono-butyl derivatives of diflunisal 
and sulindac. Similarly, the 'between day' variation in derivative formation for 
carboxylic acids was also greatest for diflunisal and sulindac. Note that mono-
butyl diflunisal was the major derivative formed for this drug (Table 4.3). 
Of the less acidic (pKa > 6) drugs tested, all the barbiturates were reproducibly 
butylated both within, and between days. The 'within day' variation was marginal 
for these drugs (from 0 to 8%) and the 'between day' variation only slightly 
greater (from 6 to 22 %). Butyl derivatives of phenols appeared to be 
reproducibly formed within a day, but showed greater variation between days, 
particularly allopurinol and paracetamol. The majority of butyl benzodiazepines 
were formed reproducibly. Derivatives of both drugs and their metabolites 
(except clonazepam and lorazepam) showed less than 23% variation in peak areas 
within a day, and slightly greater variation between days (up to 35%). 
Clonazepam, and lorazepam were the least reproducibly derivatised within a day. 
The between day formation of their derivatives, however, was similar to all other 
benzodiazepines tested. Anti-diabetic agents derivatised at their sulphonylurea 
grouping (approximately pKa 5) showed poor reproducibility both within and 
between days. Only the mono-butyl derivative of the GC artefact of tolbutamide 
was reproducibly formed. 
Despite general similarities in the reproducibility of formation of butyl derivatives 
for drugs within each group (eg. carboxylic acid and barbiturate derivatives were 
formed reproducibly; sulphonylurea derivatives were not), the reproducibility of 
formation of a number of individual drug derivatives within a group differed. For 
example, the range of variation between replicates within a group was quite broad 
with the 'within day' variation for carboxylic acids and benzodiazepines ranging 
from 0% to 26%, and 0% to 23%, respectively. In addition, some drugs with 
similar functional groups generated reproducibility data quite different from others 
of the same function (eg. diflunisal and sulindac, paracetamol, clonazepam, 
chlorpropamide). Clearly, the structure and chemistry of individual drugs was 
important in determining the reproducibility of derivative formation at a particular 
functional group. 
4.3.2.3 Chromatography of Butyl Derivatives on Narrow and Wider Bore 
Columns. 
i. Differences in Derivatives Detected 
Table 4.6 shows chromatographic data for butyl drug derivatives on both the 
narrow and wider bore columns (Section 4.2). A number of additional butyl drug 
derivatives not previously investigated are listed. These derivatives were included 
for one of the following reasons:- 
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1. the derivative was formed from a target drug which was selected through the 
process described in Section 1.2. (eg. tiaprofenic acid); 
2. the derivative was discovered unexpectedly during the investigation of drug 
extraction procedures (Chapter 7) and its chromatographic characteristics are 
included for completeness (eg tricyclic anti-depressant agents); 
3. the derivatives was detected on the wider bore column but was absent on the 
narrow bore column (eg. tri-butyl frusemide). 
• For some drugs, the peak profiles of derivatisation products chromatographed on 
the wider bore column differed from those observed on the narrow bore column. 
On the wider bore column it was noted that:- 
1. a late eluting peak identified (El full-scan mass spectrum) as tri-butyl 
frusemide was chromatographed; 
2. bis- derivatives of several drugs were identified (chlorpropamide and 
tolbutamide GC artefacts, desmethylclobazam, ketoprofen, phenytoin and 
salicylic acid); 
3. an alternate lorazepam derivative was chromatographed, and the derivative that 
was detected on the narrow bore column was chromatographed as multiple 
unresolved peaks; 
4. multiple unresolved peaks in addition to the bis- derivative of allopurinol were 
chromatographed; 
5. the lorazepam GC artefact detected on the narrow bore column was absent; 
6. a bis- derivative of oxazepam was detected which replaced the mono-butyl 
derivative detected on the narrow bore column; the GC artefact, however, was 
detected on both columns. 
In cases where the GC peak profile for derivatives of a drug differed between the 
two columns, it was found that one of the following circumstances applied. 
1. The major derivative chromatographed on the wider bore column was the same 
major derivative detected on the narrow bore column. Although the additional 
derivative detected on the wider bore column was of negligible peak height, a 
more complicated GC peak profile resulted for that drug (eg. allopurinol, 
desmethylclobazam, ketoprofen, phenytoin). 
2. The major derivative chromatographed on the wider bore column was not the 
same major derivative detected on the narrow bore column. For both 
chlorpropamide and tolbutamide, the bis- derivative of the GC artefact 
predominated; for oxazepam, primidone, salicylic acid and sulindac, the bis-
derivative predominated; for frusemide, the tri-butyl derivative predominated, 
for lorazepam, the late-eluting isomer predominated. 
Table 4.7 compares the calculated retention indices determined on both columns 
for 41 butyl drug derivatives. Derivative RI values cover a wide range (1300 to 
3200). In all cases the calculated RI for a specific derivative was greater on the 
narrow bore column than on the wider bore column. Table 4.7 shows the 
difference between the RI values determined on each column (N - W). As was 
observed in Table A.2 for underivatised drugs, the difference in RI between the 
two columns appeared to increase with increasing carbon number but the increase 
was neither consistent nor predictable for derivatives with similar RI values. 
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ii. Linearity 
Data in Table 4.8 show quantitative and qualitative chromatographic data for 
selected butyl derivatives chromatographed on both the narrow and wider bore 
columns. The majority of the quantitative data relates to narrow bore column 
chromatography, although some data determined on the wider bore column is 
included where a derivative was either:- 
1. not investigated on the narrow bore column (eg. nortriptyline, tiaprofenic acid), or 
2. quantitatively differed from data determined on the narrow bore column (eg. 
benzoylecgonine). 
Qualitative data determined on the narrow bore column is given for most derivatives 
with regard to the shape of the peak (A), carry over from the injector to a following 
sample (B), and the amount injected (when known) which caused column overload 
[x]. Similar data is given for derivatives chromatographed on the wider bore column 
where it differed from that determined on the narrow bore column. 
As described in Section 2.6.1, each data point employed in determining linear 
regression equations was a peak area ratio. Table 4.8 lists both the target m/z ion 
monitored and the reference HC marker from which the peak area ratios were 
calculated for individual butyl derivatives. Linearity data over a defined 
concentration range is shown. The concentration range is defined by the 'highest' 
and 'lowest' drug amounts. The 'lowest' amount injected refers to the smallest drug 
amount that could be integrated. One hundred- to 1000-fold differences in amounts 
injected were chromatographed for the majority of butyl derivatives. 
The linear regression equation shown for each derivative described the line of best 
fit for the logto of the data points - ie. logy (y = peak area ratio) against log x 
(x = drug amount injected). As for underivatised drug data (Tables 3.2 and 3.4) 
the log transformed data points for each derivative were fit by a linear regression 
curve over a concentration range between, and including, the 'lowest' and 
'highest' amounts injected as listed in Table 4.8. The linear regression equation 
for log-transformed data points and its relationship (y = 10c .xm) to untransformed 
data points is discussed in Section 3.3.1. 
Data in Table 4.8 show that the majority of butyl derivatives tested were 
chromatographed on both columns with good peak shape, regardless of the 
functional group derivatised. The GC peaks chromatographed were, at best, 
Gaussian in shape, and at worst, slightly tailing. Only the lorazepam artefact and 
the mono-butyl derivative of primidone, had moderately tailing peak shapes on the 
narrow bore column. Following chromatography on the wider bore column, the 
peak shapes of some derivatives were marginally improved from those 
chromatographed on the narrow bore column (eg. the barbiturates). 
Carry-over from a previous injection was minimal for all derivatives. Column 
overload, as indicated by peak shape and the plateauing of the detector response, 
did occur on the narrow bore column for butyl derivatives of ibuprofen, 
indomethacin, salicylic acid and tolbutamide. Due to differences in column 
capacity between the narrow and wider bore columns (Appendix B.3.2.3), column 
overload occurred for several derivatives chromatographed at their highest 
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amounts on the wider bore column (eg several barbiturates and carboxylic acids). 
A power equation (y = 10 c .xm) describes the linear data points in terms of the 
log io transformed data (Y = MX + C) and this equation is linear when M = 1.0 
(Section 3.3.1). Table 4.8 gives the 10 m factor which is a good indicator of 
derivative linearity over the concentration range tested (Section 3.3.1). 
Linearity data (10m) in Table 4.8 indicate the following. 
1. Data points for 31% of butyl derivatives investigated were best fitted (r 2 from 
0.995 to 1.000) by an approximately linear equation (10 m from 8.3 to 12.9):- all 
the barbiturates, chlorpropamide artefact (bis), clobazam, diclofenac, diflunisal, 
ethosuximide, ibuprofen, nortriptyline, salicylic acid (bis), theophylline, 
tiaprofenic acid and tolbutamide. Warfarin data points were also described by 
a linear equation, however, the data points were not as well fitted (r 2 0.932). 
2. Data points for 30% of butyl derivatives were best described by a gently 
sloping curve where the increase in detector response was greater for larger 
drug amounts injected (10m from 13 to 20):- desipramine, desmethyldiazepam, 
diflunisal (bis-), indomethacin, ketoprofen, lorazepam, metoclopramide, 
nitrazepam, oxazepam, oxyphenbutazone, phenytoin, probenecid, salicylic 
acid, temazepam, tolbutamide. 
3. Data points for three butyl derivatives (5%) were best described by with a 
gently sloping curve where the increase in detector response was greater for 
smaller drug amounts injected (10 m from 5.1 to 6.8):- lorazepam, sulindac, 
valproic acid. 
4. No linearity data on either column was obtained for three butyl derivatives 
(5%) as only two data points were obtained over the concentration range tested. 
5. Data points for 27% of the butyl derivatives chromatographed on the narrow 
bore column had 10 M > 20, except 7-amino clonazepam and enalaprilat, where 
10m = 1.8 and 2.0 respectively. Many of these were benzodiazepine and their 
metabolites plus captopril, enalaprilat, benzoylecgonine, morphine, 
protriptyline and quinine. These drugs were also injected at relatively high 
concentration compared with other drugs with the lowest amount detected 
usually in the nanogram range. 
6. The linearity of some butyl derivatives (benzoylecgonine, some 
benzodiazepine metabolites and valproic acid) was improved following their 
chromatography on the wider bore column from that determined on the narrow 
bore column. In all instances, the 10 m factor indicated an improvement in 
linearity over the concentration range tested. For the majority of butyl 
derivatives, however, the 10 m factors were similar between columns. 
For butyl derivatives with approximately linear characteristics, a 1000-fold 
increase in concentration on the narrow bore column and a 100-fold increase on 
the wider bore column was investigated. For the majority of other derivatives 
tested, data points were best fitted by a curve (M # 1). Of these, two-thirds of the 
derivatives had data points which covered a 100- to 1000-fold increase in 
concentration, while for a third, the concentration increase was only 10-fold. 
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iii. Detection Limit 
Data in Table 4.9 shows the lowest amount injected that produced a peak which 
could be integrated ('detected'), and the next lowest amount injected that did not 
produce a peak which could be integrated ('not detected') for 52 butyl derivatives 
chromatographed on both narrow and wider bore columns. Forty drugs are listed 
for which data on both columns was obtained. The limit of detection for a given 
drug fell between the amounts listed in the 'detected' and 'not detected' columns 
and is an indicator of differences in the chromatographic response of the 
derivative on each column. 
Data in Table 4.8 indicated that 20% of derivatives chromatographed on the wider 
bore column showed a decreased limit of detection (increased chromatographic 
response) from that achieved on the narrow bore column and, for three, the 
decrease was ten-fold (desalkylflurazepam, desmethylflunitrazepam and 
frusemide). The majority (65%) of butyl derivatives achieved similar limits of 
detection when chromatographed on either the narrow or wider bore column 
(Table 4.9). Data indicated that 15% of derivatives chromatographed on the wider 
bore column showed an increased limit of detection (a poorer chromatographic 
response) from that achieved on the narrow bore column (Table 4.9). These data 
differ from similar data obtained for underivatised drugs on the two columns 
(Table B.12). Data in Table B.12 indicated that 47% of underivatised drugs had 
an increased chromatographic response (decreased detection limit) following their 
chromatography on the wider bore column while, for 46% of drugs, instrument 
sensitivity was similar. 
Data in Table 4.9 indicate that 85% of the butyl derivatives chromatographed on the 
wider bore column had chromatographic responses similar to, or greater than, those 
obtained on the narrow bore column. 
4.4 Discussion 
The suitability of a variety of drugs to undergo alkylation reactions, and the 
chromatography of many alkyl drug derivatives on the narrow and wider bore 
columns, was explored. Alkylation was possible where the drug possessed a polar 
functional group with an acidic proton which could be replaced by a non-polar 
alkyl group. Consequently, the drugs considered for derivatisation through 
alkylation were those with any acidic functional grouping even though the relative 
acidity of the drug was weak (eg. R-COOH, R-S0 20H; R-OH, R-SH, R-NH2 , 
R2NH, RCONH2 , RSO2NH2). (5) 
It could be anticipated that the lower the pKa of a drug, the greater would be the 
potential for that drug to be derivatised by an alkylation reaction. Tables 4.1 and 
4.4 gave pKa values for many of the drugs investigated, however, during the 
development of suitable derivatisation conditions, it was soon apparent that pKa 




Table 4.1 listed the methyl derivatives formed from selected drugs with different 
functional groups and pKa values following their reaction with diazomethane. 
Strongly acidic drugs were methylated at their carboxylic acid groups and 
produced GC peaks identified as mono- derivatives. In a few cases, a bis-
derivative was also identified indicating that a second acidic proton was replaced 
at another susceptible functional group (in addition to the carboxylic acid group). 
Clearly, the acidic proton was readily dissociated in the presence of diazomethane 
(Equation 4.1), as predicted by their relatively low pKa. Many of the weakly 
acidic drugs (pKa > 6) were either incompletely methylated, or formed no 
derivative. 
Consequently, Me0H was introduced to catalyse the reaction. Methanol acts to 
both catalyse methylation by diazomethane and improve the solubility of the drug 
in the reaction mixture. (2) It was shown, however, that the inclusion of Me0H in 
the reaction medium produced no change in the GC peak heights of either methyl 
derivatives or underivatised drugs chromatographed (Section 4.3.1.1). Clearly, 
the rate limiting factor in the methylation of these drugs by diazomethane was 
related to parameters other than those that could be improved/catalysed by Me0H. 
Similarly, when reaction time was increased four-fold (from 0.5 to 2 h), there was 
no increase in the peak heights of methyl derivatives or corresponding decrease in 
peak heights of underivatised drugs co-chromatographing with them. 
Chemical reactions are driven by the formation of reaction products which are 
stable at lower energy states than the reaction precursors in the current 
environment of the reaction medium." It is postulated, therefore, that drugs for 
which no methyl derivatives were detected by GC:- 
1. were more stable as the underivatised drug than as methyl derivatives in 
reaction conditions created by the drug and diazomethane; 
2. were difficult to deprotonate and required a catalyst other than Me0H to cause 
deprotonation; 
3. were very slow to react with diazomethane under the present reaction 
conditions requiring either a reaction time greater than 2h, or the 
addition/adjustment of parameter/s not investigated to increase the reaction 
rate; or 
4. produced methyl derivatives which were very susceptible to thermal 
decomposition and which entirely decomposed either in the hot injector or 
during chromatography. 
Alkylation with MethElute® was briefly explored as it provided a very different 
reaction environment from that provided by diazomethane. It was found to be no 
more effective in the methylation of the test drugs, however, than was 
diazomethane. It is postulated that factors such as derivative stability and ease of 
deprotonation of the underivatised drug were prohibiting the formation and/or 
detection of methyl derivatives. Multiple additional peaks were detected in the 
chromatograms following reaction with MethElute® . The high injector 
temperature (270°C) required for successful methylation catalysed side-reactions 
within the derivatising mixture to produce a host of unidentified peaks. The mass 
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spectra of the end-products could not be easily related to the underivatised drugs 
which complicated the analysis of chromatograms. 
Clearly, alkylation with either diazomethane or MethElute ® was not appropriate 
for drugs other than those derivatised at a carboxylic acid group. 
The routine methylation of drugs prior to GC analysis has one distinct 
disadvantage in that methylated derivatives could be confused with other 
underivatised drugs present in the blood specimen. For example, caffeine 
(methyl-theophylline) would be formed from theophylline. Similarly, some drugs 
(eg. diazepam, flurazepam, imipramine, amitriptyline, clobazam, 
methylphenobarbitone) are metabolised in the body to produce desmethyl 
compounds and, if methylated, these desmethyl-metabolites would be 
indistinguishable from the parent. Some of the desmethylated metabolites are 
manufactured as pharmaceutical products (desmethyldiazepam, desipramine, 
nortriptyline, phenobarbitone) and following their methylation, confusion would 
exist as to which drug had been originally administered. 
Another disadvantage associated with the GC/MSD analysis of methyl derivatives 
is that derivatisation does little to alter the El full-scan mass spectra from those 
obtained from underivatised drugs (eg. M + increased by only 14 or 28). The El 
full-scan mass spectra of many of the low molecular weight drugs (eg. salicylic 
acid, valproic acid, ethosuximide) and their methyl derivatives contain relatively 
small m/z ions which may not be characteristic enough to distinguish them from 
m/z ions produced by the endogenous compounds in blood and plasma. 
Consequently, endogenous compounds may potentially interfere with the 
detection and identification of these derivatives in biological samples. 
4.4.2 Butylation 
4.4.2.1 Introduction 
Tables 4.3, 4.4 and 4.6 listed the butyl derivatives formed from selected drugs 
with different functional groups and pKa values following their TMAH-catalysed 
butylation with n-butyl iodide. As with diazomethane methylation, strongly 
acidic drugs (pKa from 3.0 to 4.8) were butylated and produced single GC peaks 
identified as either mono- or bis- derivatives. In contrast with diazomethane, 
however, some weakly acidic drugs (eg. diuretic agents with sulphonamide 
groupings) also formed several butyl products related to the drug. 
4.4.2.2 The Reaction 
Acidic compounds can be alkylated when they are present in their anionic form 
provided that the nucleophilicity of the conjugate base is sufficient to displace the 
leaving group (iodide) from the saturated C atom of n-butyl iodide (Section 4.1.3). 
The properties of the nucleophile, leaving group, reaction solvent and substrate all 
contribute in governing the rate of 5 N2 reactions.' 1) 
In the butylation of drugs listed in Tables 4.3 and 4.4, the leaving group, substrate 
and solvent were the same for every reaction while the structure of the nucleophile 
(drug) varied greatly. It is likely, then, that the formation (or not) of butyl 
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derivatives from the different drugs investigated was largely dependent on the 
properties of individual drug nucleophiles. 
Apart from the overall structural diversity of the drug nucleophiles participating in 
butylation reactions, there was also some variation in the atom attacking the 
saturated C atom of n-butyl iodide (oxygen, nitrogen, sulphur). Oxygen was the 
attacking atom for drugs butylated at a carboxylic acid, hydroxyl or phenolic 
group. For barbiturates, sulphonylureas and sulphonamides, nitrogen was the 
attacking atom. In the butylation of one of the active sites of captopril, sulphur 
was the attacking atom. In addition, some drug nucleophiles contained more than 
one attacking atom (forming bis- derivatives) which further influenced the rate at 
which the alkylation proceeded. 
The following general properties of a nucleophile affect the rate of SN2 
reactions.  1,14) 
1. In comparing nucleophiles whose attacking atom is in the same row of the 
periodic table, the nucleophilicity is approximately in order of basicity 
particularly when the structures of the nucleophiles are similar. Consequently, 
decreasing basicity follows R-NH2 > RO - > 01-1- > R2NH > Ar0 - . However 
this is not exact because the most effective nucleophile is the one whose 
attacking atom has valence electrons most available for coordination with the 
C atom (nucleophilicity) rather than H ÷ (basicity). (14) 
2. In comparing nucleophiles whose attacking atom is in the same column of the 
periodic table (eg oxygen and sulphur) then nucleophilicity is greatest for the 
larger atom in a protic solvent. The smaller the atom, the more concentrated is 
the negative charge, and the more tightly it is bound by hydrogen bonding with 
solvent molecules. Consequently any sulphur nucleophile is more powerful 
than its oxygen analog. 
3. The freer the nucleophile from intermolecular bonds stabilising electron 
density at the nucleophilic centre (eg weak bonds associated with solute and 
solvent - `solvation'), the greater the rate of reaction. 
In addition to these general principles, however, steric influences often play a 
major part in determining the rate of reaction as, the larger the bulk of the 
nucleophile, the greater is the difficulty experienced in approaching and attacking 
the saturated carbon of n-butyl iodide. 
As stated above, the greater the density of electrons at the nucleophilic centre, the 
greater its reactivity (nucleophilicity). The presence of electron attracting 
substituents on the nucleophile slow the reaction as they drain the electron density 
away from the nucleophilic centre ( ' 1 ' 14) and this 'inductive' effect decreases with 
distance from the nucleophilic centre. Consequently, the inductive effect is most 
pronounced when the electron attracting substituent is ortho to the nucleophile on 
an aromatic ring or on the a and B carbons in aliphatic compounds. 
Similarly, resonance effects in aromatic systems increase or decrease electron 
density by either supplying electron density to the system (halogens, -OH, -OR, 
-00CR,-SH, -SR, -NH 2, -NR2, -NHCOR), or withdrawing it (-NO 2 , -CN, 
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-CHO, -COR, -COOH, -COOR, -CONH2, -SOOR, -CF 3 ). (11,14) These resonance 
effects are most apparent when the substituent is para to the nucleophilic centre 
otherwise a combination of both the inductive and resonance effects of the 
substituent affect nucleophilicity. Resonance effects may also be sterically 
hindered. Resonance effects are greatest when the substituent groups are in the 
same plane as the nucleophilic centre, however, when this is not the case, the 
electron withdrawing or supplying nature of the substituent group is 
decreased. ' 1,14) 
The electron density at the nucleophilic centre can be stabilised not only by 
solvation but, where structure permits, by intramolecular hydrogen bonding. (1°) 
For example, salicylic acid has a hydroxy group ortho to the -COOH group. 
Following loss of the proton, hydrogen bonding occurs to spread the negative 
charge across the hydrogen bridge rather than localising it to the carboxylate 
group(I4) decreasing the reactivity of the nucleophile. 
Consequently, the nucleophilicity of the conjugate base (deprotonated drug) is 
dependent on:- 
1. the chemical nature of the attacking atom, 
2. the unsaturated substituents of the attacking atom, and 
3. the ability of these substituents to delocalise the negative charge remaining on 
the attacking atom after the proton is removed. 
The attacking atom and its substituents, other functional groups carried by the 
nucleophile, its size and the space it occupies (bulk), the strength of inductive and 
resonance effects around the nucleophilic centre, solvation and intramolecular 
hydrogen bonding each affect the reactivity of an individual drug nucleophile to a 
degree which would be difficult to predict. Consequently, the comparison of 
structurally-unrelated drug nucleophiles participating in alkylation reactions 
would also be extremely difficult. 
4.4.2.3 Butyl Drug Derivatives 
Data in Table 4.2 showed the effect of different reaction times on the formation of 
selected butyl derivatives. As deprotonation of the drug in the presence of TMAH 
is instantaneous (Equation 4.2), the reaction time required to form butyl 
derivatives reflected the ease with which the nucleophile approached the saturated 
C atom of n-butyl iodide and displaced F (nucleophilicity). Therefore, the rapid 
formation of butyl derivatives of ibuprofen, sulindac and methylphenobarbitone 
indicated that these drugs produced nucleophiles with greater reactivity than the 
nucleophiles of the benzodiazepines (Table 4.2). The benzodiazepine 
nucleophiles displaced F to form butyl derivatives but the rate of the S N2 reaction 
was slower than that of the other drug nucleophiles. In addition, data in Table 4.2 
showed that the reaction rate of structurally-related nucleophiles 
(benzodiazepines) was similar but not the same, indicating that even subtle 
structural differences in the chemistry of these nucleophiles resulted in differences 
in reaction rate. These data tend to support the conclusion that many interacting 
factors govern the rates of S N2 reactions (Section 4.4.2.2)(11) . Data in Table 4.2 
also indicate that long reaction times for drugs which were butylated rapidly was 
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not detrimental to the resulting derivatives as no decrease in peak heights was 
observed. Consequently, the derivatives produced were stable in the conditions 
created by the reaction mixture and no additional side-reactions occurred. 
In all butylation experiments, TMAH in Me0H (a protic solvent) was added to the 
reaction mixture. With different volumes added to the reaction mixture (from 20 
to 150 1.11_,), both the volume of protic solvent and the molar ratio of TMAH to 
n-butyl iodide changed. For the majority of test drugs, the greater the volume of 
TMAH added, the more strongly the equilibrium of the reaction was shifted in the 
direction of forming the nucleophile. At the same time, however, the greater the 
amount of TMAH added, the greater the volume of Me0H concurrently added to 
the reaction mixture with the potential to stabilise the electron density at the 
nucleophilic centre through hydrogen bonding (potentially decreasing 
nucleophilicity). Data in Table 4.3 showed that more than one derivative was 
formed for some drugs and the relative peak areas of the multiple derivatives 
changed with changing amounts of TMAH such that some completely disappeared 
while others were newly formed. Clearly, the formation of the nucleophile by 
deprotonation and its relative nucleophilicity in the reaction solvent governed the 
changes in peak height of the resulting derivatives. 
The removal of excess TMAH from the reaction mixture was important as its 
presence would make the final solution for GC injection strongly alkaline and, 
consequently, its presence would be detrimental to both the injector and GC 
column. Hence the addition of the final heating step (Section 4.3.2.1v). 
The substitution of TBAH for TMAH did not affect the butylation of the test 
drugs in any significant way. This result indicated that neither the deprotonation 
of the drug, the solubility of the intermediate salt, nor the reactivity of the 
nucleophile was significantly affected by the higher n-alkyl quaternary ammonium 
hydroxide. The formation or not of butyl derivatives was dependent on the 
corresponding nucleophile and its nucleophilicity as governed by individual drug 
chemistry. For some drugs, there was either an increase or decrease in the peak 
heights of minor products. The decreased peak heights of minor products was 
observed for six drugs and would be advantageous as simplified peak profiles 
would result for these drugs. The increase or decrease in peak height of a 
derivative which contributed negligibly to the total peak area of derivatives 
formed, however, would convey very little advantage or disadvantage. 
Preliminary experiments indicated that for a range of drugs (allopurinol, valproic 
and salicylic acids, captopril, benzodiazepines) the peak heights of butyl 
derivatives formed were extremely stable in the injection solvent for up to 32 h. 
This was a positive aspect of the butylation procedure since with automation 
which allows 'overnight' sequential analyses, the derivatised sample may not be 
analysed for up to 24 h following its preparation. 
Butyl drug derivatives were chromatographed on both the narrow and wider bore 
columns. Some differences were noted in the peak profiles and identities of 
derivatives for a number of drugs (Section 4.3.2.31). As indicated in Appendices 
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A.4 and B.3.2.2, gas flows through the narrow and wider bore columns differed, 
with the greater flow through the wider bore column. Consequently, analytes 
chromatographed on the wider bore column eluted more quickly (demonstrated by 
RI data in Table 4.6) and were exposed to lower oven temperatures for shorter 
periods of time prior to elution, than on the narrow bore column. In addition, at 
the time of injection, there was a greater flow through the injection chamber 
flushing the volatilised sample more quickly onto the front of the wider bore 
column. Therefore, the observed differences between the two columns for a 
particular drug resulted from temperature conditions experienced by derivatives 
during their chromatography. 
For example, the late eluting peak identified on the wider bore column as tri-butyl 
frusemide was absent on the narrow bore column for one of the following 
reasons:- 
1. the derivative had an RI value > 3400 on the narrow bore column and 
consequently, was not eluted before the end of the GC run; 
2. the derivative completely decomposed following prolonged exposure to 
excessive heat during its transit through the column; or 
3. the derivative completely decomposed in the injector as it was flushed more 
slowly onto the front of the column. 
It is likely that bis- derivatives of desmethylclobazam, ketoprofen, phenytoin and 
salicylic acid, absent on the narrow bore column, were detected on the wider bore 
column for similar reasons. It is postulated that, although these derivatives were 
formed during the alkylation reaction, they were not detected following 
chromatography on the narrow bore column as they were completely decomposed 
by their prolonged exposure to excessive temperatures during either splitless 
injection or column elution. 
The peak profile for lorazepam derivatives was complicated and differed between 
the two columns. A different lorazepam derivative (RI 3051) was 
chromatographed on the wider bore column and the derivative that was detected 
on the narrow bore column (RI 2977) was chromatographed as multiple 
unresolved peaks on the wider bore column. The lorazepam GC artefact detected 
on the narrow bore column was absent on the wider bore column. This suggests 
that with chromatography on the narrow bore column, lorazepam derivatives 
detected on the wider bore column were transformed in the hot injector to thermal 
decomposition products. It is difficult to ascertain which of the products 
chromatographed on the narrow bore column related to those chromatographed on 
the wider bore column without further investigation, but it is postulated that the 
multiple unresolved peaks detected on the wider bore column were decomposed to 
a single product (RI 2977) on the narrow bore column. Similarly, the GC artefact 
detected on the narrow bore column may be related to the derivative (RI 3051) 
detected on the wider bore column. The decomposition in the injector of products 
detected only on the narrow bore column from derivatives chromatographed on 
the wider bore column may also explain the different GC peak profiles observed 
between columns for allopurinol and oxazepam (Section 4.3.2.3i). 
Bis- derivatives of chlorpropamide and tolbutamide GC artefacts detected on the 
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wider bore column were either absent or of negligible peak height on the narrow 
bore column. In Section 5.3.2.3 it is shown that the GC artefact of underivatised 
tolbutamide (4-methyl-benzenesulphonamide) was formed in the acylation 
reaction medium and subsequently derivatised. It is postulated that, in the 
strongly alkaline butylation reaction medium, the sulphonamide artefacts of both 
tolbutamide and chlorpropamide are similarly formed and subsequently butylated. 
It is not clear whether both mono- and bis- derivatives of the artefacts are formed 
in the reaction medium or whether the mono- derivative arises from the bis-
derivative following its thermal decomposition in the injector. It is apparent, 
however, that the conversion of the underivatised drug to the artefact was 
incomplete as mono-butyl derivatives of the underivatised drugs (less terminal 
groups) were detected. 
It is likely, therefore, that other sulphonamide nucleophiles (eg. diuretic agents) 
also possess properties which allow them to readily displace F from n-butyl iodide 
and form butyl derivatives in the reaction medium, but these derivatives were not 
thermally stable in the injector and related products were detected (Tables 4.1 and 
4.4). Similarly, other products related to butyl derivatives (eg. the hydrolysis 
product of sulindac, the related products of benzoylecgonine and captopril, 
artefact of indomethacin) were also formed in the hot injector. 
Data in Section 4.3.2.3i indicated a difference in the major derivative which was 
chromatographed on the narrow and wider bore columns for some drugs with 
multi-peak profiles. These differences too, can be explained by the difference in 
temperature and temperature exposure experienced by temperature-sensitive 
derivatives either in the injector or during column elution. Clearly, the wider bore 
column was the most appropriate column on which to analyse the butyl 
derivatives of a wide range of drugs. 
Data in Table 4.5 indicate the reproducibility of derivative formation determined 
on the narrow bore column for sample replicates derivatised on the same day, and 
on consecutive days. Although the reproducibility tests compared only single 
samples within and between days, the data did give an indication of derivatives 
that were formed very reproducibly or not. It was indicated in Section 1.3 that 
one of the needs to be met by a comprehensive drug screening procedure was to 
extract and chromatograph the majority of target drugs well. Consequently, in the 
design of a suitable broad butylation procedure, development was not tailored to 
an individual drug but designed for a screening technique which would 
accommodate a large number of acidic drugs. As such, exhaustive studies 
regarding reproducibility of derivative formation for each of the target drugs were 
not warranted or possible within the time span of the project. Rather, it was 
necessary to determine whether butylation of a drug was promising enough for 
subsequent extraction experiments with target drugs (Chapter 7). It should be 
noted, however, that as only single samples were compared within and between 
days it is possible that further experimentation would have revealed that either R1 
or S represented 'out-lying' samples. 
The butyl derivatives for the majority of drugs tested were formed relatively 
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reproducibly. For example, the barbiturates and carboxylic acids were 
reproducibly formed both within and between days. These drugs were also shown 
to have reactive nucleophiles and high rates of reaction (Table 4.2). However, in 
general, data in Table 4.5 are difficult to interpret without an indication of the 
steric influences acting on, and the nucleophilicity of, a given nucleophile which 
affected the ease with which the butyl derivative was formed (S N2 reaction). 
Clearly some drugs were very variable in their derivative formation particularly 
between days (eg. allopurinol, benzoylecgonine, the hydrolysis product of 
sulindac, mono-butyl diflunisal, warfarin, clonazepam, chlorpropamide, 
paracetamol). It has already been indicated that some butyl drug derivatives are 
temperature-sensitive. It is postulated, therefore, that in addition to factors 
associated with individual nucleophiles, temperature-related factors during 
chromatography were contributing to the apparent variability in derivative 
formation seen in Table 4.5. It is possible that for the thermally unstable butyl 
derivatives, the proportion chromatographed as a given derivative was dependent 
on reactions occurring within the injector and some of these reactions may not 
have been reproducible. For example, the butylated artefacts of chlorpropamide 
and tolbutamide were formed in the hot injector and despite structural similarities, 
tolbutamide was far more reproducibly formed than was chlorpropamide. The 
structural features of butyl derivatives that convey thermal stability are unknown. 
It should be noted that during experiments to optimise the reaction conditions 
(Table 4.3) some of the observed changes in the peak heights of butyl derivatives 
may have been due to either the non-reproducible formation of the derivative in 
the reaction medium, or non-reproducible reactions within the hot injector, rather 
than in response to an altered reaction condition variable. 
It was hoped that, in maximising the chromatographic response of polar drugs 
through derivatisation, detection at concentrations equivalent to therapeutic blood 
levels and below would be achieved (Section 4.1). In Section 3.4, it was noted 
that the chromatographic response for any drug (or derivative) would be 
maximised when all the injected drug passed unchanged through the separating 
column to the detector in a narrow, focussed band. Five circumstances were 
discussed which influenced the chromatographic response. Clearly, for 
temperature-sensitive derivatives, the maximum chromatographic response was 
achieved on the wider bore column. 
A sixth circumstance which is applicable only to derivatised drugs is that the 
chromatographic response of a polar drug is maximised when a single non-polar 
derivative is formed from that drug which passes through the column unchanged. 
Consequently, chromatographic response of drug derivatives is influenced by:- 
1. the number of derivatives formed from a drug; 
2. the reproducibility of derivative formation; 
3. the stability of the derivative to temperatures experienced during 
chromatography; and 
4. residual polarity of the derivative as determined by its drug structure (Section 
3.3.1). 
79 
Data in Table 4.3 showed that, for some drugs, the reaction conditions were such 
that more than one derivative of significant peak height was formed (allopurinol, 
benzoylecgonine, captopril, diflunisal, lorazepam, oxazepam, phenytoin, 
primidone, salicylic acid). Consequently, instrument sensitivity to these 
derivatives would be reduced as each derivative represented some portion of the 
total drug present. Data in Table 4.9 indicated the detection limits determined on 
narrow and wider bore columns for many butyl derivatives. For each of the drugs 
where more than one derivative of significant peak height was formed, the lowest 
amount detected was relatively high compared with drugs for which a single 
significant derivative was formed. 
Data in Table 4.8 indicated that, although the linearity (reflected by 10 m values) of 
some butyl derivatives over the concentration range tested was improved on the 
wider bore column, for the majority of butyl drug derivatives, linearity was not 
significantly affected by chromatography on either the narrow or wider bore 
columns. Similarly, good peak shapes were observed for the majority of 
derivatives on both columns (Table 4.8; A1—A2). Both linearity over a broad 
concentration range and very good peak shape for a large number of butyl 
derivatives indicated that, through butylation, the polar functional groups of these 
drugs were effectively removed, minimising undesirable interaction with active 
sites on the column and excessive interaction with the stationary phase. 
Consequently, the chromatographic response of these polar drugs has been either 
significantly improved or maximised from that observed following their 
chromatography as underivatised drugs (Tables 3.1-3.4). 
As was seen for underivatised drugs (Tables 3.2 and 3.4), log transformed data 
points for all butyl derivatives were fit by regression equations; however, a curved 
relationship often described the untransformed data. Picogram to nanogram 
concentrations were monitored to determine both the concentration range for 
which a single linear equation would apply, and detection limits for all butyl 
derivatives. Untransformed data points covering a 100- to 1000-fold increase in 
concentration were best described by either a linear or a slightly curved 
relationship for approximately 85% of butyl derivatives tested. 
In practice, a concentration curve for a given drug would cover concentrations 
ranging from sub-therapeutic to high therapeutic levels and a ten-fold increase in 
concentration would be common. When the concentration range is extended 
(picogram to nanogram) the relationship observed at higher concentrations may 
not mirror that observed at low concentrations as adsorption of the drug to active 
sites on the GC column may be significant at low concentrations. Although a 
single curve is fitted to the data points in Table 4.8, two or even three linear 
equations with different gradients could also be fitted to regions of the curve 
which cover a narrower concentration range particularly where 1000-fold 
differences in concentration were investigated. Consequently, although the 
linearity of a derivative may be described by a power equation (M < 20) over an 
extended concentration range, over a restricted range, the majority of derivatives 
would be linear. 
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For 15% of butyl derivatives, three data points which covered a ten-fold increase 
in concentration were best fitted by a curve. Three data points are likely to be 
inadequate to accurately define the curve and for some, the data points were not 
well fitted (r2 from 0.962 to 0.980). Clearly, these derivatives were not linear 
even within the practical concentration range. This may have resulted from non-
reproducible derivatisation, non-reproducible thermal decomposition of 
derivatives, or the fact that a significant degree of polarity was retained by the 
derivatised drug. Butylation will only remove polar functional groups which react 
with n-butyl iodide. If a drug also possesses polar functional groups not 
susceptible to alkylation, these functions will continue to interact undesirably with 
the column and lead to irreversible adsorption and asymmetric peak shapes. 
For the majority (85%) of butyl derivatives tested on the two columns, either a 
similar, or increased instrument sensitivity was observed (Table 4.9). These data 
are comparable with data in Table B.12 for underivatised drugs. However, for 
47% of underivatised test drugs, but only 20% of butyl derivatives, an increased 
chromatographic response was observed on the wider bore column from that on 
the narrow bore column. This difference is thought to have occurred due to 
differences in the apparent 'polarity' of drugs (Section 3.3.1). The butyl 
derivatives are significantly less polar than the underivatised drugs from which 
they were formed. Many of these underivatised drugs were so polar that they 
could not be chromatographed (eg carboxylic acids - Tables 3.1-3.4). The butyl 
derivatives, however, still retain some of the polarity imparted to them by their 
drug structure. The residual polarity allows interaction with active sites on the 
column resulting in adsorption which becomes most apparent at low 
concentrations. Consequently, at the critical threshold of instrument detection, 
any chromatographic advantage conveyed following chromatography on the wider 
bore column was obscured by column adsorption and no effective decrease in 
instrument detection was observed. It should be noted that following 
chromatography on both the narrow and wider bore columns, instrument 
sensitivity for 46% of underivatised drugs was also similar. Consequently, the 
polar nature of a drug or drug derivative, though it be weak (reflected by good 
peak shape and linearity), has a significant influence on the observed detection 
limits. The residual polarity of derivatives which results in loss of the injected 
sample through column adsorption also affects the injected range over which 
chromatography is linear and power equations are observed (Sections 5.4.2.2— 
5.4.2.4). 
The chromatographic characteristics of a wide range of acidic drug derivatives 
across different drug groups was investigated following splitless injection using 
both narrow and wider bore columns. The chromatographic information recorded 
establishes a database of observed behaviour for these derivatives on a non-polar 
chromatographic system (eg. RI, peak shape, linearity over a defined 
concentration range, limit of instrument detection). 
It was indicated in Section 4.3.2 that the benzodiazepine structure allows the 
possibility that tautomeric structures form. The same can occur with the 
barbiturate structure. Bis- derivatives were always identified for barbiturates, 
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however, while isomers of a mono- derivative were identified for 
benzodiazepines. The barbiturates possess two acidic imide groups each of which 
can be alkylated at either the N or 0 atom. Through a combination of resonance 
effects and solvation, the attacking atom is nitrogen rather than oxygen, and bis-
derivatives are formed. (7) In contrast, the benzodiazepines produced two mono-
butyl isomers resulting from either an attacking 0 or N atom. It is thought that 
under the present reaction conditions, like the barbiturates, the nucleophile with an 
attacking 0 atom was substantially less reactive than the nucleophile with an 
attacking N atom and so only one mono- butyl isomer was formed predominantly. 
Chromatography of many of the benzodiazepine drugs was not linear over the 
concentration range tested (Table 4.8) and the 'lowest' amount detected 
(Table 4.9) was unrealistically high for detection of these drugs at therapeutic 
levels in biological samples. Table 4.9 indicated that, following their 
chromatography on the wider bore column, the butyl derivatives of desmethyl 
metabolites of the benzodiazepines tested had relatively low detection limits 
compared with either the underivatised drugs or derivatives of the 7-amino 
metabolite. Consequently, although butylation of benzodiazepines with n-butyl 
iodide was possible as reported(I ''' 8) and a single significant derivative was formed 
(unlike methylation with diazomethane), the procedure was not suitable for 
quantitative work except with the desmethyl metabolites. Similarly, butylation of 
morphine with n-butyl iodide under the current reaction conditions was not ideal 
as morphine showed both a high detection limit and the poorest linearity of any 
derivative tested. 
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Tables 3.2 and 3.4 showed quantitative chromatographic data for underivatised 
drugs. From these data it was apparent that many basic drugs (eg. amines) were 
too polar to chromatograph well and, consequently, these drugs were either not 
chromatographed at all, or were chromatographed as broad, tailing peaks which 
possessed poor linearity and relatively high instrument detection limits. It was 
shown in Chapter 4 that derivatisation of acidic drugs with non-polar butyl 
group/s significantly improved the chromatographic characteristics of the majority 
of drugs investigated. For example, the chromatography of drugs with carboxylic 
acid functions were so improved following their conversion to butyl derivatives 
that a GC peak was chromatographed with 'Gaussian' peak shapes where none 
was detected for the underivatised drugs. Butylation, however, is not suitable for 
the derivatisation of basic drugs. 
Acylation is possible where:- 
1. the polar functional group on the drug has an acidic proton which can be lost; 
and 
2. the resulting conjugate base has suitable nucleophilic properties which cause it 
to react with the acylating reagent. 
Table 5.1 shows the polar functional groups capable of participating in acylation 
reactions. (1-3) The majority of drugs selected for investigation possessed either 
amine (1° or 2°) or hydroxyl (alcohol or phenol) functions. 
Acylation developmental work was performed on the wider bore (0.32 mm i.d.) 
capillary column following both on-column (0C) and splitless injection. It was 
hoped that in maximising the chromatographic response of polar basic drugs through 
derivatisation, detection at concentrations equivalent to therapeutic blood levels and 
below would be achieved. 
5.1.2 The Reaction 
Acylation reactions involve reagents which contain an acyl group - a carbonyl group 
joined to an oxygen, nitrogen, halogen, sulphur or other electronegative atom. (4 '' ) 
The acylation reaction is similar to that of alkylation reactions in that a nucleophile 
(the deprotonated drug) displaces a leaving group (eg. a carboxylate ion from a 
carboxylic acid anhydride) from the derivatising reagent in a nucleophilic 
substitution reaction (Section 4.1.2). The acylation reaction, however, does not 
proceed via a SN2 mechanism as do alkylation reactions. The reaction mechanism is 
discussed in Appendix C.1. 
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5.1.3 The Acylating Reagent 
As indicated in Appendix C.1, acylation reactions involve reagents containing a 
carbonyl group joined to an electronegative atom and the most reactive of these are 
acyl chlorides or anhydrides. In early GC studies acetyl and other aliphatic reagents 
were used which produced derivatives with increased molecular weight, volatility 
and retention time. (2' 6) The corresponding fluorinated derivatives, however, proved 
to be more versatile as they produced derivatives of greater volatility (shorter 
retention times) and increased sensitivity for electron capture detectors. (2 • 6) The 
advantages and disadvantages of employing different fluorinated reagents are 
discussed in Appendix C.2. 
Pentafluoropropionic anhydride (PFPA) was selected as the acylating reagent in the 
following experiments due to its greater volatility and the stability and shorter 
retention times of PFP derivatives (lower temperature of analysis) compared with 
other fluorinated acylating reagents (Appendix C.2)(1) 
5.1.4 Reaction Catalysts 
Acid- and base-catalysed mechanisms determine the rates of formation and 
decomposition of the tetrahedral intermediate (Appendix C.1). (5) Reaction catalysts 
are discussed in Appendix C.3. 
In general, catalysis by a base or basic solvent promotes the acylation of compounds 
and in the selection of a catalyst practical factors such as the following must be 
considered:- 
1. the subsequent removal of the catalyst, 
2. its chromatographic properties if not completely removed, 
3. formation of additional products through side reactions, 
4. its ability to catalyse reactions with different nucleophiles (eg drugs with different 
functional groups) and 
5. whether or not reaction conditions with a single catalyst can be optimised for the 
acylation of drugs with different functional groups. 
5.2 Methods 
Refer to "General Procedure" (Chapter 2). In particular, for HC marker solution refer 
to Section 2.2.5.5 and 2.2.5.6; for reference drug solutions refer to Section 2.2.5.14; 
For analyses with the Hewlett Packard GC/MSD refer to:- 
Section 2.4.1 for instrumentation; 
Section 2.4.3.1 for SIM acquisition parameters; 
Section 2.4.2 and Appendix B.2.2 for gas chromatographic parameters with the 
wider bore column employing splitless and on-column injection techniques 
respectively. 
Qualitative and quantitative chromatographic data for drug derivatives was obtained 
using the method described in Section 2.6.1 unless otherwise specified. 
5.2.1 Instrumentation 
Chemical ionisation (Cl) and high resolution electron impact mass spectrometry 
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analyses were performed on the Kratos Concept ISQ magnetic mass spectrometer 
with direct insertion probe (DIP) into the ion source at either 140°C (cool source) or 
220°C (hot source). Chemical ionisation was achieved with either ammonia or 
methane gas. 
Experiments which compared splitless injection (fixed temperature) with 
programmable temperature injection employed the Varian 1094 liquid CO 2 cooled 
septum-equipped temperature programmable injector (SPI). A Varian 3400 gas 
chromatograph with both splitless (Varian 1077) and SPI injectors was coupled with 
a Varian Saturn II ion trap detector. There was a direct capillary interface to the 
detector and it was operated in full scan mode by PC-based Saturn Version 5.1 
operating software. 
5.2.2. Gas Chromatography 
The SPI analyses on the Varian Saturn II used a borosilicate glass, high performance 
liner without packing; 40°C (held for 0.2 min) to 320°C at 180 °C/min; 1 p.L splitless 
automated injection. Automated split/splitless injection at 260°C used a borosilicate 
glass liner with frit. A 30 m J&W high performance capillary column (DB-5MS) 
with 0.25 mm i.d. and 0.10pm film thickness was used with all analyses. The carrier 
	
gas was helium (10 psi) and 	1 	splitless injections were made with the split closed 
for 0.7 min. Temperature parameters were as follows:- 
transfer line 	290°C 
oven initial 
	
50°C 	hold time = 1 min 
final 
	
320°C hold time = 9 min 
temp. rate 	10°C/min 
Refer to Appendix B.2.2 for electronic pressure controlled (EPC) analyses on the 
Kratos instrument. Head pressures of 10 and 40 psi were used. Ten psi 
approximated the conditions for splitless injection on the low resolution benchtop 
GC/MS. Following injection, a column head pressure of 15 psi was established for 
the duration of the run. 
5.2.3 Derivatisation with PFPA 
Refer to Section 2.2.4 for details of reagents and to Section 2.3.2 for apparatus 
employed; refer to Figure 2.5 for the derivatisation procedure which was 
performed without the `azeotrope formation' step (Section 9.4.2). During 
development of the derivatisation procedure, variation to some parameters 
included the following:- 
1. volume of PFPA:- 2, 25, 50 and 1001..LL 
2. time of reaction:- 5, 15, 30, 60 and 120 min 
3. use of catalysts:- 3, 6 and 94, pyridine (over anhydrous sodium sulphate) 
2, 5 and 10 p.L diethylamine (DEA) 
50 JAL acetonitrile 
5.3 Results 
5.3.1 PFPA Reaction Conditions 
Preliminary experiments with PFPA used four drugs of abuse which each possessed 
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functional groups susceptible to acylation as follows:- 
amphetamine - 10 amine; 
methylamphetamine - 2° amine; 
morphine and codeine - alcohols. 
The GC peaks detected were identified by their low resolution El full-scan mass 
spectra as the mono-PFP derivatives of these drugs (either M+ + m/z 147 or a 
characteristic fragment m/z ion + m/z 147; where m/z 147 = the pentafluoropropionyl 
group -C 3F 5 0). 
Different volumes of PFPA (Section 5.2.3) were added to reaction vials which 
contained the dried residue of the test drugs (approximately 80 ng) and the GC peak 
areas of the derivatives were monitored. Initially PFPA alone, or in equal volumes 
with either toluene or ethyl acetate, was reacted at 85°C in a heating block for 
20 min. 
The greatest peak area for each derivative was obtained in the presence of ethyl 
acetate and similar peak areas were obtained with either PFPA alone or PFPA and 
toluene. When 25, 50 or 100 uL volumes of PFPA were reacted with the drugs, the 
peak areas of derivatives were similar but all were smaller when 2 III, was used. 
5.3.1.1 Catalysis 
Amphetamine, methylamphetamine, morphine and codeine were used in a test mix 
to investigate whether or not the acylating properties of PFPA were enhanced in the 
presence of strong basic catalysts (pyridine and DEA). Ethyl acetate was added to 
the reaction mixture. Each catalyst was used in the approximate molar ratio to PFPA 
(10 IlL) cited in the literature. (1,7-12) 
In the presence of either catalyst the following was observed. 
1. A strongly yellow coloured reaction mixture resulted whenever morphine or 
codeine was derivatised in the presence of either catalyst but was most apparent 
with DEA. The discolouration increased with the amount of catalyst added. 
2. The reaction mixture was difficult to evaporate under nitrogen and required 
heating. DEA was difficult to completely remove without use of excessive heat. 
After drying whenever pyridine was used, a large amount of residue remained 
which was soluble in the injection solvent (CHC1 3). 
3. In chromatograms produced following the reaction, additional peaks were 
detected which eluted in the region of the amphetamine derivatives and interfered 
particularly with m/z 91.05 and m/z 118.05. 
4. The effects of catalysts on the peak areas of the amphetamine derivatives were 
minimal, but they greatly reduced the peak areas of the opiate derivatives. For 
example, when pyridine was added at 6 tL the peak area of mono-PFP 
morphine decreased from that at 3 j.iL or when no pyridine was present. 
5. Unless the catalysts were dried, vapours were generated when the PFPA was 
added to the reaction vial and the peak areas of all derivatives were reduced or 
absent. 
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Acetonitrile both solubilises the drug residue and, as a basic solvent, acts as a weak 
basic catalyst (Section 5.1.4). The following was observed when PFPA was used in 
equal volume with acetonitrile. 
I. There was no discolouration of the reaction mixture. 
2. The reaction mixture was easily removed under nitrogen without any additional 
residue formation. 
3. The chromatograms produced were similar to those obtained with PFPA/ethyl 
acetate and no additional peaks were detected. 
4. The peak areas of the opiate derivatives were not reduced. 
5. The reproducibility and peak area of the codeine derivative increased when 
compared with that obtained with a PFPA/ethyl acetate reaction mixture. 
In all subsequent experiments, PFPA (50 !IL) and acetonitrile (50 pL) were added to 
the dried residues of test drugs and reacted at 85°C. On completion, the reaction 
mixture was removed under nitrogen and the residue solubilised in either ethyl 
acetate or the ethyl acetate GC injection solvent (Section 2.2.5.8) prior to GC 
analysis. 
5.3.1.2 Application to Drugs with Different Functional Groups 
Data in Table 5.2 show the PFP derivatives formed from an expanded number of test 
drugs possessing different functional groups. Low resolution El full-scan mass 
spectra identified GC peaks as either PFP derivatives (mono- and bis-) or related 
products which contained the PFP group (losses of m/z 147 or m/z 119; where m/z 
119 = -C2F5 ). 
For all drugs except allopurinol, a GC peak was detected which was identified as 
either a PFP drug derivative or related product. No underivatised drug was detected. 
Clearly, PFPA reacted with drugs possessing a range of different functional groups 
although the product of derivatisation was not always immediately apparent from the 
low resolution El full-scan mass spectra generated. 
5.3.1.3 Time of Reaction 
Data in Table 5.3 compares the GC peak areas of derivatives formed from some of 
the drugs tested in Section 5.3.1.2 following reaction with PFPA for 5, 15, 30, 60 
and 120 min. Duplicate samples were derivatised and the mean peak area of each 
derivative expressed as a percentage of that obtained after 60 min (100%). 
Derivatisation of codeine, THC, desipramine, methylphenidate, metoclopramide, and 
propranolol was rapid (5 min) and no further increase in the peak area of the 
derivative was observed with increased reaction time. Extended reaction times 
(>5 min) did not reduce the peak areas of these derivatives. 
The peak areas of amphetamine, lorazepam, and terfenadine derivatives increased 
with increasing reaction time up to 120 min. The peak areas of these derivatives 
(particularly lorazepam and terfenadine) may have increased further with longer 
reaction times (> 120 min). The peak areas of replicates obtained for derivatives of 
oxyphenbutazone and cimetidine were so variable that no data could be obtained. 
88 
The variability between replicates may indicate that either drug derivatisation or 
derivative chromatography was non-reproducible. In contrast, the peak areas of the 
60 min replicates for the remaining drugs (except lorazepam and terfenadine) were 
very similar. 
Following a reaction time of 60 min, all the drugs tested (except lorazepam and 
terfenadine) had formed a derivative with either the maximum or close to the 
maximum peak area. In all subsequent derivatisation reactions with PFPA, the 
reaction time was 60 min. 
5.3.2 Acylation of Drug Standards 
5.3.2.1 Identification of PFP Derivatives 
Approximately 45 test drugs with functional groups potentially suitable for acylation 
(Table 5.1) were derivatised with PFPA. The majority of derivatives were identified 
through low resolution El full-scan mass spectrometry as mono- and bis- derivatives 
(Section 5.3.2.4). The GC peaks detected following derivatisation of 22 of these 
drugs, however, could not be unequivocally identified although their mass spectra 
indicated that each contained PFP group/s. Table 5.4 shows the chemical ionisation 
(CI) and high and low resolution El mass spectral data obtained for these 
derivatisation products. 
For many of the drugs, multiple products were formed following their reaction with 
PFPA (Table 5.4). In most cases, mass spectral analyses (CI and high resolution El) 
with the direct insertion probe (DIP) were able to differentiate between different 
products as they distilled from the tip of the probe. Where sufficient resolution of 
products was not possible, the sample was introduced to the source via gas 
chromatography. 
The probable structure for the majority of derivatisation products was determined 
from the CI mass spectrum of the product and the known underivatised drug 
structure. For some derivatisation products, however, the probable structure was still 
not clear and high resolution El mass spectral data was obtained which accurately 
determined the atomic mass of the derivative and/or its fragment m/z ions. The most 
logical empirical formula 2 ppm) generated by the Kratos peak matching program 
on the basis of the accurate mass determination is listed for these drugs. 
CI was used to determine the Mt (as Fr or NH4t adducts) of the derivatisation 
product since, in low resolution El mass spectra, M t is often absent. Data in Table 
5.4 show that, in many instances, the determined Mt corresponded to either the 
mono- or bis-PFP derivative of the drug and the identity and site of derivatisation 
was often confirmed by the probable structures determined for El spectral fragments 
of the derivative (clonidine, hyoscyamine, lorazepam, methylphenidate, nifedipine, 
oxyphenbutazone, procainamide, propranolol, sulphamethoxazole, timolol, 
warfarin). For pindolol, however, the data produced from both ammonia and 
methane Cl mass spectrometry was inconclusive. The low resolution El mass 
spectra were identical for three well resolved GC peaks and indicated the formation 
of three bis- derivatives, yet no higher mass (Mt) was apparent for any peak by CI 
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mass spectrometry. This could not be explained. 
Data in Table 5.4 indicate that unexpected products were formed from some drugs 
reacted with PFPA through chemical reactions/rearrangements within the reaction 
mixture. Dehydrated underivatised drugs and dehydrated drugs acylated at other 
sites were the most commonly occurring of these unusual derivatisation products 
(disopyramide, etafedrine, haloperidol, hyoscyamine, labetolol, procainamide, 
terfenadine, warfarin). Labetolol and terfenadine were both doubly dehydrated 
during the reaction. 
Some drugs produced unique PFP derivatives which were not formed by other 
structurally-related drugs. In the majority of cases, products formed from these 
drugs in the reaction medium were subsequently acylated to PFP derivatives as 
follows. 
1. Desipramine, formed a bis-PFP derivative which was not predicted from the 
underivatised drug structure in a chemical process not encountered during the 
derivatisation of any other 2° amine. 
2. Labetalol, unlike any other I3-blocker tested, formed the bis- derivative of the 
doubly dehydrated drug. 
3. A chemical rearrangement during the formation of the bis-PFP derivative of 
captopril resulted in the expulsion of -COOH, unlike any other drug derivatised at 
its carboxylic acid function. 
Data in Table 5.4 show that the presence of the PFP group on some drugs resulted in 
El mass spectral fragmentation patterns unlike those of the underivatised drugs. 
Through unusual rearrangements resulting in the expulsion of groups from 
apparently stable structures, spectral fragments were formed with structures which 
were difficult to identify without accurate mass data and peak matching (cimetidine, 
lorazepam, nifedipine, sulphamethoxazole, tolbutamide). 
5.3.2.2 Effect of Injection Technique on the Chromatography of PFP 
Derivatives. 
During experiments identifying PFP derivatives (Section 5.3.2.1) it was observed 
that the PFP-related products detected for some drugs (etafedrine, nifedipine, 
procainamide, timolol) by GC-MS (splitless injection at 260°C) were absent during 
DIP analyses (ion source at 200°C). It was postulated that the PFP derivatives 
formed in the reaction medium were altered/decomposed during their GC analysis. 
The effect of injection temperature on the peak areas of test PFP derivatives was 
examined with three different injection techniques: electronic pressure controlled 
injection (EPC), septum-equipped programmable injection (SPI) and on-column 
(OC) injection. Through EPC injection, derivative exposure to an elevated injector 
temperature would be reduced. Through SPI, each derivative would be exposed to 
the minimum temperature required to volatilise it. Through OC injection, exposure 
to an elevated injection temperature would be removed (Appendix B.4.1.2). The test 
PFP derivatives were a mixture of mono- and bis-PFP derivatives, dehydrated drugs 
(underivatised and derivatised) and 'GC artefacts' - products thought to be formed in 
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the hot injector (eg. etafedrine and timolol). 
Refer to Section 5.2 for details of instrumentation and chromatographic parameters. 
In brief, however, EPC injection (260°C; splitless) was made at column head 
pressures of 10 and 40 psi where 10 psi approximated 'normal' splitless injection; 
SPI injection ramping from 40 to 320°C at 180°C/min was compared with splitless 
injection (260°C) on the same instrument at the same column head pressure; OC 
injection was compared with splitless injection (260°C) on the same instrument at 
the same column head pressure. 
Data in Table 5.5 show the change in peak area of a given PFP derivative following 
each of the three injection techniques as a percentage of that obtained following 
splitless injection on that instrument. The peak areas obtained with each injection 
technique for a given derivative could not be directly compared as chromatographic 
variables and instrumentation differed. Similarly, although the same test drug 
solution was used to investigate the three injection techniques, it was derivatised on 
one of three different days and without information relating to the reproducibility of 
PFP derivative formation, the data was not directly comparable. It should be noted 
that the splitless injection for comparison with SPI injection was not optimised on 
that instrument and, consequently, peak area differences were exaggerated by poor 
chromatography of the derivatives following splitless injection. Trends in the 
chromatographic behaviour of the PFP derivatives following each of the three 
different injection techniques were apparent (Table 5.5). 
Data in Table 5.5 indicate the following. 
1. The peak areas for the majority of test PFP derivatives increased following 
injection by all three injection techniques from those obtained following splitless 
injection (> 100% or +). 
2. The increase in derivative peak area from that obtained with splitless injection on 
the same instrument appeared greater for SPI and OC injections than for EPC 
injections as, for SPI and OC injections, no GC peak had been detected following 
the corresponding splitless injections (cimetidine, hyoscine, pholcodine, bis-
derivatives of clonidine and procainamide). 
3. Mono-PFP hyoscyamine was chromatographed only following OC injection. 
4. Mono-PFP etafedrine was chromatographed as a single peak following OC and 
SPI injections, but following EPC and splitless injections it was chromatographed 
as several unresolved peaks. 
5. The artefacts of both cimetidine and timolol were reduced or absent following OC 
injection, confirming initial data (Table 5.4) which indicated they were formed in 
the hot injector (GC artefacts) rather than through reaction of the drug with PFPA. 
6. The peak area of the artefact of timolol was reduced by all three injection 
techniques but that of cimetidine was reduced only following OC injection. 
7. Where drugs were associated with dehydrated products (derivatised and 
underivatised) all except procainamide were detected following all three injection 
techniques. 
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These data suggest that as dehydrated drug products were present even following OC 
injection they were formed through dehydration of the drug by PFPA in the reaction 
medium prior to GC analysis (reaction artefacts). In contrast, dehydrated 
procainamide was absent following OC injection indicating that it was formed in the 
hot injector as a GC artefact. These data indicate that, in general, the peak areas of 
reaction artefacts were unaffected by the injection technique, but that of the mono-
PFP derivative of dehydrated haloperidol was reduced following splitless injection. 
The data in Table 5.5 indicate that splitless injection at 260°C diminished the peak 
areas for this group of test PFP derivatives except where the peak was a GC artefact 
or a reaction artefact (except for haloperidol). Following OC injection, only 
derivatives formed from the reaction of drug with PFPA were chromatographed and 
related GC artefacts were absent. 
5.3.2.3 On-column and Splitless Injections 
Data in Table 5.5 showed that mono-PFP derivatives of etafedrine, hyoscine and 
hyoscyamine were only detected following OC injection. It was postulated, 
therefore that, following OC rather than splitless injection, different PFP derivatives 
of other drugs may be detected. 
Table 5.6 lists the presence or absence of a GC peak following OC and splitless 
injections for some PFPA derivatised drugs. The characteristic m/z ions from their 
low resolution El mass spectra are shown for each derivative/related product. No 
characteristic m/z ions are listed where multiple peaks (M) or broad peaks with 
changing ion profiles (R) were chromatographed. In some cases, a comment on the 
chromatographic characteristics of a particular GC peak is given. Similarly, 
conclusions are listed with regard to how/where a particular drug derivative or 
related product was formed (reaction medium or GC artefact). Where the same peak 
was detected following either injection technique, the peak area obtained following 
splitless injection was compared with that following OC injection (>, < and 	In 
some cases the peak areas of derivatisation products varied following multiple 
injections of the same type (U). 
Data in Table 5.6 indicate the following. 
1. The chromatography of some PFP drug derivatives was unaffected by injection 
technique as their GC peak areas were similar following both OC and splitless 
injections. 
2. The detection and identity of some PFP drug derivatives was dependent on the 
injection technique employed. 
3. Some drugs were not suitable for derivatisation with PFPA, as following each 
injection technique either no GC peak or multiple peaks were detected. 
The multiple peaks detected for a given drug had different but related low resolution 
El full-scan mass spectra which were difficult to relate to either the drug structure or 
the low resolution El full-scan mass spectrum of the underivatised drug. 
Consequently, the derivatised products for these drugs were not identified. 
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Following OC injection, some drugs were chromatographed either as broad tailing 
peaks (T) or as irregularly-shaped complex peaks (R; indicating irregular). The low 
resolution El mass spectra of these peaks indicated that they were a mixture of 
unresolved but related peaks. Following splitless injection, unresolved peaks (T; R) 
were chromatographed as individual GC peaks with baseline resolution (eg 
captopril, Figure 5.1). It was concluded that PFP derivatives with 'T' or 'R' 
characteristics were a mixture of thermally sensitive PFP derivatives and their 
corresponding degradation artefacts were formed as the derivatives degraded on the 
column with increasing oven temperature (Section 5.4.2.2). 
It was indicated in Tables 5.4 and 5.5 that an elevated injector temperature (splitless 
injection) could result in the formation of GC artefacts for susceptible derivatives 
which were absent following analysis by either DIP or OC injection. Underivatised 
carbamazepine, hyoscyamine and tolbutamide were detected following both OC and 
splitless injection of an underivatised drug solution (Table 5.6). Following splitless 
injection, a GC artefact was detected for each underivatised drug which was 
predictably absent following OC injection. Following derivatisation of the drug 
solution, the same GC artefacts identified following splitless injection were also 
detected following OC injection, and those of carbamazepine and tolbutamide were 
identified as mono-PFP derivatives. These data clearly indicate that these products 
were not GC artefacts but products formed in the reaction medium and subsequently 
derivatised. 
Data in Table 5.5 suggest that the dehydration of haloperidol, hyoscine and 
hyoscyamine occurred in the reaction medium and did not result from conditions 
created in the hot injector. Data in Table 5.6 confirm this and show that other 
dehydrated drugs identified in Table 5.4 were also formed in the reaction medium 
(labetolol, warfarin, terfenadine). The dehydrated products of etafedrine and 
procainamide, however, were GC artefacts. 
Unusual derivatisation products detected following both OC and splitless injections 
indicate that they, too, were reaction artefacts produced following structural 
rearrangement of the drug in the reaction medium (eg. desipramine, tolbutarnide and 
oxycodone; Table 5.6; 'Comments'). 
Data in Table 5.6 confirm data in Table 5.5 and show that GC artefacts are produced 
from derivatisation products of some drugs following their splitless injection (eg. 
cimetidine, oxazepam). 
Data in Table 5.6 indicate that some PFP drug derivatives were detected only 
following OC injection and the peak areas of others which were obtained following 
OC injection were greatly reduced following their splitless injection. These data 
suggest that, although these PFP derivatives were stable at column temperatures 
(chromatographing as single peaks), they were unstable at the splitless injection 
temperature and their degradation in the injector led to reduced peak areas. In some 
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Figure 5.1: Chromatograms obtained following 1 [tL on-column and splitless (260°C) injections of PITA derivatised captopril. 
Data in Table 5.6 show that some PFP drug derivatives detected following OC 
injection were chromatographed as one or more GC peaks with related m/z ion 
profiles following splitless injection (eg etafedrine; Figure 5.2). The GC peak 
profiles for these drugs were complicated by splitless injection. In contrast, data in 
Table 5.6 show that the peak profiles of clonidine, hyoscine and hyoscyamine were 
simplified following splitless injection. 
Following both OC and splitless injection for 40 drugs derivatised by PFPA, data in 
Table 5.6 has:- 
1. identified drugs not derivatised by PFPA; 
2. shown that an elevated injection temperature can be both detrimental to the 
stability of PFP derivatives (destroying them), and/or influence the product that is 
chromatographed (altering them); 
3. identified GC artefacts formed from the PFP derivatives of some drugs following 
their splitless injection; 
4. identified some PFP derivatives so temperature sensitive that they degrade into 
artefacts at oven temperatures; and 
5. indicated that dehydration of drugs and other structural changes can occur in the 
reaction medium resulting in reaction artefacts. 
Following identification (including data in Table 5.4) and GC analysis of derivatives 
formed from approximately 40 test drugs (splitless and OC injections) it was 
concluded that unusual derivatisation products were generally not formed at a 1° or 
2° amine group on a drug but at alcohol or 1° amide groups. Examples of drugs and 
proposed reactions and products follow, with reference to related previous reports. 
1. enol formation (6) 	oxycodone 	bis-PFP 
2. dehydrogenation(13) desipramine 	bis-PFP 
3. decarboxylation 	 captopril 	bis-PFP 
4. dehydration of 10 aMide(6,14) disopyramide 	underivatised (nitrile formation) 
5. dehydration of an alcohol 	labetolol 	bis-PFP (doubly dehydrated) 
6. deamidation 







PFP and underivatised 
PFP and underivatised 
PFP-cimetidine product 
PFP-lorazepam product 
5.3.2.4 Chromatography of PFP Derivatives 
Qualitative chromatographic data for approximately 90 PFP drug derivatives and 
related products formed in acylation reactions with PFPA are shown in Table 5.7. 
The identity of the derivatisation product (when known), characteristic m/z ions from 
low resolution El mass spectra, and RI (where calculated), are listed. Where more 
than one derivatisation product was detected following drug acylation, the dominant 
peak (I) is indicated. 'Comments' indicate the functional groups derivatised where 
polyfunctional drugs were acylated, the formation of either reaction or GC artefacts 
for some drugs, and thermally sensitive derivatisation products. Structurally-related 
drugs are grouped under headings which reflect a common chemical structure (eg. 
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Figure 5.2: Chromatograms obtained following 1 p.L on-column and splitless (260°C) injections of PFPA derivatisal etafedrine. The chromatogram 
obtained following splitless injection shows interference (I) from the closely eluting procainamide artefact. 
grouped where they possessed a common reactive functional group (eg. 10 amines, 
alcohols). The drug groupings used in this and the remaining tables in this chapter 
are discussed in Section 3.3.1. 
The data in Table 5.7 show that 17 of the drugs selected for reaction with PFPA did 
not form a PFP-related product (-). A predominant derivatisation product (PFP 
derivative, reaction artefact) was chromatographed for 49 drugs which was relatively 
stable at both oven and injector temperatures. An additional 6 drugs formed a 
predominant derivatisation product only following OC injection (eg pholcodine, 
sulphamethoxazole). Following OC injection for 4 drugs, more than one major 
product of derivatisation was chromatographed (eg procainamide). Following OC 
and splitless injection more than one product of derivatisation predominated for 
three drugs (paracetamol, oxycodone, haloperidol). Five drugs formed either single, 
or multiple (M), derivatisation products which were thermally unstable at oven (eg 
clonidine, trimethoprim) or injector temperatures (eg chlordiazepoxide). Reaction 
artefacts (derivatised and underivatised) were formed from 14 drugs following 
reaction with PFPA. GC artefacts were formed from 5 drugs (splitless injection 
only). 
Data in Table 5.7 show that a predominant PFP derivative was produced for the 
majority of drugs derivatised at 10 and 2° amine or hydroxyl (alcohol, phenol) 
groups, and the derivative formed was stable at both oven and injector temperatures. 
In contrast, the majority of benzodiazepines and drugs derivatised at a sulphonamide 
(diuretic agents) or sulphonylurea groupings (anti-diabetic agents) formed either no 
derivative, or derivatives and/or products which were thermally unstable. 
Despite these general observations, however, data in Table 5.7 clearly show that not 
all drugs with common functional groups reacted with PFPA in the same way. The 
data show that drugs with common alcohol and phenol groups did not react with 
PFPA in the same way to form derivatives with similar thermal stabilities. Clearly, 
the product/s of PFPA derivatisation and their thermal stability could not be 
predicted on the basis of the functional groups derivatised. 
The derivatives formed from structurally related drugs (eg. barbiturates, B-blocking 
agents, phenylethylamine derivatives) and their chromatographic characteristics 
were similar. For example, no PFP-related compound was formed by any of the 
diuretic agents. The anti-diabetic agents each expelled the SO 2 group in their side-
chain and permitted PFPA derivatisation of an amine. The B-blocking agents 
(except labetalol and sotalol) each produced a bis-PFP derivative with similar low 
resolution El mass spectra (m/z 366, 408) which differed only in the M. 
Phenylethylamine derivatives all produced thermally stable mono-PFP derivatives. 
Data in Table 5.7 indicate that the thermal stability of PFP derivatives ranged from 
unstable at oven temperatures (severely tailing peaks; eg clonidine) to stable at both 
oven and injector temperatures. In general, the greatest thermal stability during 
chromatography was shown by drugs derivatised at amine and hydroxyl groups. The 
greatest number of PFP derivatives were detected following OC rather than splitless 
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injection, although the GC peak profile of a drug may have been complicated as 
multiple derivatives were detected. 
i. Stability and Reproducibility 
Table 5.8 shows data relating to the reproducibility of derivative formation and their 
stability with time for some PFP derivatives. The predominant derivative 
(Table 5.7) was investigated where more than one PFP derivative was formed from a 
drug. In each case the GC peak area obtained for a given PFP derivative was 
expressed as a 'peak area ratio' (Section 2.6.1). 
The stability data were obtained over 21 h. The GC peak areas of test derivatives 
(after 11 h and after 16-21 h) were compared with those obtained from a control 
(0 h; Section 2.6.1). The percentage difference between GC peak areas obtained 
from the second and third analyses, and the control analysis was reported 
(eg. [(Ohpeak area - 1 lhpeak area)/Ohpeak ared%). In general, the percentage difference for 
a derivative indicated that the peak areas obtained in the subsequent analyses had 
decreased from that of the control. However, where an increased peak area was 
observed, a negative percentage was recorded (eg. 10 amines; Table 5.8). 
The reproducibility data shown in Table 5.8 were obtained over two days from 
working drugs solutions of approximately 4 ng/111. Derivatives of ranitidine, 
temazepam, haloperidol and terfenadine could not be detected at that concentration. 
Day 1 data was obtained from replicates which were analysed 10 to 11 h following 
their derivatisation. During that time, the sample vials were seated in the rack of the 
autosampler at room temperature. Day 2 data was obtained from replicates which 
were analysed only 1 to 2 h following their derivatisation. 
Consequently, 'within Day 2' data gave the best indication of the reproducibility of 
derivative formation within a day as Day 1 reproducibility data could not be 
interpreted independently of stability data. The 'within Day' data was the difference 
in GC peak areas obtained from replicates (R1 and R2) and reported as a percentage 
of the smallest replicate peak area [(Rlpeakarea R2peakarea)R2peakarea]%, where 
Rlpeakarea R2peakarea • The  `b/w Day' data was the difference in mean peak areas 
obtained from Day 1 and Day 2 replicates and reported as a percentage of the 
smallest mean peak area. 
The data in Table 5.8 indicate that derivatives formed from 3-blocking agents and 
drugs derivatised at 2° amine groups were both stable with time (up to 21 h), and 
reproducibly formed. As the derivatives were stable for up to 21 h, Day 1 and Day 2 
reproducibility data were directly comparable. The data show these PFP derivatives 
to be reproducible both within the day and from day to day. Of the 13-blocking 
agents investigated, timolol showed the greatest variation in derivative formation 
between days and this was likely to be a result of the slightly poorer stability of this 
derivative over time compared with those of other 13-blocking agents. The instability 
of this PFP derivative was further indicated by the 'within Day 1' data which 
showed the percent difference in peak areas between replicates after 10-11 h to be 
four times greater than that between replicates from Day 2 after 2 h. 
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Data in Table 5.8 indicate that derivatives formed from drugs derivatised at 10 amine 
groups were relatively stable with time, but showed greater variation within the 
group after 16-21 h than did the derivatives of 2° amines. Similarly, the 
reproducibility data show that PFP derivatives of 1° amines were relatively 
reproducibly formed both within a day and between days but showed greater 
variation within the group than was observed with derivatives of 2° amines. The 
peak areas of most 10 amine derivatives increased after 16-21 h from that at t = 0 h 
and the increase was dramatic for procainamide. 
Data in Table 5.8 indicate that, for drugs derivatised at alcohol groups, individual 
derivatives differed in their stability with time characteristics. The stability of these 
derivatives after 16-21 h differed and, for those with poor stability, the deterioration 
with time was non-reporducible. 
Data indicating the reproducibility of formation of individual derivatives at an 
alcohol group was more consistent within the group of drugs investigated than were 
the stability with time data. For example, all except hyoscyamine, were relatively 
reproducibly formed as indicated by the 'within Day 2' data which showed only a 
small variation in peak areas between replicates for the majority of drugs. 
Consequently, the large variation in peak areas of derivatives 'between days' 
reflected derivative instability with time rather than non-reproducible derivative 
formation. 
Table 5.8 lists only three drugs derivatised by PFPA at a phenolic group and these 
data show derivatives with stability and reproducibility characteristics which were 
dissimilar within the small test group. Data show that derivatives of 
oxyphenbutazone and paracetamol were not stable with time and the within day 
reproducibility of oxyphenbutazone was poor. ('within Day 2' data). Data in Table 
5.8 indicate that a peak was not detected for one of the 'within Day l' replicates for 
the oxyphenbutazone derivative. Although poor derivative stability may have 
influenced the presence or absence of a GC peak for this derivative, the large 
percentage difference between 'within Day 2' replicates indicate that derivative 
formation was also quite variable. In contrast, the PFP derivative of THC showed 
both good stability with time and within day reproducibility characteristics. 
Table 5.8 show stability and reproducibility data for drug reaction artefacts. These 
drugs each possessed an alcohol group except disopyramide and carbamazepine 
which each possessed an amide group. The carbamazepine reaction artefact was 
derivatised (mono-PFP) while the remaining reaction artefacts were underivatised. 
Once formed, these reaction artefacts were very stable with time except those of 
haloperidol and terfenadine. Although no stability data was collected for warfarin, 
the large percentage difference between the peak areas of 'within Day l' replicates 
and 'within Day 2' replicates indicate that the derivative may not have been stable 
after 10-11 h, and that the deterioration was not reproducible. Consequently, 3 of 
the 7 reaction artefacts tested in this group were unstable with time. Similarly, the 
reproducibility data (where obtained) indicate both the reproducible and non-
reproducible formation of reaction artefacts in the reaction medium. 
99 
The stability and reproducibility characteristics of PFP derivatives formed from two 
benzodiazepines and from ranitidine were investigated. Data in Table 5.8 clearly 
indicate that these derivatives were unstable with time. 
ii. Linearity. 
Table 5.9 shows quantitative chromatographic data for 55 PFP drug derivatives 
collected from GC analyses over 10 h. Therefore, data from Table 5.9 cannot be 
interpreted without reference to derivative stability with time (Table 5.8). 
Each data point employed in determining linear regression equations was a 'peak 
area ratio' (Section 2.6.1). Table 5.9 lists both the target m/z ion monitored and the 
reference HC marker for individual PFP derivatives from which the peak area ratios 
were calculated. Table 5.9 shows linearity data over a defined concentration range 
for PFP drug derivatives. The concentration range is defined by the 'highest' and 
'lowest' drug amounts and 100- to 1000-fold differences in amounts injected were 
chromatographed for the majority of PFP derivatives (Section 4.3.2.3ii). The 'next 
low' amount refers to the next smallest drug amount derivatised and injected which 
could not be integrated. Consequently, the limit of detection for a given PFP 
derivative fell within the range bracketed by the 'lowest' and 'next low' amounts 
listed in Table 5.9 (Section 5.3.2.4iii). 
The linear regression equation shown for each derivative described the line of best 
fit for the log io of the data points and was fitted to log transformed data points 
over a concentration range between, and including, the 'lowest' and 'highest' 
amounts injected as listed in Table 5.9. Further discussion of the linear regression 
equation for log-transformed data points and its relationship (y = 10 c .xm) to linear 
data points is given in Section 3.3.1. The 10 m factor is given for PFP derivatives 
for which a linear regression equation was obtained. The 10m factor is a good 
indicator of derivative linearity over the concentration range tested (Section 
4.3.2.3ii). 
Linearity data (10 m) in Table 5.9 indicate the following. 
1. Data for 22% of the PFP derivatives were best fitted by an approximately linear 
equation (10m from 9.2 to 13.5; r2 from 0.990 to 0.999). The equation was 
approximately linear over a 100-2000-fold increase in concentration except for 
derivatives of oxazepam and oxyphenbutazone where the increase was 20- and 
25-fold respectively. 
2. No linearity data was obtained for 13% of the PFP derivatives listed as only 
two data points were obtained in the concentration range investigated (*). 
3. Data for 66% of PFP derivatives investigated were best fitted by non-linear 
equations (M # 1). 
4. Data for 29% of PFP derivatives were best fitted by a curve where the increase 
in detector response was greater for larger drug amounts injected (10 m from 
13.8 to 20.4). The data points for the majority of these derivatives covered a 
100- to 2000- fold increase in concentration. 
5. The data for the PFP derivative of timolol and tranylcypromine were best 
described by a curve where the increase in detector response was greater for 
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smaller drug amounts injected (10m = 6.5 and 5.5 respectively) covering 60- 
and 100-fold increases in concentration. 
6. Data for 14% of the PFP derivatives had 10 m values between 20.4 and 30. 
7. Data for 20% of the PFP derivatives had 10M>  30.0 and covered an increase in 
concentration which ranged widely from 60-fold for MDMA to 1200-fold for 
ephedrine. These data indicate that the untransformed data would be best 
described by a steeply rising curve with a dramatic increase in detector response 
being observed following an increase in the amount injected. 
Data in Table 5.8 and 5.9 indicate that, where the stability of a derivative with time 
was poor, the untransformed data points would be best fitted by a power equation 
(M # 1). For example, the peak areas of the bis- derivatives of oxycodone and 
quinine had deteriorated by 81% and 85% respectively after 11 h (Table 5.8). Data 
in Table 5.9 show that the curve fitted to linear data points for these derivatives 
would be steeply rising (10 m = 72.4 and 89.1 respectively). Other derivatives shown 
to be unstable with time in Table 5.8 were found to have similar linearity 
characteristics to those of oxycodone and quinine (haloperidol, paracetamol, 
pentobarbitone, quinidine, ranitidine, temazepam, terfenadine). In contrast, 
however, unstable derivatives of oxazepam and oxyphenbutazone identified in Table 
5.8 were relatively linear over the concentration range tested (10 m = 9.5, and 10.5 
respectively). 
Data in Table 5.9 show that the PFP derivatives of the structurally-related B-blocking 
agents and drugs derivatised at a 2° amine function were all relatively linear over, a 
broad range of concentrations although individual drugs varied from this trend 
(propranolol and paroxetine respectively). Similarly, over a concentration range 
which increased by greater than 25-fold, drugs which were derivatised at the 
hydroxyl function were generally best described by power equations (except 
guaiphenasin, hyoscyamine and THC). The structurally-related drugs all showed 
similar linearity characteristics (eg phenylethylamine derivatives; B-blocking agents; 
reaction artefacts and derivatives of hyoscyamine and hyoscine; derivatives of 
metoclopramide and procainamide; nortriptyline and protriptyline). The drugs 
derivatised at a 1° amine group were more variable in their linearity over the 
concentration range tested than were drugs derivatised at a 2° amine. 
Data in Table 5.9 indicate that common linearity characteristics did not generally 
exist between drugs derivatised at the same functional group. 
iii. Detection Limit 
The limit of detection for a given PFP derivative fell within the range bracketed by 
the 'lowest' and 'next low' amounts listed in Table 5.9 (Section 5.3.2.4ii). The 'next 
low' amount was not determined for some derivatives (<x). 
Data in Table 5.9 indicate that B-blocking agents, drugs derivatised at a 2° amine 
function (10m <20), and the reaction artefacts of drugs with an amide grouping, 
were consistently detected at < 100 pg injected (except timolol). Instrument 
sensitivity was very poor (> 10 ng) for derivatives of the anti-diabetic agents 
101 
(sulphonylurea grouping), ranitidine, temazepam and dehydration products 
haloperidol and terfenadine. 
Data in Table 5.9 show similar limits of detection for PFP derivatives of structurally-
related drugs (B-blocking agents; phenylethylamine derivatives except MDMA; the 
anti-diabetic agents; quinine and quinidine; nortriptyline and protriptyline; 
metoclopramide and procainamide). 
The derivatives with the lowest detection limit were those where the linear 
regression equation described the broadest concentration range. Therefore, data in 
Table 5.9 indicate that PFP derivatives with GC peak responses which were 
approximately linear over the concentration range investigated had detection limits 
<100 pg injected (except for oxazepam and oxyphenbutazone). Similarly, PFP 
derivatives where 10m <20 (gently sloping curves), had detection limits < 100 pg 
injected (except for THC, hyoscine and phenelzine). For PFP derivatives where 10 m 
> 30 (steeply rising curves), the detection limit at best was > 200 pg and <4 ng at 
worst (except phenobarbitone > 70 pg). 
Appendix B.3.1.2 ii. and Table B.8 give the limits of detection for some stable PFP 
derivatives determined following OC and splitless injection. OC injection gave 
instrument sensitivity greater than, or equal to, that achieved following splitless 
injection and, in some cases, the increase was significant. 
5.4 Discussion 
The chromatographic characteristics of a wide range of PFP drug derivatives across 
different drug groups was investigated following splitless and OC injections. The 
chromatographic information recorded established a database of observed behaviour 
for these derivatives on a single chromatographic system. From these data it is 
possible to estimate and compare the readiness of different drugs to participate in 
acylation reactions with PFPA, and the apparent 'chromatographic polarity' (Section 
3.3.1) of their PFP derivatives. 
5.4.1 The Reaction 
5.4.1.1 General 
In the pentafluoropropionylation of drugs listed in Tables 5.7-5.9, the substrate 
(PFPA), leaving group (C 3F 5 0), solvent/catalyst (acetonitrile) and conditions created 
by the reaction medium were the same for all reactions between PFPA and a drug 
while the structures of the individual drug nucleophiles were relatively diverse. As 
an anhydride, the acyl group of PFPA possesses a reactive carbon atom (Appendix 
C.1). In the presence of acetonitrile both the rates of formation and decomposition of 
transient tetrahedral intermediates should have been enhanced by nucleophilic 
catalysis (Appendix C.3). Consequently, the formation or otherwise of PFP 
derivatives from the different drugs investigated under the given reaction conditions, 
was heavily dependent on the following:- 
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1. the readiness of the drug nucleophile to attack the reactive carbonyl carbon atom 
of PFPA (nucleophilicity) and the effectiveness of the attack; 
2. the leaving group properties of the drug nucleophile compared with that of PFPA; 
3. steric effects determined by the drug nucleophile which influenced the PFPAJdrug 
interaction; and 
4. the relative stability of the PFP derivatives in the reaction medium. 
5.4.1.2 Strength of Drug Nucleophiles 
The general factors which determine the strength of a nucleophile have already been 
discussed (Section 4.4.2). It should be noted, however, that nucleophiles which react 
rapidly with a saturated carbon atom in SN2 substitution reactions may not react 
rapidly with a carbonyl carbon atom and vice versa. The two sets of nucleophiles 
obey different rules of reactivity. (' ) In general, nucleophiles reacting in acylation 
reactions must be good proton bases. (' ) Consequently, unlike the butylation reaction 
(SN2), drugs with carboxylic acid groups (strong acids) do not make good 
nucleophiles for acylation reactions as the conjugate base is weak. 
The nucleophilicity of a given nucleophile participating in an acylation reaction with 
PFPA is dependent on the electron density at the attacking atom and its capacity to 
donate electrons to the electron deficient carbonyl carbon of PFPA. With the 
formation of the transient tetrahedral intermediate, however, the electron density at 
the reaction centre increases such that the presence of electron withdrawing 
substituents would ease the nucleophilic addition. Consequently, the attacking atom 
and its substituents, other functional groups carried by the nucleophile, the strength 
of inductive and resonance effects around the nucleophilic center, solvation and 
intramolecular hydrogen bonding, all affect the reactivity of an individual drug 
nucleophile (Section 4.4.2). 
Steric influences also participate in determining the effectiveness of the nucleophilic 
attack on the acyl carbon, as the larger the bulk of the nucleophile (its size and the 
space it occupies), the more difficult it is to approach the reactive carbon of PFPA 
(Appendix C.1). Steric hindrance occurs when contact between the reaction centers 
of the drug nucleophile and PFPA is made more difficult by interference from groups 
on the nucleophile that do not otherwise participate. (15) 
Consequently, as was found for drugs with diverse chemical structures participating 
in 5N2 reactions (Chapter 4), a comparison of the relative abilities of structurally-
unrelated drug nucleophiles to form tetrahedral intermediates with PFPA would be 
extremely difficult. The drug nucleophiles involved in the acylation reaction differed 
both in chemical structure and dimension, and in the attacking atom (N or 0). 
Similarly, some drug nucleophiles contained more than one attacking atom 
(his derivatives) which further influenced the rate at which the acylation reaction 
proceeded. 
5.4.1.3 Leaving Group Properties of Drug Nucleophiles 
To ensure the formation of PFP drug derivatives, the various drug nucleophiles must 
have poorer leaving group properties than either C 2F5 COOH or C 2F 5C00- 
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(Appendix C.1 and Figure C.2). As all good leaving groups are weak bases and as all 
weak bases have strong conjugate acids ( ' ) then the tetrahedral intermediate will 
decompose into a PFP drug derivative provided the pKa for each drug is greater than 
that of PFPA. 
5.4.1.4 Resonance Stabilisation of PFPA and PEP Derivatives 
The PFP derivative should experience greater resonance stabilisation than either 
PFPA or the tetrahedral intermediate. The resonance stabilisation of amides and 
esters (which result from the acylation of drugs at amine and hydroxyl groups 
respectively), was greater than that of anhydrides due to their ability to better 
participate in conjugation with the CO ic bond contributing, therefore, to the 
stability of the acyl group (Appendix C.1) (' ) . 
Resonance stabilisation is greatest when the participating groups are in the same 
plane and when this is not the case, the ability to delocalise electrons among the 
groups rapidly decreases (Section 4.4.2). Due to the diversity in size and structure of 
the drug nucleophiles investigated, it was possible that through steric hindrance, 
substituents on some nucleophiles may have forced the participating group out of the 
plane of the re-established double bond between carbon and oxygen and decreased 
resonance stabilisation for those derivatives. The resulting derivative may have 
subsequently decomposed into relatively more stable structures (eg reaction artefacts 
or other products which were not detected by GC). 
5.4.1.5 The Reaction Medium 
In acylation reactions with acid anhydrides, an acidic (non-aqueous) reaction medium 
was created which could potentially destroy acid-sensitive PFP derivatives and lead 
to lower derivative yields (Appendix C.2). Similarly, lower derivative yields have 
resulted following degradation of derivatives in the presence of excess anhydride. (6 ' 14) 
For example, dehydration at 10 amide groups to form nitriles has been reported in the 
presence of excess acid anhydride (6 ' 14) and nitrile formation was observed in the 
acylation of disopyramide (Table 5.4). 
The conditions created by the reaction medium were significant for those drugs 
which formed unexpected reaction artefacts following their acylation. A dehydrated 
drug structure was identified for a number of drugs derivatised at an alcohol 
functional group. In the acylation of oxycodone, enol formation in the reaction 
medium made available a hydroxyl group for a second derivatisation site. A similar 
process has been reported for medroxyprogesterone acetate. (6) The bis- derivative 
observed for desipramine resulted from side-chain dehydrogenation of desipramine 
in the reaction medium. (13 ' 17) Captopril, H2-receptor antagonists and the anti-diabetic 
agents (sulphonylurea grouping) were all observed to form unexpected reaction 
artefacts within the reaction medium. 
Conditions in the reaction medium were also significant for those drugs which 
formed reaction artefacts following acylation which would commonly be observed as 
GC artefacts following splitless injection (eg. carbamazepine, hyoscyamine, 
tolbutamide and chlorpropamide). Clearly, the instability of some underivatised 
104 
drugs at elevated injector temperatures was manifested under another set of extreme 
conditions such as those created in the reaction medium. It is postulated that in the 
PFPA acylation of untested drugs which are prone to GC artefact formation, that the 
same GC artefact is likely to be formed as a reaction artefact (derivatised or 
underivatised) in the reaction medium. 
Consequently, in conditions created by the reaction medium, the following was 
observed. 
1. The individual structure of a drug nucleophile made it susceptible to participation 
in unexpected reactions. 
2. The characteristic structure of the drug nucleophile, together with the nature of the 
PFP-drug bond, determined derivative stability in the presence of excess acid and 
acid anhydride. As reaction artefacts were not commonly formed from drugs 
derivatised at a 10 or 2° amine group (except desipramine) but were formed more 
often from drugs derivatised at an alcohol group, the carbonyl carbon-nitrogen 
bond appeared to be less reactive than the carbonyl carbon-oxygen bond in the 
reaction medium. 
3. The characteristic structures of underivatised drugs which made them thermally 
unstable at elevated temperatures were likely to impart instability in the reaction 
medium. 
5.4.1.6 Drug Nucleophiles 
A reactive drug nucleophile possessed properties which caused it to readily react 
with PFPA and form a transient tetrahedral intermediate which rapidly ejected 
C2F5COOH or C2F5C00 - and resulted in the formation of a PFP derivative of the 
drug which was stable in the acidic conditions created by the reaction mixture. The 
reactivity of a drug nucleophile was determined by factors described above (Sections 
5.4.1.2-5.4.1.5). 
From the data shown in Tables 5.7-5.9, it can be concluded that structurally-related 
drugs formed nucleophiles with similar reactivities and derivatives with similar 
properties (stability with heat and time, reproducibility, linearity). For example, the 
diuretic agents (sulphonamides) were apparently unreactive nucleophiles and no PFP 
derivatives were produced. Their low reactivity may have resulted from:- 
1. electron delocalisation at the nucleophilic center (low nucleophilicity), 
2. the sulphonamide being either greatly sterically hindered or the better leaving 
group. 
Alternatively, the sulphonamides may have reacted with PFPA, but the product of 
acylation:- 
1. possessed less resonance stability than PFPA, 
2. was unstable in the acidic conditions created by the reaction mixture, or 
3. was thermally labile and completely decomposed during GC analysis 
(Section 5.4.2). 
In contrast, 13-blocking agents were reactive nucleophiles under the present reaction 
conditions which allowed them to approach PFPA readily and form the tetrahedral 
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intermediate. The 13-blocking agents possess hydroxyl and amine groups which have 
poorer leaving group properties than either C 2F 5 COOH or C2F 5C00 - . The bis-PFP 
derivatives formed had greater resonance stabilisation (esters and amides) than PFPA 
and were stable in the reaction medium and during GC analysis. 
Table 5.7 listed the derivatives formed from drugs with different functional groups. 
Where bis- derivatives were formed there was more than one reactive nucleophile 
present in the drug structure (eg. 13-blocking agents, guaiphenasin, desipramine). The 
formation of a single major PFP-drug product indicated that the drug nucleophile had 
sufficient reactivity to progress through the successive steps of the acylation reaction 
and form a derivative that was stable both in the reaction medium and under the 
conditions required for chromatographic analysis. As might be expected, reactive 
drug nucleophiles were generally those with attacking N atoms (amines) or attacking 
0 atoms (hydroxyl). As exceptions were observed, however, the individual structure 
of the drug nucleophile together with the functional group derivatised was significant 
in determining reactivity. For example, some drugs which possessed amine and 
hydroxyl groups were unreactive nucleophiles and no derivative was formed due 
either to low nucleophilicity or steric hindrance (eg. prazosin, chloroquine, 
theophylline, benzhexol). Other drugs with these functional groups (eg 
chlordiazepoxide, fluphenazine, prednisolone, procyclidine) made more reactive 
nucleophiles as PFP-related products were chromatographed. The multiple products 
formed by these drugs, however, indicated a high degree of derivative instability. 
The unstable derivatives were short-lived and decomposed/rearranged into related 
products either within the reaction medium or during chromatographic analyses. 
Similarly, the formation of reaction artefacts from drugs with hydroxyl functions 
suggested that either the drug or the PFP derivative of the drug was unstable in the 
reaction medium. For these drugs, a greater degree of stability was attained 
following their rearrangement/dehydration than through the simple formation of a 
PFP derivative from the drug. 
Clearly, reactivity of drug nucleophiles were determined by their individual 
structures. 
5.4.1.7 Catalysis 
Acylating reagents can be used either alone, or in combination with a variety of 
different catalysts. In the literature, strong bases affect the formation and 
decomposition of the tetrahedral intermediate leading to shorter reaction times, lower 
reaction temperatures, greater derivative yields and derivatisation of a variety of 
different functional groups. (1,2,7-12) In the present work, however, the base-catalysed 
acylation of amphetamine, methylamphetamine, morphine and codeine by the strong 
bases (pyridine, DEA) proved detrimental to derivative formation. These catalysts 
were also difficult to remove following reaction and generated 'dirtier' 
chromatograms with additional peaks that interfered with the peaks of interest. The 
yellow reaction mixture observed during the derivatisation of morphine and codeine 
in the presence of either catalyst has been observed with pyridine and reported to 
contaminate the electron capture detector. (6) Similarly, the residue formed by the 
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side-reaction of pyridine with acid anhydrides (Appendix C.3) was also produced 
with PFPA although it was soluble in the GC injection solvent. 
Had the test drug group contained a greater number of drugs with different functional 
groups it is possible that catalysis may have been apparent with these strong bases. 
The improvement in derivative yield, however, would have had to be very significant 
to offset the practical problems presented by these catalysts. With the use of 
acetonitrile as a catalyst, the appearance of the reaction mixture and chromatograms 
were similar to those produced by PFPA and ethyl acetate. Acetonitrile appeared to 
be behaving simply as a solvent, although the yield of mono-PFP codeine was 
increased. 
The catalysis of drug acylation with acetonitrile would, in theory, proceed as it did 
for pyridine (Appendix C; Figure C.1; Equation 2). A protonated acetonitrile-acyl 
compound would result from the reaction of PFPA and acetonitrile following the 
rapid ejection of the carboxylate ion (the weakest base and better leaving group) from 
the unstable tetrahedral intermediate. The protonated compound produces a greater 
positive charge on its carbonyl carbon, making it more attractive to attack by a drug 
nucleophile. Acetonitrile could subsequently accept acids formed during the 
acylation. However, in comparison to pyridine, acetonitrile is only a very weak base 
despite the lone electron pair of the nitrogen atom. Although the nitrile group is 
shown as a triple bond, the greater electronegativity of nitrogen results in 
considerable polarisation of the triple bond such that there is a partial positive charge 
on the carbon and a partial negative charge on the nitrogen. (4) The electronegativity 
of nitrogen in this unsaturated state causes its electron donor capacity to be 
diminished from that in saturated states (amines). (4) It is likely then, that amine (and 
hydroxyl) drug nucleophiles would have better nucleophilic properties (greater 
electron donor capacity) than acetonitrile and more readily attack the carbonyl carbon 
of PFPA. Similarly, nitriles can be protonated only under very strongly acidic 
conditions (RCC=N+H) and is only partially protonated in sulphuric acid solution. (5) 
Although acylation with PFPA does proceed in an acidic medium, acetonitrile may 
be only a weak proton acceptor. Acetonitrile must be a very weak basic catalyst and 
although it has been said to catalyse the reactions of both amine and hydroxyl groups 
with acid anhydrides", it may simply be a good solvent for these acylation reactions. 
5.4.1.8 Reaction Time 
The rate of formation and decomposition of the tetrahedral intermediate determines 
the rate of PFPA derivatisation of drugs (Appendix C.1). Data in Table 5.3 showed 
that PFP derivative formation occurred within 5 min for some drugs (desipramine, 
codeine) while up to 120 mm was required for others (amphetamine, terfenadine) 
despite derivatisation at similar functional groups (1 0  amine, alcohol). Clearly, the 
individual structures of these drug nucleophiles were determining the rates of 
formation of the intermediate in addition to the functional group derivatised. 
Consequently, formation was slower for amphetamine and terfenadine than for 
desipramine and codeine due to differences in the reactivity of the individual 
nucleophiles as determined by structure. The individual structural characteristics of a 
particular drug nucleophile governed its nucleophilicity, the ease with which the 
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nucleophile approached the carbonyl carbon (steric hindrance) and the electron 
density at the reaction center. For a given drug nucleophile, each of these factors 
influenced the rate of formation of the tetrahedral intermediate differently, despite 
similarities in the functional group derivatised. 
5.4.2 PFP Derivatives 
5.4.2.1 Overview 
Approximately 90 drugs with functional groups capable of being acylated were 
derivatised with PFPA and their derivatisation products (if formed) were 
chromatographed and detected by low resolution El mass spectrometry. Data in 
Table 5.7 identified derivatisation products and listed their general chromatographic 
and mass spectral characteristics. It was found, however, that the low resolution El 
mass spectra obtained from these products were not easily interpreted in terms of the 
structure of the underivatised drug and the predicted derivative. For 22 of the drugs 
investigated, additional mass spectral data (CI and accurate mass determination) were 
necessary to identify the derivatisation products and sites of derivatisation 
(Table 5.4). It was found that attempting either to predict the derivative formed from 
some drugs, or to identify some new PFP derivatives from their low resolution El 
mass spectra, was unsuccessful for the following reasons:- 
1. the absence of a molecular ion, 
2. the potential for unusual mass spectral fragment rearrangements, and 
3. the potential formation of reaction artefacts (dehydration of the drug or the 
formation of unique derivatives involving chemical reactions which could not be 
predicted). 
Similarly, it has been reported in the literature that a number of compounds other 
than drugs are known to form derivatives other than those expected. (I '6) It was shown 
that during the derivatisation of drugs with PFPA, several side-reactions can 
potentially occur within the reaction medium to produce unusual derivatisation 
products which may or may not be subsequently acylated. Consequently, the identity 
of the derivative produced following the reaction of a new drug with PFPA should 
not be assumed, particularly if the drug possesses alcohol or 10 amide groups. 
From the data summarised in Table 5.7 for the drugs investigated, some general 
statements about the reaction between PFPA and drugs can be made. 
1. Mono- and bis- PFP derivatives are generally formed from drugs derivatised at 
1° and 2° amine and hydroxyl groups. Some drugs which possess these 
functional groups, however, form multiple unidentified products. 
2. Drugs with sulphonamide and sulphonylurea groupings, either form no 
derivatives, or derivatives sensitive to elevated temperatures. 
3. Similar reaction artefacts and/or derivatives are formed from structurally-related 
drugs (structural analogues) and behave similarly when chromatographed. 
4. Reaction artefacts are not commonly formed from drugs derivatised at their 
1° and 2° amine functions. 
5. Reaction artefacts commonly occur following derivatisation of drugs at their 
alcohol functional group (often the dehydrated drug), sulphonylurea or 1° amide 
group. 
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6. GC artefacts which would commonly be chromatographed following splitless 
injection are formed and sometimes derivatised within the PFPA reaction 
mixture. 
No derivatives were formed from the structurally-related diuretic drugs 
(sulphonamide grouping) and it was not the proximity of the SO 2 group to the NH2 
group (site of derivatisation) which prevented their derivatisation, as derivatised 
reaction artefacts were formed from the anti-diabetic drugs (chlorpropamide and 
tolbutamide). A PFP derivative may not have been detected for several reasons as 
follows. 
1. The diuretic drugs are much larger, bulkier compounds than the anti-diabetic 
drugs and steric hindrance may have prevented the formation of the tetrahedral 
intermediate. 
2. A PFP derivative may have been formed which was too unstable to persist either 
in the reaction medium or under chromatographic conditions. The derivatised 
reaction artefacts of the anti-diabetic agents provided evidence of the instability of 
compounds derivatised at a sulphonamide group as they were unstable at injector 
temperatures. 
3. A derivative and/or degradation products were formed which did not 
chromatograph. 
The sulphonamide grouping has been successfully derivatised with trifluoroacetic 
and heptafluorobutyric anhydride in the presence of TMA. (18) However, smaller, less 
bulky compounds than the diuretic drugs were derivatised which were very similar to 
the reaction artefacts of the anti-diabetic agents (eg. benzenesulphonamide and 
n-ethyl- and n-phenyl-benzenesulphonamide). Interestingly, the perfluoroacyl 
derivatives of benzenesulphonamide could not be chromatographed. (18) 
It should be noted that the factors above which may have prevented detection of 
diuretic drug derivatives may also explain why no derivatives were detected for other 
drugs with functional groups capable of being acylated. Alternatively, the use of 
appropriate catalysts and optimisation of chromatographic conditions may improve 
derivative formation and detection. For example, no chloroquine derivative was 
detected under the present conditions but mono-PFP chloroquine was formed in the 
presence of TMA and, following on-column injection, was chromatographed on a 
25 m OV-1 fused silica capillary column (0.33 mm i.d; oven temperature 125°C to a 
maximum temperature of 220°C). (19) The analytical conditions ensured derivative 
formation through nucleophilic catalysis and the chromatographic conditions selected 
ensured that the derivative was exposed to low oven temperatures for a short period 
of time (retention time of 7 min) during its chromatography. 
The B-blocking agents were the largest group of structurally-related drugs 
investigated and the influence of subtle structural changes on the formation of PFP 
derivatives can be demonstrated for these drugs. Predictable bis-PFP derivatives of 
each drug except labetalol and sotalol were formed. Labetalol formed an unexpected 
derivative identified as the bis-PFP derivative of the doubly dehydrated drug (Table 
5.4). Although dehydration of labetalol was not predicted, some difference in the 
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PFPA—drug reaction might have been expected given the structural difference of the 
side-chains between labetalol and other B-blocking agents (Figure 5.3). The identity 
of the sotalol derivative was not immediately apparent from the low resolution El 
mass spectrum. Having determined that dehydration reactions could potentially 
occur in the reaction medium, however, and given the structural similarity between 
labetalol and sotalol at their side-chains, it was not unexpected that the derivatisation 
product of sotalol was identified as the mono-PFP derivative of the dehydrated drug 
(confirmed by low resolution El mass spectrometry). 
In general, the B-blocking agents formed a single bis- derivatives, but multiple 
derivatives were produced following the derivatisation of pindolol and timolol. 
Although the side-chain at which derivatisation occurred was similar for these drugs, 
there were substantial differences from the other drugs in the structures of the core of 
these molecules (Figure 5.3) which may have affected the stability of derivatives 
(Section 5.4.1.6). 
The structural similarities of the sidechains at which derivatisation occurred for the 
B-blocking agents predictably resulted in similarities in their low resolution El full-
scan mass spectra, and common fragment ions (m/z 366 and m/z 408) were formed. 
Similarly, of the phenylethylamine derivatives with a 2° amine function, a common 
fragment ion m/z 204 was formed. 
Practical data was generated with regard to the stability of some PFP derivatives at 
splitless injection and oven temperatures (Tables 5.5-5.7), the reproducibility of 
derivative formation and their stability with time (Table 5.8), the linearity of 
derivatives over wide concentration ranges and instrument sensitivity to PFP 
derivatives (Table 5.9). 
5.4.2.2 Stability at Elevated Temperatures 
The chromatographic stability of some PFP derivatives was initially investigated 
using three different injection techniques and was found to improve when exposure 
to elevated injector temperatures was removed (Section 5.3.2.2). The EPC injection 
was a splitless injection. The greater gas flow through the injector at 40 psi, 
however, minimised losses of high boilers due to injector discrimination and speeded 
the transfer of the sample from the hot injector to the front of the column (Appendix 
B.3.1). Although sample exposure to the injector temperature following injection at 
40 psi was reduced from that following injection at 10 psi, all sample components 
still experienced 260°C for some period of time (seconds). The instability of some 
derivatives to elevated injector temperatures was illustrated with the chromatography 
of the etafedrine derivative. This derivative degraded into several unresolved peaks 
(GC artefacts) following EPC and splitless injections while following either SPI and 
OC injections the integrity of its structure was maintained. 
The SPI injection was also a splitless injection, but under SPI conditions individual 
sample components were exposed to the minimum temperature required to volatilise 
them rather than to a constant 260°C. The SPI injector ramped rapidly (180°C/min) 
to 320°C which implies that, although a sample component was volatilised at its 
110 
OH 
0.CH 2 sCH•CH 2 -NH•CH(CH 3 ) 2 
CH CH:CH 2 
OH 
O.CH 2 1H•CH 2 .NH•CH(CH 3 ) 2 
II 
OH 
0.CH 2 .CH•CH 2 •NH•CH(CH 3 ) 2 
0•CH 2 . CH:CH 2 
III 
OH 
0.CH 2 .CH -CH 2 -NH•CH(CH 3 ) 2 
IV 
?I-1 3 
C 6 H 5 .CH 2 .CH 2 -CH-NH -CH 
CO.NH 2 
V CHOH 
/ \N 0\ 
OH 
0.CH 2- — CH2.NH•C(CH3)3 
VII 
NH 
CH 2 .CH 2 0.C H , 
0.CH 2 .CH-CH2.NH•CH(CH3)2 
OH 	VI 
Figure 5.3: The structures of B-blocking agents - alprenOlol (I), metoprolol (II), 
oxprenolol (III), propranolol (IV), labetalol (V), sotalol (VI), pindolol (VII) and 
timolol (VIII). (16) 
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minimum temperature, it was exposed to higher temperatures during the time 
required to flush it onto the front of the column. Mono-PFP hyoscyamine was only 
chromatographed following OC injection indicating that the brief exposure to 
excessive injector temperatures it experienced during SPI injection caused its 
degradation. 
Clearly both EPC and SPI injection could result in the degradation of thermally 
sensitive derivatives and/or the formation of GC artefacts, but these occurrences 
would be very greatly reduced following SPI injection. Under OC injection 
conditions, the sample was transferred as a liquid directly onto the front of the 
column without exposure to heat. Therefore, following OC injection the peak areas 
of thermally unstable derivatives would be greatest and the peaks of GC artefacts 
absent. Consequently, the data in Table 5.5 indicated that SPI injection tended to 
mirror either EPC (splitless) injection or OC injection as this injection technique had 
some of the characteristics of both splitless and OC injection. 
Data in Section 5.3.2.2 indicate that the chromatography of temperature-sensitive 
derivatives was not consistent among the three splitless injections. Often a small 
peak was detected following splitless injection on the Kratos Concept ISQ system 
(EPC) which was absent following splitless injections on the other two systems. 
This resulted from the difference in gas flows through the three systems. The gas 
flow on the EPC system was higher (15 psi 1 min after injection) than the other 
systems (10 psi) causing sample components to elute more rapidly and experience 
lower oven temperatures during elution. The detection of these small peaks 
following splitless injection on the EPC system indicated the presence of thermally-
sensitive derivatives which were not completely destroyed in the injector. As 
chromatography on either of the other two resulted in sample components eluting 
more slowly at higher oven temperatures, these same derivatives were not detected as 
they degraded on the column during elution. 
There was an anomaly in data from Table 5.5 where the mono-PFP timolol was 
absent following SPI injection but chromatographed following both EPC and OC 
injection. This can have resulted only from the non-reproducible formation between 
days for that derivative. Although the reproducibility of this minor timolol derivative 
was not investigated, the reproducibility and stability of the major derivatisation 
product (bis- derivative) did show greater variability between replicates than any of 
the other 13-blocking agents investigated (Table 5.8). 
The increase in intramolecular energy at injector temperatures for thermally-sensitive 
derivatives was such that bonds were ruptured/reformed and the derivative fell apart 
in the injector. Degradation products and/or structurally rearranged GC artefacts 
were formed. The data in Table 5.6 indicate that degradation products/GC artefacts 
were detected for some derivatives while no GC peaks were apparent for others. 
Although the degradation products were flushed onto the front of the column with 
the carrier gas, only those able to be chromatographed were detected. 
Although conditions created by elevated injector temperatures were removed 
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following OC injection, the derivatives were still subject to rising oven temperatures. 
For derivatives with short retention times, the exposure was short and the oven 
temperatures relatively low. The longer the retention time of the derivative, 
however, the greater was its exposure to higher oven temperatures up to a maximum 
of 300°C. Derivatives unstable at oven temperatures also formed degradation 
products and artefacts and, unless substantial and sudden degradation occurred once a 
critical oven temperature was achieved, these products were not focussed on the 
column and were chromatographed as broad irregular complex peaks if able to be 
chromatographed at all. The tailing peaks chromatographed for the unstable 
derivatives would have had reduced peak areas as a result of their degradation on the 
column. If rapid degradation occurred at a critical oven temperature, then the 
unstable derivative may be completely destroyed and only degradation artefacts 
remain. Consequently, for the derivatives which were described with 'T' and 'R' 
chromatographic characteristics (OC injection; Table 7.6), the unresolved GC peaks 
were a complicated mixture of unstable derivatives and their degradation products 
which may themselves be thermally unstable. Clearly, the identification of 
derivative/s formed in the reaction mixture from their corresponding artefacts would 
be very difficult. The splitless injection of these temperature-sensitive derivatives, 
however, resulted in the instantaneous formation in the injector of the some of the 
same degradation products which, following OC injection, were formed on the 
column during elution. Following splitless injection, the original derivative/s were 
completely destroyed. 
It is interesting to note that, for the majority of the drugs listed in Table 5.7, 
RI values were <2500. Reaction artefacts of haloperidol and terfenadine were the 
only late eluting derivatives. It was shown in Table 5.5 that the peak area of 
dehydrated haloperidol was reduced following splitless injection. It was also 
observed that longer elution times (higher temperatures during chromatography) 
were detrimental. Consequently, it may be that both artefacts of haloperidol and 
terfenadine suffered degradation during their chromatography reflected by reduced 
peak areas. Similarly, for drugs for which no derivative was detected, it may be that 
derivatives with RI values > 2500 were formed in the reaction mixture which were 
completely degraded during their chromatography such that it appeared that no 
derivative had been formed. 
From data in Tables 5.5-5.7 it was found that a greater number of PFP derivatives 
was successfully chromatographed following OC than splitless injection. Data in 
Table 5.7 indicated that PFP-related compounds showed differing degrees of 
instability with increased temperatures ranging from unstable at oven temperatures to 
stable at both oven and injector temperatures. In general, drugs derivatised at their 
amine and hydroxyl groupings showed the greater stability during chromatography, 
although exceptions were observed. Consequently, the individual structures of drugs 
were critical in determining the thermal stability of their PFP derivatives. 
5.4.2.3 Stability with Time and Reproducibility 
Table 5.8 showed stability with time data for some PFP derivatives. These data were 
a measure of the relative rates of PFP derivative decomposition with time into other 
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product/s withn the injection solvent. The decomposition products would only be 
detected if they were able to be chromatographed (unchanged), but no attempt was 
made to detect or identify decomposition products. 
It was preferable to remove the excess PFPA prior to injection as irreversible 
alteration of the GC column, corrosion or other damage to the GC-MSD system may 
have resulted from its chemical reactivity.' ) In removing the reaction medium, 
however, the stability of some PFP derivatives with time may have been 
compromised. That is, some derivatives may have been stabilised by conditions in 
the reaction medium which were changed when excess PFPA and 
pentafluoropropionic acid were removed. For example, by virtue of double bond 
migration allowing keto-enol tautomerism to produce a hydroxyl group, the bis-
derivative of oxycodone was formed in the reaction medium. Ketone formation may 
have been preferred in the injection solvent, however, which led to the rapid 
deterioration of bis-PFP oxycodone with time (Table 5.8). Similarly, the reaction 
artefacts of haloperidol and terfenadine may have been stabilised by conditions in the 
reaction medium but rapidly decomposed in the injection solvent. 
Table 5.8 showed reproducibility data for the formation of derivatives on a given day 
and between days for some drugs. The reproducibility of derivative formation would 
be a measure of what proportion of the drug consistently formed a tetrahedral 
intermediate and expelled the leaving group to form the PFP derivative, and what 
proportion of the derivative was consistently stable in the reaction medium and under 
chromatographic analysis. Where reaction artefacts were formed, the reproducibility 
data would also be a measure of the proportion of PFP drug derivative consistently 
converted to that artefact in the reaction medium. 
The proportions measured would, therefore, provide a derivative yield (x% of the 
starting drug) and the reproducibility of that same yield being formed following 
another preparation (± y%). No reference standards for PFP derivatives were 
synthesised and, therefore, no measure of derivative yield was made. With the 
derivatisation of replicate drug solutions, however, the reproducibility of formation 
of a given unknown yield of derivative/reaction artefact could be obtained by 
comparing the peak areas chromatographed for that derivative in the replicates. 
Provided the derivative/reaction artefact was stable with time, then data in Table 5.8 
showed that where the variation between the peak areas was small, a similar amount 
of drug was converted to a PFP derivative/reaction artefact. Where broad variations 
were recorded between replicates, similar amounts of drug were not converted to PFP 
derivatives as a result of one or more non-reproducible steps in the acylation 
reaction. 
Where the between day variation was large for replicates which on a given day had 
shown small variation, different but reproducible derivative yields had been produced 
on each day (provided the derivative was stable with time). The between day 
variation in derivative yield was due to subtle changes in either the reaction medium, 
or chromatographic conditions between days. Either circumstance might have 
caused more or less drug to be converted to its PFP derivative, to remain stable in the 
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reaction medium, or to be chromatographed. 
The stability data in Table 5.8 indicate, however, that not all derivatives were stable 
with time. Under this circumstance the 'within Day 2' data in Table 5.8 best 
describes the reproducibility of derivative formation on a given day while 'within 
Day l' data provides supporting evidence of derivative instability. Therefore, 
depending on the stability of derivatives with time, the 'b/w Days' data sometimes 
reflected derivative instability and at other times reflected differences in derivative 
yield. 
It was indicated in Section 4.4.2.3 that exhaustive studies regarding the stability 
and reproducibility of derivative formation for each of the target drugs were not 
warranted or possible within the time span of the project. Rather, it was necessary 
to determine whether acylation of a drug was promising enough for subsequent 
extraction experiments with target drugs (Chapter 7). It is also possible that 
further experimentation would have revealed that results recorded for the 
replicates (reproducibility data) and the decomposition of a single solution 
(stability data) represented 'out-lying' samples. 
Although data in Table 5.8 represents only two pairs of replicates and the 
decomposition of a single solution, some general trends did emerged as follows. 
1. In general, PFP derivatives that were very stable with time were also reproducibly 
formed, regardless of the functional group derivatised. 
2. The PFP derivatives of B-blocking agents and drugs derivatised at their 10 and 
2° amine groups were formed reproducibly (within and between days) and, once 
formed, were stable after 16 - 21 h. 
3. Drugs derivatised at a 2° amine group showed greater consistency in the stability 
and reproducibility characteristics of their derivatives within the group than did 
those derivatised at a 1° amine group. 
4. The peak areas of some drugs derivatised at an amine function (particularly at 10 
amines) increased at 11 and 16-21 h from those recorded at t = 0. 
5. The PFP derivatives of drugs derivatised at alcohol functional groups were 
formed relatively reproducibly and were relatively stable with time except those 
of oxycodone and quinine and its stereo isomer 
6. The PFP derivatives of the small test group of drugs derivatised at phenolic 
functional groups were not similar in their stability and reproducibility 
characteristics. 
7. The stability of reaction artefacts formed from drugs possessing an alcohol 
function was inconsistent within the test group. Where data were available for 
these drugs, most reaction artefacts were relatively reproducibly formed. 
Reaction artefacts formed from drugs with a 1° amide group were both stable 
with time and reproducibly formed. 
8. The derivatives of the benzodiazepines tested were neither stable with time nor 
reproducibly formed. 
The variation between replicates recorded for some derivatives may reflect problems 
in the chromatography of those derivatives rather than their instability or non- 
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reproducibility. In general, the esters and amides formed following acylation have 
better chromatographic properties than the polar underivatised drugs. However, 
some amides retain a residual polar character and have a tendency to tail unless 
chromatographed on a moderately polar stationary phase. (I) The residual polar 
character may also cause them to adsorb to active sites on the column. Consequently, 
the influence of chromatographic factors on quantitative data may be greater for 
drugs derivatised at amine functions than at hydroxyl functions. 
The data in Table 5.8 tend to support this. The data in Table 5.8 gives the percent 
difference in derivative GC peak area at 11 and 16-21 h from that at t=0 (100%). It 
would be expected that the GC peak area would either remain constant, or decrease, 
with time. The peak areas of derivatives formed from amines, however, increased 
with time (peak areas > 100%), particularly those formed from 10 amines and the 
peak area was greatest following the third analysis (eg. methylphenidate, 
procainamide). This implies that either the derivative continued to form in the 
absence of PFPA in the injection solvent as time elapsed (which is impossible) or 
problems in chromatography affected the peak areas of derivatives via altered peak 
shape, errors in integration and adsorption to the column (Section 3.4). The data in 
Table 5.8 suggest that adsorption to active sites on the column was influencing the 
stability data for PFP derivatives which formed amides. 
The stability, reproducibility and linearity data were collected from a sequence of 17 
consecutive analyses. The control sample (t = 0) was the first sample in the sequence 
followed by samples at different drug concentrations for linearity and the Day 1 
replicates. The 11 h and 16-21 h stability samples were samples 14 and 17 
respectively. Derivative adsorption to the column would be reduced for samples 
analysed later in the sequence as active sites were filled with adsorbed sample from 
previous GC analyses. Clearly, the problem of adsorption was most serious for 
derivatives formed at 10 amines although, as it was observed for other amide 
derivatives, the individual structures of drugs also contributed to the polarity of the 
amide grouping. For example, although derivatives of metoclopramide and 
procainamide were structurally similar, their polarities must have been quite different 
as the derivative of procainamide was much more prone to column adsorption than 
that of metoclopramide. 
The greater variation in `b/w Days' data observed for 10 amines compared with 
2° amines probably reflected the decreased adsorption of these derivatives for Day 2 
replicates. Therefore, in quantitative analyses of derivatives formed at amine 
groupings, particularly at 10 amines, prior column priming would be advisable. 
Data in Table 5.8 indicates that stability and reproducibility data are not similar for 
drugs derivatised at a phenol function. Given that the individual structures of drugs 
strongly influence all aspects of derivative formation and their properties, the lack of 
consistency in reproducibility and stability data for these derivatives is not surprising 
as they are structurally very different compounds. 
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5.4.2.4 Linearity 
Table 5.9 showed linearity data for 55 PFP derivatives. No data was obtained for 
13% of derivatives. For the remaining derivatives, data indicated that linear to 
gently sloping curves best described the concentration range tested for 
approximately 50% of the derivatives investigated (10 m <20). Common linearity 
characteristics did not generally exist between drugs derivatised at the same 
functional group. For example, drugs derivatised at the 2° amine function were 
relatively linear over a broad range of concentrations, but variations did occur (eg 
paroxetine). Similarly, over a concentration range which increased by > 25 fold 
(broad concentration range), drugs derivatised at the hydroxyl function were 
generally best described by power equations. In contrast, structurally-related drugs 
had similar linearity characteristics (eg 13-blocking agents). 
Data in Table 5.9 were collected over 10 h. The data points obtained for stable PFP 
derivatives would not be affected by the time elapsed between derivatisation and 
analysis. As the time between derivatisation and analysis increased for PFP 
derivatives with relatively poor stability, the peak area obtained for a given data 
point would be proportionately smaller than if it had been analysed immediately 
following its derivatisation (Table 5.8). As the drug amounts which would define 
the upper and lower extremes of the concentration range were analysed earliest 
(Section 2.6.1), a curve rather than a straight line might be expected for derivative 
which was unstable with time. The data in Tables 5.8 and 5.9 confirm this as, where 
the stability of a derivative with time was poor, the linear data points were found to 
best fitted by power equations (Section 5.3.2.4 ii.). In contrast, unstable derivatives 
of oxazepam and oxyphenbutazone were relatively linear over the concentration 
range tested. These derivatives, however, gave responses over much narrower 
concentration ranges than other derivatives found to give linear GC responses. 
A curve rather than a straight line would best describe data over the concentration 
range tested where the chromatography of the derivative was affected by column 
adsorption. The effect of column adsorption on stability data shown in Table 5.8 
was discussed in Section 5.4.2.3. Similarly, as linearity data was generated, 
derivative adsorption to the column was reduced for samples analysed later in the 
sequence as active sites were filled with adsorbed sample from earlier analyses. 
Consequently, where column adsorption was significant, power rather than linear 
equations described the concentration range tested. 
It would not be unreasonable to assume that, as the residual polar character of 
amides was governed by overall drug structure, the polarity or otherwise of esters 
may be influenced by their drug structure. Data in Table 5.9 indicate this to be the 
case. It is postulated that as power equations described the broad concentration 
ranges of many derivatives formed at hydroxyl groups, the residual polarity of these 
derivatives resulted in column adsorption. The column adsorption influenced the 
absolute peak areas eluted and had the greatest impact for the smallest amounts 
injected (smallest absolute peak areas). In contrast, derivatives of guaiphenasin, 
hyoscyamine and THC were chromatographed without column adsorption due to 
their relatively non-polar characteristics. 
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Both linearity over a broad concentration range (Table 5.9) and good peak shapes 
for 50% of PFP drug derivatives indicate that through pentafluoropropionylation, 
the polar functional groups of these drugs were successfully eliminated, 
preventing their undesirable interaction with active sites on the column and 
excessive interaction with the stationary phase. The residual polarity apparent for 
the remaining 50% of derivatives investigated limited the concentration range 
over which they were linear. Through acylation, the chromatographic response 
for the majority of these polar drugs has been either significantly improved or 
maximised from that observed following their chromatography as underivatised 
drugs (Tables 3.2 and 3.4). 
5.4.2.5 Detection Limit 
Data in Table 5.9 indicate that similar detection limits did not generally occur 
between drugs derivatised at the same functional group while those of structurally-
related derivatives were similar. For relatively polar derivatives susceptible to 
column adsorption, linearity data from Table 5.9 suggests that the GC peaks 
chromatographed following the lowest amounts injected were so affected by losses 
to active sites on the column that they were significantly reduced or disappeared. 
All drug amounts injected which appeared in the 'next low' column (except <x) were 
unable to be integrated as a result of either complete or partial column adsorption at 
that level. Therefore, those derivatives with chromatographic linearity described by 
power equations were also those for which detection limits were relatively higher. 
The same outcome was observed for polar and non-polar underivatised drugs 
(Table B.12). 
The detection limit gave an indication of the yield of derivative from the reaction of 
PFPA and drug. Where a peak was detected following the derivatisation of a 20 pg 
amount of drug, then the yield of derivative from the reaction must have been high as 
the detection limit of the MSD is at pg levels. In contrast, where a peak could not be 
detected following the derivatisation of a 4 ng amount of drug, then it can be 
concluded that the yield of derivative from the reaction was poor. The determination 
of whether or not the derivative yield from a particular PFPA-drug reaction was high, 
however, is complicated by the affects of column adsorption, derivative instability 
with time and excessive temperatures, and the reproducibility of derivative 
formation. A linear regression equation was not obtained for derivatives of 
haloperidol, ranitidine, temazepam and terfenadine. Only the two largest amounts 
which were injected of these drugs produced a GC peak which could be integrated. 
Data in Table 5.8 indicated that these derivatisation products were very unstable with 
time. No reproducibility data was obtained as these derivatives were not detected at 
the level injected (ng quantities) even though the 'within Day 2' replicates were 
analysed almost immediately. Therefore, derivatives of these drugs were not only 
unstable but produced a very low yield of product. 
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Chapter 6. 
EXCLUSION OF SOME TARGET DRUGS FROM 
FURTHER INVESTIGATION 
6.1 Introduction 
The chromatographic information obtained for drugs and drug derivatives in 
Chapters 3-5 enabled a database to be established which recorded the observed 
behaviour of these analytes on a non-polar chromatographic system. From these data 
it was possible to estimate and compare the apparent 'chromatographic polarity' 
(Section 3.3.1) of individual drugs. Comparisons were made between the 
chromatographic properties of underivatised and derivatised drugs and their 
structural characteristics which permitted the formation of either butyl or PFP 
derivatives (Sections 3.4, 4.4 and 5.4). In many ways, these data add to the 
published information which is fragmentary as it deals mainly with either selected 
drugs, or single drug groups, and does not permit comparison across groups. The 
drugs studied were representative of a wide range of chemical structures and 
functionalities. Consequently, the chromatographic properties of other drugs and 
their suitability to participate in derivatisation reactions with either n-butyl iodide or 
PFPA may be reliably estimated provided they are structurally similar to a drug 
already investigated. 
In Section 3.1 it was stated that the development of a comprehensive drug extraction 
strategy could not be explored without first being confident that target drugs could be 
chromatographed and detected at concentrations equivalent to expected therapeutic 
blood concentrations. The primary aim of experiments in Chapters 3-5 was to 
generate data which would define the limitations of the GC/MS as an analytical tool 
for a large group of structurally-unrelated drugs which possess a variety of different 
functional groups. 
It was observed that manipulation of some chromatographic variables (eg. column 
phase ratio; absolute gas flow through the column; exposure to elevated temperatures 
during either injection or column elution) could significantly improve the 
chromatographic response of some drugs. For polar drugs, however, derivatisation 
was required to sufficiently improve their chromatographic response on the non-polar 
GC system. 
6.2 Practical Considerations 
To maximise the number and chemical diversity of drugs which can be detected by 
the broad drug screening procedure, the extract produced following the extraction of 
a blood specimen must be appropriate for both underivatised and derivatised GC 
analyses. The analysis of multiple GC fractions has the advantage that some drugs 
could be identified in two separate fractions and this would provide strong 
confirmatory evidence of the presence of a drug in a blood specimen (Section 1.3). 
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In Section 1.4.2 it was indicated that a comprehensive drug screening procedure 
which employed benchtop GC/MS operated in SIM mode would require that the 
analyses should target specific drugs. Consequently, a choice was made as to which 
drugs would be selected for investigation, given that not all drugs currently available 
(prescribed and illicit) could be included in the time frame of the present research. 
Table 1.2 listed over 220 drugs which met at least one of several criteria for inclusion 
in the drug screening procedure. Not all target drugs listed in Table 1.2 were 
investigated chromatographically (Chapters 3-5), but their chromatographic 
behaviour and the likelihood that they would form either butyl or PFP derivatives can 
be estimated where these untested drugs are structurally similar to target drugs 
already studied (Section 6.1). 
In Chapter 5 it was shown that the majority of PFP derivatives were detected 
following OC injection as some temperature-sensitive derivatives decomposed at 
splitless injection. If both OC and splitless injections were to be routinely employed 
by the broad drug screening procedure, it would require that two different injection 
ports on the GC be utilised. Consequently, from a practical perspective, all GC 
fractions could not be analysed in a single automated overnight sequence as column 
switching either at the detector (dual columns) or injector (single column) would be 
required. It was necessary, therefore, to compromise on the total number of PFP 
drug derivatives which could be detected by employing splitless injection routinely 
for the analysis of all GC fractions. 
6.3 Retention and Elimination of Target Drugs 
Table 6.1 lists the calculated lowest drug concentration in blood (j.1g/mL) which 
could be detected by GC/MS for 177 drugs and their derivatives investigated in 
Chapters 3-5. This concentration was calculated from the smallest amount of 
drug/derviative in a pure solution which was detected (Tables 3.2, 3.4, 4.8 and 5.9) 
and assumes the following conditions:- 
1. 100% drug recovery from blood; 
2. extraction of drugs from 0.5 mL of blood for those detected underivatised or as 
PFP derivatives, and from 1.0 mL of blood for those detected as butyl derivatives 
(Figure 2.1); 
3. a 1 lit splitless injection; and 
4. a final volume of 50 [IL for all underivatised and derivatised blood extracts. 
The expected therapeutic range in serum or plasma is listed where a GC peak was 
detected for either a drug and/or GC artefact, or its butyl or PFP derivatives or 
reaction artefacts in the majority of instances. (1-6) The exact data between sources 
often differed but were generally comparable, and were absent for many drug 
metabolites; a therapeutic range or peak plasma level is listed for 143 drugs and 
derivatives. The therapeutic ranges listed in Table 6.1 serve only as a guide (Section 
10.1) to the drug concentrations that might be expected in blood specimens as:- 
I. there is considerable individual variation in response to a drug; 
2. pharmacological tolerance can develop with repeated use of the same drug; and 
3. different effective ranges are cited") for different pharmacological actions of the 
same drug. 
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Many of the drugs listed in Table 6.1 were chromatographed in both underivatised 
and derivatised forms. No single GC peak ('x' or 'M') was detected for 8.5% of 
drugs following chromatography of either their underivatised or derivatised forms 
(eg. diuretic agents - acetazolamide, chlorthiazide). 
Data in Table 6.1 indicate that for 94% of drugs for which a therapeutic range or 
peak plasma level could be given, the minimum estimated level in blood which could 
be detected following GC/MS analysis fell within, or below, the reported therapeutic 
ranges for those drugs. Consequently, should a blood specimen contain these drugs 
at therapeutic levels, it would be expected that the GC/MS could detect them 
(assuming 100% recovery from blood). These drugs, therefore, were selected for 
further study (Chapter 7). 
Table 6.2 lists 120 drugs eliminated from further investigation which were 'flagged' 
in Table 1.2 for inclusion in an automated broad drug screening procedure designed 
for both clinical and forensic applications. Data in Table 6.1 indicate that, as either 
no GC peak or multiple peaks were detected for some drugs, the instrument and/or 
GC conditions were clearly inappropriate for these drugs and their derivatives (if 
formed) and so they were eliminated from further study (Table 6.2). Similarly, the 
chromatographic responses of other drugs and drug derivatives listed in Table 6.1 
were not great enough to ensure they would be detected in blood specimens at 
therapeutic levels (the minimum calculated level detected > highest reported 
therapeutic level). These drugs, therefore, were also eliminated from further study 
(Table 6.2). 
It was important that some drugs for which the minimum estimated level detected 
was greater than the highest reported therapeutic level were included in a broad drug 
screening procedure designed for a forensic (toxicological) application (Table 1.2; 
eg. oxycodone). Although these drugs would not be detected at therapeutic levels 
their presence at higher (potentially toxic/fatal) blood levels would be possible and, 
consequently, they were not excluded from further investigation. Haloperidol, 
however, could not be chromatographed at concentrations equivalent to even fatal 
blood levels on the non-polar column and GC temperature parameters selected for 
this study, and was, therefore, excluded (Table 6.2). 
Of the approximately 220 drugs selected for inclusion in the broad drug screening 
procedure (Table 1.2) the selection of some was based on their DDD > 0.3 (Section 
1.5 and Table 1.1). The DDD value of these drugs indicated that they were likely to 
be commonly encountered in the community and included many mineral 
supplements (calcium, iron), hormonal medications, antibacterial and antifungal 
agents, and topical or localised (non-systemic) medications. Some of these 
medications are high molecular weight, relatively involatile compounds and would, 
therefore, be better suited to analysis by HPLC than GC. It is not unexpected then, 
that from the data generated in Chapters 3-5, it is estimated that the instrument 
and/or GC conditions would be inappropriate for these drugs. Similarly, it can be 
reliably estimated that following either topical or localised application of some 
medications, their levels in blood would be too low to be detected (Table 6.2). 
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Similarly, some of the drugs listed in Table 6.2 were excluded from further study on 
the basis of their reported therapeutic ranges (1-6) and their estimated chromatographic 
performance. Their estimated chromatographic performance was based on the 
chromatographic behaviour of structural analogues investigated in Chapters 3-5 and 
their observed limits of detection. For example, chlorthalidone, indapamide, 
piroxicam, temoxicam and methylclothiazide were eliminated on the basis that 
hydrochlorthiazide, chlorthiazide and metolazone could not be chromatographed. 
These drugs all possess a polar —SO 2 group either on an aromatic ring, or as part of a 
heterocyclic structure. Bumetamide was compared with frusemide and it was 
estimated that it would not be detected at therapeutic levels given the high detection 
limit observed for frusemide which is administered in relatively larger doses. 
Famotidine and metformin were eliminated as cimetidine and ranitidine could not be 
detected at therapeutic levels. 
One hundred and twenty of the drugs listed in Table 1.2 were eliminated from further 
study. Approximately 40% of these were drugs which were commonly used in the 
community (as indicated by DDD) but which did not satisfy any of the other 
selection criteria applied to drugs in Table 1.2. The elimination of these drugs, 
therefore, is likely to impact most significantly on the clinical application of the 
automated broad drug screening procedure rather than on its forensic application. In 
the clinical environment, the presence or absence of these drugs (mineral 
supplements, hormonal medications, antibacterial and antifungal agents, and non-
systemic medications) at therapeutic levels in an individual's blood may be 
important. Over 106 drugs were retained for investigation of their extraction 
characteristics from whole blood. 
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Chapter 7. 
DEVELOPMENT OF A DRUG SCREENING STRATEGY 
FOR WHOLE BLOOD 
7.1 Introduction 
7.1.1 General 
In Sections 1.3 and 1.4 it was suggested that an automated comprehensive drug 
screening procedure could realistically expect to satisfy nine requirements and seven 
of these were related to the extraction of drugs from a whole blood matrix. 
In addition, other practical objectives for the drug extraction technique are as 
follows. 
1. The need for drug specificity (excluding endogenous material). 
2. The removal of unwanted protein or other endogenous material that would 
interfere with drug identification. 
3. The removal of material that would affect chromatographic performance and 
reproducibility. 
4. Solubilisation of drugs to enable injection under initial chromatographic 
conditions. 
5. Concentration of the drug to within the detection limit of the GC/MS. 
6. Stabilisation of the drug to avoid hydrolytic and/or enzymatic degradation. 
Consequently, the aim in the development of a drug extraction procedure was to meet 
as many as possible of the stated requirements and objectives. 
7.1.2 The Test Group of Representative Drugs 
A drug extraction test mix was employed to evaluate the capabilities of the drug 
extraction techniques selected for investigation. It was necessary that the test group 
include drugs. 
1. Commonly used in the community (as indicated by DDD). 
2. Considered high priority drugs in a forensic application (eg. drugs of abuse; drugs 
which act directly on the CNS, drugs of toxicological interest). 
3. With different physicochemical properties (acidic, neutral and basic). 
4. Which represented different pharmacological drug groups (eg, anti-inflammatory 
or 13-blocking agents). 
5. Which represented the different structurally-related drug groups (Section 3.3.1; 
eg. barbiturates, benzodiazepines). 
Table 7.1 lists 33 drugs which were suitable for inclusion in a drug extraction test 
mix and which satisfied at least one of the five requirements given above. Twenty-
five of the drugs were selected (bold text). The first group (1-11) represent the drugs 
of abuse (DOA). Within this group, amphetamine and methylamphetamine represent 
typical 10  and 2° amines respectively, and their extraction characteristics may be 
• indicative of the likely recovery from blood of many other drugs with these 
functional groups. Their extraction characteristics would also be representative of 
the other phenylethylamine derivatives included in Table 7.1 (ephedrine, MDMA, 
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pseudoephedrine and phentermine). Similarly, it was anticipated that the extraction 
of 7-amino flunitrazepam would be similar to that of 7-amino nitrazepam, and that 
benzoylecgonine, morphine and oxazepam would be representative of other 
amphoteric drugs. 
The second group of drugs (12-26) are the most commonly used drugs in the 
community (DDD > 5.0; Table 1.1) which could be detected at therapeutic levels by 
GC/MS. These drugs also represent several pharmacological and structurally-related 
drug groups as indicated in Table 7.1. In addition, the extraction characteristics of:- 
1. naproxen may be representative of other drugs with carboxylic acids functions 
(including those in Table 7.1; diclofenac and ketoprofen); and 
2. paracetamol (and THC-COOH) may be representative of other weakly acidic and 
neutral drugs. 
Each drug in the last group (27-33) is representative of a specific drug group not 
already represented by another drug listed in Table 7.1. These drugs were the most 
commonly used drugs within each group (highest DDD; Table 1.1). 
Except for felodipine, the chromatographic behaviour of all of the test drugs and/or 
their butyl or PFP derivatives had been investigated (Chapters 3-5). 
7.1.3 Drug Extraction 
7.1.3.1 General 
It was indicated in Chapters 3-5 and Appendix B that drug chromatography was 
adversely affected as a result of adsorption to 'active sites' in the chromatographic 
system. Consequently, any routinely employed extraction procedure must be able to 
not only isolate drugs from blood but minimise the co-extraction of endogenous 
blood products which may cause chromatographic performance to deteriorate. 
Contamination of the capillary column and injector of the GC are the most frequent 
causes of deteriorating performance. In most cases, the contaminating species are 
involatile residues present in the injected sample.' ) Therefore, the drug extraction 
technique selected for routine use in the automated broad drug screening procedure 
will influence the amount of involatile residue present in the injected sample. One 
study' reported that samples extracted by a liquid-liquid extraction (LLE) technique 
(without additional 'cleanup' steps) contaminated the chromatographic system to a 
greater extent and much faster than those extracted by a solid-phase extraction (SPE) 
method. Consequently, the extraction method employed may have a significant 
effect on the number of GC samples which can be injected before maintenance of the 
GC system is required. 
One of the major interfering substances in blood (and other biological samples) is 
protein. There are several practical reasons for the removal of proteins from the 
biological sample prior to analysis:- 
1. to inactivate metabolic activity; 
2. to remove bound drugs from their protein binding sites; 
3. to avoid protein interferences in the identification of drugs (eg, potential formation 
of artefacts in the hot injector); and 
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4. to minimise deterioration of the capillary column and reduce contamination and 
deposits in the injector. 
Traditional protein precipitation techniques (eg with trichoroacetic acid) produce 
supernatants free from excessive contamination but which are extremely acidic. 
Consequently, acid-labile drugs would be hydrolysed with trichloroacetic acid. (2) In 
addition, these traditional techniques also cause the co-precipitation of drugs with the 
protein making them unavailable for extraction. (3) In contrast, a precipitant which 
produces a 'loose floc' (eg an organic solvent) rather than a dense, compact 
precipitate will give minimal contamination and minimises drug losses as a result of 
their co-precipitation with proteins. (3) Water miscible organic solvents such as 
acetone, methanol, ethanol and acetonitrile, are used to lower the solubility of 
proteins and precipitate them from solution. (2 '3) Organic solvents deproteinise by 
destroying quaternary and tertiary structures and often release bound drugs. (2) It has 
been reported that organic solvents in a ratio of 2:1 with the aqueous phase 
precipitate more than 90% of the protein. The relative order of effectiveness of water 
miscible organic solvents in precipitating proteins is acetonitrile > acetone > ethanol 
> methanol which is approximately inversely proportional to their polarity. (4 ' 5) 
The major disadvantage of all protein precipitation techniques, however, is the 
potential loss of drug through adsorption to the precipitate. An alternative to protein 
precipitation is to separate the protein from smaller analytes through filtration. 
`Ultrafiltration' (4) is commonly applied either as pressure or as centrifugal force 
(1000-2000g). Membranes with a molecular mass cut-off between 10000 and 50000 
are chosen. The efficiency of protein removal by ultrafiltration is very high. 
Compared with protein precipitation, ultrafiltration is a very mild method with little 
risk of producing artefacts or introducing impurities. A major disadvantage is that 
certain susceptible drugs may be adsorbed to the filtration membrane itself (4) and 
only free drug is removed as the drug-protein binding is not ruptured. 
Any sample manipulation to isolate drugs from their biological matrix may involve 
loss of drugs, introduction of impurities, formation of artefacts, a decrease in 
analytical precision and an increase in analysis time. Since the drug of interest must 
not be modified or destroyed, the isolation step usually employs a physical 
distribution of compounds between two immiscible phases. The two most common 
extraction techniques are LLE and SPE. 
7.1.3.2 Liquid-liquid Extraction 
LLE commonly involves the direct extraction of the biological sample with a water-
immiscible solvent. Drugs can be removed from their biological matrix (including 
interfering endogenous products) by adjusting pH (if necessary) and extracting the 
un-ionised form with the organic solvent. The isolation of the drugs is achieved by 
partitioning between the organic and aqueous phases and an equilibrium distribution 
is established between the two phases. The aim of the technique is to create 
conditions which preferentially distribute the drug into the organic phase and the 
distribution will be influenced by the following:- 
1. the pH of the aqueous phase; 
2. the pKa of drugs; in general, two pH units above the pKa for basic drugs and two 
pH units below the pKa for acidic compounds results in optimal extraction; (3 '6) 
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3. the extracting solvent (the partition co-efficient between aqueous phase and the 
particular solvent); and 
4. the ratio of the volumes of organic to aqueous phases; if drug recovery is low, 
either successive extractions, or extraction with a large excess of solvent, 
improves recovery. (2 '4 ' 7) 
In general, lipophilic drugs pass from water into non-polar solvents while polar drugs 
tend to favour water due to their potential for H-bonding with water molecules. 
Increasing the polarity of the extraction solvent, therefore, increases the solubility of 
the polar drug in the extraction solvent. (8) 
Early techniques involved the use of non-selective solvents (eg diethyl ether, 
chloroform) which extracted lipophilic material such as lipids and fatty acids as well 
as the drug of interest. These materials both contaminated the chromatographic 
system and interfered with the peaks of interest during their chromatography. (9) One 
of the earliest reported selective extraction solvents was n-butyl chloride which also 
gave high recoveries for basic drugs. (9) 
The solubility of many organic substances in water is decreased by the presence of 
dissolved inorganic salts. (3 ' 1°) For example, buffer solutions both adjust the pH of the 
aqueous phase and decrease the solubility of drugs in the aqueous phase by this 
'salting out' effect. The 'salt-solvent' pairing has the added benefit of decreasing 
emulsion formation' 1)  but a disadvantage is that interfering species are also co-
extracted. (9) 
7.1.3.3 Solid-phase Extraction 
SPE works on the principle of selective retention of drugs on cartridges containing 
sorbents (100-1000 mg) similar to those used in HPLC. In this process, the sample 
passes over the stationary phase and the drugs are adsorbed if they have a greater 
affinity for the stationary phase than the sample matrix, but, unlike chromatographic 
separation, the drugs are completely retained on the stationary phase rather than 
retarded. Retained drugs can be removed at a later stage by eluting with a solvent (if 
the drugs have greater affinity for the solvent than the stationary phase). Several 
reviews have explored the analytical variables associated with solid-phase 
extraction. (7 '9 ' 12) SPE provides very high theoretical recoveries due to the large 
capacity of the sorbent bed. A typical SPE consists of four steps as follows:- (7,9,12) 
1. The sorbent bed is conditioned (solvent + aqueous phase) to prepare the dry/stored 
cartridge to receive the sample, to improve reproducibility of drug retention and to 
rinse away materials contaminating the sorbent. 
2. The sample is applied to the sorbent and drugs are retained together with 
undesirable matrix constituents; unretained matrix constituents pass through the 
sorbent and are discarded. 
3. The cartridge is rinsed with a weak solvent to remove some of the undesirable 
matrix constituents. 
4. A sufficiently strong solvent selectively elutes the drugs leaving undesirable 
components retained on the sorbent. 
Therefore, drugs are selectively isolated from the sample matrix with minimal 
contamination from interfering species. 
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During cartridge conditioning, the siloxane structure of the silica binds a permanent 
layer of water molecules. Protruding from the water layer are the bonded silica 
chains and interdispersed between them are molecules of water and the conditioning 
solvent. The higher the organic content of any washing, conditioning or eluting 
solution which is applied to the cartridge, the more extended are the chains. (7) 
Consequently, it might be expected that the bonded silica chains are more extended 
during sample elution than during sample application. The analyte can be bound to 
the sorbent by a number of different mechanisms which have been reviewed. (7) The 
different mechanisms of retention or elution result from intermolecular forces 
between the analyte, the active sites on the surface of sorbent, and the liquid phase 
(sample matrix and subsequent washing and eluting solutions). (12) 
The sorbents employed in SPE are generally similar to those used in column liquid 
chromatography: nonpolar, polar and ion exchange phases each designed for 
particular analytes. 'Mixed phases' are also available which possess various 
functional groups of different character attached to the same adsorbent particle which 
can isolate drugs (polar and non-polar) over the entire pH range. (12) For example, 
Bond Elut Certify (Varian) and CleanScreen (Worldwide Monitoring) are mixed-
mode bonded silica gel SPE cartridges which contain both nonpolar (hydrophobic) 
and cation exchange functional groups specifically designed for broad drug 
screening. (13,14) 
Much of the literature addresses SPE of drugs from urine and serum. As a result of 
the tightly packed sorbent within the cartridges, the analysis of drugs in blood and 
tissues by SPE poses an analytical problem not encountered with LLE due to the 
potential for clogging of the cartridge. In addition, many drugs are present inside red 
blood cells and/or are bound to them and must be released prior to extraction. (14) The 
preparation of serum or plasma from haemolysed whole blood is not possible and, 
therefore, whole blood requires pretreatment prior to SPE. Pretreatment involves 
either protein precipitation, or dilution of the blood with a suitable buffer solution. (15) 
It has been previously indicated that protein precipitation leads to reduced drug 
recovery due to co-precipitation of drugs. A comparison of blood pretreatments prior 
to SPE has been reported. (14) It was found that drug recovery from whole blood with 
SPE was greater following sonication of the blood sample and dilution than after 
protein precipitation. 
7.1.3.4 Selection of Drug Extraction Techniques 
It was indicated in Section 1.4.1 that there had been a vast amount of literature 
published in the area of drug analysis in biological materials. Many procedures were 
designed to extract a specific drug or drug group rather than to be broadly applicable 
across drug groups. Similarly, the volume of literature devoted to the subject of drug 
analysis via chromatographic techniques indicated that it was constantly being 
explored. Consequently, published extraction techniques were considered for 
investigation if they possessed at least two the following characteristics. 
1. A range of chemically diverse drugs were extracted. 
2. Drugs were extracted from blood (including serum and plasma) or the technique 
could be easily modified to extract drugs from blood. 
3. Drugs were extracted from a single, limited volume sample (<3  mL). 
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4. The technique was routinely employed in either a forensic or clinical laboratory. 
5. The extraction efficiency for a wide range of drugs was indicated. 
6. Drug detection was by a chromatographic method of analysis (GC in particular). 
7. The technique was either very selective, or a 'cleanup' step was incorporated, 
which ensured that interfering and/or contaminating endogenous material was 
removed prior to analysis. 
8. Recovery data were given for some drugs included in the extraction test mix 
(Table 7.1). 
Table 7.2 gives limited details of 23 published drug extraction techniques selected 
for consideration. Both LLE and SPE techniques are included. SPE techniques 
which employed the mixed-mode phases designed for broad drug screening 
(extraction of acidic (A) neutral (N) and basic (B) drugs) were selected in preference 
to those which employed the more traditional bonded phases. 
Data in Table 7.2 indicate the following. 
1. Details of the identity and number of drugs recovered by the technique was often 
incomplete. 
2. Recovery data was generally not supplied for all drugs investigated. 
3. LLE techniques were more common pre-1990 and SPE techniques (with mixed-
mode sorbents) more common post-1990. 
4. LLE techniques were routinely used in forensic and clinical laboratories. 
5. LLE techniques employed either a selective extraction solvent (n-butyl chloride) 
or a non-selective extraction solvent coupled with an extract 'cleanup' step (eg. 
back extraction) prior to analysis. 
6. LLE techniques often did not investigate, or did not recover, drugs of abuse (eg. 
amphoteric drugs; benzoylecgonine, morphine, oxazepam). 
7. LLE techniques developed for blood were generally not able to extract A, N and 
B drugs from the same aliquot. 
8. 'Salting out' techniques (with strong/saturated solutions of inorganic salts) were 
commonly employed in LLE techniques. 
9. SPE techniques which analysed biological fluids other than whole blood were 
most common. 
10. SPE techniques were able to extract A, N and B drugs from a single aliquot of 
sample. 
11. SPE techniques were drug specific and did not generally employ any 'cleanup' 
steps prior to chromatographic analysis. 
12. The amphoteric drugs were sometimes difficult to elute from the cartridge during 
SPE and required more polar eluants. 
The number of published extraction methods for consideration was further reduced 
by selecting methods from Table 7.2 which:- 
I. were in routine use in either forensic or clinical laboratories; 
2. extracted a large number of the drugs listed in Table 7.1 with minimal 
manipulation (eg no protein precipitation, back extraction and pH adjustments); 
3. were developed in whole blood and analysed by GC; and 
4. represented both LLE and SPE techniques. 
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Consequently, methods 8, 17 and 21 were selected for further investigation. In all 
future references to these methods in the chapter, numbers '8', '17', and '21' will 
identify them. 
Method 8 was designed for the extraction of acidic and neutral drugs (Table 7.2) and 
was routinely employed in a toxicology laboratory but neither the number of samples 
which had been analysed by this method, nor how long it had been in routine use by 
the laboratory, was stated. (23) As the method employed a `salting-out' step (Table 
7.2) it might be expected that emulsion formation and lipid contamination were 
minimised, and drug recovery was improved from that with ethyl acetate alone. As 
there was no significant pH adjustment, protein was not excessively 
denatured/precipitated and the blood remained fluid. (23) Consequently, it might be 
anticipated that drug loss through sample pretreatment was minimal and all the 
sample remained available to the extraction solvent. There was no 'cleanup step' 
incorporated into the procedure despite the use of a non-selective extraction 
so1vent; (23) therefore, some modification of the method would be likely if it were 
adopted for routine use in the present study. 
Method 17 employed mix-mode stationary phase cartridges to extract A, N and B 
drugs from plasma (and whole blood; Table 7.2 Method 23). Minimal sample 
pretreatment was required (sonication and dilution) prior to SPE. (32) Successive pH 
adjustments of the cartridge allowed the elution of A/N drugs first followed by BIN 
drugs. (32) The cartridge washing prior to drug elution removed some blood proteins 
and other interfering matrix constituents. (32) The use of relatively weak solutions to 
alter pH ensured that any blood protein retained on the cartridge was not precipitated, 
otherwise clogging of the cartridge would have resulted. It was indicated that 
amphoteric drugs were not eluted from the sorbent but more polar eluants did elute 
these drugs (Table 7.2; methods 19, 20 and 22). Consequently, some modification of 
the eluants used in this method would be expected it were to successfully extract the 
majority of drugs in the extraction test mix (Table 7.1). 
Method 21 was similar to Method 11 in design and in the range of drugs extracted, 
but was more extensively tested in forensic laboratories (Table 7.2). No sample 
pretreatment was employed. (36) Reference was made to the chromatographic 
performance of the GC system following the repeated injection of forensic samples 
with 100 injections being made before any maintenance was required (replaced 
injector liner). (36) 
7.2 Methods 
7.2.1 General 
Refer to "General Procedures" (Chapter 2). In particular, for HC marker solution 
refer to Section 2.2.5.5 and 2.2.5.6; for reference drug solutions refer to Section 
2.2.5.14; for instrumentation refer to Section 2.4.1; for SIM acquisition parameters 
refer to Section 2.4.3.1; for gas chromatographic parameters with the wider bore 
column refer to Section 2.4.2; for the butylation of drugs refer to Sections 2.2.3 and 
2.2.5.4 for details of reagents, to Section 2.3.2 for apparatus employed and to Figure 
2.4 for the derivatisation procedure; for the pentafluoropropionylation of drugs refer 
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to Section 2.2.4 for details of reagents, to Section 2.3.2 for apparatus employed and 
to Figure 2.5 for the derivatisation procedure. 
Blank blood was obtained from the Government Analytical and Forensic Laboratory 
(GAFL). It was 2 year old blood obtained for alcohol determination under the Road 
Safety (Alcohol and Drugs) Act which had been stored at 4°C in bottles with sodium 
fluoride and potassium oxalate as preservative and anti-coagulant, respectively. 
Thirty to 40 individual blood samples were bulked together and used in all 
experiments. Although the individual blood specimens may not have been drug-free, 
by bulking a large number of specimens together, the final drug concentration would 
become negligible. 
7.2.2 Drug Extraction Test Mix 
Refer to Table 7.1 for drugs included in the test mix. A mixed drug solution 
(10 p.g/mL) in methanol was prepared. 
7.2.3 Mixed Deuterated Internal Standard Solution 
Deuterated drug standards (amitriptyline-d3, amphetamine-d6, benzoylecgonine-d3, 
codeine-d3, methadone-d3, methylamphetamine-d6, morphine-d3, nordiazepam-d5, 
oxazepam-d3, temazepam-d5, and THC-COOH-d3) were obtained from Alltech 
Australia. A mixed drug solution (10 pg/mL) was prepared in methanol. 
7.2.4 Liquid-liquid Extraction 
7.2.4.1 General 
Refer to Sections 2.2 and 2.3 for details of reagents and apparatus. Refer to 
Figure 2.2 for the extraction procedure. Method 8(23) and 21 (36) (Table 7.2) were 
investigated but with some immediate modifications as follows. 
1. The volume of blood extracted was 1.5 mL and pH adjustments were made 
with correspondingly increased volumes of buffer (Method 8; 0.75 mL 
saturated ammonium chloride and Method 21; 1.5 mL 2M TRIS). 
2. Extraction was performed with two aliquots of the solvent rather than one to 
improve drug recovery (Method 8; 2 x 5 mL ethyl acetate and Method 21; 
2 x 3 mL n-butyl chloride). 
During investigation of LLE, the following parameters in Methods 8 and 21 were 
varied. 
7.2.4.2 Variations to Method 8. 
1. Volume of ethyl acetate (3 and 5 mL); 
2. n-Butyl chloride was substituted for ethyl acetate as the extraction solvent; (this 
variation is indicated by 'BC' in future tables and discussions); 
3. The aqueous phase was made more acidic (pH 5) with 150 p1 acetate buffer; 
(this variation is indicated by `A8' in future discussions); 
4. Methods 8 and 21 were combined to investigate the feasibility of A, N and B 
drug extraction from a single aliquot of blood (Section 7.2.4.3); 
5. One of two 'cleanup' steps ('AH' or 'E') was incorporated following drug 
extraction (1 mL of blood + 0.5 mL of saturated ammonium chloride were 
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extracted with 2 x 5 mL aliquots of ethyl acetate); only underivatised and 
butylated blood extracts were analysed. 
`AH' :- Involved the partitioning (x 3) of drugs and contaminants between 
hexane saturated with acetonitrile (0.5 mL) and acetonitrile (50 p.L) (24) but, in 
the present study, partitioning was performed only twice (Section 2.5.1.4). The 
top hexane layer was aspirated to waste. 
`E':- Involved the partitioning of drugs and contaminants between water 
miscible and immiscible solvents. (21) The extract residue was redissolved in 
7 mL of hexane:ethanol (10:4). Water (0.5 mL) was added and the phases 
separated. The top hexane layer was aspirated to waste. 
7.2.4.3 Variations to Method 21. 
1. The aqueous phase was made more basic (pH 10.6) with 50 1.1L, 20% NaOH; 
(this variation is indicated by 1321' in future tables and discussions); 
2. Methods 8 and 21 and Methods 8 and 1321' were combined to investigate the 
feasibility of A, N and B drug extraction from a single aliquot of blood; (these 
variations are indicated by '8 + 21' and '8 + B21' in future tables and 
discussions); the extraction procedures were combined as follows:- 
The blood was extracted with 5 mL of ethyl acetate (Method 8); the pH of the 
blood was then adjusted with 2 mL 2M TRIS (pH 9.4; Method 21) or 2 mL 2M 
TRIS + 50 pt 20% NaOH (pH 10.6; Method 1321') and extracted with 5 mL 
of n-butyl chloride. The organic phases were combined and evaporated under 
nitrogen prior to the addition of HC markers and the internal standard solution 
(Section 7.2.6). 
7.2.5 Solid-phase Extraction 
Refer to Sections 2.2 and 2.3 for details of reagents and apparatus. Refer to Figure 
2.3 for the extraction procedure. Method 17 (32) (Table 7.2) was investigated but with 
some immediate modifications as follows. 
1. All solutions/eluants were passed through the cartridge without the application of 
a vacuum which was only applied during the cartridge drying stage. 
2. Blood (1.5 rather than 1 mL) was applied to the extraction cartridges without a 
corresponding increase in the volume of phosphate buffer used to dilute it. 
3. Eluants were applied in 2 x 2 mL aliquots rather than a single 4 mL aliquot. 
4. The basic/neutral drug eluant was 5% ammonia in dichloromethane/isopropyl 
alcohol (80:20) rather than 2% ammonia in ethyl acetate. 
During development of a drug extraction strategy for the automated broad drug 
screening procedure, the following parameters in modified Method 17 were 
varied. 
1. Elution of basic/neutral drugs with a single 2 mL aliquot of 5% ammonia in 
methanol (this variation is indicated by `MEOH' in future tables and discussions). 
2. Separation of the pH adjustment of the cartridge from the elution of basic/neutral 
drugs; the pH of cartridge was adjusted with 200 pi, of a dilute ammonium 
hydroxide solution in methanol (25% ammonium hydroxide:methanol - 1:20) and 
was followed by the elution of basic/neutral drugs with dichloromethane/isopropyl 
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alcohol (80:20); (this variation is indicated by 'NH3 ' in future tables and 
discussions). 
7.2.6 Evaluation of Drug Extraction Procedures. 
Three extracts for GC were prepared following each extraction procedure - 
underivatised (U), butylated (B) and pentafluoropropionylated (P). Each extract was 
equivalent to 0.5 mL of extracted blood. Each extract contained the drug extraction 
test mix, the HC marker solution and the mixed deuterated internal standard solution. 
The drug extraction test mix (1501AL) was added to glass culture tubes and reduced 
under nitrogen to approximately 20 pL. Blank blood (1.5 mL) was added to the 
culture tube and allowed to equilibrate for approximately 15 min. Tubes of blank 
blood containing no drug test mix were also prepared. The blood (spiked and blank) 
was extracted by the test extraction procedures (Sections 7.2.4 and 7.2.5). The 
HC marker solution (150 1_11,) was added to the resulting extraction solvents (LLE) or 
eluants (SPE) which were then divided by eye into three approximately equal 
aliquots. Mixed deuterated internal standard solution (50 lat) was added to each of 
the three aliquots. Each aliquot was reduced to dryness under nitrogen prior to either 
the addition of the injection solvent (U) or derivatisation (B, P). Unextracted 
reference solutions were prepared concurrently (Ustd, B std and P std) for comparison 
with extracts generated from the test extraction procedures and each contained 50 mt 
of the drug extraction test mix, the HC marker solution and the mixed deuterated 
internal standard solution. The final volume of all extracts and reference solutions 
for GC was 50 1AL. 
The peak area ratio (Section 2.6.1) was obtained for all test drugs in both extracts and 
reference solutions and enabled a direct comparison (as a percentage) of extracted 
drugs with drugs in reference solutions. For those drugs with corresponding 
deuterated internal standards, the peak area ratio was determined from the absolute 
peak areas of the drug and deuterated drug rather than from the closest eluting 
HC marker. 
Experiments testing each extraction technique were performed in triplicate on 
different days and the mean percentage of drug recovered by the technique was 
calculated together with the standard deviation from the mean (SD). 
7.3 Results 
7.3.1 Liquid-liquid Drug Extraction 
The recovery from blood of a drug extraction test mix (Section 7.1.2) was 
investigated employing variations to two LLE techniques (Methods 8, and 21; 
Sections 7.2.4 and 7.2.6). 
Table 7.3 shows the percentage of drug recovered (mean, SD) by each of the LLE 
techniques investigated. The drugs of the extraction test mix were analysed in either 
their underivatised or derivatised forms. In general, the underivatised drugs can be 
considered as weakly acidic, neutral and basic drugs; the butyl derivatives are formed 
from acidic drugs (Chapter 4); and the PFP derivatives are formed from basic drugs 
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(Chapter 5). Within these groups, however, there is an overlap of drug chemistries 
(eg. amphoteric drugs). Different extraction methods are indicated by the 
abbreviated labels assigned to them in Section 7.2.4 and these are summarised in 
Figure 7.1. 
Data in Table 7.3 indicate the following. 
1. The greatest number of drugs was recovered by Methods 8, '8 + 21' and 
8 + B21' but the recovery of basic drugs was higher by the combined techniques 
(eg. amphetamine, methylamphetamine, metoprolol). 
2. The least number of drugs was recovered by Methods 21 or '1321'. 
3. Benzoylecgonine and captopril were not recovered by any method tested. 
4. Morphine was recovered only by Methods 8, '8 +21' and 8 + B21' but 
recoveries were poor. 
5. Acidic drugs were not recovered by Methods 21 or 1321' unless they were 
performed in combination with Method 8. 
6. Strongly basic drugs (amphetamine and methylamphetamine) were best 
recovered by Methods 21 and 1321'; Method `B21' recovered basic drugs 
relatively better than Method 21, however, neither method recovered acidic 
drugs. 
7. Choice of solvent was important for the extraction of drugs by Method 8; for 
example, recovery of drugs by Methods 8 and `BC' were comparable for the 
majority of basic drugs (excluding metoprolol) but, for acidic drugs 
(paracetamol, theophylline, naproxen and frusemide) recovery was better by 
Method 8 than `BC'. 
8. Recovery of drugs by Methods '8 + 21' and 8 + B21' were comparable. 
9. Apart from the extraction of morphine and the strongly basic drugs, neither 
combined extraction technique recovered drugs significantly better than Methods 
8 and 21 alone. 
During investigation of the LLE techniques, the following practical observations 
were made. 
1. During initial investigations of Method 8, blood was extracted with 2 x 3 mL 
aliquots of ethyl acetate. However, emulsions were quickly formed with the 
blood precipitating into thick lumps which adhered to the walls of the culture 
tubes. Following extraction, the tubes were very dirty and difficult to clean. 
There was difficulty separating the aqueous and organic phases by centrifugation 
and often these tubes would have to be shaken and spun down again to achieve 
separation. Increasing the volume of ethyl acetate from 3 to 5 mL alleviated all 
of these problems. No emulsions were formed and the blood remained relatively 
fluid at end of the extraction process. There was no difficulty in separating the 
phases by centrifugation and the glassware was significantly cleaner. All 
subsequent experiments employed 5 mL aliquots of ethyl acetate. Following 
extraction, ethyl acetate was straw coloured and, when concentrated, was 
strongly yellow (presumably due to co-extraction of endogenous lipids, etc). 
2. During the investigation of Method `A8' (acidification of the blood/ammonium 
chloride solution prior to extraction) the pH of the solution was decreased from 7 
(Method 8) to 5. When the acidified solution was extracted with ethyl acetate, 
emulsions were immediately formed which coated the walls of the culture tubes 
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Figure 7.1: A schematic representation of extraction procedures and their variations described in Sections 7.2.4 and 7.2.5. 
EtAc = ethylacetate Me0H = methanol 
BuCl = n - butylchloride CHC1 3 = chloroform 
Et0H = ethanol DCM = dichloromethane 
ACN = acetonitrite isoPrOH = isopropylalcohol 
and had a very viscous almost 'oily' appearance. On centrifugation, the blood 
formed a very solid precipitate and the solvent was discoloured red-brown. 
Exchanging the acetate buffer for a citrate buffer (0.1M; pH 5) did not improve 
the appearance of the blood or solvent. As a result of these problems Method 
'A8' was abandoned. 
3. Methods which employed n-butyl chloride (Methods 21,1321' and `BC) were 
always free of emulsions, no blood adhered to the glass walls of the culture tubes 
and the aqueous and organic phases separated rapidly on standing. n-Butyl 
chloride was more quickly evaporated under nitrogen than was ethyl acetate and 
the concentrated solvent was not significantly discoloured. 
4. When n-butyl chloride was substituted for ethyl acetate (Method `BC), it was 
observed that the organic and aqueous phases did not really ever appear to mix 
but moved over each other during extraction as though they repelled each other. 
Much more vigorous shaking was required rather than the `end-over-end' mixing 
employed for all other extraction techniques. 
5. Cholesterol was the major contaminating peak in chromatograms from blank 
blood extracted produced by Methods 21 and `B21'. A cholesterol peak was 
present but reduced in chromatograms from blood extracts produced by Methods 
8 and `BC'. 
6. The cholesterol peak significantly interfered with the detection and integration of 
butyl-THC-COOH and thioridazine peaks. 
7. During the investigation of Method '1321' (basification of the blood/TRIS 
solution prior to extraction) the pH of the solution was increased from 
9.5 (Method 21) to 10.6. When the basified solution was extracted with the 
3 mL aliquot of n-butyl chloride emulsions were formed immediately. This 
problem was alleviated by increasing the volume of n-butyl chloride to 5 mL. 
The cholesterol contaminant was much reduced in chromatograms from 
Method 1321' compared with Method 21 but continued to interfere with 
integration of thioridazine and butyl-THC-COOH peaks. 
8. Chromatograms from blood extracts produced by the combined extraction 
techniques ('8 + 21' and '8 + B21') contained more non-drug related peaks 
(presumably endogenous blood products) which interfered with the detection 
and/or integration of drugs from the extraction test mix compared with either 
Methods 8 or 21 alone. These were apparent in the early part of chromatograms 
for each of the extracts, but in particular those of butylated extracts. 
9. During investigation of the LLE methods, it was quickly apparent that the 
concurrent chromatography of extracted blood products with some of the 
underivatised drugs of the test mix improved their chromatographic response 
from those observed for Ustd (Section 7.2.6); particularly the responses of 
promethazine, temazepam and the high boilers (thioridazine and verapamil). 
However, with repeated injection of blood extracts, and in particular of PFP 
extracts, the peak areas of many underivatised drugs were significantly reduced; 
verapamil, thioridazine, temazepam (practically disappeared) nordiazepam, 
codeine, phenobarbitone. 
10. During investigation of the combined extraction techniques, it was always 
observed that emulsions formed during extraction with the second aliquot of 
solvent (n-butyl chloride) and that the absolute peak areas of temazepam and 
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deuterated temazepam were significantly reduced compared with any other 
method. 
11. The absolute peak areas of THC-COOH and deuterated THC-COOH in blood 
extracts from all methods were significantly reduced from those of B std (Section 
7.2.6). 
19. The glass wool of the injector was discoloured at the end of the GC/MS 
sequence regardless of the extraction technique employed. Chromatographic 
performance of susceptible underivatised drugs could not be returned to that 
observed at the beginning of the sequence without replacing the liner with a 
clean liner and glass wool. The chromatographic performance of some drugs 
was improved following priming of the clean liner (by repeated injection of the 
performance test mix) and conditioning with 1 to 2 injections of an underivatised 
blood extract. 
13. When the SD recorded for a drug was large (Table 7.3), this was generally as a 
result of poor integration caused either by a closely eluting interfering peak 
(eg. early eluting butyl derivatives), or the drug peak tailing out of the time 
window over which it was monitored (eg. nordiazepam and thioridazine). 
• It was concluded that Method 8 was the most effective extraction technique for the 
recovery of the majority of drugs in the test mix with the least practical problems, 
particularly if extract cleanliness could be improved. Consequently, drug recovery 
by Method 8 was investigated following the incorporation of two different 'cleanup' 
steps ( ' AH ,(24) and , E ,(21) ; Section 7.2.4.2 and Figure 7.1). 
Table 7.4 shows the percentage of drug (mean, SD) recovered following extraction of 
1 mL of blood by Method 8 with and without 'cleanup' steps incorporated. It also 
shows the mean percentage of drug recovered by Method 8 when 1.5 mL of blood 
was extracted (same data as shown in Table 7.3 and included to permit easy 
comparison). Naproxen is absent from the drugs listed as it was found that the 
'blank' blood used in these experiments contained a significant amount of naproxen. 
Data in Table 7.4 indicate the following. 
1. No large differences in drug recovery were observed whether 1.0 or 1.5 mL of 
blood was extracted by Method 8. The recovery of codeine, tolbutamide, 
theophylline and frusemide, however, appeared to be slightly improved when 
only 1.0 mL of blood was extracted. 
2. No large differences in the recovery of the test drugs (except THC-COOH) was 
observed following extraction by Methods 'AH' or `E' from that observed by 
Method 8. 
3. Drug recovery across the extraction test mix was most variable by Method `E' 
(highest value recorded for the sum of SD). 
4. The recovery of benzodiazepines (nordiazepam, temazepam and oxazepam) and 
weak acid drugs (paracetamol, theophylline) was marginally lower following 
extraction by Methods 'AH' and `E' from that observed by Method 8. 
5. The recovery of THC-COOH was significantly reduced following extraction by 
Method `AH' from that observed by Method 8. 
During investigation of drug recovery by the Methods 8, `AH' and `E', the following 
practical observations were made. 
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1. The addition of 0.5 mL of water to the hexane/ethanol organic phase (Method 'E') 
saw the very rapid re-partitioning of the three solvents and cloudiness developed 
in the newly formed ethanol/water phase. The evaporation of the water/ethanol 
mixture under nitrogen was very time consuming compared with any other 
evaporation step tested (both LLE and SPE methods). Acetone was added 
(approximately 2 mL) to increase the rate of evaporation (azeotrope formation). 
In addition, the volume of water added was reduced:- the minimum volume of 
water required to cause the repartitioning of the three solvents was found to be 
approximately 0.15 mL (rather than 0.5 mL). 
2. Following the addition of the GC injection solvent (Section 2.2.5.7), the 
underivatised extract from Method 'E' was cloudy with either residual water or 
extracted water soluble products. 
3. During investigation of Method `AH', it was observed that the 50 p.L of 
acetonitrile was very yellow in colour. Following mixing (x 2) with hexane, the 
hexane took on an obvious yellow discolouration but the acetonitrile still retained 
some colour. The drugs extracted from the blood were dissolved in the 
acetonitrile. There was a danger, therefore, that some portion of the acetonitrile 
would be aspirated and lost if all the hexane was removed. Therefore, some 
residual hexane always remained. 
4. The cholesterol peak observed in chromatograms from blank blood extracted by 
Method 8 was either significantly reduced or absent in chromatograms from 
Methods 'E' and `AH' respectively. In addition, early eluting peaks observed in 
chromatograms from Method 8 were absent in those of Method `AH' and reduced 
in those of Method 'E'. 
5. The absolute peak areas of temazepam and deuterated temazepam in 
chromatograms from Method 8 were significantly reduced compared with those in 
Methods `AH' and `E'; their peak areas were greatest in chromatograms from 
Method `AH'. 
6. Visual inspection of the underivatised and butylated blood extracts prior to GC 
analysis showed that those produced from Method 8 were the most discoloured 
(yellow), and those from Method `AH', the least. 
Following the evaluation of the different LLE techniques, it was concluded that 
Method `AH' offered the best LLE drug screen. It satisfied four important criteria as 
follow. 
1. The majority of drugs from the extraction test mix were recovered. 
2. There were fewer practical problems encountered with the extraction of blood 
and the preparation, derivatisation and GC analysis of extracts. 
3. Clean extracts were produced which may extend the period of time over which 
acceptable chromatographic performance of the GC system can be maintained. 
4. There was a minimum of interfering peaks (eg. cholesterol and early eluting 
peaks) in chromatograms from underivatised and derivatised extracts. 
7.3.2 Solid-Phase Drug Extraction 
Data in Table 7.5 show the percentage of drug recovered (mean, SD, n=3) by each of 
the SPE techniques investigated. The drugs of the extraction test mix were analysed 
in either their underivatised or derivatised forms. Different extraction methods are 
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indicated by the abbreviated labels assigned to them in Section 7.2.5 and summarised 
in Figure 7.1. 
Data in Table 7.5 indicate the following. 
1. Captopril was not recovered by any extraction technique tested. 
9. Recovery was poor for strong acids (naproxen, frusemide) and some weakly 
acidic drugs (paracetamol, theophylline and tolbutamide). 
3. Large SD values (> 10%) were associated with the recovery of some drugs by 
one technique but not another (eg. thioridazine, verapamil, phenytoin). 
4. The variability in recovery across the extraction test mix by each method was 
comparable (similar values recorded for the sum of SD). 
5. There were no large differences observed in the recovery of any drug by the 
various methods tested except for benzoylecgonine and metoprolol; there was 
less benzoylecgonine recovered by Method 'NH 3 ' than by the other two methods 
in which ammonia was incorporated into the B/N drug eluant; there was less 
metoprolol recovered by Method `MEOH' than by the other two methods in 
which dichloromethane/isopropyl alcohol was the B/N drug eluant. 
6. Recovery was consistently high for all B/N drugs. 
7. All amphoteric drugs were recovered by all methods tested (morphine, 
oxazepam and benzoylecgonine). 
During investigation of SPE techniques, the following practical observations were 
made. 
1. Following the application of the blood to the cartridge, the packing was saturated 
with the blood/buffer solution and discoloured red. The 1 mL water wash of the 
cartridge effectively removed residual blood/buffer solution from the packing 
and the packing was discoloured pink/brown. The application of the A/N drug 
eluant removed still further material from the packing which was discoloured tan 
following application of 2 x 2 mL aliquots of acetone/chloroform (1:1). 
2. The application of the ammoniacal methanol B/N drug eluant effectively 
stripped the packing of all colour (Method `MEOH'). 
3. With the application of the pretreated blood sample, cartridges always appeared 
by eye to be evenly wetted. With subsequent applications of either sorbent 
washes or eluants, however, some cartridges appeared to be unevenly wetted by 
these solutions. In some cases, it appeared that portions of the cartridge had 
never been exposed to the washes and eluants. 
4. The combined eluants from Methods `MEOH' and 'NH 3 ' were discoloured 
yellow/brown compared with those from Method 17. 
5. The time required to evaporate the combined eluants was greatest for Method 
`MEOH' (despite a smaller volume of B/N drug eluant) and least for Method 17. 
6. It was difficult to completely dry the combined eluants from Methods `MEOH' 
and `NH3 ' under nitrogen prior to their derivatisation as each contained a 
noticeable amount of residue which was absent from Method 17. Consequently, 
evaporation times were longer for these techniques than for Method 17. 
7. With the addition of PFPA to the residue from Method `MEOH', fumes 
developed and the final extract was dark brown compared with those of PFP 
extracts from either Methods 17 or `NH 3 '. 
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8. Following sequential GC analysis of a series of extracts produced by Methods 
17, `MEOH' and 'NH3 ', the glass wool of the injection port liner was very dirty 
(compared with LLE experiments) but the 'performance test mix' (Sections 
2.2.5.10 and 2.6.2) still indicated acceptable performance of the GC system; 
phenobarbitone, temazepam and promethazine were still apparent, although the 
absolute peak areas of temazepam, thioridazine and verapamil were reduced. 
9. The absolute peak areas of temazepam and deuterated temazepam in blood 
extracts from all methods were comparable with those in Ustd (Section 7.2.6). 
10. The absolute peak areas of THC-COOH and deuterated THC-COOH in blood 
extracts from all methods were reduced compared with those of B„d (Section 
7.2.6). 
11. A cholesterol GC peak was either reduced or absent in chromatograms from 
blood extracts produced by each method and did not interfere with the 
integration of any drug peak. 
Following the evaluation of the different SPE techniques, it was concluded that 
Method 17 (modified; Section 7.2.5) offered the best drug screen. Although there 
were no large differences in the recovery of the majority of drugs by the three tested 
methods (except benzoylecgonine and metoprolol), and all extracts were relatively 
clean (reflected by the subsequent chromatography of the 'performance test mix'), 
there were differences in the practical problems associated with each technique. 
Method 17 satisfied the same four criteria met by Method `AH' in Section 7.3.1 
7.3.3 Drug Recovery by the Selected Extraction Techniques 
The suitability of the LLE (Method `AH') and SPE (modified Method '17') methods 
to broad drug screening was further evaluated by measuring their capacity to extract 
all of the 106 target drugs retained for further study in Section 6.3. Working drug 
solutions were prepared from reference drug solutions (Section 2.2.5.13) and spiked 
into whole blank blood. Where drugs were able to be detected in more than one 
extract (as underivatised drugs or as butyl or PFP derivatives), recovery data were 
obtained for each (eg. clobazam, desipramine, diclofenac). Each extract was 
equivalent to 0.5 mL of whole blood. The percentage of drug recovered (mean, SD, 
n=3) was determined on different days by both methods (Table 7.6). The 
chromatographic response of some drugs and drug derivatives was affected by co-
chromatographing extracted material. Consequently, recovery data for these drugs 
was determined by redissolving Ustd, B std and/or Pstd  (Section 7.2.6) in a blank blood 
extract so that both spiked blood sample and reference were chromatographed with 
similar extracted material. 
Data in Table 7.6 indicate the following. 
1. Forty-one percent of the tested drugs were similarly recovered by each technique 
(Table 7.7). 
2. Thirty-eight percent of the tested drugs were better recovered by SPE than LLE 
(Table 7.8). 
3. Twenty-one percent of the tested drugs were better recovered by LLE than SPE 
(Table 7.9). 
4. Unusual recovery data was determined for 3 drugs (nifedipine, quinine and 
quinidine). 
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5. The recovery of 88% of tested drugs by either SPE or LLE (or both) was greater 
than 75%. 
6. The recovery of 51% of tested drugs by either SPE or LLE (or both) was greater 
than 90%. 
7. The recovery of 6% of tested drugs by either SPE or LLE (or both) was less than 
30%, and all were acidic drugs. 
8. Baclofen and captopril were not recovered by SPE or LLE techniques. 
9. Some drugs were recovered only by SPE (LLE recovery <10%); atenolol, 
disopyramide, ephedrine, phentermine, prednisolone, sotalol. 
10.Some drugs were recovered only by LLE (SPE recovery <10%); chlorpropamide, 
diflunisal, naproxen and nicotinic, salicylic and valproic acids. 
11 .Strong acids were not recovered by SPE and poorly recovered by LLE; nicotinic 
acid (<10%), salicylic acid (18%) and valproic acid (21%). 
12.The sum of SD (Table 7.6 - Note 4) associated with the recovery of all test drugs 
was greater following SPE than LLE. 
Data in Table 7.6 clearly indicate that if a broad drug screen were based only on the 
LLE method several important drugs of abuse (amphetamine-like drugs, 
benzoylecgonine, morphine, THC and THC-COOH) would be excluded. Similarly, a 
broad drug screen based only on the SPE method would exclude several drugs which 
are either prevalent in the community or of toxicological interest (eg. frusemide, 
naproxen and other anti-inflammatory drugs, paracetamol, phenytoin, theophylline, 
salicylic and valproic acids). Consequently, the most comprehensive drug screening 
strategy would be attained by applying both extraction techniques to the same sample 
of blood and combining their results. 
The design of the drug screening strategy illustrated in Figure 2.1 was based on data 
in Tables 7.6-7.9 (Section 7.4.2). Four GC/MS (SIM) methods (Tables 2.1-2.4) 
were created for the acquisition of m/z ion pairs which would identify target drugs in 
each extract ('U, '5', '13' and `13 '; Figure 2.1). Where a drug could be identified in 
two extracts, target m/z ions for that drug were included in both GC methods. Four 
drugs.bct files (Tables 2.6-2.9) were created which contained drug data used by the 
automated drug identification and quantitation macro to detect drugs (Chapter 8.). 
It was necessary to minimise the number of target m/z ions monitored over any given 
time window during GC acquisition to ensure that a scanning rate of at least 
3.0 cycles/s (Section 2.4.3.2) was obtained. Consequently, if a drug was able to be 
identified in more than two extracts (eg. carbamazepine, codeine, nordiazepam) 
target m/z ions were monitored in either:- 
1. the two extracts for which drug recovery was greatest and least variable, or 
2. in one underivatised and one derivatised extract rather than in the two 
underivatised extracts (Section 7.4). 
7.4 Discussion 
7.4.1 Drug Extraction Procedures 
A comprehensive screen for over 100 pharmacologically and structurally diverse 
drugs in whole blood can be accomplished by:- 
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I. isolating target drugs from blood through an extraction procedure (combined LLE 
and SPE) where 90% of drugs are recovered with greater than 75% efficiency; and 
2. identifying target drugs through the GC/MS analysis (SIM) of separate extracts in 
which drugs and their corresponding butyl or PFP derivatives are detected. 
The LLE technique was based on a previously described method (23) but the use of a 
non-specific extraction solvent necessitated the incorporation of a 'cleanup' step 
prior to GC analysis. The price for 'cleaner' extracts, was a slight reduction in the 
recovery of some drugs. The reduction in drug recovery was an acceptable 
compromise given that the affected drugs were either well recovered by SPE (eg. 
benzodiazepines, THC-COOH) or were acidic drugs (eg, paracetamol, theophylline) 
which have comparatively high effective blood concentrations. 
The SPE technique was based on a previously described method (32) but some 
immediate modifications were made as the unchanged method would fail to recover 
benzoylecgonine and morphine. It was essential that these drugs be recovered by the 
SPE technique as they were either not recovered (benzoylecgonine) or recovered 
poorly (morphine) by the LLE technique. Some of the published methods listed in 
Table 7.2 indicated the following:- 
1. benzoylecgonine could be eluted with a more polar solvent (5% ammonium 
hydroxide in dichloromethane/isopropylalcohol 80:20); Method 20;( 35) 
2. opiates were well extracted in ammoniacal dichloromethane/isopropylalcohol 
(80:20); Method 20; (35) 
3. excellent recoveries of benzoylecgonine, oxazepam and morphine with 
ammoniacal methanol; Method 14. (24) 
The recovery of these drugs, however, with more polar eluants was at the expense of 
the cleanliness of the extract and additional endogenous matrix material was also 
extracted. Experiments in the present study indicate that, despite the use of polar 
eluants (Methods `MEOH' and 'NH 3 '), the chromatographic performance of the GC 
system was still satisfactory (Section 2.6.2) at the end of a sequence of GC analyses 
(although additional peaks were present in chromatograms). This was in contrast to 
the deterioration of the chromatographic performance observed following analysis of 
a sequence of liquid-liquid extracts. These observations confirm the literature (1) 
which found that SPE yields cleaner extracts then LLE and would, therefore, prolong 
the satisfactory chromatographic performance of the GC system (Section 9.4) 
Apart from the presence or absence of a cholesterol and other blood-related GC 
peaks in chromatrograms, the absolute areas determined for temazepam and 
deuterated temazepam peaks were sensitive indicators of extract cleanliness. It is 
thought that the peak area of temazepam was reduced in the presence of co-extracted 
matrix products as the drug either adsorbed to these products in the injector or on the 
column, or adsorbed to active sites created in the injector in the presence of these 
products. Consequently, the chromatographic performance of temazepam and 
deuterated temazepam varied from sample to sample. The peak areas were greatest 
in solid-phase extracts, and smallest in Methods '8 + 21' and '8 + B21', presumably 
as a result of the accumulation of endogenous material in the final extract from the 
combined LLE methods. 
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The sum of SD (Table 7.6 - Note 4) associated with the recovery of all test drugs was 
greater following SPE than LLE. In Section 7.3.2 it was indicated that during the 
washing of the solid-phase packing and elution of drugs, the packing that was visible 
(packing immediately adjacent to the wall of the cartridge) appeared to be unevenly 
exposed to solutions passing through it. It is possible that within the packing some 
of the micro-channels between the particles of sorbent were partially or wholly 
occluded by matrix products which subsequently reduced the exposure of the sorbent 
particles to the eluants. Consequently, the reproducibility of extraction was 
compromised as indicated by the larger SD values obtained compared with LLE. It 
is also possible that the larger SD values may have arisen through experimental error 
as the SPE technique has a greater number of steps and is generally more 
manipulative than the LLE method. 
It was consistently observed that the absolute peak area of deuterated THC-COOH 
was reduced following its analysis in blood extracts compared with that observed in 
Bstd• As deuterated THC-COOH was added to extracts after LLE and SPE (Section 
7.2.5), it underwent butylation in the presence of extracted blood products. It is 
thought these blood-related products, absent in B std, interfered with the butylation of 
the drug. Consequently, the sensitivity of the instrument to THC-COOH has 
decreased (Section 9.4). 
The unusual drug recovery data obtained for nifedipine, quinine and quinidine 
indicated that, although both LLE and SPE techniques could extract these drugs from 
blood, either their recovery from sample to sample, or chromatographic response 
from injection to injection, varied. In part, the variability in observed behaviour for 
derivatives of quinine and quinidine may have arisen due to their poor reproducibility 
and stability with time (Chapters 4 and 5). Consequently, if the drug screen were to 
identify one of these drugs, there would be no possibility of determining at what 
concentration it might be present in the blood. 
7.4.2 Design of the Drug Screening Strategy 
Data in Table 7.6 indicate that the LLE technique (Method `AH') was most efficient 
in the extraction of weak to moderately acidic and basic drugs, and neutral drugs. 
The recovery of stronger acids (eg salicylic acid) and bases (eg. amphetamine) was 
relatively poor. Data in Table 7.6 indicate that the SPE technique (modified Method 
17) was most efficient in the extraction of weakly acidic, neutral and weak to 
strongly basic drugs (including amphoteric drugs) but that the recovery of moderate 
to strong acids was poor. No one procedure was able to extract drugs with relatively 
high recoveries over the entire chemical range (strongly acidic to strongly basic). 
If the broad drug screen employed both these extraction procedures (thus enabling 
detection of drugs over the entire chemical range), and if each of the 6 GC extracts 
was equivalent to 0.5 mL of blood (thus ensuring sufficient sensitivity; Table 6.1), 
then a total of 3 mL of blood would be required for the analysis. Total GC/MS 
analysis time would be long (4 hours with a 'turn around time' of 40 min from one 
GC injection to the next). Consequently, a drug screening strategy was devised 
(Figure 2.1) which minimised both the volume of blood required, and total GC/MS 
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analysis time, but which did not sacrifice the number and range of drugs identified. 
The drug screening strategy has the capacity to efficiently recover a chemically 
diverse range of drugs (moderately acidic to strongly basic drugs) and to detect 
strongly acidic drugs although their recovery is less efficient; however, their blood 
concentrations are usually high. 
The analysis of a butylated extract produced following SPE is essential as this extract 
contains benzoylecgonine and THC-COOH (if present in the blood specimen). 
Analysis of this extract, however, does not exclusively identify any other target drug. 
Therefore, combining an extract from both LLE and SPE prior to butylation resulted 
in the following:- 
1. a reduction in total GC/MS analysis time by approximately 40 min; 
2. an increase in sensitivity towards some butyl drug derivatives; as the combined 
butyl extract is equivalent to 1 mL of blood, sensitivity will be increased where a 
drug is recovered by both LLE and SPE (eg. barbiturates, desipramine, diclofenac, 
desmethyl-benzodiazepine metabolites, phenytoin, warfarin). 
The analysis of a pentafluoropropionylated extract produced following SPE is 
essential as this extract would contain the majority of drugs of (eg. amphetamine-like 
drugs, morphine, codeine, 7-amino-benzodiazepine metabolites, THC). Although 
some of these PFP derivatives would also be detected in the equivalent extract 
produced following LLE, analysis of the liquid-liquid extract does not exclusively 
identify any target drug. Consequently, a decision was made not to analyse a 
pentafluoropropionylated extract produced following LLE. This resulted in the 
following:- 
1. a reduction in the total volume of blood required from 3 to 2.5 mL; and 
2. a reduction in the total GC/MS analysis time by a further 40 min. 
As a consequence, however, it was not possible to confirm the presence of some 
drugs by an alternate method (the 7-amino- benzodiazepine metabolites and some 
13-blocking agents). 
It was stated in Section 7.1 that, in the development of a drug extraction procedure, 
the aim was to meet as many of the seven requirements and six practical objectives as 
possible. One requirement was that the majority of drugs be identified and 
confirmed by at least two different methods. Through the drug screening strategy, 
confirmation of the identity of 60% of the target drugs is possible by an alternate 
method as follows:- 
1. confirmation in an extract produced following extraction by a different technique 
(SPE or LLE), or 
2. confirmation of a drug as its corresponding butyl or PFP derivative. 
The identity of all drugs (except chloroquine, methaqualone, methylprylone and 
prednisolone) which would be detected in an underivatised extract could be 
confirmed in either the alternate underivatised extract (`L' or `S'; Figure 2.1.), or as 
butyl or PFP derivatives. The identity of 47% of drugs detected as butyl derivatives 
and 48% of drugs detected as PFP derivatives could be confirmed in another extract. 
The drug screening strategy developed could be expected to satisfy the remaining 
requirements (Sections 1.3 and 1.4) and meet the practical objectives (Section 7.1) 
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although validation of the automated broad drug screening procedure would be 
necessary to determine the effectiveness of drug quantitation (Chapter 9). 
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Chapter 8. 
AUTOMATED DRUG IDENTIFICATION AND QUANTITATION 
8.1 Introduction 
During discussion of the needs and limitations of a forensic laboratory and the 
development of an ideal drug screen (Sections 1.2 and 1.3) it was indicated that a 
screening procedure which automated the interpretation of complex multi-peak 
chromatograms and gave an indication of the concentration of drug present in the 
specimen would be highly advantageous. 
It was indicated in Section 1.4.1 that automated identification of drugs in 
chromatograms (GC or HPLC) is currently based on matching either the RI or 
spectra (eg UV and mass spectra) of unknown peaks against commercially available 
or 'in-house' libraries of data on similar drugs. In the following studies, the RI of 
unknown peaks in complex chromatograms were automatically calculated and 
compared with a library of drug RI. The matches were identified as drugs. 
In two studies(l2)  a drug RI was calculated through linear interpolation between 
adjacent HC markers. Each day a HC marker calibration standard was run 
independently of blood extracts (C9-C26, C28, C30 and C32 ;and C 10-C34 except C33 
respectively). The HC marker retention times obtained for that day were used to 
calculate the RI of all unknowns in the chromatogram. Peaks were identified as 
drugs when the calculated RI matched a drug RI in a library of over 100 drugs. 
Windows of ± 3.5 and ± 5 RI units were set respectively. 
Another study(3) reported automated drug identification on the basis of drug RI 
calculated from a test mix of eleven drugs. In this case, the relationship between 
drug retention time and RI was not linear and, consequently, the slope and intercept 
of lines connecting adjacent drugs in the test mix were determined. The RI of an 
unknown was calculated from those of the two drug standards which bracketed it and 
was matched against a RI library of 112 drugs. A window of ± 10 RI units was set. 
A similar study (4) using a test mix of nine drugs obtained a linear relationship 
between retention time and molecular mass and, consequently, the RI of unknowns 
was determined via linear interpolation between 'bracketing' test drugs. A window 
of ± 5 RI units was set and the RI of unknowns matched with drug RI in a library of 
over 170 drugs. 
The narrow windows of up to ± 10 RI units applied in these studies indicate the 
accuracy with which RI values can be assigned to GC peaks using a marker system 
(HC or drug). 
Another study (5) reported automated identification and quantitation of 30 weakly 
acidic and neutral drugs. Identification was based on drug RI and determined 
through interpolation from nitrogen-containing standards fitted with a cubic spline 
(non-linear). Quantitation was based on a single point calibration (through zero) and 
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relative response to a single internal standard (which was also one of the standards 
used to determine drug RI). The quantitative precision of the method appeared good 
and was based on 10 separate determinations over 3 months, but was shown for only 
8 drugs. 
In Section 1.4.1 it was argued that drug identification based on only a single criterion 
(RI) was relatively non-specific (compared with other more specific techniques; eg 
GC/MS, HPLC-DAD) and the identity of the eluting peak required additional 
confirmation. An endogenous blood product, other contaminant or non-target drug 
with characteristics which cause it to elute with the same RI as a drug may be falsely 
identified as that drug. Similarly, should conditions arise which cause the RI of an 
eluting drug to shift slightly (Appendix A.4) then it may not be matched with the 
corresponding drug standard and a false negative would result. For example, the RI 
of acidic, neutral and basic drugs showed concentration-dependent behaviour with 
marked increases in RI when concentrations exceeded 100 p.g/mL. In some cases, 
the RI differences caused by differing concentration were over 100 RI units (6). This 
phenomenon was also observed in the present study (Section 8.4.2). 
More specific drug identification would be obtained through mass spectrometry. The 
advantages and disadvantages of full-scan and SIM mass spectrometry were 
discussed in Section 1.4.2. Searching complex, multi-peak chromatograms generated 
by mass spectrometry for drugs is generally performed either:- 
1. automatically by commercial or 'in-house' full-scan library search programs, (7) or 
2. manually by the experienced analyst. 
The advantages and disadvantages of each method were discussed in Section 1.2. 
Some studies (8-12)employing GC/MS report more specific and sensitive automated 
drug identification. For example, screening for specific drug groups and/or their 
metabolites was achieved by monitoring (SIM) groups of typical fragment m/z ions 
which, in combination, uniquely identified the drugs from other co- 
chromatographing compounds. Following data acquisition, the m/z ions which 
identified a specific drug from the group were automatically reconstructed in a 'mass 
fragmentogram' which was compared with a library full-scan mass spectrum of the 
drug. Individual drugs from target analyses for benzodiazepines (8'9) , B-blocking 
agents", neuroleptics(11) and anti-inflammatory agents (12) have been automatically 
identified in urine extracts employing this technique. Disadvantages associated with 
this approach to target drug analyses, however, are as follows:- 
I. the m/z ions monitored were generally characteristic of acetylated products rather 
than the drug itself, and 
2. the technique could not be applied to the identification of chemically dissimilar 
drugs in broad drug screening. 
In addition, the application was developed in urine rather than blood. 
One study(13) described automated identification of a diverse range of drugs in SIM 
generated ion chromatograms from blood extracts. A pair of target m/z ions which 
characterised each drug or drug derivative was monitored over a narrow time window 
about the expected retention time of the drug. A peak was identified as a drug if both 
the target m/z ions and their relative m/z ion abundance matched those of reference 
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standards. The macro which automated drug identification in multi-peak 
chromatograms consisted of repeating units. These units contained the drug name, 
retention time, the m/z target ions, integration threshold and the permissible range of 
ion ratio. In contrast with other automated drug identification techniques, this 
procedure utilised both retention time and specific mass spectral information in the 
identification of a diverse range of drugs providing both specificity and sensitivity. 
However, the application of the macro was restricted to the instrument on which it 
was developed as, for each target drug, it was dependent on absolute retention time 
(governed by GC parameters), absolute peak area threshold (instrument specific) and 
on relative ion abundance (dependent on MS tuning parameters). Similarly, the 
macro was developed on the now relatively obsolete Hewlett Packard 59970A 
Chemstation with Pascal software. 
The automated drug identification and quantitation technique developed in the 
present work was an extension of that used in the study above. (13) It was designed for 
universal application to complex chromatograms generated on any non-polar column 
and any mass spectrometer and automates both drug identification and quantitation. 
8.2 Methods 
Chromatograms generated from GC/MS analyses of blood extracts and underivatised 
and derivatised drug solutions were used in the development of the macro. 
Refer to "General Procedure" (Chapter 2). In particular, for HC marker solution refer 
to Section 2.2.5.5 and 2.2.5.6; for reference drug solutions refer to Section 2.2.5.14; 
For analyses with the Hewlett Packard GC/MSD refer to Section 2.4.1 for 
instrumentation; Sections 2.4.3.2 and 2.6.2 for SIM acquisition parameters; 
Section 2.4.2 or gas chromatographic parameters with the wider bore column 
employing splitless injection; and Section 2.5 for drug extraction from blood and 
derivatisation techniques. 
8.3 Results 
8.3.1 The Macro 
Automated drug detection and quantitation was performed by a series of eight 
macros which themselves used internal macros and commands recognised by the 
Hewlett Packard (HP) operating software. 'Hits' identified by the macro are listed in 
• an automatically generated report which displays the m/z ion chromatograms for each 
'hit' together with other relevant information (Section 8.3.2). The analyst interprets 
each macro-generated report and eliminates false 'hits' identified by the macro 
(Section 8.3.3). 
The data processing of all blood extracts was performed by identical macros which 
differed only in the text generated for the final report. The following series of 
macros were used for the detection of butyl drug derivatives and consequently, the 
text generated relates specifically to butyl extracts. The macros employ internal 
macros and commands recognised by Hewlett Packard operating software (eg. 
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Ret_Time, Peak_Area, rteintparams, peakvars, TIC, print using #). Each new macro 
is preceded by 'NAME' and comments (in italics) which briefly describe the 
working of the macro appear throughout the program. During the development of 
the 'CheckFor' macro, 'debugging' messages were used to help locate the point at 
which the macro failed. These debugging messages appear in a smaller font and do 
not routinely operate unless activated by the user at the command line or in the 
'CustomAnalysis' macro. 
Start automated drug detection and quantitation macro. 
NAME Locate Hydrocarbons 
A macro which locates HC marker GC peaks and records their retention times (RTs). 
local RI,start,finish 
orientpr = 1 
print #2, 
print "Locating markers" 
print #2," 
print #2,"Peaks identified as HC marker markers" 
print #2," 
Macro chromato graphs m/z 71 (the HC marker m/z ion which is monitored during 
data acquisition) and integrates the largest 20 peaks; the integrated chromatogram 




LastPeak = npeaks 
draw 
R1=X 
Macro locates the HC marker peaks by assuming that the last three peaks in the 
integrated chromatogram are C32, C34 and C36 (refer 8.4.1); RTs and Peak Areas 
(PAs) are stored in two individual arrays of 14 for future reference. 
last integrated peak = C36 
PEAKNUMBER LastPeak,TOP,R1 
RTs[14] = Ret_Time 
print #2,"Marker Time 	Area" 
print using #2,"C## ##.### ########/",36,Ret_Time,Peak_Area 
PAs[14] = Peak_Area 
second- last peak = C34 
PEAKNUMBER LastPeak-1,TOP,R1 
RTs[13] = Ret Time 
print using #2,"C## ##.### ########/",34,Ret_Time,Peak_Area 
PAs[13] = Peak_Area 
third-last peak = C32 
PEAKNUMBER LastPeak-2,TOP,R1 
RTs[12] = Ret_Time 
print using #2,"C## ##.### ########/",32,Ret_Time,Peak_Area 
PAs[12] = Peak_Area 
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Macro sets the initial interval to the next HC marker (C30) as the RT difference 
between C32 and C34, 
interval = RTs[13] - RTs[12] 
and works backwards looking for HC markers; the interval is adjusted to that 
between the last found HC markers ± 0.5 min to better locate the next expected HC 
marker in the series. 
last= 12 
i=1 1 
n = 11 
rteintparms „1 
while i> 0 do 
NumToRI i,RI 
expect = RTs[last] + ((i-last)*interval) 
start = expect - 0.5 
finish = expect + 0.5 
if finish > File Start then 
print "Looking for C"+val$(R1/100) 
if start < File Start then 





if npeaks = 1 then 
Macro found the next expected HC marker; RT and PA for that HC marker are 
placed into the arrays. 
PEAKNUMBER 1,TOP,X 
RTs[i] = Ret_Time 
PAs[n] = Peak_Area • 
print using #2,"C## ##.### ########/",RI/100,Ret_Time,Peak_Area 
Macro sets new interval 
interval = (RTs[last] - RTs[i]) / (last - i) 
last = i 
i = i - 1 
n = n - 1 
endwhile 
The Area Threshold for peak detection is set to a fraction of C32 peak area such that 
no absolute threshold value needs to be set (Section 8.4.2). 
AreaThreshold = Pas[12]/10000 
print #2," 
print #2,"Area threshold set to "+val$(AreaThreshold) 
print #2," 
return 
End of macro locateHydrocarbons'. 
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NAME CheckFor 
A macro which checks for a target drug on the basis of Retenion Index (RIndex) and 
a pair of identifiiing m/z ions (mass] and mass 2) which must have coincident RTs; 
parameters for each drug are listed in a table - drugs.txt (Section 2.7). 
parameter name$,Rindex,mass I,mass2 
local rtime,ActualRI 
print "Check for" + name$ 
if debugging then 
print #2,"Check for "+name$ 
endif 
Macro converts drug RIndex listed in drugs. txt to a corresponding retention time 
(rtime) on the basis of the RTs determined for the HC markers found in the current 
chromatogram; the conversion is performed by the RIToTime ' macro. 
RIToTime rindex,rtime 
The two m/z ions for each drug are chromato graphed over a time window (± 0.2 
min) around the calculated rtime. 





areal = Peak_Area 
timel = Ret_Time 
If mass] is found, the peak area and retention time are assigned as variables areal 
and time] respectively. 
If no mass] is found then the drug is not identified/detected by the macro. 
if npeaks = 0 then 
if debugging then 





Macro stores the mass2 chromatogram for later use in the RI register. 
RI=X 
Up to two peaks are integrated in the ion chromatogram for mass2 and the peak 






If no mass2 is found then the drug is not identified/detected by the macro.. 
if npeaks = 0 then 
if debugging then 




If only one mass2 peak is found in the time window, then the PA and RT are assigned 
as variables area2 and time2 respectively. 
if npeaks = 1 then 
peakvars 1,top,x 
area2 = Peak_Area 
time2 = Ret_Time 
endif 
The macro checks that the RTs of mass] and mass2 are coincident to within 0.03 
min; if RTs are not coincident (> 0.03 min) then no drug is identified/detected by the 
macro. 
if (npeaks =1 and abs(timel - time2) > 0.03) then 
if debugging then 




If mass] and mass2 peaks are coincident then the PA and RT of mass2 are assigned 
as variables used later in quantitation (areaq and timeq respectively). 
if (npeaks =1 and abs(timel - time2) <0.03) then 
timeq = time2 
areaq = area2 
endif 
If two peaks were integrated in the mass2 ion chromatogram then the peak that is 
coincident 0.03 min) with mass] is determined (Section 8.4.2). 
if npeaks = 2 then 
peakvars 1,top,x 
area3 = Peak_Area 
time3 = Ret_Time 
peakvars 2,top,x 
area4 = Peak_Area 
time4 = Ret_Time 
endif 
if (npeaks = 2 and (abs(timel time3)> 0.03) and (abs(timel - time4) > 0.03)) then 
if debugging then 





The PA and RT of the appropriate mass2 peak are assigned as variables used later in 
quantitation (areaq and timeq respectively). 
if (npeaks = 2 and abs(timel - time3) <0.03) then 
timeq = time3 
areaq = area3 
endif 
if (npeaks = 2 and abs(timel - time4) <0.03) then 
timeq = time4 
areaq = area4 
endif 
The average RT of mass] and mass2 is recorded as the RT of the drug detected, 
AverageTime = (timel + timeq)/2 
and is rounded to two decimal places for the report. 
AverageT = (trunc (((AverageTime*1000) + 5)/10))/100 
The RT of the drug is calculated as a Rlndex (performed by the macro TimeToRI), 
compared with the Rlndex listed for that drug in drugs.txt, and the retention index 
error (RI error) calculated (rounded to the nearest whole number for the report). 
TimeToRI AverageTime,ActualRI 
RIDifference = RIndex - ActualRI 
if RIndex > ActualRI then 
RIDiff = truncR(RIDifference *10)+5)/10) 
endif 
if Acutal RI > Rindex then 
RIDiff = trunc(((RIDifference *10)-5)/10) 
endif 
Drugs detected by the macro are not reported as 'hits' if any one of the following 
three statements is satisfied:- 
1). If the RI error determined is too great (> ± 25);Section 8.4.2 
if abs(RIDifference) > 25 then 
if debugging then 




2). If the PA of mass2 is less than 0.001 of the PA of mass]; Section 8.4.2. 
if ((areal > AreaThreshold) and (areaq < area1/1000)) then 
return 
endif 
3). If the PA of mass 1 is less than the AreaThreshold; Section 8.4.2. 




If none of the statements is satisifed, the drug detected is recorded as a 'hit' and 
placed in an array. 
if ((areal > AreaThreshold) and (areaq > area 1/1000)) then 
z=1 
hits$ = 
hits = hits + 1 
found[hits] = AverageTime 
The macro determines whether the current 'hit' is coincident with another and 
reports the other coincident 'hit' (identified by a number #x); Section 8.4.2. 
while z < hits do 
if abs(AverageTime - found[z]) <0.03 then 
coincident 
hits$ = 	+ val$(z) 
z = hits 
endif 
z = z + 1 
endwhile 
The macro determines whether the current `hit' is coincident with a HC marker and 
reports the HC marker with which it is coincident; Section 8.4.2. 
XI 
while X < 15 do 
if RTs[X] > 0 and abs(AverageTime - RTs[X]) < 0.03 then 
coincident 
if not eqstr(hits$, ") 
hits$ = hits$ + 
endif 
hits$ = hits$ + "=C" + val$(X*2 + 8) 
endif 
X = X + 1 
endwhile 
The macro determines whether the RI error of current `hit' is larger than expected 
(10< RIerror > 25) and reports an "Analyst Alert" - 
errors$ = 
if abs(RIDifference) > 10 then 
if not eqstr(errors$, ") then 
errors$ = errors$ + "," 
endif 
errors$ = errors$ + "*" 
endif 
The macro re-integrates mass! with integration parameters that allow for either 
tailing or nosiy peak profiles and assigns the new PA of mass] as a variable (areaT) 





The peak height of the peak is assigned a variable (Thigh) and is compared with Ytop 
determined for the mass2 peak Which ever is the tallest peak is assigned Ytop for 
later use. 
get scalars point „x 
if Yhigh > Ytop then 
Ytop=Yhigh 
endif 
if npeaks = 1 then 
peakvars 1,top,x 
areaT = Peak_Area 
endif 
By broadening the time window over which the mass] m/z ion is integrated, a second 
peak with incorrect RT but larger PA than the target peak may be integrated and 
potentially used in quantitation by error; therefore the macro determines that the 
correct peak was within 0.03 min of AverageTime (drug RT). 
if npeaks = 2 then 
peakvars 1,top,x 
area5 = Peak_Area 
time5 = Ret_Time 
peakvars 2,top,x 
area6 = Peak_Area 
time6 = Ret_Time 
endif 
if (npeaks = 2 and abs(AverageTime - time5) <0.03) then 
areaT = area5 
endif 
if (npeaks = 2 and abs(AverageTime - time6) <0.03) then 
areaT = area6 
endif 
In the event that the wrong peak was integrated as a result of broadening the time 
window (AverageTime - RT > 0.03) an "Analyst Alert" - t' is reported. 
quant$ = 
if (npeaks = 2 and (abs(AverageTime - time5) > 0.03) and 
(abs(AverageTime - time6) > 0.03)) then 
if not eqstr(quant$, ") then 
quant$ = quant$ + "," 
endif 
quant$ = quant$ + "a" 
endif 
Calculation of quantitative value; Section 8.3.3.2. 
PAn=PAs[val(n$)] 
logquant=(log(areaT/(PAn*2))+val(C$))/val(M$) 
quant = EXP(logquant* I n(10))*100/val(Recovery$) 
quantl = (trunc(((quant*10000) +%)/10))/1000 
159 
if not eqstr(hits$, ") then 
hits$ = 	+ hits$ + 
endif 
If no calibration curve was determined for this drug (no M and C values) then the 
macro reports the blood level as '99.999'. 
if val(C$) = 9 and val(M$) = 9 then 
quantl = 99.999 
endif 
If no recovery from blood data was determined for this drug then the macro reports 
an "Analyst Alert" (<) which indicates that the minimum blood level has been 
reported. 
if val(Recovery$) = 100 then 
if not eqstr(quant$, ") then 
quant$ = quant$ + "," 
endif 
quant$ = quant$ + "<" 
endif 
If recovery from blood was found to be very variable for this drug then the macro 
reports an "Analyst Alert" - 
if val(Recovery$) = 200 then 
if not eqstr(quant$, "") then 
quant$ = quant$ + "," 
endif 
quant$ = quant$ + "±" 
endif 
The macro displays both m/z ions for the current 'hit' in a specified window and 
prints the window to the report together with related information (name, RT, 
RIerror, absolute mass] peak area, blood concentration, extract in which to confirm 





w = w + 1 
if w= 1 then 
startprint 
endif 
draw (w),x,AverageTime-(delta/2):AverageTime+(de1ta*2.5), 0 :Ytop*1.3 
strprint "#" + val$(h its) +": 7 + name$,50,w*10-6 
strprint "Ret.Time: "+ valS(AverageTime) + hits$,50,w*10-5 
strprint "RI error: "+ val$(R1Difference) + errors$,50,w*10-4 
strprint "Mass 1 area: "+ val$(areaT),50,w*10-3 
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strprint "Conc(ug/mL): "+ val$(quantl) + quant$,50,w*10-2 
strprint "confirm in: "-I- confirm$,50,w*10-1 
winprint w,4,w*10-6,45,10 
if w = 1 then 
R2=x 
endif 
if w = 2 then 
R3 = x 
endif 
if w = 3 then 
R4 = x 
endif 
if w = 4 then 
R5 = x 
endif 
if w = 5 then 
R6 = x 
endif 
if w = 6 then 
R7 = x 
The macro prints a page which displays the chromatogram and related information 
for each of 6 'hits' found. The windows are then cleared and filled sequentially 







End of macro rheckFor' 
NAME TimeToRI 
A macro used in the rheckFor' macro which converts the RT determined for a 
detected drug to a RI. The RT to RI conversion is based on linear interpolation 
between the two HC markers which bracket the drug and for which a RT and RI are 
known (stored in arrays). 
parameter RT,RI by value 
local ril,ri2,n1,n2,t1,t2 
The macro locates array index containing earliest time AFTER drug RT 
n2 = 1 
while RTs[n2] < RT and ri? < 14 
n2 = n2 + 1 
endwhile 
t2 = RTs[n2] 
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The macro locates array index, with latest time BEFORE drug RT 
n1 = n2- 1 
if n2 = 0 then 
return 
endif 
while RTs[nl] = 0 and n1 > 1 
nl=n1- 1 
endwhile 
ti = RTs[n 1] 
NumToRI nl,ril 
NumToRI n2,ri2 
if n1 = n2 then 
return 
endif 
RI = ril + (ri2-ril)*(RT-t1)/(t241) 
return 
End macro TimeToRI 
NAME RIToTime 
A macro used in the rheckFor' macro to convert the RI listed in drugs.txt to a RT 
for each drug The RI to RT conversion is based on linear interpolation between the 
two HC markers which bracket the drug and for which a RT and RI are known 
(stored in arrays). 
parameter RIndex, rtime by value 
local nl,n2,rt 1,rt2,ril,r12 
RIToNum RIndex,n1 
n2 = n1 + 1 
while RTs[nl] = 0 and n1 > 1 do 
n1 = n1 - 1 
endwhile 
while RTs[n2] = 0 and n2 < 14 do 
n2 = n2 + 1 
endwhile 
NumToRI n 1 ,ri 1 
rtl = RTs[nl] 
NumToRI n2,ri2 
rt2 = RTs[n2] 
rtime = rt 1 + (RIndex-ri 1)*(rt2-rt1)/(ri2-ri 1) 
return 
End of macro `RIToTime' 
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NAME PickOff 
A macro which allows the rheckFor' macro to refer to and use the different 
parameters listed in drugs.txt which describe each target drug. 
parameter s by value 
p = instr(line$,",") 
if p = 0 then 
s = line$ 
line$ = 
else 
s = lineS[1:p-1] 
line$ = I ine$[p+1 : len(line$)] 
endif 
return 
End of macro TickOff 
NAME RIToNum 
A macro which converts the retention index numbers for the HC markers (1000, 
1200, 1400 etc) to array numbers (I, 2, 3 etc) and is used in the 
locateHydrocarbons', RIToTime' and TimeToRI' macros. 
parameter RI, n by value 
n = trunc ((RI-1000)/200) + 1 
return 
End of macro `RIToNum' 
NAME NumToRI 
A macro which converts the array numbers (1, 2, 3 etc) for the HC markers to 
retention index numbers (1000, 1200, 1400 etc) and used in the 
locateHydrocarbons', R1ToTime' and TimeToRl' macros. 
parameter n, RI by value 
RI = 1000 + (200*(n-1)) 
return 
End of macro `NumToRP 
NAME CustomAnalysis 
The 'top level' macro which directs the automated drug search and prints the final 
report. 
Turns 'debugging' on or off 
if CHECK("VARIABLE","debugging") = 0 then 
debugging = 0 
end if 
The following are specific lines of text related to report generation for butyl extracts. 
footer$ = "**Combined SPE and LLE** 
pagenum = 1 
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path$ = _MethPath$ + _MethFile$ + "I" 
open path$ + "drugs.txt" for input as #1 
open path$ + "REPORT.TXT" for output as #2 
print #2, 
print #2," 	Broad Drug Screen in Blood for Drugs" 
print #2, " (Butyl Derivatives)" 
print #2, 
print #2, 
print #2,"Data File : "+ _DataFile$ 
print #2,"Data Name : "+ _DataName$ 
print #2,"Misc Info : "+ _MiscInfo$ 





hits = 0 
w = 0 







Initiates the locateHydrocarbons' macro. 
LocateHydrocarbons 
The macro continues to refer to drugs.txt for target drugs and their relevant 
parameters until it reaches the line "--END--". 
input #1,line$ 
while not egstr(line$,"--END--") do 
drug$ = 
ri$ = 




C$ = "" 
M$ =fill 
Recovery$ = 
The macro ignores any lines in drugs.txt preceded by "*". 











ri = val(ri$) 
ml = val(ml$) 
m2 = val(m2$) 
n = val(n$) 
confirm = val(confirm$) 
C = val(C$) 
M = val(M$) 
Recovery = val(Recovery$) 






In the event that no 'hits' are found, the macro reports 'No Drugs Detected'. 
if hits = 0 then 
print #2," ** NO DRUGS DETECTED*" 
endif 
With the completion of the rheckFor' macro, the final report is generated which 
lists the various notes and "Analyst Alerts" relevant to the 'hits'. 
print 
#2," 	 If 
print #2," 
print #2," Analyst Alerts" 
print #2," 
print #2," 	= Absolute Rlerror > 10." 
print #2," o 	= Quantitation incorrect! The wrong peak was integrated by" 
print #2," 	the macro - refer to chromatogram for that drug." 
print #2," < 	= No recovery data. Report 'at least' x 
print #2," ± 	= Recovery from blood very variable." 
print #2," 
print #2," Notes" 
print #2," 
print #2," 	= Area of drug target ion > set threshold area." 
print #2," 2 	= Macro calculated RI - Actual RI." 
print #2," 99.999 = No quantitative value due to poor reproduciblity of either" 
print #2," 	 the day-to-day GC reponse, or derivatization." 
print #2," LLE = Liquid-liquid extract." 
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print #2," SPE = Solid phase extract." 
print #2," PEP = Pentafluoropropionylated solid phase extract." 




print #2," 	 **ANALYST INTERPRETATION**" 
print 	#2," 
print #2," 
print 	#2," 	 DETECTED DRUGS 	1." 
print 	#2," 2. " 
print 	#2," 	 3." 
print 	#2," 4." 
print 	#2," 	 5.0 











The macro prints the remaining windows (< window 6) generated in the rheckFor ' 
macro. 





The macro prints the front page of the report. 
printtextfile "report.txt" 
The macro prints the full page chromatogram generated by the butyl extract. 







End automated drug detection and quantitation macro. 
8.3.2 The Final Report 
Report 8.1 is a reproduction of one page of a macro-generated report following the 
GC/MS analysis of a derivatised (PFPA) mixed drug solution. The drug solution 
contained 19 drugs at concentrations of approximately 1 ilg/mL. The first six 
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'hits' identified by the macro are displayed together with:- the retention time 
(Ret.Time); RI error; the absolute peak area of mass 1; the calculated drug 
concentration; and the alternate extract in which the same 'hit' would also be 
expected if the drug were present in the blood specimen. Of the six `hits' shown 
in Report 8.1, the presence of only two can be confirmed in an alternate extract 
(carbamazepine and codeine). Common to all the 'hits' displayed in the report are 
the following. 
1. 'Hits' are reported alphabetically. 
2. 'Hits' are aligned and shown in the first third of the window. 
3. The pair of target m/z ions which characterise each 'hit' are coincident. 
4. Massl is the second m/z ion listed in each window (eg. for 7-amino 
flunitrazepam; massl = 401.00). Mass 1 is integrated (for quantitation) and an 
integration line is apparent. 
5. The pair of target m/z ions have differing relative abundances but identical peak 
profiles. For example, alprenolol mass2 is much smaller than mass 1; massl 
and mass2 of 7-aminoflunitrazepam are both moderately tailing. 
6. Although each `hit' is displayed so as to fill the window, the peaks shown have 
differing peak heights as indicated by abundance (y axis). 
7. The RI error indicates that all 'hits' are within 10 RI units of the RI listed in 
drugs.txt. 
8. The calculated drug concentration approximates the true concentration of the 
mixed drug solution. 
Reports 8.2-8.5 are reproductions of the reports generated following the analysis 
for drugs of a single forensic blood specimen (Figure 2.1). Reports 8.2 and 8.3 
were generated from underivatised blood extracts following liquid-liquid and 
solid-phase extractions respectively. Report 8.4 was generated from the butylated 
blood extract (combined fractions from liquid-liquid and solid phase extractions). 
Report 8.5 was generated from the pentafluoropropionylated blood extract 
following solid-phase extraction. The "Analyst Interpretation" (first page of each 
report) shows a list of "Drugs Detected". These are 'hits' identified by the macro 
which, following analyst interpretation, have been confirmed as drugs identified in 
each extract. Note that during macro development, typographical errors occurred 
while entering drug names into the drugs.txt file. These errors are permanently 
recorded in the macro reports and some are apparent in Reports 8.2-8.5. 
8.3.3. Analyst Interpretation of Macro Generated Reports 
8.3.3.1 Elimination of False Positives 
Table 8.1 shows the completed summary sheet routinely used by the analyst to 
collate the drugs detected from each of the four reports generated following the 
analysis of a blood specimen. In this case, the four columns of data (left to right) 
correspond to the drugs detected in Reports 8.2-8.5 respectively. As indicated in 
Section 8.3.2, each macro-generated report indicates in which alternate extract a 
'hit' might also be expected (eg. "confirm in: LLE/PFP"). Where the expected 
confirmation of a 'hit'from one extract did not occur in the other, the analyst 
indicates this with "- UNCONFIRMED -" (codeine, cotinine, trimethoprim). For 
all other drugs listed, there was either confirmation as expected (eg. amitriptyline, 
diazepam, methadone), or no alternate extract in which to confirm the presence of 
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a 'hit' (eg. paracetamol, 7-amino nitrazepam). The estimated blood concentration 
of the drug is given for each extract in which it was detected. No quantitation was 
performed by the macro for some drugs (-). 
Based on the sequence of analyst checks outlined in Section 8.4.3, 'hits' identified in 
Reports 8.2-8.5 which possessed the necessary features to assign them as drugs were 
reported as 'Drugs Detected' by the analyst as follows:- amitriptyline and 
nortriptyline (metabolite), caffeine, carbamazepine, cotinine, diazepam and 
nordiazepam (metabolite), methadone, and paracetamol. The majority of 'hits' listed 
in the four reports had been falsely identified as drugs by the macro and were 
eliminated by the analyst for at least one of the nine reasons listed in Table 8.2. The 
false 'hits' from Reports 8.2-8.5 are listed below with the reason/s (1-9, Table 8.2) 
that the analyst did not include them in "Drugs Detected" lists. 
Report 8.2 indicates the following drugs were present in the blood extract:- 
amitriptyline, caffeine, diazepam, methadone, nordiazepam. 

























tiaprofenic acid (7) 
Report 8.3 indicates the following drugs were present in the blood extract:- 
amitriptyline; caffeine (relatively large and distorted peak); carbamazepine (identical 
tailing peak profiles for the two target m/z ions); codeine (although the analyst would 
expect a slightly poorer peak shape); cotinine (identical tailing peak profiles for the 
two target m/z ions); diazepam; methadone; and trimethoprim (grossly overloaded 
peak and consequently m/z ion abundances are meaningless). 


















phenylbutazone (2,6,7) 	procainamide (3,7) 
prochlorperazine (7) quinine (3,7) 
trimeprazine (7) 	• 
Report 8.4 correctly indicates the following drug derivatives were present in the 
butylated blood extract:- nordiazepam, nortriptyline, paracetamol. 















Report 8.5 correctly indicates the following drug derivatives were present in the 
pentafluoropropionylated blood extract:- 7-aminonitrazepam, carbamazepine and 
nortriptyline. 
Falsely identified 'hits' and reasons for their rejection (Table 8.2) were as follows:- 
7-aminoflunitrazepam(7) 	codeine (4) 
desipramine (3,7) 	ephedrine (4,7,9) 
fenfluramine (3,7) flecainide (7) 
hyoscyamine (3) 	MDMA (9) 
metoclopramide (4,6) 	oxyphenbutazone (3,7) 
phenylpropanolamine (2,4,7) pseudoephedrine (3,7,9) 
sotalol (3,7) 	 warfarin (7) 
For all drugs listed except 7-amino nitrazepam and paracetamol, a drug detected in 
one extract could be checked for in another, thus confirming the presence of that drug 
in the blood sample. The presence in the blood sample of amitriptyline, caffeine, 
carbamazepine, diazepam, methadone, nordiazepam and nortriptyline could all be 
confirmed in this way. Similarly, the presence of the drug metabolites, nordiazepam 
and nortriptyline, provided additional confirmation of the presence of the parent 
drugs, amitriptyline and diazepam, respectively. 
In contrast, Table 8.1 indicates that trimethoprim, cotinine and codeine detected in 
the solid-phase blood extract (Report 8.3) were not confirmed in other extracts where 
their presence would have been expected (`- UNCONFIRMED -'). 
8.3.3.2. Quantitation of Drugs Detected 
The `CheckFor' macro estimates the concentration in blood of each 'hit' it identifies 
in a GC extract from a predetermined calibration curve based on log transformed data 
points (Section 3.3.1). The peak area ratio (Section 2.6.1) for each 'hit' identified by 
the macro is automatically calculated using the HC marker specified in drugs.txt. 
The C and M values which describe the linear regression equations fitted to log 
transformed data points are listed in the drugs.txt. file to which the `CheckFor' macro 
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refers. The C and M values were determined for each drug from reference drug 
solutions at concentrations of approximately 0.25 p.g/mL up to approximately 3 
p.g/mL. As these solutions were not first extracted from blood prior to GC analysis, 
the estimated concentration of the 'hit' determined from the calibration curve must 
be adjusted for its recovery from blood. The `CheckFoe macro refers to recovery 
data for each drug (Table 7.6) in the drugs. txt file and reports an estimated blood 
concentration (pg/mL). 
Table 8.3 reproduces the recovery from blood data which was given in Table 7.6 for 
each of the drugs detected and quantitated in Reports 8.2-8.5. It also shows the 
estimated blood level reported by the analyst which was derived from the 
quantitative data summarised in Table 8.1 for each drug detected. Two estimated 
blood levels were listed in Table 8.1 for the majority of drugs and the mean value 
was reported by the analyst in Table 8.3 with an error based on the sum of the 
standard deviations associated with each extraction procedure. For example, the 
mean quantitative value for diazepam from liquid-liquid and solid-phase extractions 
was 0.21 fig/mL (Table 8.1). Table 8.3 shows standard deviations for the two 
extraction techniques (LLE and SPE) as 4.3% and 3.5% respectively and the error 
associated with the estimated diazepam blood level is based on their sum (= 7.8%), 
ie. ± 0.016 pg/mL (Table 8.3; ± 0.02 pg/mL). Paracetamol quantitation was based 
on calibration standards which did not exceed 5.5 pg/mL, therefore, the analyst 
reports an estimated figure of "> 5.5 p.g/mL (R-- 14 ± 2.5 pg/mL)". 
A relatively simple modification to the macro would ensure that the analyst was 
alerted to blood levels in excess of the highest calibration point being reported by the 
macro. The `CheckFor' macro could refer to an additional variable for each drug in 
the drugs. txt file which would list the highest calibration point (eg. `highpoine). 
This could be compared with the concentration determined for the current 'hit' 
(`CheckFor' macro; quantl) and if it were smaller, the macro could report "quantl > 
highpoint". 
if val(highpoint$) < quant I then 
if not eqstr(quant$, "") then 
quant$ = quant$ + "," 
endif 




Drugs were detected in complicated multi-peak chromatograms on the basis of fixed 
parameters (RI and a pair of target m/z ions) which together uniquely identified each 
target drug. The macro searched for over 100 drugs in the four blood extracts and 
estimated the levels of identified drugs using predetermined quantitative information 
(drug recovery from blood; M and C values from linear regression equations). A 
report was generated with an m/z ion chromatogram for each 'hit', retention time and 
RI error which allowed the analyst to eliminate false positives and confirm the macro 
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'hits' as drugs detected. The report provides a hard-copy of drug identification and 
quantitation in a given blood sample which can:- 
1. be produced in court at a later time (eg forensic application), 
2. be re-interpreted by an independent analyst, 
3. provide a history of the blood analysis, and 
4. remove the necessity to archive or store the raw data. 
Data acquisition was performed in SIM rather than full scan mode giving greater 
instrument sensitivity (Section 1.4.2). The drug identification and quantitation macro 
had significant advantages over the automated techniques described in Section 8.1. 
1. It has greater specificity than identification on the basis of drug RI alone as the 
mass spectrum of the unknown peak must also possess the required pair of 
characteristic target m/z ions. Consequently, an interfering endogenous product or 
contaminant would be falsely identified as a drug only if it too possessed the two 
characteristic m/z ions. In addition, as four blood extracts were analysed, where 
appropriate the interfering product must also be identified as the same drug in the 
corresponding extract (and possibly as a derivative). 
2. It is able to identify small peaks which are present at levels close to the limit of 
instrument detection and 'lost' within a baseline complicated by endogenous 
blood products (eg. Report 8.5, 7-aminonitrazepam). 
3. It is able to identify small peaks on the leading or tailing edge of other larger 
peaks in the chromatogram. 
4. It is able to identify drugs from a mixed mass spectrum produced by co-eluting 
peaks. 
5. It is able to offer confirmation of a drug identification by alerting the analyst to 
the alternate extract in which the same 'hit' might also be expected. 
6. It provides an estimation of the concentration of the drug in blood on the basis of a 
multi-point calibration curve. 
7. It is able to identify drugs in chromatograms generated on any non-polar column 
(regardless of column length, internal diameter and film thickness, gas flow 
through the column, oven temperature rate) as macro operation is independent of 
absolute retention time. The only necessary requirement for successful operation 
is the chromatography of a series of HC markers. 
8.4.2 The Macro 
8.4.2.1 General 
The program consisted of three major macros. 
1. `CustomAnalysis' was the top level macro and directed and initiated other macros 
(`LocateHydrocarbons,'CheckFor'and `PickOff ). It opened and closed a path for 
the generation of the report (#2) and printed part of the final report. It opened and 
closed a path for the `drugs.txt' table (#1) which contained the unique data for 
each drug used by the `CheckFor' macro. It established arrays for several 
variables used in `LocateHydrocarbons' and `CheckFor' macros and turned a 
debugging macro on or off (useful during macro development). 
2. `CheckFor' was the drug detection and quantitation macro and incorporated the 
minor macros `TimeToRF and 'RIToTime'. Using parameters accessed in 
`drugs.txr this macro chromatographed the two characteristic m/z ions for a 
particular drug over a time window calculated from the drug RI. A drug was 
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identified if peaks generated from the two m/z ion chromatograms coincided to 
within 0.03 min. The peak area of the one m/z ion was used to calculate the drug 
level in blood (ug/mL). Various analyst warnings and 'fail-safe' mechanisms 
were incorporated to reduce the number of false 'hits' and errors in quantitation. 
The 'CheckFor' macro printed part of the final report. 
3. locateHydrocarbons' was the macro which identified the HC markers added to 
each blood extract and which stored the retention time and peak area of each 
marker for use by 'TimeToRI', 'RIToTime' and `CheckFor' macros. It created 
some text and data for the final report. It established the peak area threshold value 
referred to by the 'CheckFor' macro as C32peakarea/5000. 
8.4.2.2 Transfer of the Macro Between Different GC Systems 
Macro operation was independent of absolute retention time and, consequently, could 
be employed in the automated analysis of chromatograms generated on any non-polar 
column. From the drug RI values listed in drugs.txt, the expected drug retention time 
could be calculated and was based on linear interpolation between a pair of HC 
markers which bracketed the drug. The macro searched for target m/z ions over a 
narrow but specific time window. It was shown in Section 3.3 that drug RI did alter 
slightly in response to altered chromatographic variables. Consequently, although 
the drug RI values from drugs..txt could be employed in the analysis of 
chromatograms generated on other instruments, an absolute RI error of greater than 
25 may be required. Greater macro precision would be obtained by determining the 
RI of target drugs on individual GC systems (Section 3.4). 
The majority of integration parameters incorporated into the macro were independent 
of GC conditions and instrumentation. 
1. The minimum peak area threshold was not an absolute value but set as a fraction 
of the peak area of C32. It was, therefore, independent of instrument sensitivity. If 
the operator were to decide that the threshold was set too low, then a single 
change in the `LocateHydrocarbons' macro would customise the macro. In the 
present study, the peak area threshold was set low to ensure drugs present in the 
blood at low levels were detected. As a result, there was an increase in the 
number of false positives reported by the macro for the analyst to eliminate 
(Section 8.4.3.1). 
2. The time window over which m/z ions were chromatographed was determined 
from drug RI ± 0.2 min (ie. ± 12 s). If 0.2 min was either too large or small a 
window on some instruments, a single change to the 'delta' variable in the 
`CheckFor' macro would customise the macro. 
The parameters set for the integration of `areaT', however, were very specific and 
may not be applicable to other GC systems. Integration parameters used to obtain 
the `areaT' value were set to accommodate the occurrence of a 'spiky' or tailing peak 
and ensured its accurate integration. Consequently, if the macro were used to 
quantitate drugs on other instruments, it is possible that some peaks may be poorly 
integrated. Similarly, the chromatographic responsiveness of drugs observed on the 
current GC system may differ on other systems. Therefore, the C and M values listed 
in drugs.txt may no longer accurately describe the linear regression equation which 
would be fitted to calibration data points on other systems. As indicated for drug RI 
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values, greater quantitative accuracy would be attained by determining new 
parameters (C and M values) on individual instruments. 
Therefore, automated drug identification (but not quantitation) was independent of 
specific instrument sensitivity, MS tuning parameters or chromatographic conditions 
and would be transportable between different GC systems and laboratories. 
8.4.2.3 Macro Operation 
Macro operation was based on correctly identifying the 14 HC markers present in 
every chromatogram and assigning their retention times. The macro did this on the 
assumption that the last three peaks in the m/z 71.05 profile were C32, C34 and C36. If 
the HC markers were incorrectly identified, the macro would search for pairs of 
target m/z ions at times when the GC method was not acquiring them. The most 
common outcome of mis-assignment was the "NO DRUGS DETECTED" message. 
The only cause of incorrect assignment encountered either during macro 
development or validation (Chapter 9) was the mis-identification of C36 which was 
the smallest of the HC markers. The macro integrated 20 peaks in the m/z 71.05 
profile with the greatest peak areas. If more than 20 peaks were chromatographed, it 
was possible that one of the additional peaks had a greater peak area than C36 (`TIC' 
in Reports 8.2-8.5). Consequently, the macro would overlook C36 and mistakenly 
assign C34 as C36. This was observed to occur most often in chromatograms 
generated from post-mortem blood specimens which contained large putrefaction 
products (Chapter 9). When mis-assignment occurred, increasing the number of 
peaks integrated in the m/z 71.05 profile from 20 to 21-25 resulted in the correct 
identification of all the HC markers. The number of peaks routinely integrated in the 
rn/z 71.01 profile could be any number (eg. 50) provided that no small peaks between 
C32, C34 and C36 were integrated. In general, this was unlikely to occur as the ion 
trace was very 'clean' in the region of these high boiling compounds (`TIC' in 
Reports 8.2-8.5). 
From the drug RI values listed in drugs.txt, the expected drug retention time was 
calculated and the macro searched for the drug's target m/z ions over a narrow but 
specific time window (drug retention time ± 0.2 min). Within the 'search' window, 
the macro integrated the peaks with the greatest areas; one peak was integrated for 
mass I and the two peaks (if present) were integrated for mass2. Two peaks (if 
present) rather than one were integrated for mass2, as often the mass2 m/z ion was 
either the less unique and/or less abundant of the target ions. On the basis of peak 
area alone, the macro may have selected the wrong peak if the multiple peaks were 
chromatographed over the search window for mass2. As a consequence, the macro 
would determine that massl and mass2 were not coincident (differing by > 0.03 min) 
and no drug would be identified. For example, the M+ (mass2) for many of the PFP 
derivatives of 13-blocking agents and underivatized anti-depressant agents were very 
small relative to massl and chromatographed with relatively small peak areas (eg. 
alprenolol, Report 8.1). Consequently, if another peak were to elute close by (within 
the 24 s search window) and also possessed the mass2 m/z ion in its full-scan mass 
spectrum, then the macro may have determined that it had the greater peak area. 
Similarly, although the HC markers have a negligible contribution of higher masses 
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in their mass spectra, as the largest peaks in the chromatograms, the macro may still 
have found that a HC markers had a greater peak area for mass2 than the target drug 
which was eluting close by. Fewer false negatives were reported, therefore, if the 
macro integrated two peaks (if present) over the specified time window. Where two 
peaks were integrated for mass2, the macro identified the correct peak as the one 
coincident with mass 1. If neither peak was coincident, then the macro did not 
identify a 'hit'. 
The macro eliminated some false positives by applying the following criteria. The 
'hit' was not reported if the following conditions applied. 
1. The RI error was greater than ± 25. In general, an RI error of less than ± 10 was 
observed for the majority of drugs, but ± 25 RI units was selected as it permitted 
some variation in the RI of drugs chromatographed in a particular run. It was 
found during development and validation of the macro that drugs which were 
chromatographed with poor peak shape sometimes eluted with an absolute RI 
error of greater than 10 (eg. temazepam, butyl oxazepam). Similarly, the elution 
of large amounts of drug tended to be retarded by more than 10 RI units (Section 
8.1). Drugs which co-eluted with other large amounts of drug were similarly 
retarded. The elution of large amounts of endogenous material (eg as found in 
decomposing blood samples) also altered the RI of drugs eluting nearby. It was 
generally observed, however, that absolute RI did not alter by more than 25 RI 
units. Therefore, drugs with an RI error greater than 10 but less than 25 were 
reported as 'hits' which would then allow the analyst to reject or accept them 
following consideration of the information in the report (Section 8.4.3). 
2. The massl peak area was less than the peak area threshold. This ensured that 
false 'peaks' integrated from a 'spiky' base-line were not reported. 
3. The peak area of mass2 was less than 0.001 the peak area of massl. Although 
some very small mass2 peak areas were to be expected as indicated previously, 
they were not so small as to satisfy this criterion. This criterion was set to ensure 
that false 'peaks' integrated from a 'noisy' base-line were not found to be 
coincident with mass 1. 
The macro alerted the analyst to the fact that the current 'hit' was coincident with 
either a HC marker or a previously identified 'hit' (eg Report 8.2; metoclopramide 
"= C26"; Report 8.3 dihydrocodeine "= #6"). In such cases, the retention times of 
the two coincident 'hits' were often identical. When the current 'hit' was coincident 
with a HC marker, it was always the case that the macro had falsely identified the 
current 'hit'. Drugs susceptible to false identification were those with a 
RiDrug = RIHCmarker 25. As previously stated, although the HC markers had a 
negligible contribution of higher masses in their mass spectra, as the largest peaks in 
a chromatogram, the macro sometimes determined that the peak areas of these 
negligible ions (identical to drug massl and mass2) were greater than the area 
threshold and, of course, coincident. The C 18 , C22 and C26 peaks were regularly 
falsely identified as pheniramine, moclobemide and metoclopramide respectively in 
underivatised blood extracts (Reports 8.2 and 8.3). When determining the RI for the 
target drugs and their derivatives (Tables 3.2, 3.4, 4.6 and 5.6), none was found to be 
exactly the same as the HC markers. 
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Similarly, when the current 'hit' was coincident with a previous 'hit', it was always 
the case that the macro had falsely identified one or other of the "hits' particularly 
when one 'hit' corresponded to a drug present in the blood specimen. The false 
identification occurred for exactly the same reasons as a false 'hit' coincident with a 
HC marker (eg diflunisal was falsely identified in the presence of nortriptyline; 
Report 8.4). The presence of large amounts of endogenous blood compounds 
(eg. putrefaction products) sometimes also resulted in the macro falsely identifying 
drugs (eg codeine and trimethoprim. Report 8.3). The analyst was generally alerted 
to the presence of endogenous products as large, tailing peaks observed in the full-
page 'TIC' with each report (eg Report 8.3). Consequently, the coincident peaks 
indicated in the macro-generated reports would usually lead to the rejection of some 
of the identified 'hits'. 
During the identification of drugs, the macro searched a narrow time window for the 
target m/z ions. To obtain the peak area used in calculations of drug concentration 
(areaT), the massl peak area was re-integrated under a different set of integration 
parameters (including peak smoothing) and over a larger time window (chrom 
AverageTime -(delta/2):AverageTime+(delta*2),mass1). The initial massl peak area was 
not used in the generation of quantitative figures as it often underestimated the peak 
area due to poor integration. For example, drugs which were chromatographed with 
a broad or tailing peak shape were sometimes not integrated 'baseline-to-baseline' as 
the 'tail' lay outside the window over which the m/z ion was drawn (chrom rtime-
delta:rtime+delta,mass1) and the integrator dropped a perpendicular to the baseline. 
Similarly, peaks chromatographing at close to the threshold of detection for the 
instrument were often 'spiky and noisy' rather than smooth peaks (eg. nordiazepam; 
Table 8.2) such that the integrator often dropped to the baseline at what it perceived 
was a valley instead of at the tailing edge of the peak. The new integration 
parameters better integrated the majority of peaks chromatographed including broad, 
tailing, and 'spiky' peaks. 
The drug concentration was determined by the macro from information obtained 
from drugs.txt. The peak area ratio was calculated for each drug (Section 2.6.1) 
using areaT and the peak area obtained by TocateHydrocarbons' for the HC marker 
specified in drugs. txt. The log transformed ratio was then used in the linear 
regression equation with C and M values specified in drugs.txt. These equations 
were determined from unextracted drug solutions and consequently, an adjustment 
for drug recovery from blood (specified in drugs.txt) was made to calculate the 
'quane variable. The `quantl ' variable ensured that the drug concentration was 
reported to no more than 3 decimal places. Several analyst alerts were associated 
with the quantitative figure generated by the macro as follows. 
1. The appearance of "a" indicated that the quantitative figure generated did not 
relate to the peak area of the 'hit' (see below) and the analyst must perform the 
integration manually. This occurred most often in relation to false 'hits' with peak 
areas very close to the threshold area. 
2. The appearance of "<" indicated that no recovery data was available for the 
current 'hit' and 100% recovery was assumed (directly comparable with standard 
solutions from which the calibration curve was derived). It might be expected that 
recovery was less than 100% for these drugs and, consequently, the macro would 
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apply a recovery factor if known (drugs. txt). Consequently, the blood level 
calculated was the minimum possible level. 
3. The appearance of "±" indicated that recovery and/or derivatisation of the current 
'hit' was very variable from day-to-day and the blood level calculated should be 
regarded as varying by up to ± 100%. 
Occasionally, the macro mistakenly generated a quantitative figure which did not 
relate to the current 'hit' ("a"). This can be explained as follows. The macro used a 
number of variables which were not assigned any value until a 'hit' was identified 
(eg. time2; time 3). Consequently, the `CustomAnalysis' macro assigned arbitrary 
values to these variables (eg. time2 = 200) which were continually overwritten by the 
value related to the next 'hit' detected. This caused no problems except in rare 
instances where the macro integrated the wrong peak for massl during its re-
integration to obtain areaT. On some occasions, the wrong peak was re-integrated 
because, by extending the time window over which massl was drawn (chrom 
AverageTime-(delta/2) :AverageTime + (delta*2),mass1), an additional peak was found 
with a peak area greater than that of mass 1. The new peak was not coincident with 
the retention time of the drug (AverageTime) and no new areaT value was 
determined. However, as the macro still retained the areaT value assigned from the 
previous 'hit', it went on to calculate a meaningless drug concentration. The analyst 
was alerted to this problem by '0'; however, it was also indicated by the massl area 
being identical with that of the previous 'hit' immediately above it in the report. 
During macro development and validation, this occurrence was observed only for 
falsely identified 'hits' where there was no real mass! peak (eg. Report 8.2; 
dihydrocodeine, thioridazine). 
The `CheckFor' macro printed the part of the report which was related to individual 
'hits'. The m/z ion chromatogram was drawn, its position on the page was specified 
and the drug name, retention time, RI error, absolute massl area, drug concentration, 
and other extracts in which to confirm the presence of the drug were given. All the 
information displayed for each drug was used by the analyst during report 
interpretation (Section 8.4.3). The absolute massl peak area was included should the 
analyst wish to manually re-calculate the drug concentration or use the peak area in 
some other way. The macro was designed to display six 'hits' to a page and each 
page was printed only when the sixth 'hit' was detected. Consequently, the last 'hits' 
(less than six) were printed by the 'CustomAnalysis' macro. 
A 'hit' was identified if the retention times of both massl and mass2 were coincident 
(differing by <0.03 min). The macro would fail to identify a 'hit' for the following 
reasons. 
1. The peak area of mass 1 was less than the threshold area. 
2. More than two peaks were present in the massl chromatogram and the 'wrong' 
peak was integrated as it had the greater peak area; consequently, mass 1 was 
assigned the wrong retention time. 
3. The peak area of mass 2 was less than 0.001 that of mass 1 
4. The mass2 chromatogram had more than two peaks present with greater peak 
areas than the drug peak; consequently, neither of these had retention times which 
were coincident with mass 1. 
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5. Integration of either the massl or mass2 peaks was poor (eg poor peak shape, 
weak signal leading to a noisy peak profile) and the resultant retention times were 
not coincident. 
6. The drug RI shifted by greater than ± 25 RI units. 
The macro has not been observed to fail as a result of reasons 1, 3 and 4 during either 
the course of the study or its routine use at the Government Analytical and Forensic 
Laboratory (GAFL) over 12 months. The macro has been observed to fail, however, 
in the following two instances. 
1. When a very low level of underivatised metoclopramide (RI = 2608, 
massl = 86.10) could not be distinguished by the macro from the large C26 peak 
eluting immediately in front of it (within the 24 s time window); reason 2. 
2. When a drug was present at a level close to the detection limit of the instrument 
and which tended to be poorly chromatographed (eg butyl-oxazepam). In this 
instance only part of the peak for one mass was integrated due to its spiky peak 
profile and a retention time was assigned which differed by greater than 0.03 min 
from the other mass; reason 5. Smoothing the peak caused a greater proportion of 
the peak to be integrated and assigned a new retention time which was coincident 
with the other mass. Peak smoothing was not routinely incorporated in the macro 
(except in the determinatio of areaT), although it would be advantageous for low 
level drugs. 
Consequently, the macro is more likely to fail to detect drugs which chromatograph 
poorly at levels close to the limit of detection. However, it is unlikely that manual 
searching of a chromatogram by an analyst would be any more reliable for these low 
level drugs. For example, the macro clearly identified underivatised nordiazepam in 
Report 8.2 but visual inspection of the relatively 'clean' mixed m/z ion 'TIC' does 
not indicate a peak (similarly 7-amino nitrazepam; Report 8.5). 
The macro has failed on a number of occasions to detect drugs in amounts which 
caused column overload (reason 6). The therapeutic levels of some acidic drugs are 
relatively high compared with most basic drugs (Table 6.1). Consequently, during 
validation experiments (Chapter 9) therapeutic levels of paracetamol, phenytoin and 
theophylline were often chromatographed with overloaded/distorted peak and their 
elution was retarded. The 'TIC' from Report 8.4 shows a peak which dominates the 
chromatogram. This peak was identified as paracetamol by the macro. In some 
instances, drug RI shifts of greater than 25 RI units were observed and the macro did 
not report a 'hit'. In such instances, however, the analyst could not fail to observe 
the large GC peak which was chromatographed for these drugs and which dominated 
the 'TIC' and suppressed the HC markers. The analyst was immediately alerted to 
the presence of a significant unidentified peak with an approximate retention time 
similar to that of either paracetamol, phenytoin or theophylline. The macro could be 
forced to identify these drugs by temporarily altering the drug RI by approximately 
25 RI units in drugs.txt. As a result of the overloaded peak shapes, however, any 
quantitative value generated by the macro was not meaningful. The inclusion of the 
'TIC' in the generation of the report is an important safeguard for the analyst against 
missing a large GC peak. 
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In the majority of cases, drugs were identified with an absolute RI error of less than 
10 RI units. This was consistent with RI errors reported in the literature (Section 8.1) 
for studies which employed either a homologous series of HC markers (up to 25), or 
drug or nitrogen-containing markers. 
8.4.3 Interpretation of the Final Report 
The automated drug identification macro mimicked some of the interpretative skills 
employed by an experienced analyst and the report generated served as an aid to the 
analyst. The macro significantly reduced the time required to analyse 
chromatograms, guarded against the reporting of false negatives when the drug was 
present at low blood levels, and estimated the approximate level of drugs in blood 
(.1g/mL) which could be used for the future, more accurate, quantitation of that drug 
if necessary (Section 8.4.4). 
The macro, however, did not replace the experienced analyst. As indicated 
previously (Section 8.4.2.3) the peak area threshold for integration was set very low 
to ensure that drugs present at low blood levels were identified by the macro. Clearly 
the low area threshold setting was a contributing factor in the false identification of 
many of the 'hits' in Reports 8.2-8.5. Consequently, even in a blood sample free 
from drugs, the macro assigned 'hits' to peaks which resulted, for example, from a 
noisy baseline. Consequently, the analyst was responsible for correctly interpreting 
the macro-generated reports and identifying false 'hits' from true. 
To interpret a macro report correctly, the analyst applied a 'Check List' of points 
(Table 8.4) many of which were signalled by Notes and Analyst Alerts listed on each 
report. A single report generally took less than 1 min of the analyst's time to 
interpret. An explanation of some of the individual checks listed in Table 8.4 follows 
and indicates why they are important to the correct interpretation of the macro 
reports. 
1. Check the correct identification of HC markers. (Section 8.4.2.2). 
2. Check the 'TIC': At a glance the analyst could observe the general 
chromatography of the HC markers, the cleanliness of the extract, and the 
presence of large and/or overloaded peaks which potentially have either an altered 
RI ,or have altered the RI of drugs co-eluting with them. 
3. Check m/z ion chromatograms produced for each 'hit': The m/z ion 
chromatograms were of the greatest benefit to the analyst as the validity of 'hits' 
could rapidly be assessed by eye. With every 'batch' of blood specimens 
analysed, mixed underivatised and derivatised drug solutions were also 
chromatographed (Section 2.6.2). Consequently, the analyst had a drug reference 
with which to compare a 'hit' (refer ii, v, vi). The analyst needed to consider 
several factors during the examination of ion chromatograms as follow. 
i. 'Hits' must be aligned down the page (Report 8.1) such that off-set peaks 
were likely to have been falsely identified (large RI error). The pair of target 
m/z ions for a particular drug must have identical peak profiles with each peak 
beginning and ending at the same time (Report 8.1). 
ii. The peak shapes of the 'hit' and reference drug standard must be similar. 
Some underivatized drugs are known to be poorly chromatographed (Table 3.2 
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and 3.4; tailing peak shapes - metoclopramide, nordiazepam, phenindione, 
primidone, quinine, temazepam). Consequently, if one of these drugs was 
identified by the macro, it must also have a relatively poor peak shape. 
iii. The maximum m/z ion abundance (y axis) of each chromatogram should be 
noted. The majority of 'hits' encountered have significantly greater 
abundances than falsely identified 'hits' (Reports 8.1-8.5) except when the 
'hit' is close to the instrument detection limit. 
iv. The 'peak' may be an artefact of data acquisition. A change in abundance 
sometimes occurred as monitoring for one group of m/z ions ceased and 
another began, resulting in a sudden increase or decrease in the baseline. The 
'step' produced was sometimes falsely interpreted by the macro as a peak and 
a'hit' assigned where RI was appropriate (eg Report 8.2:- benztropine, 
fenfluramine, thioridazine). 
v. The 'hit' may be an interfering endogenous blood and/or derivatisation 
product (Report 8.4:- indomethacin, theophylline; Report 8.5:- MDMA). In 
general, interference products were easily identified by the analyst during the 
interpretation of a 'batch' of blood specimens, as they tended to recur in each 
extract. Similarly, peak shapes did not match those of reference standards, RI 
errors were generally large and ion abundance ratios were incorrect. 
vi. The 'hit' must have an ion abundance ratio which matches the reference 
drug standard. Ion abundance ratios were not incorporated into the macro as 
they are heavily dependent on the tuning of individual instruments. Similarly, 
the relative abundances of m/z ions change with time even on the same 
instrument. Consequently, the automated search macro was more universally 
applicable without such a criterion incorporated. In general, 'hits' could be 
confirmed without specific reference to the relative abundance of the target m/z 
ions. However, a comparison of the 'hit' ratios with the reference standards 
was useful when eliminating a 'hit'. For example, metoclopramide (Report 
8.5) had an incorrect ion abundance ratio. 
4. Check the RI error of the suspected 'hit'. In the majority of cases, a 'hit' with an 
error of greater than ±10 could be quickly dismissed (Report 8.4:- indomethacin, 
theophylline). However, very large to overloaded peaks (concentrations of 
approximately 1-5 ug/mL) generally eluted later than might otherwise be 
expected and the late elution was particularly apparent for drugs with lower 
retention indices (1100 to 1800). For example, regularly encountered social 
drugs, caffeine, cotinine and nicotine which were present in significant amounts 
were often identified with an absolute RI error > 10. It was also found that the RI 
of poorly chromatographed drugs (eg cotinine, nordiazepam, temazepam) were 
not as reproducible as drugs chromatographed with good peak shape and a 
retention index shift of greater than ±10 could occur (Section 8.4.2). 
5. Check the suspected 'hit' for coincidence with another peak: (Section 8.4.2). 
If the analyst was satisfied that the suspected 'hit' was real following Checks 1-5, the 
'hie was recorded on the report under "Analyst Interpretation - Drugs Detected". 
The reports for the remaining three extracts were interpreted in the same manner. 
The analyst collated the data generated from all four reports (Table 8.2) for further 
consideration as follows. 
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6. Check that a specific 'hit is present in all extracts indicated by the reports. As 
the majority of target drugs would be expected to be found in two or more 
extracts, this check provides important additional confirmation of the presence of 
a drug in a blood sample. 
7. Check for the metabolite (if included as a target drug) of a parent drug detected. 
The screening procedure included several important drug metabolites (eg. 
nortriptyline, nordiazepam, THC-COOH) and the presence of both drug and 
metabolite was strong evidence of the presence of a drug in a blood sample. 
During validation experiments (Chapter 9) it was observed that in some cases, no 
drug was present and the metabolite was the only compound detected (eg. 
THC-COOH, nordiazepam). The identification of only the metabolite might be 
explained by pharmacokinetic differences between the drug and its metabolite. 
Consequently, the analyst requires some pharmacological knowledge to best 
interpret the report findings in relation to drugs and their metabolites such that 
obvious discrepancies are identified (eg. the occurrence in blood of amitriptyline 
or diazepam in the absence of nortriptyline or nordiazepam is extremely unlikely). 
8. Check the raw chromatograms if necessary. In general the analyst would only 
find it necessary to manually examine the raw data if a report from one extract did 
not confirm the presence of a drug detected in another and it was suspected that 
drug RI may have altered as a result of poor chromatography. The possibility that 
a drug RI had altered as a result of either interference from large amounts of 
endogenous compounds or an overloaded peak would be indicated in the 'TIC'. 
9. Check the quantitative figure against 'Analyst Alerts'. The `CheckFor' macro 
quantitates drugs detected in each blood extract. Those drugs for which there was 
no quantitation were indicated by "99.999". Consequently, if a drug was detected 
in two or more blood extracts, two or more drug blood levels were calculated and 
reported by the macro. The analyst checks these figures against any 'Analyst 
Alerts' (Section 8.4.2) and reports the mean value of these figures (Section 
8.3.2.2). 
10 .Check that quantitative figures in each blood extract are similar. The recovery 
data for each drug shown in Table 7.6 give the expected standard deviation from 
the mean following both solid-phase and liquid-liquid extractions. Consequently, 
the quantitative values reported for drugs have an error associated with them. In 
general, less variability in the recovered drug amount resulted from liquid-liquid 
extraction (Section 7.3.3) and quantitative values from the liquid-liquid blood 
extract would, therefore, be most accurate. The derivatisation process introduced 
still further error and, therefore, quantitative figures for PFP derivatives (derived 
from solid-phase extraction) would incur the greatest error. In general, where the 
chromatography of the underivatised drug was good, or the reproducibility and/or 
stability of the drug derivative was poor, the underivatised drug figure was used. 
Where multiple quantitative figures for a drug were reported each should 
approximate and confirm the other. 
In Section 8.3.3 the falsely identified 'hits' from Reports 8.2-8.5 and reasons for 
their rejection were listed. Further explanation is required to explain the elimination 
of trimethoprim and codeine. The apparent trimethoprim peak was a very large 
overloaded. Trimethoprim is known to chromatograph very poorly, implying that a 
peak of this size represented drug present at several p.g/mL in the blood. However, it 
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was entirely absent in the liquid-liquid blood extract despite similar, though variable, 
recovery from blood and this did not confirm the finding in Report 8.3. The analyst 
interpreted this discrepancy as trimethoprim being falsely identified as a 'hit' in 
Report 8.3. It was postulated that the very large peak arose from a strongly basic 
putrefaction blood product which would co-elute with trimethoprim if it were 
present. This would be extracted under the conditions of solid-phase extraction 
which extracts strong bases but would be poorly extracted (if at all) by liquid-liquid 
extraction conditions. Similarly, codeine was detected in the solid-phase blood 
extract but was unconfirmed in either the liquid-liquid extract or as a PFP derivative 
in the solid-phase extract. The 'hit' detected in Report 8.3 chromatographed with an 
exceptionally good peak shape, although codeine generally chromatographs as a 
slightly tailing broader peak (Table 3.2). Although the recovery of codeine from 
blood by either solid-phase or liquid-liquid extraction was similar (Table 7.6) and the 
stability and reproducibility of its PFP derivative good (Table 5.8), the 'hits' 
identified as codeine in Reports 8.2 and Reports 8.3 and 8.5 were not comparable in 
either peak area or height. The 'hit' detected in Report 8.3 had both a significant 
peak area and m/z ion abundance of approximately 400000. The 'hits' eliminated by 
the analyst in Reports 8.3 and 8.5 were much smaller peaks, close to the baseline and 
with noisy peak profiles indicating that these peaks were close to the limit of 
instrument detection. Consequently, as with trimethoprim, a strongly basic 
putrefaction blood product was considered to have been falsely identified as codeine 
in Report 8.3. 
In the routine application of the automated drug identification and quantitation 
macro, usually, no attempt was made to establish the standard deviation associated 
with the quantitative figure as described in Section 8.3.3.2. As the relationship 
between the level of a drug in blood and its effect on an individual is influenced by 
many factors (Section 10.1), an accurately quantitated blood level may be of no more 
interpretative value than a semi-quantitative level which indicates that a drug was 
present at sub-therapeutic, therapeutic, or toxic levels (Section 9.4.1). Therefore, 
even if the absolute value generated by the macro had an error associated with it of 
up to ± 100%, in most cases, the blood level could still be placed within the broad 
therapeutic or toxic ranges described for most drugs (Section 9.4.1). If greater 
accuracy was required, the blood specimen could be re-analysed and quantitated 
against a calibration curve which covered an appropriate range as indicated by the 
macro-generated figure. 
8.4.3 Forensic Application and Assessment 
The automated drug screening procedure has been in routine use at the Government 
Analytical and Forensic Laboratory for the past 12 months and applied to over 200 
forensic blood specimens. The macro was successfully transported from the 
development laboratory to the service laboratory with no change made to drug RI in 
drugs.txt. The GC/MS instrumentation was similar to that used in the present study 
(Section 2.4.1), but there was a direct capillary interface to the MSD giving greater 
instrument sensitivity. Gas chromatographic parameters were similar to those used 
in the present study for chromatography with the narrow bore column (Appendix 
A.2.1). The macro was only used for drug identification. 
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A full scan acquisition was performed on the underivatised liquid-liquid extract to 
detect drugs (and pesticides) not included in the target drug screen. Drugs were 
identified in the TIC chromatogram by automated comparison of individual peaks 
with both a Hewlett Packard supplied library of drug mass spectra, and an 'in-house' 
library of drug mass spectra. In general, the TIC chromatogram had many additional 
small peaks at the baseline compared with the mixed ion chromatogram generated by 
SIM analyses. To date, the full-scan mass spectral data has not indicated the 
presence of a drug which had not already been identified by the macro in the 
underivatised blood extracts. Rarely did the full-scan mass sPectral data confirm all 
drugs identified by the macro in the target SIM analyses. Drugs which were present 
at relatively high blood levels (eg. cotinine, caffeine, lignocaine, diazepam, 
methadone) were repeatedly identified in TIC chromatograms. Often, however, no 
drugs were detected in the TIC chromatograms while the macro indicated that 
therapeutic levels of drugs were present following target SIM analysis of the same 
extract. The absence of some drugs in TIC chromatograms which were identified by 
the macro in target SIM analysis of the same extract indicates the following. 
1. Greater sensitivity was achieved through target SIM analyses compared with full 
scan analyses. 
2. The macro was able to identify low levels of drugs amongst general interference at 
the baseline. 
3. The macro was able to differentiate between co-eluting peaks which produced a 
peak with a mixed mass spectrum which could not be matched against a drug 
library of full-scan mass spectra. 
Currently, three different analysts interpret reports generated by the macro. 
However, a technician without GC training has difficulty in interpreting the reports 
correctly. The difficulty arises from a general lack of understanding of fundamental 
GC concepts and of what the multiple m/z ion chromatograms generated from blood 
extracts represent. Consequently, although the macro has speeded the analysis of 
complicated chromatograms and reproduced some of the skills that would be used by 
an experienced analyst, without an understanding of general GC concepts, 
interpretation of reports is not "fool-proof'. 
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Chapter 9. 
VALIDATION OF THE AUTOMATED SEMI-QUANTITATIVE 
BROAD DRUG SCREENING PROCEDURE 
9.1 Introduction 
An automated semi-quantitative comprehensive drug screen for 105 
pharmacologically and structurally diverse drugs in whole blood was developed 
(Chapters 7 and 8). Target drugs are isolated from the blood matrix through an 
extraction strategy (combined LLE and SPE) which recovers approximately 90% of 
target drugs with greater than 75% efficiency. From each blood specimen, four 
extracts (Figure 2.1) are produced which are analysed by GC/MS (SIM) and drugs or 
their butyl or PFP derivatives are detected. A macro (Chapter 8) analyses 
complicated multi-peak chromatograms using fixed parameters (RI and a pair of 
target m/z ions) which together uniquely identifies target drugs. The macro 
calculates an approximate level in blood for each drug using predetermined 
quantitative information (Section 8.3.3.2) and generates a report. Validation of this 
procedure was necessary to evaluate its ability to identify drugs and estimate their 
concentrations in whole blood. 
Three types of blood specimens were selected for validation experiments. 
1. Postmortem forensic blood specimens previously analysed using other routine 
methods by the Government Analytical and Forensic Laboratory (GAFL). 
2. Blood specimens distributed to forensic laboratories within Australia and New 
Zealand as part of a Proficiency Testing Program (PTP) on the identification and 
analysis of drugs in blood. 
3. Blood specimens obtained from hospitalised patients at the Royal Hobart Hospital 
(RHH) for whom details of drug adminstration (drug, dose, time) were available. 
9.2 Methods 
Refer to "General Procedure" (Chapter 2). 
9.2.1 Blood specimens 
All blood specimens were stored at 4°C. Blank blood was obtained from GAFL 
(Section 7.2). Postmortem forensic blood specimens (66) varied in age (up to two 
years old) and all were haemolysed. The majority of bloods were in blood tubes with 
sodium fluoride and potassium oxalate as preservative and anti-coagulant 
respectively, but some contained no preservative or anti-coagulant. The condition of 
the blood was also very variable as it was dependent on the nature of the death and 
the time elapsed after death before blood was taken. 
Blood specimens (9) distributed through the PTP on the identification and analysis of 
drugs in blood also varied in age (up to two years old). The spiked blood sample was 
prepared by the Division of Analytical Laboratories (DAL) NSW using outdated 
blood from the NSW Red Cross Blood Bank, spiked with accurately prepared 
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methanolic solutions of drugs. A blank (drug free) blood sample was also included. 
The blood samples were distributed to participating laboratories in bottles containing 
sodium fluoride and potassium oxalate. The spiked and blank bloods distributed 
through the program to GAFL were tested in validation experiments. 
The stability of drugs in the postmortem and PTP blood specimens following an 
extended period of storage (up to 2 years) at 4°C is not known. 
Blood specimens (28) obtained from hospitalised patients at the RHH were selected 
by a clinical pharmacist on the basis of each patient's current drug therapy and a list 
of the target drugs. These blood specimens were 7 days old, stored at 4°C and 
contained whole blood with EDTA as the anti-coagulant. Prior to analysis, the 
specimens were frozen to haemolyse the blood. 
9.2.2 Evaluation of the Automated Broad Drug Screening Procedure. 
All blood specimens were analysed blind. Blood specimens were extracted (Figures 
2.1-2.5) and analysed (GC/MS; Section 2.4) in an overnight sequence of samples 
(Section 2.5 and 2.6). In addition to blood extracts (4 extracts for each of 6 blood 
samples), the sequence included the analysis of:- 
1. three mixed reference solutions of drugs (U std) and their butyl (Bstd) and PFP (Pstd) 
derivatives, and 
2. the 'performance test mix' (3) which allowed the chromatographic performance of 
the GC system to be monitored as the sequence progressed (Sections 2.6.2 and 
9.4). 
The analyst interpreted the macro-generated reports (Sections 2.7 and 8.4.3) which 
were produced following the automated analysis of chromatograms from each extract 
and recorded the drugs detected and their estimated concentrations in blood (Table 
8.1). The results obtained from the test procedure were compared with those of 
GAFL and the stated concentrations of the PTP samples. Drug charts relating to the 
blood specimens from hospital in-patients were obtained by the clinical pharmacist 
who selected the specimens and drugs detected were compared with the drugs 
administered. 
9.3 Results 
9.3.1 Forensic Blood Specimens 
9.3.1.1 Identification 
Seventy-five forensic blood specimens (postmortem and spiked samples) submitted 
to GAFL for drug analysis were re-analysed using the automated drug screening 
procedure (Table 9.1). The drugs identified in these specimens by the test procedure 
and the number of times they were detected in different samples were compared with 
those identified in postmortem specimens by GAFL techniques and those known to 
be present in spiked samples. Consequently, data in Table 9.1 indicates the variety 
of drugs encountered in these specimens and the ability of the screening procedure to 
repeatedly detect them. 
Two broad screening methods had been employed by GAFL to identify drugs in the 
postmortem blood specimens. The screen for B/N drugs was based on Method 21 (I) 
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(Table 7.2) but with reduced volumes of blood (0.5 mL) and n-butyl chloride (1.5 
mL) and it was applied to all specimens. The other was a HPLC-DAD method 
(modified) for A/N drugs (2) but it was not routinely used on all specimens. Some 
blood samples were forwarded to the Clinical Chemistry Department of the RHH 
where specific drugs were detected and quantitated through RIA procedures (eg. 
carbamazepine, salicylates, paracetamol, phenytoin, theophylline, valproate). 
Similarly, a drugs of abuse screen was sometimes performed on urine specimens at 
RHH which alerted analysts to the potential presence of amphetamines, 
cannabinoids, benzodiazepines, cocaine, methadone or opiates in the blood. Selected 
blood specimens were forwarded to the State Forensic Centre in South Australia for 
the identification and quantitation of morphine. Therefore, drugs identified by 
GAFL in postmortem specimens were the results of these combined techniques 
(when employed) and the ability of the test procedure to identify drugs can be 
compared with that of the combined GAFL techniques. 
Drugs which were known to be present in the PTP samples, and the number of times 
they occurred in different samples are indicated in Table 9.1. On one occasion 
GAFL supplied a spiked blood sample for analysis by the test procedure and these 
are included. 
Data in Table 9.1 indicate the following. 
1. Fifty-four different drugs and drug metabolites were identified in postmortem 
specimens (by GAFL and/or the test procedure) or were known to be present in 
PTP samples. 
2. Twenty-seven different drugs and drug metabolites were included in the spiked 
specimens and some were present in more than one sample. These specimens 
provided 38 instances for a positive drug identification. Of these, 4 were non-
target drugs and, therefore, were not detected by the test procedure (doxylamine, 
flunitrazepam, midazolam, norpropoxyphene). The test procedure identified all 
but one of the other target drugs present in the spiked specimens in 33 instances; 
the exception was metoclopramide (Table 9.1 - Comment 8). 
3. No false positives were identified by the test procedure following analysis of the 
spiked specimens and only one false negative was reported (metoclopramide). 
4. Forty-three different drugs and drug derivatives were identified in postmortem 
specimens by either the test procedure or combined GAFL techniques or both. Of 
these, 3 were non-target drugs and, therefore, not detected by the test procedure 
(7-aminoclonazepam, clonazepam, clozapine). Target drugs (excluding caffeine, 
cotinine, nicotine and theophylline; Table 9.1 -Comment 6), were identified in 
postmortem samples by the test procedure in 123 instances, and by the combined 
GAFL procedures in 96 instances. 
5. The test procedure identified 9 drugs in postmortem blood specimens which were 
not identified by the combined GAFL techniques (7—aminoflunitrazepam, 
7—aminonitrazepam, doxepin, ibuprofen, naproxen, nicotine, nortriptyline, THC 
and theophylline). 
6. Where the same target drug was identified in postmortem specimens on at least 
one occasion by both the test procedure and combined GAFL techniques, the test 
procedure made an additional 22 identifications. The majority of these were in 
relation to nordiazepam (6), paracetamol (8) and phenytoin (3). Other drugs 
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identified on single occasions were diazepam, fluoxetine, morphine, oxazepam 
and oxycodone. 
7. Where the same target drug was identified in postmortem specimens on at least 
one occasion by both the test procedure and combined GAFL techniques, the 
combined GAFL techniques made an additional 9 identifications. Five of these 
were in relation to THC-COOH (Table 9.1; Comment 18), one was in relation to 
sertraline prior to its inclusion as a target drug in the test procedure and, 
promethazine was once reported as a false positive reported by GAFL (Table 9.1; 
Comment 14). In two instances, pethidine (Table 9.1; Comment 13) and 
thioridazine (Table 9.1; Comment 17) were not identified by the test procedure. 
Many of the forensic blood specimens were in very poor conditions (green-black in 
colour; putrid; ranging from fluid to thick or clotted). The LLE technique was able 
to accommodate any condition of blood without encountering practical problems. 
The SPE of some of these specimens, however, was troublesome and difficulties 
were encountered in applying the diluted blood solution to the solid-phase cartridge. 
For the majority of blood specimens, the diluted blood solution was passed onto the 
cartridge without the application of a vacuum (Section 2.5.2.4) although the time 
required to apply the full volume was variable and sometimes slow. For some 
specimens, the full volume of blood solution could only be pulled through the 
cartridge under strong vacuum. In one instance, the packing became so occluded that 
the cartridge was discarded and the procedure begun again with 1.0 mL of blood 
(instead of 1.5 mL). Following the water wash of the cartridge (Section 2.5.2.5), the 
passage of all other eluants through any cartridge was comparable despite any 
previously encountered difficulties. 
9.3.1.2 Estimation of the Concentration in Blood of Identified Drugs 
Data in Table 9.2 compare the drug concentrations estimated by the automated drug 
screening procedure (Sections 8.3.3.2 and 8.4.3) with those determined by GAFL for 
the same drugs; on many occassions, GAFL reported a drug as 'present' without 
quantitation. These data exclude the PTP blood samples where the spiked drug 
concentration was known (Table 9.3) and drugs identified by the test screening 
procedure which were either chromatographed with overloaded peak shapes or were 
present at a concentration greater than the highest calibration point (Section 8.3.3.2). 
Drug concentrations reported by GAFL were obtained as follows. 
1. External results for morphine (State Forensic Centre, South Australia) and 
carbamazepine and phenytoin (Clinical Chemistry, RHH) by specific RIA 
techniques. 
2. Semi-quantitative results using either an HPLC technique and a one point 
(5 i_ig/mL) calibration curve drawn through the origin, or a GC/MS technique and 
a one point (11.ig/mL) calibration curve drawn through the origin. 
3. Quantitative results using a GC/MS technique and a multi-point calibration curve 
(but these determinations were rarely performed). 
Data in Table 9.2 indicate the following. 
1. Similar quantitative results were obtained by the test and GAFL procedures for 
many individual determinations but there were sometimes inconsistent results 
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obtained for multiple determinations of the same drug (eg. diazepam and 
nordiazepam). 
2. In all instances where the test and GAFL results differed greatly (Table 9.1; 
italics'), the GAFL result was always higher than the test result (GAFL > 2x 
Test). 
3. The concentration of diazepam was determined on 13 occasions by the test and 
GAFL (GC/MS) procedures and was often similar but, in three instances, differed 
greatly. 
4. The concentration of nordiazepam was determined on 9 occasions by the test 
procedure as the butyl derivative, and by GAFL procedures as the underivatised 
drug (GC/MS x 8 and HPLC). The results were often similar but, in three 
instances, differed greatly. 
5. Eight specimens were analysed twice (blind) by the test procedure but re-analysis 
was up to 5 months later (Table 9.2 - Comment 7). The results of duplicate 
analyses by the test procedure were similar on four occasions (diazepam, 
methadone, oxazepam, propoxyphene) but paracetamol and phenytoin results 
differed widely between duplicates. The duplicate results by the test procedure 
were similar on two occasions to those of GAFL (diazepam, methadone) but the 
carbamazepine and oxazepam results were consistently lower. 
6. The test procedure estimated the concentration of a drug in 60 instances. In 49 
instances, the results did not differ greatly (GAFL < Test ± 50%) from those 
determined by GAFL procedures. In 3 instances where the test and GAFL 
procedures differed greatly, the result was one of duplicate results for the same 
specimen but determined 5 months later. 
9.3.2 Proficiency Testing Program Blood Specimens 
Data in Table 9.3 compare the estimated concentrations of target drugs determined 
by the automated drug screening procedure (Sections 8.3.3.2 and 8.4.3) with the 
known concentrations spiked into the PTP blood specimens. These data also include 
one spiked blood specimen prepared by GAFL which contained drugs at 0.5 vtg/mL. 
Data in Table 9.3 indicate the following. 
1. Concentrations in blood were estimated for 19 drugs but, for two drugs, the 
estimation was not reliable (Table 9.1; `*'); a concentration was estimated in 26 
instances. 
2. Good agreement (< 10% absolute difference) was obtained between estimated and 
spiked blood concentrations in 11 instances. 
3. A difference of greater than 10% but less than 40% was obtained between 
estimated and spiked blood concentrations in 12 instances. 
4. Poor agreement (greater than 40% difference) was obtained between estimated 
and spiked blood concentrations for 3 drugs (temazepam, paroxetine, fluoxetine). 
5. Approximately 90% of concentrations determined by the test procedure 
reasonably estimated the true concentration of drug present in the PTP specimens 
(maximum difference ± 40%). 
6. The large difference between the estimated and true concentration of temazepam 
confirms the finding in Section 7.4.1 which found that the chromatographic 
response of temazepam was affected by the sample and the current 
chromatographic performance of the GC system. 
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9.3.3 Hospital In-Patient Blood Specimens 
Data in Table 9.4 list the target drugs administered (drug, route, dose) to 28 
hospitalised patients prior to obtaining whole blood specimens for analysis by the 
test procedure. The drug therapy charts indicated that, of the drugs administered to 
these patients, 28 were target drugs. Table 9.4 shows the drugs identified by the test 
procedure in the blood specimens and their estimated concentrations. The time 
elapsed since the last drug dose is indicated together with the elimination half-life 
(ty) of the drug. The LA value indicates how long a therapeutic level might be 
expected to persist following the last dose of drug before the blood concentration 
falls to a sub-therapeutic level. These values, however, provide a guide only as they 
may be subject to considerable individual variation (dependent on dose, single or 
maintenance dosing, route of administration, age, sex, liver and kidney function, 
concurrently administered drugs, etc). For Case No. 17, the time elapsed since the 
last dose was not specified. The day the blood specimen was taken was known but 
not the time it was drawn. 
Data in Table 9.4 indicate the following. 
1. The drug therapy charts listed 28 target drugs which were administered on 112 
occasions to hospital in-patients 0 to 5 days prior to their blood samples being 
drawn. 
2. On 64% of occasions where a target drug had been administered, the test 
procedure identified that drug in the blood specimen. 
3. The social drug caffeine was frequently detected in the blood specimens and trace 
levels of theophylline (a caffeine metabolite) were often detected in the presence 
of caffeine. 
4. In 7 cases, drugs were identified which, according to the corresponding drug 
charts, had not been recently administered. There were 7 identifications of 
diazepam and nordiazepam, and 2 identifications of pentobarbitone. Trace levels 
of diazepam and nordiazepam were consistently detected whenever midazolam (a 
non-target drug) had been administered. The presence of nordiazepam was not 
always confirmed in the alternate extract in which it was also expected. In two of 
these cases (Nos. 2 and 17) pentobarbitone was also identified. 
5. In one case (No. 6), 7-aminonitrazepam was identified but, according to the 
corresponding drug chart, nitrazepam had not been recently administered. 
6. On 36% of occasions where a target drug had been administered, the test 
procedure did not identify that drug in the blood specimen (Table 9.4; `ND'). One 
of these occasions can be discounted as the drug was administered orally at the 
same time the blood specimen was taken (No. 3; morphine). 
7. Prednisolone, felodipine and prochlorperazine were orally administered within 
their approximate t y, but were not identified by the test procedure in any blood 
specimen. 
8. The identification of salicylic acid was inconsistent. In only 2 of 5 cases where 
salicylic acid (100 mg) was orally administered within the approximate t y, of the 
drug, was the drug identified (Table 9.4; Nos. 2 and 9). 
9. Following the minimum nightly dose (10 mg), temazepam was consistently not 
detected approximately 12 h later (the following morning). When a 20-30 mg 
dose was administered, temazepam was identified 12 h later but the drug was not 
consistently identified in both underivatised fractions (Table 8.4). 
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10. Failure to identify felodipine, prednisolone, prochlorperazine, salicylic acid and 
temazepam at apparent therapeutic blood levels accounted for 33% of reported 
'ND' 
11. On 66% of occasions where *ND' was reported, the time elapsed since 
administering the last dose was greater than 2t 1/2 (excluding 2 instances:-
morphine; No. 3; nifedipine where time elapsed since the last dose was not 
known; No. 17) For example, No. 2:- frusemide > 24tiA ; No. 4:- metoclopramide 
> 6tiA , 
12. Paracetamol was administered in 23 cases and identified in 19. The test 
procedure failed to detect the drug (Nos. 16, 20, 21, 24) only when several t y, had 
elapsed since the last dose (18-80 h elapsed) but, in one case (No. 4), it was 
identified 100 h after the last recorded dose. 
13. Drug charts indicated the administration of metoclopramide (10 mg) in 5 cases 
and it was identified in 2 (Nos. 22, 24). In three instances, the drug was not 
detected following oral administration where the time elapsed since the last dose 
was > 2t. 2 . The drug was detected, however, 18 h later following an intra-
muscular administration (No. 24). 
14. Drug charts indicated the administration of frusemide (40 and 80 mg) in 8 cases. 
The drug was not detected in 3 cases and drug charts for two of these indicated 
that > 60 h had elapsed since the last dose. Frusemide was not detected in Case 
No. 15 even though the time elapsed since the last recorded dose was within the 
one t 1/2 . 
15. Estimated drug concentrations appear to reflect therapeutic and sub-therapeutic 
ranges. For example, large doses of paracetamol (500-1000 mg) are reflected by 
large blood concentrations (eg 10-20 ug/mL) when the time elapsed since the 
last dose was similar to LA . As the time elapsed since the last dose increased 
(multiple ty,), the estimated blood concentration decreased (<lug/mL). 
16. Estimated drug concentrations at close to the limit of instrument detection may 
be associated with a large error (Table 9.4; Note `±` and Section 9.4). 
It is assumed that hospital administered drugs reflect therapeutic drug use. 
Consequently, the drug blood concentrations estimated by the test screening 
procedure should fall within the reported therapeutic ranges for these drugs (Table 
6.1). If the elapsed time since the last recorded dose was equivalent to multiple t y„ 
then the estimated blood concentration should reflect sub-therapeutic levels. The 
estimated blood concentrations for the great majority of drugs listed in Table 9.4 
were found to be within or below the therapeutic range. Exceptions were noted for 4 
drugs in Table 9.4 as follow. 
1. Estimated blood levels of salicylic acid were consistently sub-therapeutic. 
2. Estimated blood concentrations of morphine (No. 24), nifedipine (No. 8) and 
metoclopramide (Nos. 22 and 24) were greater than the therapeutic range. 
9.4 Discussion 
9.4.1 General 
In excess of 100 blood specimens were analysed by the automated broad drug 
screening procedure to evaluate its ability to identify all drugs present in a blood 
specimen and estimate their levels. During validation experiments, approximately 65 
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different target drugs and drug metabolites were encountered. The test procedure 
identified 97% of target drugs known to be present in PTP blood specimens and, in 
approximately 90% of instances, reasonably estimated their true concentrations 
(Table 9.3; maximum difference ± 40%). The test procedure compared favourably 
with methods routinely employed at GAFL for the identification and analysis of 
drugs in blood and identified a greater number of drugs in the same blood specimens. 
During the analysis of blood specimens drawn from hospital in-patients, it was found 
that the test procedure was likely to identify the majority of drugs at therapeutic 
levels, particularly if administered within 2t y, of the blood being taken. In addition, 
by screening for and identifying target drug metabolites, the test procedure provided 
additional confirmation of the presence of a drug (eg Table 9.1: nortriptyline in the 
presence of amitriptyline; Table 9.4 No. 26: nordiazepam and temazepam in the 
presence of diazepam). Drugs and their metabolites were also repeatedly identified 
at realistic relative concentrations in the blood specimens of drivers involved in road 
traffic accidents (Tables 10.1, 10.3 and 10.4). 
Non-target drugs were encountered in both forensic and hospital blood specimens. 
To increase the versatility of the test procedure, it is suggested that one of the 
underivatised extracts be re-analysed in the full-scan mode. If a non-target drug is 
present in the blood at sufficient levels to permit detection and is able to be 
chromatographed without derivatisation, it may be identified following GC/MS 
analysis in the less sensitive full-scan mode (Section 8.4.4). Individual peaks in the 
TIC chromatogram could be automatically matched against a commercial or in-house 
library of drug mass spectra (Section 1.2). The re-analysis of an underivatised 
extract would increase overall analysis times but this could be accommodated in 
overnight analyses of GC samples. The advantages and disadvantages associated 
with full-scan and SIM mode analyses are discussed in Section 1.4.2. 
It was indicated in Section 7.4 that following analysis of solid-phase extracts, the 
observed chromatographic performance of the GC system deteriorated less than 
following the analysis of liquid-liquid extracts. During validation experiments, 
underivatised extracts from SPE were analysed first followed by underivatised 
extracts from LLE. The 'performance test mix' (Section 2.2.5.10) was analysed 
immediately following each set of extracts. In general, the chromatographic 
performance was satisfactory (Section 2.6.2) following analysis of solid-phase 
extracts although the absolute peak areas of temazepam, phenobarbitone and high 
boilers (verapamil and thioridazine) were reduced. Following analysis of the liquid-
liquid extracts, often chromatographic performance remained satisfactory (but with a 
further reduction in the peak areas of some drugs) but, on other occasions, 
chromatographic performance had deteriorated so much that temazepam and 
phenobarbitone were absent. This was dependent on the nature of the blood samples 
analysed (some were severely decomposed). Consequently, it is likely that extracted 
material from both LLE and SPE techniques contributed to the deterioration of the 
GC system and frequent and regular maintenance would be required to restore 
performance. 
The drug screening procedure was developed in 2 year old blank blood with sodium 
fluoride and potassium oxalate as preservative and anti-coagulant, respectively. 
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During validation experiments, the majority of blood specimens encountered 
contained these compounds but others contained either no anti-coagulant or 
preservative, or EDTA as an anti-coagulant (Section 9.2.1). No differences were 
observed in either drug extraction or macro identification and quantitation when 
blood specimens which contained either EDTA, or no sodium fluoride and potassium 
oxalate, were analysed. 
9.4.2 Identification of Drugs 
Data in Table 9.4 indicated that some drugs could not be detected at therapeutic 
levels (prednisolone, prochlorperazine, felodipine). Similarly, some drugs present at 
low levels (eg. temazepam, diltiazem) were detected in only one of the fractions in 
which these drugs could be expected. It was apparent that the test procedure did not 
reliably identify all target drugs and confirm their presence when their concentrations 
in blood were low (Table 9.4; ` 4 '). During the analysis of forensic samples, it 
sometimes occurred that a peak was present in one extract but was not confirmed in 
the alternate extract (eg. thioridazine; Table 9.1). It may be possible that these 
unconfirmed, low level 'hits' were, in fact, unreported drugs. The analyst would 
have to assess such occurrences on a case by case basis. 
In Section 7.4.1, it was indicated that the sensitivity of the procedure to THC-COOH 
would be decreased as a result of impaired butylation of the drug in the presence of 
co-extracted blood products. During validation experiments, it was found that the 
test procedure did not identify THC-COOH in blood specimens when GAFL 
procedures had determined it was present but at concentrations less than 25 ng/mL. 
The test procedure does, however, detect THC which is the psychoactive constituent 
of Cannabis. It is the presence or absence of this drug in the blood that has the 
greater interpretative value as the metabolite (THC-COOH) is not pharmacologically 
active. Consequently, the limit of detection for THC-COOH by the automated drug 
screening procedure (approximately 25 ng/mL) is satisfactory and THC may be 
detected in the apparent absence of its metabolite. 
Data in Table 9.1 indicate that morphine was not detected by the test screening 
procedure in the first forensic specimen which contained it. It was often found that 
the poor condition of the blood specimens resulted in extracts which were difficult to 
dry completely without use of excessive heat. It was postulated that the residual 
water retained in the extract residues hindered the derivatisation of morphine. 
Consequently, a slight modification to the PFPA derivatisation procedure was 
introduced using acetonitrile (originally present to solublise the extract residue; 
Section 5.3.1.1). The residual water was successfully removed through the formation 
of an azeotrope with acetonitrile (Figure 2.5). Morphine was identified in all 
subsequent blood specimens which contained the drug and estimations of blood 
concentration were reliable (Table 9.3). 
Data in Table 9.4 indicate that trace levels of diazepam and nordiazepam were 
repeatedly identified in blood specimens from 7 patients who had been administered 
midazolam (a non-target drug) and, in two cases, pentobarbitone was also identified. 
In each case, the midazolam had been administered 3-4 days prior to the blood 
sample being drawn. The metabolism of midazolam does not produce diazepam or 
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its metabolite. Similarly, it is not possible that diazepam or its metabolite were 
formed as artefacts during extraction or GC analysis (particularly since nordiazepam 
was detected as the butyl derivative). Consequently, it is likely that the patient had 
been recently administered diazepam and, in two cases, pentobarbitone. The drug 
therapy charts provided with the blood specimens did not detail the complete drug-
taking histories of the patients. In routine procedures at the RHH, drugs 
administered in the Intensive Care Unit (ICU), Department of Emergency (DEM) 
and during anaesthesia are not recorded on the drug therapy chart. Further 
investigation of the medical records belonging to the 7 patients indicated that all had 
undergone 3 or 4 vessel coronary artery bypass grafting within the last 5-6 days and 
arrived on the ward from ICU where they had been sedated, intubated and ventilated. 
`Omnipon' (morphine derivative) + diazepam are often given (iv) as a crash 
induction to anaesthesia prior to intubation. (6) Similarly, diazepam is given to 
premedicate surgical patients. (6) Pentobarbitone is a metabolite of thiopentone - a 
short acting barbiturate used in anaesthesia. (6) It is likely, therefore, that the 
midazolam listed on the drug chart was administered to irritable or uncomfortable 
patients immediately following their surgery. The presence of trace levels of 
diazepam and nordiazepam indicate the tail end of a dose administered in either ICU 
or during surgery. 
It was indicated in Section 9.3.3 that the estimated blood concentration of four drugs 
did not correspond well with their therapeutic use in supervised hospitalised patients. 
1. Salicylic acid determinations were either consistently sub-therapeutic, or not 
detected. This may be explained by the very poor recovery of this drug from 
blood (< 6%; Table 7.6). Consequently, the automated broad drug screening 
procedure is not suitable for the reliable therapeutic monitoring of salicylic acid or 
its level in blood. 
2. One estimated morphine concentration was well in excess of therapeutic levels 
and likely to be fatal in non-tolerant individuals. However, it is likely that the 
estimated drug concentration realistically represented the true concentration in the 
blood specimen. The specimen was obtained from a patient who had experienced 
5 months of pain prior to surgery for the "resection of a paravertebral tumour and 
reconstruction with a lattismus dorsalis flap and split skin grafting from the thigh" 
(surgical consultant correspondence included in the patient's medical records). 
The operation was performed 5 days before the blood specimen was taken and two 
days before the patient was returned to the ward with a morphine infusion (18 
mg/h). The infusion continued for 3 days (decreasing by 2 mg/h each day) and 
was occurring when the blood sample was taken. The patient was both admitted 
and discharged with prescriptions for 'MS Contin' (morphine) and morphine 
elixir. In such a case, it would not be unexpected that the patient had developed 
considerable pharmacological tolerance to the drug with its long term use and was 
able to tolerate very large doses of the drug; a dose which might otherwise be fatal 
to an individual with no previous exposure to morphine. In addition, the 
automated broad drug screening procedure performed well in estimating the 
concentration of morphine in the 3 spiked PTP specimens (Table 9.3). 
3. Two estimated metoclopramide concentrations exceeded the therapeutic range for 
this drug. On re-examining drug recovery by the test procedure, data in Table 7.6 
indicate that the chromatographic response of metoclopramide was greater when 
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chromatographed with co-extracted endogenous blood products than when 
analysed in a reference solution of mixed drugs (Section 7.3.3; tth P ) resulting in - s 
greater than 100% recoveries being recorded. Consequently, the elevated blood 
levels determined for metoclopramide in Case Nos. 22 and 24 (Table 9.4) are 
likely to reflect that the drug was chromatographed with a greater response than 
when the calibration curve was established from reference drug standards 
(Sections 2.6.1 and 8.3.3.2). In addition, by 'contaminating' the GC system with 
repeated injection of blood extracts, reference solutions of mixed drugs containing 
metoclopramide (approximately 1 iag/mL) which were analysed in the same 
batches as Case Nos. 22 and 24 (Section 9.2.2) were also elevated (> 1 p.g/mL). 
Consequently, estimated metoclopramide blood concentrations calculated by the 
automated drug screening procedure are likely to be consistently elevated. 
4. One estimated nifedipine concentration exceeded the therapeutic range for this 
drug. It was not unexpected that the estimated concentration would be unreliable 
as data in Table 7.6 indicate that nifedipine recovery was non-reproducible. 
Similarly, it was stated in Section 7.4 that, although the screening procedure may 
be able to report that the drug was present or absent, it could not reliably offer any 
estimation of the amount present. This was confirmed in the validation 
experiments. 
9.4.3 Estimated Drug Levels 
Data in Table 9.2 indicate that, although similar quantitative results were obtained by 
the test and GAFL procedures for many individual determinations, there were 
inconsistent results obtained for multiple determinations of the same drug (eg. 
diazepam). Similarly, duplicate analyses by the test procedure performed up to 5 
months apart (Table 9.2) did not always generate similar quantitative results. This 
inconsistency in quantitative results may reflect the time period elapsed between 
analyses conducted by GAFL and the test procedure rather than the inability of the 
procedure to reproducibly estimate blood levels of drugs. It was indicated in Section 
9.2.1 that some forensic blood specimens were up to 2 years old. Consequently, the 
quantitative inconsistencies between GAFL and the test procedure may reflect the 
deterioration of some drugs in the sample itself after months of storage. This cannot 
be proven, however, as there was no re-analysis of old specimens by GAFL 
techniques. 
A comparison of quantitative figures generatedipy GAFL methods and he test 
screening procedure may not be the best indicator of the ability of the screening 
procedure to estimate drug concentrations reliably. Unknown errors may have arisen 
from GAFL methods (eg. use of a one point calibration curve forced through the 
origin). 
Data in relation to the spiked blood samples provide a more valuable assessment of 
the success of the test screening procedure to identify drugs (Section 9.3.1.1) and 
estimate their level in blood (Table 9.3). These data indicate that in approximately 
90% of instances, the test procedure reasonably estimated the true concentration of 
drugs in spiked specimens (Table 9.3; maximum difference ± 40%). Of what 
'interpretative value' is an estimated drug level in blood with a potential error of up 
to ± 40% for many drugs and even greater for some (eg. temazepam)? 
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I. From a clinical perspective, a quantitative result for a drug has meaning only in 
relation to its clinically effective range in blood; eg. sub-therapeutic, therapeutic, 
toxic and fatal. 
2. From a forensic perspective (Section 1.2) the blood concentration of a drug which 
is likely to impair judgement or psychomotor skills or both over some critical time 
period is important only in that it reflects a therapeutic or excessive dose. In fact, 
the actual concentration of a drug which acts on the CNS is likely to be of less 
interpretative value than the knowledge that one or more psychoactive drugs are 
present (Section 10.1). 
3. Where significant pharmacological tolerance to a drug can develop with repeated 
use (Section 10.1; eg. benzodiazepines, methadone, morphine), the estimated (or 
true) concentration of that drug in blood has little value when compared with the 
reported therapeutic range as a concentration that would either impair or be fatal 
to a non-tolerant individual, would have much less effect on a tolerant individual. 
Therefore, although quantitative precision is highly desirable, an estimate of the drug 
level in blood may be no less valuable than an accurately determined figure, 
particularly when the therapeutic range of a drug is relatively broad. For example, 
the therapeutic range of propranolol is 0.01-0.34 pg/mL (Table 6.1). Consequently, 
a blood concentration of 0.07 ± 100% 1.1g/mL still falls within the therapeutic range. 
However, this is not true of all drugs. For example, data in Table 9.3 show the true 
and calculated concentrations of fluoxetine as 0.52 and 0.11 pg/mL, respectively. 
The true concentration represents a potentially toxic dose (but less than reported in 
fatalities from fluoxetine alone(7)) while the estimated concentration is therapeutic 
(Table 6.1). (7) Therefore, estimated blood concentrations generated by the test 
screening procedure with a potential error of up to ± 40% would have to be 
individually evaluated as to whether or not they could be useful or misleading. 
It was indicated in Section 9.3.3 that estimated drug concentrations at close to the 
limit of instrument detection may be associated with a large error. This error resulted 
from the following:- 
1. the spiky/noisy profiles of the integrated peaks; as the number of samples across 
the peak was small, a poorly defined peak shape resulted; 
2. poor chromatography and adsorption to active sites in the chromatographic system 
which become more pronounced at levels close to limit of instrument detection 
(Sections 3.4, 4.4 and 5.4). 
In addition, data in Table 7.6 indicated the non-reproducible recovery of some drugs 
(eg. nifedipine, metoclopramide); therefore, any concentration determined by the test 
procedure for these drugs should be used cautiously in interpretation. 
In Table 9.2, attention was drawn to the quantitative results obtained by the test and 
GAFL procedures for underivatised drugs, nordiazepam and temazepam. Both these 
drugs were included in the 'performance test mix' (Section 2.6.2) as they are good 
indicators of a deteriorating chromatographic system (reflected by tailing peaks with 
decreased areas). It would be expected that either the HPLC analysis of these drugs, 
or the GC/MS analysis of the butyl derivative (of nordiazepam) would decrease the 
likelihood that a variable chromatographic response would occur in response to the 
changing performance of the GC system. These analyses would more accurately 
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reflect the true concentration of these drugs in the blood. This expectation was 
confirmed by data in Table 9.3 which indicated that estimated nordiazepam 
concentrations (as the butyl derivative) were more accurate than estimated 
temazepam concentrations (underivatised drug). 
More accurate quantitation might be achieved by the test procedure if it were to 
analyse mixed drug standards (underivatised, butyl and PFP derivatives) at three 
different spiked concentrations with every batch of blood samples. This would 
eliminate problems associated with increased or decreased chromatographic response 
due to matrix effects, response variations associated with the current condition of the 
GC system and variations in drug recovery. To automate the quantitation, however, 
a more complicated macro would be required which would use the three spiked 
standards as 'calibrators', create a calibration curve, calculate C and M values for the 
linear regression equation and automatically insert them into the drugs. txt file for 
each drug in the mixed standard. 
The test screening procedure was perhaps too sensitive an assay for some acidic 
drugs (eg. phenytoin, paracetamol, theophylline) which are administered in relatively 
high doses and result in high therapeutic blood concentrations. During analysis of 
forensic and hospital specimens, overloaded peaks occurred as a result of the large 
amount of drug injected onto the column and no reliable estimate of drug 
concentration could be obtained. It could not be determined, therefore, whether or 
not these drugs were present at therapeutic or potentially toxic levels. In contrast, an 
overloaded peak identified as a basic drug (Table 9.3; doxepin, propoxyphene) would 
almost certainly represent a toxic level as a therapeutic drug amount (Table 6.1) is 
well within the column loading capacity (Tables 3.2, 4.9 and 5.9). 
During investigation of drug recovery by the test procedure (Section 7.3.3) it was 
indicated that the chromatographic response of some drugs was affected by extracted 
blood products which were co-chromatographed with them. For these drugs, 
recovery data was more reproducible when the reference standards (U std , Bstd or Pstd) 
were redissolved and analysed in blank blood extracts (Table 7.6). Although the 
chromatographic response of some drugs (eg temazepam) was adversely affected by 
their chromatography with extracted endogenous material, the response of others (eg. 
some drugs in the 'performance test mix') were improved following priming of a 
clean liner with 1 to 2 injections of an underivatised blood extract (Section 7.3.1); in 
effect, 'contaminating' the GC system. For example, with repeated injections of 
blood extracts during overnight analyses of a batch of samples, the response of 
metoclopramide in a reference solution of mixed drugs was improved (Section 9.4.2). 
In Sections 3.4, 4.4 and 5.4 it was indicated that some drugs were more susceptible 
than others to adsorption by 'active sites' in the injector port or on the column and to 
'interfacial' adsorption (Section 3.4). This was reflected by decreased peak area and 
asymmetric peak shape. Extracted drugs represent a very small proportion of the 
total extracted material present in a sample for GC analysis. Consequently, the 
improved chromatographic response of some drugs is likely to be due to sites in the 
GC system which, had adsorbed these drugs when analysed in a reference solution of 
mixed drugs, and became saturated with extracted blood products when analysed in a 
blood extract. The expected outcome, therefore, should be improved sensitivity to 
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these drugs but, during validation experiments, this could not be confirmed as no 
drugs were quantitated at levels close to their limits of instrument detection (Table 
6.1). 
During the pilot study (Chapter 10) it was observed that THC was identified at 
concentrations in blood which were lower than the apparent limit of detection 
indicated by data in Table 6.1 which were established in chloroform solutions of 
mixed drug standards. For example, the THC concentration estimated by the 
screening procedure for Table 10.3-Case No. 7 (Table 10.4) was 10 ng/mL but that 
determined by GAFL with a deuterated THC internal standard was 7 ng/mL; 
approximately half the apparent detection limit established for that drug as indicated 
in Table 6.1. Similarly, Table 10.3-Case No. 6 (Table 10.4) indicated trace levels of 
THC estimated to be approximately 7 ng/mL. Therefore, THC is one drug for which 
evidence suggests that a lower limit of detection is possible following its GC analysis 
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PILOT STUDY — INCIDENCE OF DRUGS AND ALCOHOL IN 
TASMANIAN DRIVERS INVOLVED IN ROAD ACCIDENTS 
10.1 Introduction 
10.1.1 General 
Over the last 20 years a great deal of literature has been published which discuss the 
relationship between driving performance and the presence of drugs in the blood of 
drivers, and the possible causal role of drugs in road traffic accidents (RTA). It is 
generally accepted that drugs which act on the central nervous system (CNS) have 
the potential to affect some, or all, of the functions associated with the multi-skilled 
task of driving. Drug classes with the potential to impair driving can be broadly 
grouped as follows. ° '3) 
1. CNS depressants - sedating types of antidepressants and anti-histamines; 
benzodiazepines; barbiturates; anti-psychotic agents. 
2. Narcotic analgesics - opiate drugs (eg. morphine, methadone, oxycodone). 
3. CNS stimulants - amphetamine and its analogues; cocaine, ephedrine isomers; 
anorectic agents. 
4. Cannabis. 
5. Hallucinogens - LSD; MDMA. 
6. Other therapeutic agents - anti-diabetic, antihypertensive and anticonvulsant 
agents. 
Numerous studies have reported the relative prevalence of drugs in the blood of 
impaired, injured and killed drivers. In every study, the most prevalent drug/drug 
group other than alcohol was Cannabis, with CNS stimulants, (especially cocaine), 
benzodiazepines and opiates varying between second, third and fourth ranking. (1,4-10) 
The mere presence of centrally acting drugs in the blood of a driver, however, is not 
sufficient evidence of driver impairment. 
Drugs are designed to produce specific pharmacological effects. Despite the 
specificity of drugs, it is not uncommon to find that in addition to producing the 
desired pharmacological effect, a drug exerts its effects at other receptor sites and 
undesirable side-effects become apparent. In general, the desired pharmacological 
effect is achieved when the drug blood concentration is within the 'therapeutic 
range'. The therapeutic range is the concentration of drug that provides a 
therapeutically desirable response in the majority of individuals with minimal 
toxicity/side effects. ° 1 ' 12) But it is possible that even healthy individuals may vary 
considerably in their responsiveness to a drug and underlying diseases/disorders can 
further alter responsiveness. The same individual may even respond differently to a 
drug at different times during the course of treatment. This means that should the 
drug blood level exceed the reported therapeutic range, the individual need not be 
intoxicated or suffering excessively from drug side-effects. Sources of variability in 
an individual's response to a drug include individual differences in first pass 
metabolism, age, gender, weight, degree of obesity, genetic makeup, the 
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administration of other drugs concurrently, type and degree of disease and prior 
experience with the drug or structurally-related drugs.  1-13) 
For the majority of drugs, reported therapeutic ranges were developed in plasma or 
serum and not whole blood. Consequently, for a given drug, the level determined in 
whole blood and the therapeutic range may not be directly comparable. Therefore, 
because of these sources of uncertainty (inter-individual variation; drug 
plasma/whole blood relationship), the therapeutic range serves only as a guide to the 
expected therapeutic response which might be achieved at a particular drug 
concentration. 
An alcohol blood level of > 0.1 g/100 mL in the driver is a significant contributing 
factor in road accidents. (4 ' 8 ' 14-17) But no similar quantitative data is currently 
available for any other drug, largely owing to the wide variation observed between 
drug level and pharmacological effect in different individuals. (3) Consequently, a 
wide range of drug blood levels may give equal levels of impairment and drug levels 
producing impairment in one individual may not impair another. For example, one 
study reported the blood concentration of oxazepam in 14 drivers apprehended by 
police together with comments from the arresting officer. In each case, no other drug 
was detected. The blood concentrations covered a wide range from 0.2 - 8 mg/L with 
gross impairment of the driver indicated by the attending police officer in every 
case. (5) 
Some drugs have different pharmacological effects at different blood concentrations. 
For example, diazepam has a muscle relaxant effect at one concentration and is an 
anti-convulsant agent at higher blood levels. (18) The pharmacological effect of 
lignocaine is dependent on the route of administration; subcutaneous injection 
produces local anaesthetic effects While the intravenous injection of lignocaine 
produces an anti-arrhythmic response. (18) 
With repeated use of the same drug, tolerance can develop to the side-effects and 
sometimes the therapeutic effects of the drug, and so larger and/or more frequent 
dosing may be required to produce the same pharmacological effects. Consequently, 
therapeutic blood levels in tolerant individuals could greatly exceed reported 
therapeutic ranges. Not only may tolerance develop to the drug being used but so 
may cross-tolerance to structurally similar drugs. Therefore, a tolerant individual 
with a drug blood level which might be considered toxic or even lethal to an 
intolerant individual may exhibit no signs of impairment and proper control of a 
motor vehicle may be expected.(19) For example, morphine, a narcotic analgesic and 
CNS depressant, has the capacity to impair driving performance. In intolerant 
individuals, morphine causes sedation, affects mood and impairs reaction time, 
muscle coordination, attention and short-term memory. (20) One study compared 
driving ability in cancer patients receiving long term morphine analgesia with a 
control group of cancer patients. Cancer patients receiving long term morphine 
analgesia can achieve very high blood concentrations of morphine exceeding cited 
therapeutic ranges. Yet it was found that morphine had only a very slight and 
selective effect on some functions related to driving in the group receiving morphine, 
compared with its effect on the control group, because of the remarkable 
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pharmacological tolerance these patients had developed to the side effects of 
morphine. (20) It is noted, however, that the group of cancer patients receiving long 
term morphine analgesia regularly received the same dose of morphine. Should an 
individual omit doses or increase the dose, then this irregularity in the dosing 
regimen may prevent the development of pharmacological tolerance and so the 
possibility of drug impairment remains. (19) 
In summary, then, the presence of drug/s in the blood of an individual is not 
sufficient evidence of impairment because of the possibility of individual differences 
in response to the same blood drug concentration. In addition, individuals with 
diseases such as epilepsy, schizophrenia, anxiety etc. may present a greater risk to 
other road users if they were to go untreated than if they were taking their 
antiepileptic, antipsychotic or antidepressant medications. (2,2 1-2) 
In 1983 a consensus panel representing the disciplines of clinical pharmacology, 
analytical and forensic toxicology, law and forensic medicine concluded that:- 
The major value of [drug blood level] determinations is to suggest that 
demonstrated clinical impairment of function is probably related to the presence 
of the drug in the body fluid, in the absence of other reasonable explanations. 
Conversely, impairment of function without the presence, in significant amounts, 
of a drug that might be expected to produce impairment would strongly suggest 
some cause, unrelated to drug use. (21) 
Consequently, a drug blood level alone cannot establish driver impairment but in 
conjunction with other evidence (eg. eye witness accounts, medical examination and 
an estimation of the impairing potential of the drug/drug combination) it can help 
support or exclude a diagnosis of driving impairment due to a specific drug. 
Despite the potential for centrally acting drugs to impair driving performance, in 
most cases where these drugs are taken as directed, significant or prolonged 
impairment is unlikely. The period where impairment is likely to be greatest is 
during the initial stage of taking a prescribed drug; before the nature and extent of 
any intended or side-effect is known with respect to the individual concerned, and 
before tolerance develops. (19 '27) Therefore, impairment is usually only likely where a 
single drug is taken in excess or two or more CNS affecting drugs are taken 
together.' ) 
Blood alcohol concentration is relatively easily assessed at the road side with breath 
determinations of alcohol. Poor driving performance or unusual or inappropriate 
behaviour, however, constitute the only signs of possible drug intoxication for the 
arresting officer. One study (1) reported that in 90% of cases where police officers 
specially trained in recognising signs of drug impairment said they suspected 
impairment, one or more psychotrophic drugs was present.' ) Another study(I°) 
reported that traffic police who were not trained in drug recognition often concluded 
that accidents involving drivers who were subsequently found to be drug but not 
alcohol positive, were caused by lack of driver care and attention. Ideally, the 
assessment of both the officer and the examining doctor would be required to identify 
drug impairment but, if the driver was unconscious as a result of serious injury 
following the accident, then eye-witness accounts of possible driver impairment prior 
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to the accident would be necessary. In addition, it may be virtually impossible for 
the police to distinguish between driver impairment by drugs and by injury (shock, 
concussion etc). Consequently, injury in drug impaired drivers tends to protect them 
against successful prosecution. 27) It has been reported that police were reluctant to 
request blood and urine samples unless very strong visual evidence of impaired 
driving performance was available. (3) 
The causal role of drugs in road accidents has been difficult to establish as there are 
driver-related factors other than potential impairment of the driver by drugs which 
are likely to contribute to the occurrence of road accidents. For example, driver age, 
sex, personality, confidence, psychomotor skills, driving experience, risk perception 
and acceptance all interact to affect individual driving performance. (2 ' 16 '22) Road 
accidents may arise as a result of other contributory factors which are unrelated to 
driving performance such as the type, size and road worthiness of the vehicle; road 
conditions; time of day; weather; other traffic; location (urban/rural; 
curve/intersection). (2,10,16,22) For example, one comprehensive study investigated 
potential drug impairment in fatally injured truck drivers. (8) The study included 
detailed on-site accident investigation and found that, in the absence of drugs, 
multiple factors (eg. driver fatigue, inexperience, medical problems, failure to heed 
warning signs or to yield, mechanical problems and load shifts) contributed to the 
fatal accident. It is not surprising then, that several studies have found that large 
percentages of drivers involved in road accidents (injured/fatally injured) were drug 
and alcohol free as follows:- 42% (4) , 43%(10), 43%(17), 45%(7) ,51%(28) , 66%. (8) These 
percentages further indicate, however, that many drivers were not drug and alcohol 
free at the time of the accident. 
The possibility that influences outside driver control contributed to an accident has 
been recognised(4 ' 14) and, in many recent studies, a driver responsibility analysis has 
been conducted in which each driver is rated for responsibility in causing the 
accident. If more drugs were detected in drivers assessed as responsible for accidents 
than in drivers not responsible, then this would be considered evidence of driver 
impairment by drugs. It is now generally accepted that the risk of having a road 
accident increases with increasing blood alcohol(1714l727)  and subsequent studies 
based on driver responsibility analysis confirm this. (4,8,14,28) Alcohol consumption is 
implicated as a major factor in fatal motor vehicle crashes, and there is a clear 
association between the seriousness of the crash and alcohol involvement. (4) 
Although driver responsibility analysis determined that driver impairment by alcohol 
was causal in road accidents, the same analysis has still not consistently indicated 
impairment caused by other drug groups (Cannabis, tranquillisers, anti-histamines, 
opiates, 	 (1,4,8, 14,28,30) For example, results from separate studies 
employing responsibility analysis do not agree that Cannabis use impairs the driver 
although no results were statistically significant because of the small number of 
Cannabis positive drivers detected. (1,4,8,28,31) 
The low incidence of individual drugs other than alcohol in drivers makes trends 
suggesting driver impairment, as indicated by responsibility analysis, difficult to 
validate statistically. Such studies have indicated, however, that drivers with 
multiple drugs (excluding alcohol) in their blood who are involved in accidents are 
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more likely to be responsible for the accident than drug free drivers or drivers with a 
single drug (excluding alcohol) in their blood. (14) The responsibility rates for these 
drivers was similar to those of alcohol positive drivers (alcohol either alone or in 
combination with another drug). (1) In addition, these types of studies indicate that 
drug positive drivers are more likely than drug free individuals to be involved in an 
(4 accident, in particular, a single vehicle accident. ,8,22,29)  
There are few, if any, consistent findings in the current literature relating any specific 
drug or drug group to driver impairment. Apparent from the literature is that alcohol, 
alcohol + drug, or multiple drugs, either impair or have the potential to impair 
driving performance, and increase driver responsibility rates for accidents. (1-4) 
10.1.2 Drugs and Tasmanian Drivers 
The most recent analytical study of the incidence of drugs in Tasmanian drivers 
involved in RTA was performed in 1987. (32) The study involved the analysis of 200 
whole blood samples taken from road users for alcohol analysis over a 20 month 
period by the Tasmanian Police. The blood samples represented all drivers killed in 
road accidents during that period and drivers that had come to the attention of the 
police who would not accept the alcohol breath test reading or who were incapable of 
being breath tested. A further 387 blood samples were taken from donors at two 
Tasmanian Blood Banks as the control group. 
Drug analysis was performed by gas chromatography on a slightly polar capillary 
column and drugs detected were confirmed by GC/MS. The analytical procedure 
was designed to detect lipophilic drugs which would be expected to have effects on 
the CNS. Basic drugs were extracted at pH 9.6 into n-butyl chloride (Table 7.2; 
Method 1) and chromatographed without derivatisation. Solid phase extraction at pH 
1.5 extracted acidic drugs which were methylated prior to chromatographic analysis. 
Cannabinoids in blood were screened by RIA and confirmed by GC/MS. 
Ninety-six reference drugs (not listed) were chromatographed which included 
sedative-hypnotic, antidepressant, antipsychotic, anticonvulsant, analgesic, anti-
histamine and nonsteroidal anti-inflammatory agents. The study, however, did not 
determine whether all these drugs were able to be extracted from blood by the two 
extraction procedures employed or, if they could be detected at therapeutic levels. 
The study reported that the screening procedure did not detect two important illicit 
drug groups (opiates and amphetamines) or some commonly occurring licit 
medications (paracetamol, salicylates and some antidepressants). It is also postulated 
that many other commonly prescribed medications containing weakly acidic and 
basic drug would also be excluded from the screen due to their poor extraction at pH 
1.5 or 9.6. 
Alcohol > 0.05 g/100 mL was detected in 75% of blood samples taken from road 
users involved in road accidents. The study detected 34 drugs other than alcohol in 
194 drivers, bicycle riders and pedestrians, with cannabis being the most frequently 
identified. (32) In the control group, 16% contained alcohol but none exceeded the 
legal limit of 0.05 g/100 mL. From the control group, only one blood sample 
contained a drug (Cannabis) other than caffeine. The study recognised that, although 
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blood donors were not an appropriate control group for a driving study, had their 
pattern of drug use been similar to that of road users involved in road accidents, then 
it could have been concluded that drugs were not contributing to accidents. The 
findings of the study, however, did not support a similar pattern of drug use between 
the control and test groups. 
10.1.3 Analytical Techniques 
The broad drug screening procedure will be used in a pilot study to investigate the 
incidence of drugs in Tasmanian drivers involved in road accidents (1995 to 1996) 
but, more importantly, to assess whether the procedure is readily applicable to these 
types of studies. As indicated previously (Section 1.4.1) broad drug screening is 
commonly achieved through a combination of techniques which target specific drug 
groups and employ a variety of instrumentation. Many of the studies cited in Section 
10.1.1. adopted this approach to the identification and confirmation of drugs in 
blood. For example, one major study (4) screened for drugs in blood using SPE with 
GC/MS analysis and RIA and confirmed their presence with either HPLC, GC-ECD 
or immunoassay. A minimum of 6 mL of blood was required for the complete drug 
assay which encompassed approximately 50 drugs. The screen included alcohol and 
LSD which are not identified by the procedure developed in this study. Other studies 
employed techniques which identified specific drug groups in blood using, for 
example, enzyme-multiplying techniques, HPLC, GC and GC/MS. (64 ' 1°) Still other 
studies were based on drugs identified in the urine of drivers following an 
accident. (19,27,29) Clearly, if the screening procedure developed in this study was 
applicable to the study of drugs in drivers, it could significantly minimise the 
resources (sample volume, staff, instrumentation, time) required by laboratories 
undertaking such studies and may increase the number and diversity of drugs they 
can currently detect. 
10.2 Methods 
Refer to "General Procedure" (Chapter 2). 
Blood specimens submitted to GAFL for analysis were re-analysed by the automated 
broad drug screening procedure. The specimens were taken from fatally injured 
drivers (33) or obtained under the Road Safety (Alcohol and Drugs) Act from drivers 
involved in road traffic accidents (16). The majority of bloods had been stored (up to 
16 months) at 4°C with sodium fluoride and potassium oxalate as preservative and 
anti-coagulant respectively. Some blood specimens from fatally injured drivers, 
however, contained either no preservative or anti-coagulant, or EDTA as an anti-
coagulant (Section 9.4). 
10.3 Results 
Table 10.1 lists the drugs and/or alcohol detected in the blood of fatally injured 
drivers involved in road traffic accidents (RTA) over a 16 month period (September 
1995—December 1996). Not all blood specimens belonging to fatally injured drivers 
over this period were re-analysed by the automated drug screening procedure. The 
specimens excluded were those for which there was an insufficient volume of blood 
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remaining for re-analysis, or those from drivers who underwent an extended period 
of hospitalisation prior to death. Consequently, data in Table 10.1 includes 7 of the 
12 driver fatalities in the 1995 period and 26 of 37 fatalities in the 1996 period. 
From additional written information available about each accident (included in the 
coronial reports, and police reports to the pathologist and to the Accident 
Investigation Unit of the Department of Transport), an assessment was made as to 
whether or not the driver was responsible for causing the accident. Table 10.2 gives 
examples of the statements and circumstances included in the reports which enabled 
the drivers to be assigned as 'Responsible', 'Partly Responsible' or 'Not 
Responsible' in Table 10.1. In general, drivers assessed as responsible for the 
accident failed to maintain their designated lane on the road. For those drivers who 
were found to be partly responsible, poor weather or road conditions, driver 
inexperience, inattentiveness or fatigue, or an unroadworthy vehicle also contributed 
to the accident. 
Associations between variables were assessed by chi-squared tests (X 2). It should be 
noted, however, that for the resulting theoretical distribution to be reasonably 
accurate, "the expected number of individuals in all cells must be at least 5.' (33) The 
data in Table 10.1 does not satisfy this assumption as the number of individuals in 
the three categories are small with the 'Not Responsible' group containing only 5. 
Also, some drugs were excluded from analysis as not being likely to impair driving 
(eg. paracetamol). Consequently, the probabilities (P) resulting from the X 2 statistics 
suggest trends rather than significant differences between variables. 
Data in Table 10.1 indicate the following. 
1. Regardless of drug findings, an alcohol concentration greater than the legal limit 
of 0.05 g/100 mL was identified more frequently in blood from drivers who were 
responsible for the accident than for those who were either partly, or not, 
responsible as shown below; X2 = 9.144; df = 2; P = 0.0103. 
Findings Responsible Partly Responsible Not Responsible 
Alcohol > 0.05' 13 6 0 
Alcohol <0.051 6 3 5 
0.05 g/ 100 mL of blood. 
2. All drugs detected in the blood specimens of driver, except paracetamol, were able 
to affect the CNS(t,18,21,36,37) or indicated the use of a drug which affects the CNS 
(eg THC-COOH). 
3. Although the screening procedure is capable of identifying a wide range of drugs 
in blood, the drugs identified in the blood specimens of 'responsible' drivers were 
limited to drugs of abuse, benzodiazepines, anti-depressants, anti-convulsants, 
non-steroidal anti-inflammatory agents (and paracetamol). 
4. Of the 33 fatally injured drivers, approximately one third were female. No 
difference was observed in the relative proportion of females within each 
responsibility category (X2 =0.405; df = 2; P = 0.817). 
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5. Drugs (which affect the CNS) and/or alcohol (> 0.05 g/100 mL) were identified 
more frequently in blood from drivers who were responsible for an accident than 
for those who were either partly, or not, responsible; ie. A to C versus D below; 
X2 =16.536; df= 2; P = 0.0003. 
Findings Responsible Partly Responsible Not Responsible 
A Alcohol' alone 8 1 0 
B Alcohol' + Drugs 3 0 0 
C Drugs alone 5 1 0 
D No alcohol'/drugs 3 7 5 
1 Alcohol concentration > 0.05 g/100 mL of blood. 
6. Single vehicle (SVA) rather then dual vehicle (DVA) accidents tended to occur 
more frequently in the responsible and partly responsible driver categories than in 
not responsible driver category as shown below; X2 =8.005; df = 2; P = 0.0183). 
Findings Responsible Partly Responsible Not Responsible 
SVA 13 6 0 
DVA 6 3 5 
7. No difference was observed between the 3 responsibility categories in the age of 
drivers as the upper and lower 95% confidence intervals (CI) overlapped each 
other as shown below. 
Age (years) Responsible Partly Responsible Not Responsible 
mean (SD) 34 (15) 26 (15) 43 (22) 
19 9 5 
CI (95%) upper 41 37 71 
lower 26 15 15 
Table 10.3 lists the drugs identified in the blood of drivers involved in RTA which 
the attending police officer/s suspected were impaired by drugs. These data, 
therefore, represent a select group of drivers and exclude the following. 
1. Those involved in accidents which the police did not attend. 
2. Those which had a high enough breath alcohol reading to explain any signs of 
impairment which were recognised by the police. 
3. Those in which signs of impairment were not recognised by the police. 
4. Those which were unconscious immediately after the accident (in these cases, 
police usually only request that the blood be analysed for alcohol). 
Full details were not available or were not able to be obtained for all accidents 
recorded in Table 10.3 (`-'). In cases where an elapsed time was recorded, the 
minimum elapsed time was 11/4 h. It was assumed, therefore, that the elapsed time 
for Case Nos. 7, 9 and 14 was at least 11/4 h. 
Data in Table 10.3 indicate the following: 
I. In every case where the attending police officer/s suspected drug impairment, 
CNS affecting drugs or their metabolites were identified. 
2. Although the screening procedure is capable of identifying a wide range of drugs 
in blood, the drugs identified in the blood specimens of these drivers were drugs 
of abuse, benzodiazepines, anti-depressant agents, ibuprofen and paracetamol. 
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3. More than one CNS affecting drug was identified in the blood of 7 of 16 drivers 
and, in two cases, alcohol was also present. 
4. Cannabis use was indicated by the presence of THC or its metabolite in the blood 
of 11 drivers. Despite obvious impairment at the time of the accident which was 
recognised by the attending police officer/s, in approximately half of these cases, 
the level of THC in the blood was below the level of instrument detection 
5Y2 h after the accident. 
5. Benzodiazepines were detected in the blood of 7 drivers. 
6. Anti-depressant agents were identified in the blood of 3 drivers. 
7. Three of the 16 drivers were female. 
8. A greater number of the accidents were SVA although the accident type was not 
specified for all cases. 
Table 10.4 lists the estimated concentrations of drugs which were identified and 
quantitated by the automated drug screening procedure in Tables 10.1 and 10.3. 
These data confirm the finding in Chapter 9 which indicates that the developed 
procedure could reliably estimate sub-therapeutic, therapeutic and toxic levels of 
drugs in blood as demonstrated by the following examples. 
1. Eye-witness accounts of driving impairment (Table 10.3) would suggest either 
ingestion of drugs at greater than therapeutic levels where undesirable side-effects 
are manifested, or ingestion of multiple drugs where the possibility exists for 
potentiation of the pharmacological effects of the individual drugs. Where police 
had suspected that drugs were impairing an individual's driving ability, data in 
Table 10.4 indicate that licit drugs were present at therapeutic and toxic levels 11/4 
to 2 h after the accident. 
2. Where benzodiazepines (diazepam and temazepam) and their metabolites were 
detected, the screening procedure estimated relative blood levels which were 
similar to those reported in the literature (33 '34) following the metabolism of 
ingested diazepam and temazepam. 
3. The blood specimen analysed in Table 10.1—Case No. 2 was taken 42 h after the 
accident during the individual's hospitalisation. The estimated drug levels 
determined by the screening procedure accurately reflect the expected levels for 
drugs present; those administered in hospital (diazepam and morphine) were 
present at therapeutic levels and those taken prior to the accident (phenytoin and 
carbamazepine) were present at sub-therapeutic levels. 
10.4 Discussion 
A pilot study investigating the incidence of drugs in the blood of Tasmanian drivers 
involved in RTA was undertaken to:- 
1. demonstrate one application of the broad drug screening procedure, and 
2. revisit the types and frequency of drugs identified in the blood of Tasmanian 
drivers as determined in 1983 by an earlier study. (32) 
Although the sample size was very small, the sample revealed findings that are 
consistent with data reported by other studies as follows, and this consistency lends 
some confidence to the reliability of the data from the pilot study. 
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1. Drugs (which affect the CNS) and/or alcohol (>0.05 mg/100 mL) were identified 
more frequently in blood from drivers who were responsible for the accident than 
from those who were partly, or not, responsible. (4,8,22,29) 
2. Single vehicle accidents rather then dual vehicle tended to occur more frequently 
in the responsible, or partly responsible, driver categories than in the not 
responsible, categories. (4,8,10,22.29) . 
3. In every case where the attending, police officer/s suspected drug impairment, 
CNS affecting drugs or their metabolites were identified.' ) The drugs detected in 
the blood of apparently impaired drivers and their pattern of use were similar to 
those found in other studies; Cannabis use was prevalent; it was common to either 
administer multiple centrally acting drugs concurrently or administer a large 
amount of a single drug. (I) 
The similarity between results determined in the pilot study and those reported in the 
literature validates the useful and successful application of the screening procedure to 
a study which investigates the incidence of unknown drugs in a limited volume of 
blood. A small number of centrally acting drugs was detected in driver blood despite 
the ability of the screening procedure to identify a diverse range of drugs. Although 
the data did not contribute anything new towards clarifying the 'drugs and driver' 
issue so far described in the literature, these unsurprising results lend credibility to 
•the data determined by the developed screening procedure. 
Data in Table 10.1 were grouped in relation to assessed driver responsibility in 
causing the accident. This study found that alcohol (a known risk factor for road 
accidents) was associated with driver responsibility. Consequently, this finding 
supports the assignment of driver responsibility as assessed from information 
included in the coronial reports, and police reports to the pathologist and to the 
Accident Investigation Unit of the Department of Transport. 
The data determined in this study was similar to that determined by an earlier 
study (32) suggesting that the types of drugs (drugs of abuse, sedative-hypnotic agents, 
drugs taken for the relief of pain and inflammation) identified in the blood of 
Tasmanian drivers has changed little in 10 years. Anti-convulsants, antidepressants 
and paracetamol which were detected in the present study were, however, not 
reported in the previous study and this difference may be as a result of the different 
analytical methods employed by each study. The earlier study reported that the drug 
extraction procedure which was employed did not recover paracetamol and some 
antidepressants and it was postulated in Section 10.1.2 that other drugs (eg. weakly 
acidic drugs such as the anticonvulsants) might also be poorly recovered. 
As a result of the extremely limited sample size of this study, the frequency with 
which drugs were detected in the blood of drivers cannot be compared with the 
findings of the earlier study. A comprehensive study into the incidence of drugs in 
the blood of Tasmanian drivers involved in RTA which utilises the developed 
screening procedure has the potential to expand on the previous study (32) undertaken 
in Tasmania as follows. 
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1. It would permit identification of a broader range of target drugs including those 
for which the previous study did not screen (eg. amphetamines, opiates, anti-
depressants, anti-convulsants, paracetamol). 
2. It would be able to detect the majority of target drugs within their therapeutic 
ranges. 
3. It would be able to reliably estimate drug concentrations which may reveal their 
therapeutic use or abuse. 
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An automated semi-quantitative comprehensive drug screen for 105 
pharmacologically and structurally diverse drugs in whole blood was developed. 
Target drugs were isolated from the blood matrix through an extraction strategy 
(combined liquid-liquid and solid-phase extraction) which recovered approximately 
90% of target drugs with greater than 75% efficiency. From each blood specimen, 
four extracts were produced which were analysed by GC/MS (SIM) and drugs, or 
their butyl or PFP derivatives, were detected. A novel macro analysed complicated 
multi-peak chromatograms using fixed parameters (retention index and a pair of 
target nilz ions) which together uniquely identified target drugs. The macro 
calculated an approximate level in blood for each drug using predetermined 
quantitative information and generated a report. 
In excess of 100 blood specimens were analysed by the screening procedure to 
evaluate its ability to identify all drugs present and estimate their levels. During 
validation experiments, approximately 65 different target drugs and drug metabolites 
were encountered. The test procedure identified 97% of target drugs known to be 
present in spiked blood specimens and, in approximately 90% of instances, 
reasonably estimated their true concentrations. The screening procedure compared 
favourably with methods routinely employed at Government Analytical and Forensic 
Laboratory for the identification and.analysis of drugs in blood and identified a 
greater number of drugs in the same blood specimens. During the analysis of blood 
specimens drawn from hospital in-patients, it was found that the procedure was likely 
to identify the majority of drugs present at therapeutic levels, particularly. if 
administered within two half-lives of the blood being taken. In addition, by 
screening for, and identifying, target drug metabolites the test procedure provided 
additional confirmation of the presence of a drug. 
Chromatographic information was obtained for a wide range of drugs and their 
derivatives and enabled a database to be established which recorded the observed 
behaviour of these analytes on a non-polar chromatographic system (retention index, 
peak shape, linearity over a defined concentration range, limit of instrument 
detection). From these data it was possible to estimate and compare the apparent 
'chromatographic polarity' of individual drugs. Comparisons were made between 
the chromatographic properties of underivatised and derivatised drugs and their 
structural characteristics which permitted the formation of either butyl or PFP 
derivatives. In particular, it was found that some unusual derivatisation products 
were formed following reaction with PFPA. These were generally not formed at 1° 
or 2° amine groups on a drug but at alcohol or 1° amide groups. These data add to 
the published data which deals mainly with either selected drugs, or single drug 
groups, and is not able to be compared between groups. The drugs studied were 
representative of a wide range of chemical structures and functionalities. 
Consequently, the chromatographic properties of other drugs and their suitability to 
213 
participate in derivatisation reactions with either n-butyl iodide or PFPA may be 
estimated provided they are structurally similar to a drug already investigated. 
A pilot study investigating the incidence of drugs in the blood of Tasmanian drivers 
involved in RTA was undertaken to demonstrate one application of the broad drug 
screening procedure. Although the screening procedure was capable of identifying a 
diverse range of drugs, a limited number of centrally acting drugs was detected in 
driver blood (drugs of abuse, benzodiazepines, anti-depressants, anti-convulsants, 
non-steroidal anti-inflammatory agents and paracetamol). Findings determined in the 
pilot study were similar to those previously reported in the literature. The 
consistency of data between the pilot and other studies suggests that the screening 
procedure can be reliably employed in studies which investigate the incidence of 
unknown drugs in a limited volume Of blood. If laboratories undertaking such 
studies were to employ this procedure, it is possible that the resources they require 
could be significantly minimised while increasing the number and diversity of drugs 
they can currently detect. 
In the design of any drug screening procedure, the particular needs and limitations of 
the laboratory in which it was to be employed would need to be accommodated 
(Section 1.2). In this study, the needs and limitations of a Tasmanian forensic 
laboratory were considered and it was indicated that a drug screening procedure 
which satisfied the nine criteria identified in Sections 1.3 and 1.4.1 would be highly 
desirable. It can be concluded that the screening procedure developed in this study 
did successfully satisfy, or satisfy in part, the 9 criteria as follows. 
1. The drug screen was developed in a limited volume (2.5 mL) of whole, 
haemolysed blood. 
2. The procedure extracted a large number of available drugs with at least one 
representative drug from each of the major drug classes (eg. benzodiazepines, 
anti-depressants, anti-epileptics etc.) but, of the drugs 'flagged' in Table 1.2 for 
inclusion in a broad drug screening procedure designed for both clinical and 
forensic applications, 120 drugs Were eliminated. Approximately 40% of those 
eliminated were drugs which were commonly used in the community (eg. mineral 
supplements, hormonal medications, antibacterial and antifungal agents, and non-
systemic medications) but which did not satisfy any of the other selection criteria 
(potential drug of abuse; toxicologically significant; possessing pharmacological 
properties with the potential to effect driving performance or judgement; a marker 
of an underlying disorder). The elimination of these drugs, therefore, is likely to 
impact more significantly on the potential clinical application of the drug 
screening procedure rather than on its forensic application. 
3. The procedure was able to detect the majority of target drugs at therapeutic blood 
concentrations. 
4. The study included data which indicated which drugs could or could not be 
recovered by the extraction technique and listed the extraction efficiency of the 
procedure for each drug. 
5. Drug recovery was relatively high (90% of target drugs recovered with greater 
than 75% efficiency). The recovery of only 6% of tested drugs by either SPE or 
LLE (or both) was less than 30%, and all were acidic drugs. Baclofen and 
captopril were not recovered by SPE or LLE techniques. The variability in the 
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recovery of many test drugs was greater following solid-phase than liquid-liquid 
extraction. 
6. The procedure was able to provide an indication of whether the drug was present 
in the blood at sub-therapeutic, therapeutic or toxic levels in both forensic 
specimens and blood from hospitalised patients. 
7. The drug screening procedure was able to confirm the identity of 60% of the 
target drugs by an alternate method; either in an extract produced by a different 
technique (SPE or LLE), or as the corresponding butyl or PFP derivative. The 
identity of nearly all drugs which would be detected in an underivatised extract, 
and approximately half the drugs detected as either butyl, or PFP derivatives, 
could be confirmed in another extract. 
8. The majority of target drugs were chromatographed with good peak shape and 
with a limit of instrument detection which fell within or below the reported 
therapeutic range of the drug. 
9. The macro developed for automation of data analysis provided greater specificity 
than commercially available library-based search programs and mimicked some of 
the interpretative skills which would be employed by an experienced analyst The 
macro was able to identify low lei/els of drugs amongst general interference at the 
baseline and was able to differentiate between co-eluting peaks which produced a 
peak with a mixed mass spectrum (which could not be matched against a drug 
library of full-scan mass spectra). 
The novel macro developed in this study was independent of absolute retention time 
and, consequently, could be employed in the automated analysis of chromatograms 
generated on any non-polar column. From the drug RI values listed in drugs. txt, the 
expected drug retention time could be calculated and was based on linear 
interpolation between a pair of HC markers which bracketed the drug. The majority 
of integration parameters incorporated into the macro were independent of GC 
conditions and instrumentation. Therefore, automated drug identification (but not 
quantitation) was independent of specific instrument sensitivity, MS tuning 
parameters or chromatographic conditions and was able to be transported between 
different GC systems and laboratories (transferred from the development laboratory 
• to the service laboratory). The automated drug identification macro incorporated 
some of the expertise of the experienced operator and the report generated by the 
macro served as an aid to the analyst. The macro significantly reduced the time 
required to analyse chromatograms, guarded against the reporting of false negatives 
when the drug was present at low blood levels, and estimated the approximate 
concentration of drugs in blood which could be used for the future, more accurate, 
quantitation of that drug if necessary. The macro, however, did not replace the 
experienced analyst who was responsible for correctly interpreting the macro-
generated reports and identifying false 'hits' from true. 
The screening procedure developed in this study appears well suited to forensic work 
and has been in routine use at the Government Analytical and Forensic Laboratory 
for the past 12 months. During validation experiments it was found that the 
procedure correctly identified drugs present in spiked blood samples distributed 
through the Proficiency Testing Program indicating that it is capable of performing 
as well, or better than, other forensic laboratories in Australia and New Zealand 
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which undertake similar analyses but which use a combination of different 
techniques and instrumentations. At the Goverment Analytical and Forensic 
Laboratory, the procedure has been routinely used to analyse specimens submitted by 
the Tasmania Police and Coroner where it has been necessary to determine the 
presence of unspecified drugs in a lirhited volume of blood. Confirmation of the 
identity of approximately twenty-five drugs detected as butyl and/or PFP derivatives 
has been recently achieved by combining, silylating and re-analysing the 'S' and 'L' 
extracts for trimethylsilyl (TMS) drug derivatives. Through silylation, the identity of 
some high priority target drugs can be confirmed (eg. benzoylecgonine, morphine, 
oxazepam, temazepam, THC and THC-COOH). The additional step was easily 
incorporated into the automated screening procedure once the retention index and m/z 
ions of TMS derivatives had been determined and a new drugs. txt table created. 
Total analysis time was increased by a further 25 min. It is possible that some target 
drugs eliminated in Section 6.3 may be detected as TMS derivatives at therapeutic 
blood levels, but this has not yet been investigated. 
The screening procedure was applied to a limited number of clinical specimens 
(blood from hospitalised patients) during validation experiments. Many of these 
were blood specimens from surgical patients and, as a result, only a limited number 
of target drugs (28) were encountered. To evaluate whether the procedure is suitable 
for routine clinical applications, blood specimens from patients on different hospital 
wards (eg. medical, psychiatric) would need to be analysed. 
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